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A B S T R A C T
Background
Cyclophosphamide, in combination with corticosteroids, has been first-line treatment for inducing disease remission for proliferative
lupus nephritis, reducing death at five years from over 50% in the 1950s and 1960s to less than 10% in recent years. Several treatment
strategies designed to improve remission rates and minimise toxicity have become available. Treatments, including mycophenolate
mofetil (MMF) and calcineurin inhibitors, alone and in combination, may have equivalent or improved rates of remission, lower
toxicity (less alopecia and ovarian failure) and uncertain effects on death, end-stage kidney disease (ESKD) and infection. This is an
update of a Cochrane review first published in 2004 and updated in 2012.
Objectives
Our objective was to assess the evidence and evaluate the benefits and harms of different immunosuppressive treatments in people with
biopsy-proven lupus nephritis. The following questions relating to management of proliferative lupus nephritis were addressed: 1) Are
new immunosuppressive agents superior to or as effective as cyclophosphamide plus corticosteroids? 2) Which agents, dosages, routes
of administration and duration of therapy should be used? 3) Which toxicities occur with the different treatment regimens?
Search methods
We searched the Cochrane Kidney and Transplant Specialised Register up to 2 March 2018 with support from the Cochrane In-
formation Specialist using search terms relevant to this review. Studies in the Specialised Register are identified through searches of
CENTRAL, MEDLINE, and EMBASE, conference proceedings, the International Clinical Trials Register (ICTRP) Search Portal and
ClinicalTrials.gov.
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Selection criteria
Randomised controlled trials (RCTs) and quasi-RCTs comparing any immunosuppressive treatment for biopsy-proven class III, IV,
V+III and V+VI lupus nephritis in adult or paediatric patients were included.
Data collection and analysis
Data were abstracted and the risks of bias were assessed independently by two authors. Dichotomous outcomes were calculated as risk
ratio (RR) and measures on continuous scales calculated as mean differences (MD) with 95% confidence intervals (CI). The primary
outcomes were death (all causes) and complete disease remission for induction therapy and disease relapse for maintenance therapy.
Evidence certainty was determined using GRADE.
Main results
In this review update, 26 new studies were identified, to include 74 studies involving 5175 participants overall. Twenty-nine studies
included children under the age of 18 years with lupus nephritis, however only two studies exclusively examined the treatment of lupus
nephritis in patients less than 18 years of age.
Induction therapy
Sixty-seven studies (4791 participants; median 12 months duration (range 2.5 to 48 months)) reported induction therapy. The effects
of all treatment strategies on death (all causes) and ESKD were uncertain (very low certainty evidence) as this outcome occurred very
infrequently. Compared with intravenous (IV) cyclophosphamide, MMF may have increased complete disease remission (RR 1.17,
95% CI 0.97 to 1.42; low certainty evidence), although the range of effects includes the possibility of little or no difference.
Compared to IV cyclophosphamide, MMF is probably associated with decreased alopecia (RR 0.29, 95% CI 0.19 to 0.46; 170 less
(129 less to 194 less) per 1000 people) (moderate certainty evidence), increased diarrhoea (RR 2.42, 95% CI 1.64 to 3.58; 142 more
(64 more to 257 more) per 1000 people) (moderate certainty evidence) and may have made little or no difference to major infection
(RR 1.02, 95% CI 0.67 to 1.54; 2 less (38 less to 62 more) per 1000 people) (low certainty evidence). It is uncertain if MMF decreased
ovarian failure compared to IV cyclophosphamide because the certainty of the evidence was very low (RR 0.36, 95% CI 0.06 to 2.18;
26 less (39 less to 49 more) per 1000 people). Studies were not generally designed to measure ESKD.
MMF combined with tacrolimus may have increased complete disease remission (RR 2.38, 95% CI 1.07 to 5.30; 336 more (17 to
1048 more) per 1000 people (low certainty evidence) compared with IV cyclophosphamide, however the effects on alopecia, diarrhoea,
ovarian failure, and major infection remain uncertain. Compared to standard of care, the effects of biologics on most outcomes were
uncertain because of low to very low certainty of evidence.
Maintenance therapy
Nine studies (767 participants; median 30 months duration (range 6 to 63 months)) reported maintenance therapy. In maintenance
therapy, disease relapse is probably increased with azathioprine compared with MMF (RR 1.75, 95% CI 1.20 to 2.55; 114 more (30
to 236 more) per 1000 people (moderate certainty evidence). Multiple other interventions were compared as maintenance therapy, but
patient-outcome data were sparse leading to imprecise estimates.
Authors’ conclusions
In this review update, studies assessing treatment for proliferative lupus nephritis were not designed to assess death (all causes) or ESKD.
MMFmay lead to increased complete disease remission compared with IV cyclophosphamide, with an acceptable adverse event profile,
although evidence certainty was low and included the possibility of no difference. Calcineurin combined with lower dose MMF may
improve induction of disease remission compared with IV cyclophosphamide, but the comparative safety profile of these therapies is
uncertain. Azathioprine may increase disease relapse as maintenance therapy compared with MMF.
P L A I N L A N G U A G E S U M M A R Y
Immunosuppressive treatment for people with proliferative lupus nephritis
What is the issue?
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In lupus, the body’s immune system for fighting infection attacks different parts of the body, including the kidneys. About half of all
people with lupus have kidney problems. An estimated one in every 10 people who have lupus kidney disease (lupus nephritis) can
develop kidney failure. The goal of treatment is to protect kidney function and avoid side-effects.
While the life expectancy of patients who have lupus has dramatically improved, available treatments can cause serious side effects such
as hair loss, serious infection, and infertility. It is important to know about which treatments help to treat lupus while causing the fewest
side-effects.
What did we do?
We searched the Cochrane Kidney and Transplant Specialised Register up to 2 March 2018 and we combined all studies testing
treatments aimed to control the body’s immune system for lupus nephritis.
What did we find?
In this review update, 74 studies involving 5175 patients with lupus nephritis could be studied. Treatments included intravenous (given
through a vein) cyclophosphamide, oral (tablets by mouth) mycophenolate mofetil (MMF), azathioprine, and tacrolimus (used alone
or together with MMF). We also found studies of treatments called “biologic” therapies, that have been designed to change very specific
parts of the body’s immune system that cause it to attack itself. We looked particularly at key outcomes such as whether treatment
prevented patients from needing dialysis and controlled the lupus damage to the kidney tissue (called remission). We also looked at
serious side-effects including death, infection, infertility, and hair loss.
After combining the available studies, compared with cyclophosphamide, MMF may be better at getting the lupus damage to the
kidneys under control. However, the range where the actual effect may suggest that MMF may make little or no difference to disease
remission compared to treatment with cyclophosphamide. MMF treatment given with tacrolimus may lead to more disease remission.
MMF may result in less hair loss and worse diarrhoea, but we were not certain whether MMF reduces infertility or other serious
side effects. MMF was better than azathioprine for preventing kidney disease in the longer term. None of the studies told us whether
treatment had any effect on death or need for dialysis, and there was very low certainty of evidence for the use of biologics in patients
with lupus nephritis.
Conclusions
Patients with lupus nephritis may have similar or slightly better outcomes when treated with MMF orMMF with tacrolimus compared
to those patients who receive intravenous cyclophosphamide. We are still not certain which is the best treatment for lupus nephritis to
protect against needing dialysis in the longer term.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Patient or population: pat ients with induct ion therapy in lupus nephrit is
Settings: all sett ings
Intervention: MMF
Comparison: IV CPA
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No. of participants
(studies)
Certainty of evidence
(GRADE)
Comments
Assumed risk Corresponding risk
IV CPA MMF
Death
Follow-up: mean 24
weeks
40 per 1000 53 per 1000
(29 to 98)
RR 1.12
(0.61 to 2.06)
826 (8) ⊕©©©
very low1,2,3
Downgraded as fol-
lows:
1 Indirectness: t ime
f rame insuf f icient
2 Total number of
events small
3 Severe imprecision (2
grades): risk est imate
includes null ef fect
and est imate consis-
tent with both apprecia-
ble benef it and harm
ESKD
Follow-up: mean 32
weeks
85 per 1000 61 per 1000
(23 to 157)
RR 0.71 (0.27 to 1.84) 231 (3) ⊕©©©
very low1,2,3
Downgraded as fol-
lows:
1 Indirectness: t ime
f rame insuf f icient
2 Total number of
events small
3 Severe imprecision (2
grades): risk est imate
includes null ef fect
and est imate consis-
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tent with both apprecia-
ble benef it and harm
Complete renal remis-
sion
Follow-up: mean 24
weeks
222 per 1000 260 per 1000
(216 to 316)
RR 1.17 (0.97 to 1.42) 828 (8) ⊕⊕©©
low1,2,3
Downgraded as fol-
lows:
1 Study lim itat ions
2 Total number of
events small
3 Impreci-
sion (2 grades): risk es-
t imate includes null ef -
fect and est imate con-
sistent with both appre-
ciable
benef it and harm
Partial renal remission
Follow-up: mean 24
weeks
415 per 1000 423 per 1000
(369 to 490)
RR 1.02
(0.89 to 1.18)
868 (9) ⊕⊕©©
low1,2
Downgraded as fol-
lows:
1 Study lim itat ions
2 Serious indirectness:
dif f erences in the out-
come def init ion be-
tween studies
Ovarian failure 41 per 1000 15 per 1000
(2 to 90)
RR 0.36
(0.06 to 2.18)
539 (3) ⊕©©©
very low1,2,3
Downgraded as fol-
lows:
1 Study lim itat ions
2 Severe heterogeneity:
point est imates varied
widely
3 Total number of
events small
4 Severe imprecision (2
grades): risk est imate
includes null ef fect and
est imate consistent
with both appreciable
benef it and harm
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Major infection
Follow-up: mean 24
weeks
114 per 1000 116 per 1000
(76 to 175)
RR 1.02
(0.67 to 1.54)
699 (6) ⊕⊕©©
low1,2
Downgraded as fol-
lows:
1 Study lim itat ions
2 Total number of
events small
3 Severe imprecision (2
grades): risk est imate
includes null ef fect and
est imate consistent
with both appreciable
benef it and harm
Alopecia
Follow-up: mean 24
weeks
239 per 1000 69 per 1000
(45 to 110)
RR 0.29
(0.19 to 0.46)
622 (3) ⊕⊕⊕©
moderate1,2,3
Downgraded as fol-
lows:
1 Study lim itat ions
2 Total number of
events small
Upgraded as follows:
3 Large magnitude of
ef fect
Diarrhoea
Follow-up: mean 24
weeks
100 per 1000 241 per 1000
(163 to 357)
RR 2.42
(1.64 to 3.58)
609 (4) ⊕⊕⊕©
moderate1,2,3
Downgraded as fol-
lows:
1 Study lim itat ions
2 Total number of
events small
Upgraded as follows
3 Large magnitude of
ef fect
* The basis for the assumed risk f or part ial renal remission was prognost ic studies (Fernandes das Neves 2015; Moroni 2007; So 2011; Zakharova 2016); and the assumed
risk for other outcomes was calculated using the median control group risk across studies in the meta-analysis. The corresponding risk (and its 95% conf idence interval) is
based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its 95%CI)
CI: Conf idence interval; RR: risk rat io
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GRADE Working Group certainty of evidence
High certainty: Further research is very unlikely to change our conf idence in the est imate of ef fect
Moderate certainty: Further research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate
Low certainty: Further research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate
Very low certainty: We are very uncertain about the ef fect est imate
xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx
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B A C K G R O U N D
Description of the condition
Lupus nephritis occurs in about 20% to 75% of all people with
systemic lupus erythematosus (SLE) (Cervera 2009), leading to
end-stage kidney disease (ESKD) in 10% to 17% of patients at
10 years (Houssiau 2010; Tektonidou 2016). Predominantly af-
fecting young women, lupus nephritis is also more common in
certain ethnicminority groups, particularly among African-Amer-
icans and Hispanics who may also have a more aggressive form
of the disease that is less responsive to treatment (Hanly 2016;
Korbet 2007; Sexton 2014).
Kidney involvement ranges from mild subclinical disease, which
is associated with favourable outcomes and a low chance of pro-
gression to ESKD, to severe nephritic and/or nephrotic syndrome
with kidney impairment and greater risk of progression to ESKD.
In the United States of America, and Australia and New Zealand,
approximately 1% of patients commencing dialysis had ESKD as
a consequence of lupus nephritis (ANZDATA 2016; Costenbader
2011). Patients with SLE and active lupus nephritis have reduced
health-related quality of life (Daleboudt 2011; McElhone 2006;
Vu 1999). Fatigue is a frequent symptom and often identified as
the most disrupting aspect of the disease in patients with lupus
nephritis (Daleboudt 2011; Tench 2000), as it can limit their ca-
pacity to participate in the workforce, family, and social activities
(Sutanto 2013).
Renal biopsy is required for the precise diagnosis and classification
of lupus nephritis. Histological classification was introduced by
the World Health Organization (WHO) in 1982 and revised in
2003 by the International Society of Nephrology (ISN) and the
Renal Pathology Society (RPS). The ISN/RPS 2003 Class I and II
lesions have a good prognosis and are generally not an indication
for specific therapy, although some guidelines recommend therapy
for people with WHO Class II lupus nephritis and proteinuria (>
2 g/d) (Tunnicliffe 2015). Proliferative disease (WHO Class III,
IV, V+III and V+IV; ISN/RPS 2003 Class III (A) and (A/C), Class
IV-G and IV-S, and Class III or IV in combination with Class
V) is usually symptomatic, more fulminant, and requires treat-
ment to induce remission and prevent significant kidney injury
and premature death. Active proliferative (WHO Class IV) lupus
nephritis is the most aggressive form of the condition, and has the
worst prognosis without intensive immunosuppressive treatment.
Description of the intervention
Immunosuppressive therapy in the management of proliferative
lupus nephritis aims to induce and maintain disease remission,
in order to maximise patient and renal survival while minimis-
ing complications or treatment related adverse effects. The in-
duction phase of therapy usually lasts six to 12 months. Com-
mon immunosuppressive agents in induction therapy include cor-
ticosteroid and an anti-proliferative agent such as cyclophospha-
mide, mycophenolate mofetil (MMF), or azathioprine. Less com-
monly used treatments that are added to corticosteroids include
tacrolimus, cyclosporin, plasma exchange or plasmapheresis, or a
biologic therapy such as rituximab. Intravenous (IV) cyclophos-
phamide in combination with corticosteroids became standard of
care therapy for inducing remission based on a landmark National
Institutes of Health (NIH) trial that showed cyclophosphamide
was superior over corticosteroids alone in preventing renal flares
and kidney failure (Decker 1975). A meta-analysis (Bansal 1997)
and our earlier systematic review (Flanc 2004a) identified that the
addition of an immunosuppressant to corticosteroids was superior
to corticosteroids alone in managing proliferative lupus nephri-
tis. Subsequently, low-dose cyclophosphamide (Euro-lupus regi-
men) has been reported to have equivalent efficacy to the NIH
protocol (Houssiau 2002). The dose of corticosteroid is tapered
as the disease activity is controlled and the anti-proliferative ther-
apy is replaced with a less toxic alternative once remission is in-
duced. Maintenance therapy aims to maintain remission and po-
tential treatments include: azathioprine, MMF, tacrolimus and cy-
closporin.
How the intervention might work
Active lupus nephritis is characterised by an inflammatory response
to immune complexes in the kidneys. Mediators of inflamma-
tion, including complement, leukocytes, and cytokines injure the
kidney and amplify inflammation. The release of kidney antigens
in response to this inflammatory kidney injury may result in the
production of kidney-specific autoantibodies. This organ-specific
autoimmunity may perpetuate inflammation and result in kid-
ney injury (Rovin 2014). The mechanisms of action of therapies
used in the management of lupus nephritis are diverse, and aim
to attenuate inflammation. Corticosteroids and IV cyclophospha-
mide and other conventional treatments have a broad spectrum
immunosuppressive effect, while biologic therapies, which have
been of increasing focus of trials in the last decade, target B-cells,
T-cells, cytokines or growth factors to suppress the immune re-
sponse (Murphy 2013).
First-line therapy has transformed lupus nephritis from an acute
illness with five-year survival rates at less than 50% in the 1950s
to a chronic illness with five-year survival rates greater than 90%
(Houssiau 2010; Mok 2002). Response to treatment is often slow,
and although remission is induced in a significant proportion of
patients, the risk of relapse has been reported between 18% and
46% (Ponticelli 1998), and treatment can cause considerable tox-
icity, and increase the risk of infertility (Henderson 2012).
Why it is important to do this review
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We conducted a systematic review of immunosuppressive treat-
ment of proliferative lupus nephritis in 2004 (Flanc 2004a), and
updated this systematic review in 2012 (Henderson 2012). The
2012 review identified 50 randomised controlled trials (RCTs)
that enrolled a total of 2846 participants. The conclusion was that
compared with IV cyclophosphamide, MMF was as effective in
inducing disease remission, but with a lower risk of ovarian fail-
ure. MMF was more effective than azathioprine in maintaining
disease remission. A recent network meta-analysis identified that
compared to IV cyclophosphamide either MMF or tacrolimus or
their combinationwasmore effective in inducing remission. Com-
pared with IV cyclophosphamide, the combination of MMF and
tacrolimus reduced ovarian failure, but either treatment alone con-
ferred a similar risk of ovarian failure. The use of these newer ther-
apies on outcomes such as: death, ESKD and doubling of serum
creatinine (SCr) were inconclusive (Palmer 2017).
In the past five years, numerous studies have evaluated a number
of regimens including MMF, tacrolimus or their combination and
various biologic agents. Given the uncertainty that surrounds the
safety and efficacy of these therapies, the aim of our updated review
was to evaluate the relative effects of all available immunosuppres-
sive therapies for the induction and maintenance treatment of lu-
pus nephritis using IV cyclophosphamide as the main comparator
in induction therapy and azathioprine as the main comparator in
maintenance therapy.
O B J E C T I V E S
Our objective was to assess the evidence and evaluate the benefits
and harms of different immunosuppressive treatments in people
with biopsy-proven lupus nephritis. The following questions relat-
ing tomanagement of proliferative lupus nephritis were addressed:
1. Are new immunosuppressive agents superior to or as
effective as cyclophosphamide plus corticosteroids?
2. Which agents, dosages, routes of administration and
duration of therapy should be used?
3. Which toxicities occur with the different treatment
regimens?
M E T H O D S
Criteria for considering studies for this review
Types of studies
We included all RCTs andquasi-RCTs,whether published or avail-
able only in abstract form, which evaluated any of the treatment
options in the focus of this review, singularly or in combination,
determining the benefits and harms of different treatment options
for lupus nephritis.
Types of participants
We included adults and children with biopsy-proven proliferative
lupus nephritis.
Types of interventions
We considered studies that investigated the following treatment
options for either induction or maintenance therapies for lupus
nephritis.
• Corticosteroids including prednisone and
methylprednisolone
• Other immunosuppressive agents including azathioprine,
cyclophosphamide, MMF, tacrolimus and cyclosporin
• Plasma exchange or plasmapheresis
• Biologic therapy (for example, abatacept, atacicept,
laquinimod, ocrelizumab, rituximab and sirukumab).
Non-specific treatment options (e.g. antihypertensive agents) were
not included in the present analysis because these do not specifi-
cally aim to treat underlying lupus nephritis, but rather more gen-
erally, aim to prevent the progression of chronic kidney disease
(CKD).
Types of outcome measures
Primary outcomes
• Death (all causes)
• ESKD, requirement for renal replacement therapy
• Complete renal remission: defined as return to normal SCr,
urinary protein excretion < 0.5 g/24 h, and inactive urinary
sediment) following induction therapy
• Relapse of lupus nephritis: maintenance therapy
Secondary outcomes
The following dichotomous outcome measures were considered:
• Partial renal remission: defined as a fall to < 3.0 g/d protein
if baseline ≥ 3.0 g/d or ≥ 50% reduction if < 3.0 g/d at baseline
and stabilisation of SCr ± 25% (ALMS 2007)
• Remission in proteinuria: complete and partial.
◦ Complete remission in proteinuria: defined as urinary
protein excretion ≤ 0.3 g/24 h (Chan 2000)
◦ Partial remission in proteinuria: defined as < 3.0 g/d
protein if baseline ≥ 3.0 g/d or ≥ 50% reduction if < 3.0 g/d at
baseline (ALMS 2007)
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• Relapse of lupus nephritis - induction therapy
• Doubling of SCr
• Deterioration of kidney function: defined as more than
20% worsening of SCr
• Stable kidney function: defined as a less than 20%
worsening of SCr.
The following side effects (toxicity) of treatments were considered:
• Ovarian failure (sustained amenorrhoea)
• Menstrual irregularities
• Infection
◦ Major infection: all-cause infection excluding herpes
zoster virus infection
◦ Herpes zoster virus infection
• Development of any malignancy
• Leucopenia (defined as < 4 x 109 cells/L)
• Bone toxicity (avascular necrosis or fracture)
• Bladder toxicity (haemorrhagic cystitis)
• Alopecia
• Gastrointestinal (GI) adverse effects including diarrhoea,
vomiting and nausea.
The following continuous outcomes were analysed at the end of
treatment.
• Daily proteinuria (24 hour urinary protein excretion) (g/24
h)
• Creatinine clearance (CrCl) (mL/min)
• SCr (µmol/L)
• Health-related quality of life
• Fatigue
• Disease activity (e.g. British Isles Lupus Assessment Group
(BILAG), SLE Disease Activity Index (SLEDAI)
Search methods for identification of studies
Electronic searches
We searched the Cochrane Kidney and Transplant Specialised
Register up to 2March 2018 through contactwith the Information
Specialist using search terms relevant to this review. The Cochrane
Kidney and Transplant Specialised Register contains studies iden-
tified from several sources.
1. Monthly searches of the Cochrane Central Register of
Controlled Trials (CENTRAL)
2. Weekly searches of MEDLINE OVID SP
3. Handsearching of kidney-related journals and the
proceedings of major kidney conferences
4. Searching of the current year of EMBASE OVID SP
5. Weekly current awareness alerts for selected kidney and
transplant journals
6. Searches of the International Clinical Trials Register
(ICTRP) Search Portal and ClinicalTrials.gov.
Studies contained in the SpecialisedRegister are identified through
search strategies for CENTRAL,MEDLINE, andEMBASE based
on the scope of Cochrane Kidney and Transplant. Details of these
strategies, as well as a list of handsearched journals, conference
proceedings and current awareness alerts, are available in the Spe-
cialised Register section of information about Cochrane Kidney
and Transplant.
See Appendix 1 for search terms used in strategies for this review.
Searching other resources
1. Reference lists of review articles, relevant studies and
clinical practice guidelines
2. Handsearching of proceedings of major rheumatology
conferences
3. Letters seeking information about unpublished or
incomplete studies to investigators known to be involved in
previous studies.
Data collection and analysis
Selection of studies
The search strategy described was performed to identify eligible
studies. The titles and abstracts resulting from the searches were
screened by two authors who independently assessed retrieved ab-
stracts, and if necessary the full text, to determine which studies
satisfied the inclusion criteria. Disagreement about inclusion was
resolved by discussion with a third author.
Where duplication reports of the same study were confirmed, the
initial first complete publication was selected (the index publica-
tion) and was the primary data source, but any other additional
prior or subsequent reports were also included. These additional
prior or subsequent reports containing supplementary outcome
data (such as longer-term follow up, or different outcomes) also
contributed to the meta-analysis.
Data extraction and management
Data abstraction was performed independently by two authors us-
ing a standardised form. Unclear data were clarified by contacting
the author of the study report and any relevant data obtained in
this manner was included in the review (see Acknowledgements).
Assessment of risk of bias in included studies
The following items were independently assessed by two authors
using the risk of bias assessment tool (Higgins 2011) (see Appendix
2).
• Was there adequate sequence generation (selection bias)?
• Was allocation adequately concealed (selection bias)?
10Immunosuppressive treatment for proliferative lupus nephritis (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
• Was knowledge of the allocated interventions adequately
prevented during the study (detection bias)?
◦ Participants and personnel (performance bias)
◦ Outcome assessors (detection bias)
• Were incomplete outcome data adequately addressed
(attrition bias)?
• Are reports of the study free of suggestion of selective
outcome reporting (reporting bias)?
• Was the study apparently free of other problems that could
put it at a risk of bias?
Disagreements regarding the risk of bias adjudications were re-
solved by consultation with a third review author.
Measures of treatment effect
Dichotomous data
For dichotomous outcomes (death (all causes), complete or par-
tial renal remission, complete or partial remission in proteinuria,
ESKD, renal relapse, doubling of SCr, stable kidney function,
ovarian failure, menstrual irregularities, major infection, herpes
zoster virus infection, malignancy, leucopenia, bone toxicity, blad-
der toxicity, alopecia and GI disorders) results were expressed as
risk ratio (RR) with 95% confidence intervals (CI).
Continuous data
Where continuous scales of measurement were used to assess the
effects of treatment (urinary protein excretion, CrCl, SCr, health-
related quality of life, fatigue, disease activity) the mean difference
(MD) with 95% CI was used.
Unit of analysis issues
Studies with multiple treatment groups
In studies comparing the efficacy of more than two interventions
we considered the following:
1. If different interventions were of different classes (for
example, MMF or tacrolimus versus IV cyclophosphamide), we
included each treatment group in separate meta-analyses,
ensuring we did not include outcome data for the control group
participants more than once in a single meta-analysis.
2. If interventions were of the same therapy (for example, high
dose or low dose abatacept, laquinimod), we summarised into a
single group that was compared with the control group for
dichotomous outcomes (we summed the sample sizes and the
number of people with events across the treatment groups). For
continuous data, we entered the means and standard deviations
of a single intervention group (usually the highest dosage) for
comparison with the control group. Where appropriate, we
considered sensitivity analyses, testing the impact of including
the alternative intervention group in analyses.
Dealing with missing data
Where a study reported outcome data after excluding some ran-
domised participants from the denominator, further information
required from the original author was requested by electronic mail
and any relevant information obtained in this manner was in-
cluded in the review. Evaluation of important numerical data such
as screened, randomised patients as well as intention-to-treat, as-
treated and per-protocol population were carefully performed. At-
trition rates, for example drop-outs, losses to follow-up and with-
drawals were investigated. Issues of missing data and imputation
methods (for example, last-observation-carried-forward) was crit-
ically appraised (Higgins 2011).
Assessment of heterogeneity
We first assessed for statistical heterogeneity visually by inspecting
forest plots of standardised mean effect sizes and of risk ratios.
Furthermore, we applied aChi2 test to assess heterogeneity.With P
< 0.05 used to denote statistical significance, andwith I2 calculated
to measure the proportion of total variation in the estimates of
treatment effect that was due to heterogeneity beyond chance (
Higgins 2011) and we used conventions of interpretation that
were defined by Higgins 2003.
Assessment of reporting biases
Detection of potential for publication bias was planned for among
the primary outcomes. We made every attempt to minimise pub-
lication bias by including unpublished studies (for example, by
searching online trial registries). In order to assess publication bias
we used funnel plots of the log odds ratio (OR) (effect versus stan-
dard error of the effect size) when sufficient number of studies were
available (Higgins 2011). For the analysis and the interpretation of
the funnel plots, other reasons for asymmetry besides publication
bias were considered (for example, differences in methodological
quality and true heterogeneity in intervention effects). However,
the limited amount of study data published did not enable mean-
ingful interpretation. We had also planned to conduct subgroup
analysis and meta-regression to evaluate potential sources of het-
erogeneity but this was not possible because of the small number
of studies of paired interventions.
Data synthesis
Data were abstracted from individual studies and then pooled for
summary estimates using a random-effects model. The random-
effects model was chosen because it provides a more conservative
estimate of effect in the presence of known or unknown potential
heterogeneity (Deeks 2001).
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Subgroup analysis and investigation of heterogeneity
Subgroup analyses are hypothesis-forming rather than hypoth-
esis-testing and should be treated with caution. We considered
subgroup analyses on the ethnicity of participants, class of lupus
nephritis, age of the patient (adults versus children) and the type
of induction therapy patients were treated with before randomi-
sation in maintenance therapy studies in order to explore whether
clinical differences between the studies may have systematically
influenced the differences that were observed in the treatment out-
comes. However, insufficient data were available to conduct sub-
group analyses for the primary outcomes.
Sensitivity analysis
The following sensitivity analyses were considered:
• Repeating the analysis excluding unpublished studies
• Repeating the analysis taking account of risk of bias, as
specified
• Repeating the analysis excluding any very long or large
studies to establish how much they dominate the results
• Repeating the analysis excluding studies using the following
filters: language of publication, source of funding (industry
versus other), and country the study was conducted in.
However insufficient data were available to determine these factors
influence of the on effect size.
’Summary of findings’ tables
We presented the main results of the review in ’Summary of find-
ings’ tables. These tables present key information concerning the
quality of the evidence, the magnitude of the effects of the in-
terventions examined, and the sum of the available data for the
main outcomes (Schünemann 2011a). The ’Summary of findings’
tables also include an overall grading of the evidence related to
each of the main outcomes using the GRADE (Grades of Recom-
mendation, Assessment, Development and Evaluation) approach
(GRADE 2008; GRADE 2011). The GRADE approach defines
the quality of a body of evidence as the extent to which one can
be confident that an estimate of effect or association is close to the
true quantity of specific interest. The quality of a body of evidence
involves consideration of within-trial risk of bias (methodological
quality), directness of evidence, heterogeneity, precision of effect
estimates and risk of publication bias (Schünemann 2011b). We
presented the following outcomes in the ’Summary of findings’
tables.
• Death (all causes)
• ESKD, requirement for renal replacement therapy
• Complete renal remission
• Partial renal remission
• Renal relapse
• Doubling of SCr
• Stable kidney function
• Ovarian failure
• Major infection
• Leucopenia
• Alopecia
• Diarrhoea
R E S U L T S
Description of studies
Results of the search
For this update, a search was conducted on 2 March 2018 (Figure
1). This new search identified 110 reports. After full-text review 71
new studies were identified. Twenty-six (43 reports) new studies
were included and 17 (19 reports) were excluded. We identified
26 ongoing studies which will be assessed in a future update of this
review. We also identified 20 new reports of 11 existing included
studies. One study identified as a primary study in the 2012 review
update was reallocated as a secondary report of ALMS 2007 (Sun-
del 2008). Four previously excluded studies have been included as
they met our inclusion criteria (Abedi 2007; Florez-Suarez 2004;
Loo 2010; Zhang 1995a).
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Figure 1. Study flow diagram.*Non-RCTs have been deleted from this update
Included studies
See Characteristics of included studies
After including the studies identified from the 2018 update search,
a total of 236 reports of 74 studies were included in this review
(Figure 1) which included a total of 5175 randomised partic-
ipants (Abedi 2007; ACCESS 2014; ALMS 2007; APRIL-LN
2012; AURA-LV 2016; Balletta 1992; Bao 2008; Barron 1982;
Belmont 1995; BELONG 2013; Boedigheimer 2017; Boletis
1999; Boumpas 1992; Cade 1973; Chan 2000; Chen 2011;
Clark 1981; Clark 1984; Contreras 2004; CYCLOFA-LUNE
2010; Decker 1975; Deng 2016; Derksen 1988; Donadio 1972;
Donadio 1976; Doria 1994; Dyadyk 2001; El-Sehemy 2006;
El-Shafey 2010; Florez-Suarez 2004; Fries 1973; Fu 1997; Furie
2014; Ginzler 1976; Ginzler 2005; Gourley 1996; Grootscholten
2006; Hahn 1975; Hong 2007; Houssiau 2002; Jayne 2013;
Kaballo 2016; Kamanamool 2017; Lewis 1992; Li 2009c; Li
2012; Liou 2007; Liu 2015; Loo 2010; Lui 1997; LUNAR 2012;
MAINTAIN Nephritis 2010; Mehra 2018; Mendonca 2017;
Mitwalli 2011; Mok 2016; Moroni 2006; Mulic-Bacic 2008;
MyLupus 2011; Nakamura 2002e; Ong 2005; Pal 2017; Rathi
2016; Rovin 2016; Sabry 2009; Sedhain 2016; Sesso 1994a;
SIMPL 2014; Steinberg 1971; Sun 2015;Wallace 1998; Yap 2017;
Yee 2004; Zhang 1995a).
Twenty-nine studies enrolled adults and children (< 18 years)
(ACCESS 2014; ALMS 2007; Bao 2008; BELONG 2013;
Boumpas 1992; Cade 1973; Chen 2011; Derksen 1988; Donadio
1972; Donadio 1976; Doria 1994; El-Shafey 2010; Houssiau
2002; Kaballo 2016; Lewis 1992; Li 2012; Loo 2010; LUNAR
2012; MAINTAIN Nephritis 2010; Mehra 2018; Mendonca
2017; Moroni 2006; Ong 2005; Rathi 2016; Sesso 1994a;
Steinberg 1971; Sun 2015; Wallace 1998; Yee 2004), 29 only en-
rolled adults (APRIL-LN 2012; AURA-LV 2016; Balletta 1992;
Belmont 1995; Boedigheimer 2017; Boletis 1999; Chan 2000;
Clark 1984; Contreras 2004; CYCLOFA-LUNE 2010; Dyadyk
2001; El-Sehemy 2006; Furie 2014; Ginzler 1976; Ginzler 2005;
Gourley 1996; Grootscholten 2006; Hahn 1975; Hong 2007;
Kamanamool 2017; Li 2009c; Lui 1997; Mitwalli 2011; Mok
2016; MyLupus 2011; Nakamura 2002e; Rovin 2016; Sabry
2009; SIMPL 2014), 2 only enrolled children (Barron 1982; Fu
1997), and 14 studies did not specify the age of the participants.
There were 67 studies of induction therapy (4791 participants),
and nine studies of maintenance therapy (767 participants; 297
had already completed an induction phase study (ALMS 2007;
Chen 2011)). Follow-up ranged frommedian 12months duration
(range 2.5 to 48 months) for induction therapy, and median 30
months duration (range 6 to 63 months) for maintenance therapy.
The numbers of patients included in the studies ranged from 6 to
378 with a median number of 45 patients.
Of all authors contacted for further clarification for the 2012
review update, nine responded (Drs Belmont, Doria, Donadio,
Fries, Gourley, Houssiau, Solomons, Wofsy and Florez-Suarez).
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For the 2018 update, one author provided supplementary data
(Dr Rathi).
Induction therapy
Comparators for induction therapy included the following.
1. MMF plus corticosteroid versus IV cyclophosphamide plus
corticosteroid (10 studies, 878 participants: Abedi 2007; ALMS
2007; El-Shafey 2010; Florez-Suarez 2004; Ginzler 2005; Li
2012; Mulic-Bacic 2008; Ong 2005; Rathi 2016; Sedhain 2016)
2. MMF plus corticosteroid versus oral cyclophosphamide
plus corticosteroids (1 study, 62 participants: Chan 2000)
3. MMF plus tacrolimus plus corticosteroid versus IV
cyclophosphamide plus corticosteroid (2 studies, 402
participants: Bao 2008; Liu 2015)
4. MMF plus IV cyclophosphamide and corticosteroids versus
cyclophosphamide plus corticosteroids (1 study, 82 participants:
Sun 2015)
5. MMF plus corticosteroids versus tacrolimus plus
corticosteroids (2 studies, 190 participants: Li 2012; Mok 2016)
6. Calcineurin inhibitors (tacrolimus or cyclosporin) plus
corticosteroids versus IV cyclophosphamide plus corticosteroids
(4 studies, 178 participants: Chen 2011; CYCLOFA-LUNE
2010; Hong 2007; Li 2012) or oral cyclophosphamide plus
corticosteroids (1 study, 34 participants: Lui 1997)
7. Cyclophosphamide plus corticosteroid versus azathioprine
plus corticosteroid (4 studies, 219 participants: El-Sehemy 2006;
Decker 1975; Dyadyk 2001; Grootscholten 2006) or lefluomide
plus corticosteroid (1 study, 30 participants: Deng 2016)
8. Rituximab plus MMF versus placebo plus MMF (both
arms included corticosteroids) (1 study, 144 participants:
LUNAR 2012)
9. Rituximab plus cyclophosphamide versus rituximab alone
(both arms included corticosteroids) (1 study, 19 participants: Li
2009c)
10. Abatacept versus placebo (2 studies; 432 participants:
ACCESS 2014, Furie 2014)
11. Low dose or high dose laquinimod versus placebo (1 study,
46 participants: Jayne 2013)
12. Low dose or high dose ocrelizumab versus placebo (1 study;
378 participants: BELONG 2013)
13. Sirukumab with or without corticosteroids plus MMF or
azathioprine versus placebo with or without corticosteroids plus
MMF or azathioprine (1 study, 25 participants: Rovin 2016)
14. IV versus oral cyclophosphamide (2 studies, 74
participants: Decker 1975; Yee 2004)
15. Low versus high dose IV cyclophosphamide (3 studies, 253
participants: Houssiau 2002; Mitwalli 2011; Sabry 2009)
16. Standard dose corticosteroid versus reduced dose
corticosteroid with both arms receiving enteric-coated
mycophenolate sodium (EC-MPS) (1 study, 81 participants:
MyLupus 2011)
17. IV versus oral corticosteroid (1 study, 22 participants:
Barron 1982).
18. IV cyclophosphamide with or without corticosteroid versus
corticosteroid alone (5 studies, 261 participants: Decker 1975;
Boumpas 1992; Gourley 1996; Sesso 1994a; Steinberg 1971)
19. Cyclophosphamide versus azathioprine with or without
corticosteroids versus corticosteroid alone (4 studies, 94
participants: Decker 1975; Cade 1973; Donadio 1972; Hahn
1975)
20. Azathioprine plus corticosteroids versus corticosteroids
alone (3 studies, 78 participants: Cade 1973; Decker 1975;
Hahn 1975)
21. Cyclosporin plus corticosteroids versus corticosteroids alone
(1 study, 10 participants: Balletta 1992)
22. Misoprostol plus corticosteroids versus corticosteroids alone
(1 study, 14 participants: Belmont 1995)
23. Plasma exchange plus immunosuppression plus
corticosteroids versus immunosuppression plus corticosteroids (5
studies, 174 participants; Clark 1981; Clark 1984; Doria 1994;
Lewis 1992; Wallace 1998)
24. Plasma exchange versus immunosuppression alone (2
studies, 40 participants; Derksen 1988; Nakamura 2002e)
25. Long versus short duration IV cyclophosphamide (1 study,
40 participants: Boumpas 1992)
Other comparisons
• Plasma exchange versus immunoadsorption (1 study, 28
participants; Loo 2010)
• MMF versus cyclophosphamide (unclear if oral or IV) (1
study, 14 participants: Yap 2017)
• Tacrolimus + azathioprine versus IV cyclophosphamide (1
study, 58 participants: Pal 2017)
• Atacicept plus MMF and corticosteroid versus placebo plus
MMF and corticosteroid (1 study, 6 participants: APRIL-LN
2012)
• Low dose or high dose voclosporin versus placebo (1 study;
256 participants: AURA-LV 2016)
• AMG811 (anti-IFN-γ antibody) versus placebo (1 study;
28 participants: Boedigheimer 2017)
• Cyclophosphamide till remission versus cyclophosphamide
for 1 year (1 study, 36 participants: Zhang 1995a).
Maintenance therapy
Six studies (541 participants) compared azathioprine plus corti-
costeroid to another immunosuppressive agent (MMF, cyclophos-
phamide, cyclosporin or tacrolimus) (ALMS 2007; Chen 2011;
Contreras 2004; Kaballo 2016; MAINTAIN Nephritis 2010;
Moroni 2006); two studies had already completed an induction
phase (ALMS 2007; Chen 2011). One study (40 participants)
compared cyclophosphamide with cyclosporin (Fu 1997), one
study (14 participants) compared IV cyclophosphamide to IV im-
munoglobulin (IVIG) (Boletis 1999) and one study compared
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prednisone withdrawal versus prednisone continuation (SIMPL
2014).
The maintenance phase of one study (Chan 2000) underwent a
significant post-randomisation protocol adjustment. The MMF
induction arm originally switched to maintenance azathioprine at
one year, but the protocol changed mid-trial to continue MMF
for two years. This was prompted by an unexpectedly high rate of
renal relapse in the azathioprinemaintenance group.Data for those
participants on the original protocol were not reported separately
from the adjusted protocol, so accordingly, only the induction
phase data of this study could be included in our synthesis.
Excluded studies
See Characteristics of excluded studies.
Forty-eight studies were excluded (Andrade-Ortega 2010;
Antunes 2001; ASPEN 2008; ATLAS 2016; Austin 2009; Balow
1981; Balow 1984; Ble 2011; Chanchairujira 2009; Clark 1993;
Clark 2001a; CONTROL 2016; Davis 1999; Daza 2005; Deng
2017a; Feng 2014; Frutos 1997; Hebert 1987; Khajehdehi
2012; Kuo 2001; Li 2005; Li 2014a; LJP 394-90-05 2003;
LJP 394-90-09 2005; Lu 2002; Miyasaka 2009; NCT00001212;
NCT00404157; NCT00429377; NCT00436438;
NCT00539799; NCT00659217; NCT01299922;
NCT01342016; NCT01930890; NCT02176486; Pierucci
1989; Schaumann 1992; Su 2007; Sztejnbok 1971;Wallace 2006;
Wang 2007;Witte 1993; Yap 2012; Ye 2001; Yoshida 1996;Zhang
2015c; Zheng 2005a).
The major reasons for exclusion were:
1. Diagnosis of lupus nephritis was not biopsy-proven or was
not proliferative lupus nephritis
2. That the randomised treatment comparison was not
immunosuppression.
For this update non-RCTs have been deleted.
Risk of bias in included studies
Reporting of details of study methodology was incomplete for the
majority of studies, and are summarised in Figure 2.
Figure 2. Risk of bias graph: review authors’ judgements about each risk of bias item presented as
percentages across all included studies.
Allocation
Random sequence generation
Of the included studies, 25 reported adequate sequence genera-
tion (Bao 2008; Chan 2000; Chen 2011; Decker 1975; Derksen
1988; Donadio 1972; Donadio 1976; Fu 1997; Ginzler 2005;
Gourley 1996; Grootscholten 2006; Hahn 1975; Houssiau 2002;
Kaballo 2016; Kamanamool 2017; Lewis 1992; Li 2009c; Liu
2015; Mehra 2018;Mok 2016; Moroni 2006; Ong 2005; SIMPL
2014; Steinberg 1971; Yee 2004). Sequence generation was inade-
quate in five studies where alternation was used to allocate patients
to treatment groups (Barron 1982; Cade 1973; Contreras 2004;
Loo 2010; Sabry 2009). These studies were included in the review
but deemed high risk for selection bias. Sequence generation was
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unclear in the remaining 44 studies.
Allocation concealment
Allocation concealment was adequate in 17 studies (ALMS 2007;
Boletis 1999; Boumpas 1992; Chen 2011; Contreras 2004;
CYCLOFA-LUNE 2010; Fu 1997; Ginzler 2005; Hahn 1975;
Kamanamool 2017; Lewis 1992; Li 2009c; Liu 2015; Moroni
2006; Ong 2005; SIMPL 2014; Steinberg 1971), inadequate in
four studies (Barron 1982; Cade 1973; MyLupus 2011; Sabry
2009), and unclear in the remaining 53 studies.
Blinding
Performance bias
Low risk of bias was assigned to 14 studies (ACCESS 2014;
APRIL-LN 2012; AURA-LV 2016; Belmont 1995; BELONG
2013; Boedigheimer 2017; Furie 2014; Ginzler 1976; Jayne
2013; LUNAR 2012; Mitwalli 2011; Rovin 2016; SIMPL 2014;
Steinberg 1971).
High riskwas assigned to 47 studies, with 46 studies being open-la-
bel (Abedi 2007; ALMS 2007; Bao 2008; Barron 1982; Boumpas
1992; Cade 1973; Chen 2011; Clark 1981; Clark 1984; Contreras
2004; CYCLOFA-LUNE 2010; Donadio 1972; Donadio 1976;
Doria 1994; Dyadyk 2001; El-Shafey 2010; Florez-Suarez 2004;
Fries 1973; Fu 1997; Ginzler 2005; Gourley 1996; Grootscholten
2006; Hahn 1975; Hong 2007; Kamanamool 2017; Lewis 1992;
Li 2009c; Li 2012; Liou 2007; Liu 2015; Lui 1997; MAINTAIN
Nephritis 2010; Mehra 2018; Mendonca 2017; Mok 2016;
Moroni 2006; Mulic-Bacic 2008; MyLupus 2011; Nakamura
2002e;Ong2005; Pal 2017;Rathi 2016; Sedhain 2016; Sun2015;
Wallace 1998; Yee 2004; Zhang 1995a), and one study was un-
likely to have treatment allocation blinded (Loo 2010). The re-
maining 13 studies were unclear, as they did not report blinding.
Detection bias
Nine studies reported blinding of subjective outcomes adequately
(ALMS 2007; AURA-LV 2016; Bao 2008; Chan 2000; Gourley
1996; Liu 2015; Mitwalli 2011; Moroni 2006; SIMPL 2014),
the remaining studies were classified as unclear, as blinding of the
outcome assessor was not reported.
Incomplete outcome data
Incomplete outcome data was addressed adequately in 54 studies
(ACCESS2014; ALMS2007; APRIL-LN2012; AURA-LV2016;
Balletta 1992; Bao 2008; Belmont 1995; Boedigheimer 2017;
Boletis 1999; Boumpas 1992; Cade 1973; Chan 2000; Chen
2011; Clark 1981; Clark 1984; Contreras 2004; CYCLOFA-
LUNE 2010; Decker 1975; Doria 1994; El-Sehemy 2006; Fu
1997; Furie 2014; Ginzler 1976; Ginzler 2005; Gourley 1996;
Grootscholten 2006; Hahn 1975; Houssiau 2002; Jayne 2013;
Kaballo 2016; Kamanamool 2017; Lewis 1992; Li 2009c; Li
2012; LUNAR 2012; MAINTAIN Nephritis 2010; Mehra 2018;
Mendonca 2017; Mitwalli 2011; Mok 2016; Moroni 2006;
Mulic-Bacic 2008;MyLupus 2011; Ong 2005; Rovin 2016; Sabry
2009; Sesso 1994a; SIMPL 2014; Steinberg 1971; Sun 2015;
Wallace 1998; Yee 2004). Three studies were inadequate (Barron
1982; BELONG 2013; Liu 2015), and the remainder were un-
clear.
Selective reporting
We found that 36 studies were free of selective reporting
bias (ACCESS 2014; ALMS 2007; Bao 2008; Belmont 1995;
BELONG 2013; Boletis 1999; Boumpas 1992; Cade 1973; Chan
2000; Chen 2011; Clark 1981; Contreras 2004; CYCLOFA-
LUNE2010;Decker 1975;Donadio 1976;Doria 1994; El-Shafey
2010; Furie 2014; Ginzler 1976; Gourley 1996; Grootscholten
2006; Houssiau 2002; Kaballo 2016; Kamanamool 2017; Lewis
1992; Li 2012; LUNAR 2012; MAINTAIN Nephritis 2010;
Mitwalli 2011;Mok 2016;Moroni 2006; Ong 2005; Rathi 2016;
Sesso 1994a; Steinberg 1971; Sun 2015). Thirty-five studies were
considered to be at high risk of reporting bias (Abedi 2007;
APRIL-LN 2012; AURA-LV 2016; Balletta 1992; Barron 1982;
Boedigheimer 2017; Clark 1984; Deng 2016; Derksen 1988;
Donadio 1972; Dyadyk 2001; El-Sehemy 2006; Florez-Suarez
2004; Fries 1973; Fu 1997; Ginzler 2005; Hahn 1975; Hong
2007; Jayne 2013; Li 2009c; Liou 2007; Liu 2015; Loo 2010;
Mehra 2018; Mendonca 2017; Mulic-Bacic 2008; MyLupus
2011; Nakamura 2002e; Pal 2017; Rovin 2016; SIMPL 2014;
Wallace 1998; Yap 2017; Yee 2004; Zhang 1995a), and the re-
maining three studies (Lui 1997; Sabry 2009; Sedhain 2016) were
unclear.
Other potential sources of bias
Eighteen studies declared their funding sources to be indepen-
dent or academic funding bodies and were judged to be free of
other potential bias (Boumpas 1992; Clark 1981; Clark 1984;
CYCLOFA-LUNE2010;Donadio 1972;Donadio 1976;Gourley
1996; Grootscholten 2006; Houssiau 2002; Kamanamool 2017;
Li 2012; Liou 2007; Liu 2015; MAINTAIN Nephritis 2010;
Mendonca 2017; Mok 2016; Sun 2015; Yap 2017). Eight studies
that declared independent funding sources were deemed high risk
because of either early termination (Ginzler 2005; Lewis 1992;
Yee 2004), heavy cross-over between treatment arms (Fries 1973;
Ginzler 1976; Ginzler 2005; Steinberg 1971), pooling of stud-
ies (Decker 1975) or differences between treatment arms at base-
line (Sesso 1994a). A further 20 studies declared sponsorship
by a pharmaceutical industry company. Ten of the pharmaceuti-
cal sponsored studies included an author who declared pharma-
ceutical company affiliation; these were judged as carrying high
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risk of a potential source of bias (ACCESS 2014; ALMS 2007;
APRIL-LN 2012; AURA-LV 2016; BELONG 2013; Contreras
2004; Furie 2014; LUNAR 2012; Moroni 2006; MyLupus 2011;
Rovin 2016). Thirty-three studies did not disclose study funding
sources. Eleven studies exhibited potential biases, which included
inadequate reporting of results (Deng 2016; Sedhain 2016), pool-
ing of interventions into study arms (Derksen 1988), low statisti-
cal power (Boedigheimer 2017; SIMPL 2014), and differences be-
tween treatment arms at baseline (El-Sehemy 2006; Mehra 2018;
Mitwalli 2011; Loo 2010; Rathi 2016; Sabry 2009).
Effects of interventions
See: Summary of findings for the main comparison
Mycophenolate mofetil (MMF) versus IV cyclophosphamide
(CPA) for induction therapy; Summary of findings 2
Mycophenolate mofetil (MMF) + tacrolimus (TAC) versus IV
cyclophosphamide (CPA) for induction therapy; Summary of
findings 3 Azathioprine (AZA) versus mycophenolate mofetil
(MMF) for maintenance therapy
Induction therapy
Main comparisons and outcomes for induction therapy, graded by
certainty of the evidence, are presented in Summary of findings
for the main comparison and Summary of findings 2.
1 & 2. MMF plus corticosteroids versus cyclophosphamide
plus corticosteroid
1. Intravenous cyclophosphamide
Primary outcomes
Compared to IV cyclophosphamide, treatment with MMF may
have led to increased complete disease remission (Analysis 1.2.2
(8 studies, 828 participants): RR 1.17, 95% CI 0.97 to 1.42; I
2 = 0%) (low certainty evidence), although the range of effects
includes the possibility of little or no difference. It is uncertain
if MMF compared to IV cyclophosphamide reduced death and
ESKD because the certainty of the evidence is very low (Analysis
1.1; Analysis 1.3.1).
Secondary outcomes
The studies reported that MMF may be as effective as IV cyclo-
phosphamide in the stabilisation of kidney function (Analysis 1.4
(6 studies, 641 participants): RR 1.05, 95% CI 0.94 to 1.17; I2
= 0%) (low certainty evidence), and may be as effective in induc-
ing partial renal remission (Analysis 1.2.2 (9 studies, 868 partici-
pants): RR 1.02, 95% CI 0.89 to 1.18; I2 = 0%). It is uncertain
if MMF compared to IV cyclophosphamide increased complete
remission in proteinuria (Analysis 1.2.1) and partial renal remis-
sion in proteinuria (Analysis 1.2.4) because the certainty of the
evidence was very low. In terms of adverse kidney outcomes, it
is uncertain if MMF compared to IV cyclophosphamide reduced
renal relapse (Analysis 1.3.2) and doubling of SCr (Analysis 1.3.3)
because the certainty of the evidence was very low, as few studies
reported these outcomes.
Compared to IV cyclophosphamide, treatment with MMF may
have made little to no difference to SCr at the end of the study
(Analysis 1.14 (6 studies, 759 participants): MD 2.14 µmol/L,
95%CI -3.09 to 7.37; I2 = 0%) (low certainty evidence), although
we cannot be certain of its effect on daily proteinuria (Analysis
1.13) because the certainty of evidence was very low. A consider-
able level of heterogeneity was observed among studies examining
daily proteinuria (I2 = 63%). One study (Ong 2005) recruited
patients with significantly greater proteinuria among cyclophos-
phamide treated patients at baseline, an observation which per-
sisted to follow-up. Exclusion of this study reduced the level of
heterogeneity slightly (I2 = 26%).
MMF probably reduced alopecia (Analysis 1.11 (3 studies, 622
participants): RR 0.29, 95% CI 0.19 to 0.46; I2 = 0%), but prob-
ably increased diarrhoea (Analysis 1.12.1 (4 studies, 609 partici-
pants): RR 2.42, 95% CI 1.64 to 3.58) (moderate certainty ev-
idence). Compared to IV cyclophosphamide, MMF may have
made little or no difference to major infection (Analysis 1.7.1 (6
studies, 699 participants): RR1.02, 95%CI 0.67 to 1.54; I2 = 0%)
(low certainty evidence). We were unable to determine if MMF
reduced ovarian failure (Analysis 1.5), herpes zoster virus infection
(Analysis 1.7.2), malignancy (Analysis 1.8), leucopenia (Analysis
1.9), vomiting (Analysis 1.12.2), nausea (Analysis 1.12.3), or GI
upset (Analysis 1.12.4) compared to IV cyclophosphamide be-
cause the certainty of evidence was very low, as few studies reported
these outcomes and events. In this review update, the introduc-
tion of a new study increased heterogeneity and imprecision of the
effect estimates, to include both appreciable benefit and harm for
the outcomes ovarian failure (RR 0.36, 95% CI 0.06 to 2.18; I
2 = 39%) and leucopenia (RR 0.59, 95% CI 0.33 to 1.08; I2 =
59%). As a result, the certainty of the evidence for these outcomes
was downgraded to very low. For the ovarian failure outcome, the
inclusion Rathi 2016 which compared a low dose IV cyclophos-
phamide (“Euro-lupus”) toMMF, introduced three events and the
benefit of MMF demonstrated in the 2012 Cochrane review up-
date was no longer apparent.
2. Oral cyclophosphamide
Only one study examined the use of MMF plus corticosteroids
versus oral cyclophosphamide and corticosteroids in induction
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therapy of proliferative lupus nephritis (Chan 2000).
Primary outcome
We were unable to determine if MMF compared to oral cyclo-
phosphamide reduced death because the certainty of the evidence
was very low (Analysis 2.1). However, MMF may have made little
or no difference to ESKD (Analysis 2.3.1 (62 participants): RR
0.19, 95% CI 0.01 to 3.76)
Secondary outcomes
Chan 2000 reported MMF compared to oral cyclophosphamide
may make little or no difference in the inducing complete remis-
sion inproteinuria (Analysis 2.2.1 (62participants): RR0.98, 95%
CI 0.74 to 1.30) and partial remission in proteinuria (Analysis
2.2.2 (62 participants): RR 1.07, 95% CI 0.44 to 2.59) (low cer-
tainty evidence). Similarly, MMF may have made little or no dif-
ference to renal relapse (Analysis 2.3.2 (62 participants): RR 1.15,
95% CI 0.55 to 2.37), doubling of SCr (Analysis 2.3.3 (62 par-
ticipants): RR 0.63, 95% CI 0.11 to 3.48), and daily proteinuria
(Analysis 2.10 (42 participants): MD 0.30 g/24 h, 95% CI -0.19
to 0.79) (low certainty evidence).
Chan 2000 reported the use of MMF may have reduced ovarian
failure (Analysis 2.4 (53 participants): RR 0.10, 95% CI 0.01 to
0.73), major infection (Analysis 2.5.1 (62 participants): RR 0.21,
95% CI 0.05 to 0.89), leucopenia (Analysis 2.6 (62 participants):
RR 0.06, 95% CI 0.00 to 0.92), and alopecia (Analysis 2.8 (62
participants): RR 0.05, 95% CI 0.00 to 0.81) compared to oral
cyclophosphamide (low certainty evidence). MMF compared to
oral cyclophosphamide may have made little or no difference to:
herpes zoster virus infection (Analysis 2.5.2 (62 participants): RR
0.38, 95% CI 0.08 to 1.79) and GI upset (Analysis 2.9 (62 par-
ticipants): RR 2.81, 95% CI 0.31 to 25.58) (low certainty evi-
dence). We were unable to determine if MMF compared to oral
cyclophosphamide reduced bone toxicity (Analysis 2.7) because
the certainty of the evidence was very low.
3. MMF plus tacrolimus and corticosteroid versus IV
cyclophosphamide plus corticosteroid
Primary outcomes
MMF in combination with tacrolimusmay improve the induction
of complete renal remission (Analysis 3.2.1 (2 studies, 402 partic-
ipants): RR 2.38, 95% CI 1.07 to 5.30; I2 = 57%) (low certainty
evidence), while it is uncertain whether combination therapy re-
duces death (Analysis 3.1) because the certainty of the evidence
was very low.
Secondary outcomes
MMF in combination with tacrolimus may have increased induc-
tion of complete remission in proteinuria (Analysis 3.2.3 (2 stud-
ies, 402 participants): RR 2.38, 95% CI 1.07 to 5.30; I2 = 57%),
and achievement of stable kidney function stable kidney function
(Analysis 3.4 (2 studies, 402 participants): RR 1.78, 95% CI 1.40
to 2.26; I2 = 0%) (low certainty evidence). Combination therapy
may have made little or no difference in inducing partial renal
remission (Analysis 3.2.2 (2 studies, 402 participants): RR 1.00,
95% CI 0.78 to 1.28; I2 = 0%) and partial remission in protein-
uria (Analysis 3.2.4 (2 studies, 402 participants): RR 0.98, 95%
CI 0.76 to 1.26; I2 = 0%) when compared with IV cyclophospha-
mide (low certainty evidence). It is uncertain if combination ther-
apy compared to IV cyclophosphamide reduced daily proteinuria
(Analysis 3.12 (1 study, 40 participants): MD -1.69 g/24 h, 95%
CI -2.8 to -0.57) because the certainty of the evidence was very
low.
MMF plus tacrolimus compared to IV cyclophosphamide may
have made little or no difference to menstrual irregularities
(Analysis 3.6 (1 study, 323 participants): RR 0.28, 95% CI 0.06
to 1.35) (low certainty of evidence). It is uncertain the effects
that MMF plus tacrolimus may have had on the following out-
comes: doubling of SCr (Analysis 3.3.1), ovarian failure (Analysis
3.5), major infection (Analysis 3.7.1), herpes zoster virus infection
(Analysis 3.7.2), leucopenia (Analysis 3.8), bone toxicity (Analysis
3.9), alopecia (Analysis 3.10), diarrhoea (Analysis 3.11.1) and GI
upset (Analysis 3.11.2), because the certainty of the evidence was
very low, due to risk of bias concerns, indirectness of the popu-
lation and imprecision of the point estimates because of a small
sample size and few event numbers.
4. MMF plus IV cyclophosphamide versus IV
cyclophosphamide alone
One study compared MMF plus Iv cyclophosphamide versus IV
cyclophosphamide alone (Sun 2015).
Primary outcomes
Compared to IV cyclophosphamide alone, It is uncertain if MMF
in combination with cyclophosphamide improves the induction
of complete renal remission (Analysis 4.2.1) and reduces death
(Analysis 4.1) because the certainty of the evidence was very low.
Secondary outcomes
MMF in combination with IV cyclophosphamide may reduce
major infection compared to treatmentwith IV cyclophosphamide
alone (Analysis 4.4.1 (82 participants): RR 0.37, 95% CI 0.14 to
0.93) and may make little or no difference to daily proteinuria
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(Analysis 4.6 (77 participants): MD -0.54 g/24 h, 95% CI -1.12
to 0.04).
Compared to IV cyclophosphamide alone, It is uncertain if the
combination of MMF and IV cyclophosphamide reduces men-
strual irregularities (Analysis 4.3) or leucopenia (Analysis 4.5).
5. MMF plus corticosteroid versus tacrolimus plus
corticosteroid
Primary outcomes
MMF compared to tacrolimus may have made little or no dif-
ference in inducing complete renal remission (Analysis 5.2.1 (3
studies, 273 participants): RR 1.02, 95% CI 0.83 to 1.26; I2 =
0%) (low certainty evidence). It is uncertain if MMF compared to
tacrolimus reduced death (Analysis 5.1) or ESKD (Analysis 5.3.1)
because the certainty of the evidence was very low.
Secondary outcomes
For secondary efficacy outcomes, MMF compared to tacrolimus
may have made little or no difference in achieving partial renal
remission (Analysis 5.2.2 (2 studies, 190 participants): RR 0.83,
95% CI 0.51 to 1.36; I2 = 0%), complete remission in proteinuria
(Analysis 5.2.3 (1 study, 40 participants): RR 1.00, 95% CI 0.50
to 1.98), partial remission in proteinuria (Analysis 5.2.4 (2 studies,
190 participants): RR 0.90, 95% CI 0.79 to 1.03; I2 = 0%),
deterioration in kidney function (Analysis 5.3.5 (1 study, 150
participants): RR 0.54, 95% CI 0.27 to 1.09), and stable kidney
function (Analysis 5.4 (1 study, 40 participants): RR1.00, 95%CI
0.50 to 1.98) (low certainty evidence). The use ofMMFmay have
reduced renal relapse (Analysis 5.3.2 (1 study, 150 participants):
RR 0.67, 95% CI 0.48 to 0.98) compared to tacrolimus (low
certainty evidence). It is uncertain whether MMF improves daily
proteinuria (Analysis 5.9), SCr (Analysis 5.11), andCrCl (Analysis
5.12), because the certainty of the evidence was very low. MMF
compared to tacrolimus may have made little or no difference to
renal disease activity (SLEDAI) (Analysis 5.10.1 (2 studies, 233
participants): MD -0.21, 95% CI -2.05 to 1.63; I2 = 71%) and
extrarenal disease activity (SLEDAI) (Analysis 5.10.2 (2 studies,
233 participants): MD -0.26, 95% CI -0.74, 0.22; I2 = 0%) (low
evidence certainty).
For outcomes, menstrual irregularities (Analysis 5.5: 1 study, 40
participants), major infection (Analysis 5.6.1: 2 studies, 190 par-
ticipants), herpes zoster virus infection (Analysis 5.6.2: 1 study,
150 participants), leucopenia (Analysis 5.7: 1 study, 40 partici-
pants), and alopecia (Analysis 5.8: 1 study, 150 participants), we
were unable to be certain of the effect of the MMF compared to
tacrolimus because the certainty of the evidence was very low.
6. Calcineurin inhibitors plus corticosteroids versus
cyclophosphamide plus corticosteroid
Primary outcomes
Compared to IV cyclophosphamide, calcineurin inhibitors
(tacrolimus and cyclosporin) may have made little or no differ-
ence to the induction of complete renal remission (Analysis 6.2.1
(4 studies, 178 participants): RR 1.35, 95% CI 0.94 to 1.93; I2
= 0%) (low certainty evidence). It is uncertain if calcineurin in-
hibitors decreased death (Analysis 6.1) or ESKD (Analysis 6.3.1)
compared to IV cyclophosphamide because the certainty of the
evidence was very low.
Secondary outcomes
Compared to IV cyclophosphamide, calcineurin inhibitors may
have improved the induction of complete remission in proteinuria
(Analysis 6.2.3 (3 studies, 105 participants): RR 1.71, 95% CI
1.08 to 2.70; I2 = 0%) andmay havemade little or no difference to
the induction of partial renal remission (Analysis 6.2.2 (4 studies,
178 participants): RR 0.88, 95% CI 0.61 to 1.26) (low certainty
evidence). The effect of calcineurin inhibitors compared to IV cy-
clophosphamide on doubling of SCr (Analysis 6.3.2), stable kid-
ney function (Analysis 6.4), ovarian failure (Analysis 6.5), men-
strual irregularities (Analysis 6.6),major infection (Analysis 6.7.1),
herpes zoster virus infection (Analysis 6.7.2), leucopenia (Analysis
6.9), alopecia (Analysis 6.10), and GI symptoms (Analysis 6.11)
is unclear because the certainty of the evidence was very low. It is
unclear the effect that calcineurin inhibitors have on continuous
outcomes daily proteinuria (Analysis 6.12), CrCl (Analysis 6.13),
and SCr (Analysis 6.14) at 9, 12 and 18 months compared to IV
cyclophosphamide because the certainty of the evidence was very
low.
An extended follow-up study of 38 participants from CYCLOFA-
LUNE 2010 examined long-term safety and efficacy outcomes,
but it was uncertain if cyclosporin reduced doubling of SCr (
Analysis 6.3.3), premature ovarian failure (Analysis 6.5.3), and
malignancy (Analysis 6.8), or improved daily proteinuria (Analysis
6.12) and SCr (Analysis 6.14) because the certainty of the evidence
was very low.
7. Cyclophosphamide plus corticosteroid versus
azathioprine plus corticosteroids
Primary outcome
The risk of death at five years (Analysis 7.1.1: 2 studies, 146 partic-
ipants) and at 10 years (Analysis 7.1.2: 1 study, 59 participants) is
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uncertain because the certainty of the evidence was very low. Addi-
tionally, it is uncertain if azathioprine compared to cyclophospha-
mide reduced ESKD (Analysis 7.3.1: 2 studies, 144 participants).
Secondary outcomes
For efficacy outcomes it is uncertain if azathioprine compared
to cyclophosphamide improved the rates of complete remission
in proteinuria (Analysis 7.2.1: 1 study, 59 participants), partial
remission in proteinuria (Analysis 7.2.2: 1 study, 59 participants),
and stable kidney function (Analysis 7.4: 1 study, 57 participants)
because the certainty of the evidence was very low. Similarly, for
adverse renal outcomes it is not certain if azathioprine compared to
cyclophosphamide reduced renal relapse (Analysis 7.3.3: 1 study,
87 participants) and deterioration of kidney function (Analysis
7.3.6: 1 study, 30 participants) because the certainty of evidence
was very low; although, it may have reduced doubling of SCr
(Analysis 7.3.5 (2 studies, 144 participants): RR 0.48, 95% CI
0.24 to 0.95; I2 = 0%) (low certainty evidence).
For safety outcomes, azathioprine may have made little or no dif-
ference to ovarian failure (Analysis 7.5 (2 studies, 126 partici-
pants): RR 2.11, 95% CI 0.59 to 7.53; I2 = 34%) (low certainty
evidence). However, it is uncertain if it reduced menstrual ir-
regularities (Analysis 7.6: 1 study, 15 participants), major infec-
tion (Analysis 7.7.1: 1 study 57 participants), herpes zoster virus
infection (Analysis 7.7.2: 1 study, 57 participants), malignancy
(Analysis 7.8: 2 studies, 144 participants), bone toxicity (Analysis
7.9: 1 study, 87 participants), and bladder toxicity (Analysis 7.10:
2 studies, 144 participants) because the certainty of the evidence
was very low.
8. Rituximab + MMF versus placebo + MMF (both arms
included corticosteroids)
Primary outcomes
It is uncertain if rituximab plus MMF versus placebo plus MMF
improved the induction of complete renal remission (Analysis
8.2.1) or reduced death (Analysis 8.1.1), because the certainty of
the evidence was very low.
Secondary outcomes
Rituximab plus MMF compared to placebo plus MMF may have
made little or no difference in the stabilisation of kidney function
(Analysis 8.3 (1 study, 144 participants): RR 1.24, 95% CI 0.90
to 1.7) (low certainty evidence). It is uncertain if it improved the
induction of complete remission in proteinuria (Analysis 8.2.3),
partial renal remission (Analysis 8.2.2), or reducedmajor infection
(Analysis 8.4.1), herpes zoster virus infection (Analysis 8.4.2), and
leucopenia (Analysis 8.5) because the certainty of the evidence was
very low.
9. Rituximab plus cyclophosphamide versus rituximab alone
One study compared rituximab plus cyclophosphamide versus rit-
uximab alone (Li 2009c).
Primary outcomes
It is uncertain if rituximab plus cyclophosphamide compared to
rituximab alone improved the induction of complete renal remis-
sion (Analysis 9.1.1) because the certainty of the evidence was very
low.
Secondary outcomes
Similarly, it is uncertain if rituximab plus cyclophosphamide im-
proved the induction of partial renal remission (Analysis 9.1.2),
reduced major infection (Analysis 9.2.1) and herpes zoster virus
infection (Analysis 9.2.2), or improved daily proteinuria (Analysis
9.3), CrCl (Analysis 9.4), and SCr (Analysis 9.5) compared to rit-
uximab alone because the certainty of the evidence was very low.
10, 11, 12, & 13. Other biologics versus placebo (both arms
included standard of care therapy (MMF or CPA))
Primary outcomes
It is uncertain if biologics: abatacept, atacicpet, laquinimod, ocre-
lizumab and sirukumab improved the induction of complete renal
remission (Analysis 10.2.(1,2,3); Analysis 11.2.(1,2,3); Analysis
12.2.(1,2,3)), reduced death (Analysis 10.1.(1,2,3); Analysis
11.1.(1.2.3); Analysis 12.1.(1,2,3); Analysis 13.1), and reduced
ESKD (Analysis 10.3.(1,2,3)) compared to standard of care ther-
apy because the certainty of the evidence was very low.
Secondary outcomes
It was uncertain if the abatacept or ocrelizumab improved the in-
duction of partial renal remission (Analysis 10.2.(4.5.6); Analysis
12.2.(4,5,6)) because the certainty of the evidence was very low.
Likewise, it was uncertain if the biologics compared to placebo plus
standard of care therapy reduced renal relapse (Analysis 10.3.4);
major infection (Analysis 10.4.(1,2,3); Analysis 12.3.(1,2,3);
Analysis 13.2), herpes zoster virus infection (Analysis 10.5), ma-
lignancy (Analysis 13.3), and diarrhoea (Analysis 13.4) because
the certainty of the evidence was very low.
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It is uncertain if abatacept with standard of care therapy compared
to placebo with standard of care therapy improved the physical
and mental component of the health-related quality of life (SF-
36) (Analysis 10.6) and disease activity (BILAG) (Analysis 10.7)
because the certainty of the evidence was very low.
14. Intravenous versus oral cyclophosphamide
Primary outcomes
We were unable to determine if IV cyclophosphamide compared
to oral cyclophosphamide reduced death (Analysis 14.1) because
the certainty of the evidence was very low. IV cyclophosphamide
compared to oral cyclophosphamide may have made little or no
difference to ESKD (Analysis 14.2.1 (2 studies, 67 participants):
RR 0.23, 95% CI 0.04 to 1.28; I2 = 0%) (low certainty evidence).
Secondary outcomes
For adverse renal outcomes, IV cyclophosphamide may havemade
little or no difference to doubling of SCr (Analysis 14.2.2 (2 stud-
ies, 67 participants): RR 0.67, 95% CI 0.23 to 1.98; I2 = 0%)
(low certainty evidence). It is uncertain if IV compared to oral
cyclophosphamide reduced the deterioration of kidney function
(Analysis 14.2.3) and improved the achievement of stable kidney
function (Analysis 14.3) because the certainty of the evidence was
very low. For safety outcomes, IV compared to oral cyclophos-
phamide may have made little or no difference to ovarian failure
(Analysis 14.4 (2 studies, 56 participants): RR 0.70, 95% CI 0.37
to 1.30; I2 = 0%) and major infection (Analysis 14.5.1 (2 stud-
ies, 67 participants): RR 1.16, 95% CI 0.47 to 2.90; I2 = 0%)
(low certainty evidence), and it is uncertain if IV cyclophospha-
mide reduced herpes zoster virus infection (Analysis 14.5.2), ma-
lignancy (Analysis 14.6), bladder toxicity (Analysis 14.7), and GI
upset (Analysis 14.8.1) because the certainty of the evidence was
very low.
15. High versus low dose cyclophosphamide
Primary outcomes
Compared to high dose cyclophosphamide, the use of low dose
cyclophosphamide may have been as effective in inducing com-
plete renal remission (Analysis 15.2.1 (3 studies, 267 participants):
RR 1.09, 95% CI 0.63 to 1.86; I2 = 67%) and may have made
little or no difference to ESKD (Analysis 15.3.1 (2 studies, 135
participants): RR 0.49, 95% CI 0.05 to 5.20) (low certainty evi-
dence). However, it is uncertain if compared to high dose cyclo-
phosphamide, low dose cyclophosphamide reduced ESKD at 5
years (Analysis 15.3.2) and 10 years (Analysis 15.3.3), and reduced
death at 6months (Analysis 15.1.1), 12 months (Analysis 15.1.2),
5 years (Analysis 15.1.3), and 10 years (Analysis 15.1.4) because
the certainty of the evidence was very low.
Secondary outcomes
Low dose cyclophosphamidemay havemade little or no difference
to efficacy outcomes of partial renal remission (Analysis 15.2.2
(3 studies, 267 participants): RR 0.88, 95% CI 0.69 to 1.14; I
2 = 0%) and stabilisation of kidney function at 3 years (Analysis
15.4.1 (1 study, 89 participants): RR 0.72, 95% CI 0.50 to 1.03),
and at 5 years (Analysis 15.4.2 (1 study, 85 participants): RR 0.96,
95% 0.77 to 1.20) compared to high dose cyclophosphamide (low
certainty evidence). It is uncertain if low dose cyclophosphamide
improved daily proteinuria (Analysis 15.12: 3 studies, 242 partic-
ipants), CrCl (Analysis 15.13: 1 study, 177 participants), and SCr
(Analysis 15.14 (3 studies, 247 participants) compared to high
dose cyclophosphamide because the certainty of the evidence was
very low.
Compared to high dose cyclophosphamide, low dose cyclophos-
phamide may have made little or no difference to renal relapse
(Analysis 15.3.4 (3 studies, 211 participants): RR 2.75, 95% CI
0.47 to 15.98; I2 = 66%) (low certainty evidence). The risk of
ovarian failure may be two times higher in patients on high dose
cyclophosphamide compared to those on low dose cyclophospha-
mide (Analysis 15.5 (4 studies, 299 participants): RR 1.73, 95%
CI 0.70 to 4.31; I2 = 19%) (low certainty evidence). Compared
to high dose cyclophosphamide, low dose cyclophosphamide may
make little or no difference to major infection (Analysis 15.6.1
(4 studies, 327 participants): RR 1.44, 95% CI 0.83 to 2.49; I2
= 25%), herpes zoster virus infection (Analysis 15.6.2 (3 studies,
281 participants): RR 1.58, 95% CI 0.41 to 6.05), malignancy
(Analysis 15.7 (2 studies, 206 participants): RR1.44, 95%CI 0.09
to 23.31; I2 = 41%), and leucopenia (Analysis 15.8 (3 studies, 281
participants): RR 0.82, 95% CI 0.13 to 5.15; I2 = 51%) (low cer-
tainty evidence). It is uncertain if low dose cyclophosphamide use
reduced bone toxicity (Analysis 15.9: 2 studies, 164 participants)
compared to high dose cyclophosphamide because the certainty
of the evidence was very low.
16. Standard versus reduced dose oral corticosteroid
One study compared standard versus reduced dose oral corticos-
teroid (MyLupus 2011).
Primary outcomes
It was uncertain if reduced dose oral corticosteroid compared to
standard dose oral corticosteroid improved the induction of com-
plete renal remission (Analysis 16.2.1: 81 participants) and re-
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duced death (Analysis 16.1: 81 participants) because the certainty
of the evidence was very low.
Secondary outcomes
It is uncertain of the effect of reduced dose oral corticosteroid com-
pared to standard dose oral corticosteroid improved the induc-
tion of partial renal remission (Analysis 16.2.2: 81 participants),
CrCl (Analysis 16.6: 74 participants), and SCr (Analysis 16.7: 81
participants), or reduced renal relapse (Analysis 16.3: 50 partic-
ipants) because the certainty of the evidence was very low. For
safety outcomes, compared to standard dose corticosteroids it was
uncertain if reduced dose oral corticosteroids reducedmajor infec-
tion (Analysis 16.4.1: 81 participants), herpes zoster virus infec-
tion (Analysis 16.4.2: 81 participants), diarrhoea (Analysis 16.5.1:
81 participants), vomiting (Analysis 16.5.2: 81 participants), and
nausea (Analysis 16.5.3: 81 participants) because the certainty of
the evidence was very low
17. Intravenous versus oral corticosteroids
One study compared IV versus oral corticosteroids (Barron 1982).
It was uncertain if the use of pulsedmethylprednisolone compared
to oral corticosteroids alone reduced death (Analysis 17.1) or renal
relapse (Analysis 17.2) because the certainty of the evidence was
very low. The certainty of the evidence was downgraded because
of the potential risk of bias, small sample size and small event
numbers.
Other comparisons (18 to 25)
Older comparisons - immunosuppressive agent plus corticos-
teroids versus corticosteroids alone (18 to 22), plasma exchange
plus immunosuppression versus immunosuppression alone (23),
plasma exchange (no immunosuppression) versus immunosup-
pression (24) and long versus short-duration cyclophosphamide
(25) - have been reported in the original Cochrane review (Flanc
2004a) and can also be found in the Data and analyses section of
this review.
Maintenance therapy
Main outcomes for maintenance therapy, graded by certainty of
the evidence, are presented in Summary of findings 3.
26. Azathioprine plus corticosteroid versus mycophenolate
mofetil plus corticosteroid
Primary outcomes
Compared to MMF, azathioprine probably increased renal relapse
(Analysis 26.2 (4 studies, 452 participants): RR 1.75, 95% CI
1.20 to 2.55; I2 = 0%) (moderate certainty evidence). However,
it is uncertain if azathioprine compared to MMF reduced death
Analysis 26.1) or ESKD because the certainty of the evidence was
very low (Analysis 26.3).
Secondary outcomes
It is uncertain if azathioprine compared to MMF improved daily
proteinuria (Analysis 26.12) because the certainty of the evidence
was very low;while itmay have increased doubling of SCr (Analysis
26.4 (4 studies, 452 participants): RR 2.19, 95% CI 1.03, 4.66;
I2 = 0%) (low certainty evidence).
For safety outcomes, the use of azathioprine compared to MMF
may have increased leucopenia (Analysis 26.8 (3 studies, 412 par-
ticipants): RR 5.61, 95% CI 1.68 to 18.72; I2 = 0%) and may
have made little or no difference to major infection (Analysis 26.6
(3 studies, 412 participants): RR 1.08, 95% CI 0.60 to 1.96; I2
= 0%), alopecia (Analysis 26.10 (3 studies, 412 participants): RR
0.95, 95% CI 0.46 to 1.95; I2 = 0%), nausea (Analysis 26.11.2
(2 studies, 307 participants): RR 1.08, 95% CI 0.65 to 1.80; I
2 = 0%), and diarrhoea (Analysis 26.11.3 (2 studies, 307 par-
ticipants): RR 0.74, 95% CI 0.31 to 1.73; I2 = 33%) (low cer-
tainty evidence). It is unclear if azathioprine compared to MMF
reduced ovarian failure (Analysis 26.5), herpes zoster virus infec-
tion (Analysis 26.6.2), malignancy (Analysis 26.7), bone toxicity
(Analysis 26.9), and vomiting (Analysis 26.11.4) because the cer-
tainty of the evidence was very low.
27, 28 & 29. Azathioprine plus corticosteroid versus
cyclophosphamide, cyclosporin or tacrolimus plus
corticosteroid
Primary outcomes
It is uncertain if azathioprine compared to cyclosporin, cyclo-
phosphamide and tacrolimus made little or no difference to death
(Analysis 27.1; Analysis 28.1; Analysis 29.1), ESKD (Analysis
27.2.1; Analysis 28.2.1), and renal relapse (Analysis 27.2.2;
Analysis 28.2.2; Analysis 29.1.1) because the certainty of the evi-
dence was very low.
Secondary outcomes
It is uncertain if azathioprine compared to cyclosporin, cyclo-
phosphamide and tacrolimus made little or no difference to daily
proteinuria (Analysis 27.6), CrCl (Analysis 28.4), disease activ-
ity (SLEDAI) (Analysis 27.7), doubling of SCr (Analysis 28.2.3),
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major infection (Analysis 27.3.1; Analysis 29.2.1), leucopenia
(Analysis 27.4), bladder toxicity (Analysis 28.3), and GI distur-
bance (Analysis 27.5.1; Analysis 29.3.1) because the certainty of
the evidence was very low.
30. Prednisone withdrawal versus prednisone continuation
Primary outcomes
It is uncertain if prednisone withdrawal compared to prednisone
continuation made little or no difference to renal and non-renal
relapse (Analysis 30.1) because the certainty of the evidence was
very low.
Secondary outcomes
It is uncertain if prednisone withdrawal compared to prednisone
continuation made little or no difference to major infection
(Analysis 30.2) because the certainty of the evidence was very low.
31. Intravenous immunoglobulin versus intravenous
cyclophosphamide
Secondary outcomes
It is uncertain if IV immunoglobulin compared to IV cyclo-
phosphamide improved SCr, CrCl or proteinuria (Analysis 31.1;
Analysis 31.2; Analysis 31.3) because the certainty of the evidence
was very low.
Three studies reported health-related quality of life, one study
reported fatigue and 21 studies reported disease activity. Given
the heterogeneity of reporting of these outcomes, the results have
been presented in tables (Table 1; Table 2; Table 3).
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A D D I T I O N A L S U M M A R Y O F F I N D I N G S [Explanation]
MMF + TAC compared with IV CPA for lupus nephritis
Patient or population: Patients with prolif erat ive lupus nephrit is
Settings: all sett ings
Intervention: MMF + TAC
Comparison: IV CPA
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No. of participants
(studies)
Certainty of evidence
(GRADE)
Comments
Assumed risk Corresponding risk
IV CPA MMF + TAC
Complete renal remis-
sion
f ollow-up: mean 24
weeks
244 per 1000 580 per 1000
(261 to 1000)
RR 2.38 (1.07 to 5.30) 402 (2) ⊕⊕©©
low1,2,3,4
Downgraded as fol-
lows:
1Study lim itat ion: con-
cern regarding the in-
complete report ing of
IV CPA group
2Heterogeneity: sub-
stant ial heterogeneity
indicated by I2 stat is-
t ic. Although Chi2 test
was sat isf ied, the small
number of studies may
make this unreliable
3Indirectness: Concern
regarding the popula-
t ion, as all studies
have largely included
pat ients of Asian eth-
nicity
Upgraded as follows:
4Large ef fect size
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Partial renal remission
f ollow-up: mean 24
weeks
378 per 1000 378 per 1000
(295 to 484)
RR 1.00 (0.78 to 1.28) 402 (2) ⊕⊕©©
low1,2
Downgraded as fol-
lows:
1Study lim itat ion: con-
cern regarding the in-
complete report ing of
IV CPA group
2 Indirectness: dif f er-
ences in the out-
come def init ion be-
tween studies and con-
cern regarding the pop-
ulat ion, as all studies
have largely included
pat ients of Asian eth-
nicity
Stable kidney function
f ollow-up: mean 24
weeks
284 per 1000 505 per 1000
(397 to 641)
RR 1.78 (1.40 to 2.26) 402 (2) ⊕⊕©© low1,2,3,4 Downgraded as fol-
lows:
1Study lim itat ion: con-
cern regarding the in-
complete report ing of
IV CPA group
2
Indirectness (2 grades)
: dif f erences in the
outcome def init ion be-
tween studies and con-
cern regarding the pop-
ulat ion, as all studies
have largely included
pat ients of Asian eth-
nicity
3Total number of
events small
Upgraded as follows:
4Large ef fect size
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* The basis for the assumed risk was calculated using the median control group risk across studies in the meta-analyses. The corresponding risk (and its 95% conf idence
interval) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its 95% CI).
CI: Conf idence interval; RR: Risk Ratio
GRADE Working Group certainty of evidence
High certainty: Further research is very unlikely to change our conf idence in the est imate of ef fect.
Moderate certainty: Further research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low certainty: Further research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low certainty: We are very uncertain about the est imate.
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Patient or population: pat ients with maintenance treatment in lupus nephrit is
Settings: all sett ings
Intervention: AZA
Comparison: MMF
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No. of participants
(studies)
Certainty of evidence
(GRADE)
Comments
Assumed risk Corresponding risk
MMF AZA
Death
Follow-up: 36 to 72
months
22 per 1000 25 per 1000
(7 to 84)
RR 1.15
(0.34 to 3.87)
451 (4) ⊕©©©
Very low1,2,3
Downgraded as fol-
lows:
1Total number of
events small
2Severe imprecision (2
grades): risk est imate
includes null ef fect
and est imate consis-
tent with both apprecia-
ble benef it and harm
3Indirectness: t ime
f rame insuf f icient
ESKD
Follow-up: 36 to 72
months
17 per 1000 30 per 1000
(9 to 96)
RR 1.70
(0.52 to 5.54)
452 (4) ⊕©©©
Very low1,2,3
Downgraded as fol-
lows:
1Total number of
events small
2Severe imprecision (2
grades): risk est imate
includes null ef fect
and est imate consis-
tent with both apprecia-
ble benef it and harm
3Indirectness: t ime
f rame insuf f icient2
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Renal relapse
Follow-up: 36 to 72
months
152 per 1000 266 per 1000
(183 to 388)
RR 1.75
(1.20 to 2.55)
452 (4) ⊕⊕⊕©
moderate1
Downgraded as fol-
lows:
1 Total number of
events small
Doubling of serum cre-
atinine
Follow-up: 36 to 72
months
39 per 1000 86 per 1000
(40 to 182)
RR 2.19
(1.03 to 4.66)
452 (4) ⊕⊕©©
low1,2
Downgraded as fol-
lows:
1 Study lim itat ions:
(studies generally at un-
clear or high risk of bias
for many domains)
2Total number of
events small
Major infection
Follow-up: median 53
months
91 per 1000 98 per 1000
(55 to 178)
RR 1.08
(0.69 to 1.96)
412 (3) ⊕⊕©©
low1,2
Downgraded as fol-
lows:
1 Total number of
events small
2 Imprecision: wide risk
est imate includes null
ef fect
Leucopenia
Follow-up: 36 to 53
months
10 per 1000 54 per 1000
(16 to 179)
RR 5.61
(1.68 to 18.72)
412 (3) ⊕⊕©©
low1,2
Downgraded as fol-
lows:
1Study lim itat ions:
(studies generally at un-
clear or high risk of bias
for many domains)
2 Imprecision: wide risk
est imates
Alopecia
Follow-up: median 53
months
67 per 1000 64 per 1000
(31 to 131)
RR 0.95
(0.46 to 1.95)
412 (3) ⊕⊕©©
low1,2
Downgraded as fol-
lows:
1Study lim itat ions:
(studies generally at un-
clear or high risk of bias
for many domains)
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2 Total number of
events small
* The basis for the assumed risk f or other outcomes was calculated using the median control group risk across studies in the meta-analysis. The corresponding risk (and its
95% conf idence interval) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its 95% CI).
CI: Conf idence interval; RR: Risk rat io
GRADE Working Group certainty of evidence
High certainty: Further research is very unlikely to change our conf idence in the est imate of ef fect.
Moderate certainty: Further research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low certainty: Further research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low certainty: We are very uncertain about the est imate
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D I S C U S S I O N
The management of lupus nephritis has become complex and dif-
ficult to navigate because of the recent proliferation of new in-
terventions and studies, which have been compared in numer-
ous combination regimens. In the 1970s, it was demonstrated
that compared with corticosteroids alone, the combined use of cy-
clophosphamide and corticosteroids induced remission, reduced
ESKD and death, resulting in the use of this regimen as first-line
therapy for over 30 years.
Our earlier systematic review (Flanc 2004a) of immunosuppres-
sive treatment of proliferative lupus nephritis found that adding
cyclophosphamide or azathioprine to steroids improved or pre-
served kidney function when compared to steroids alone, and that
plasma exchange conferred no additional benefit. In the subse-
quent update of the review (Henderson 2012), we found that
MMFcompared to cyclophosphamide had similar effects on death
and inducing complete renal remission at six months, with a bet-
ter safety profile as indicated by a reduced risk of ovarian failure,
alopecia and leucopenia but with an increased risk of diarrhoea.
Additionally, for maintenance therapy, MMF was more effective
than azathioprine at preventing renal relapse with less leucopenia
and no difference in other safety outcomes. Data regarding newer
agents such as tacrolimus, cyclosporin and rituximab were insuf-
ficient to permit any meaningful conclusions at the time of publi-
cation. Numerous recent studies have examined the combination
of MMF and tacrolimus and the use of biologics in induction
therapy.
Summary of main results
As shown by eight studies involving over 800 participants with
proliferative lupus nephritis in the analysis of this updated review,
MMF dosed at 2 g to 3 g daily may have increased the induction
of complete disease remission and stable kidney function at six
months compared to cyclophosphamide, although the certainty
of the evidence was low, because of study limitations and impre-
cision concerns, with the risk estimate including the possibility of
no effect. Treatment with MMF compared to cyclophosphamide
reduced the risk of alopecia but increased the risk of diarrhoea.
These data justify the current use of MMF as the first-line agent in
proliferative lupus nephritis. MMF provided no benefit for other
adverse events compared with cyclophosphamide, although its ef-
fect on ovarian failure is unclear. As the inclusion of one new study
(Rathi 2016) has introduced greater imprecision in the ovarian
failure treatment estimate, a total of three events has altered the
summary estimate to suggest no benefit. This finding cannot be
definitively stated as the treatment estimate is susceptible to change
with addition of a few events; as a result, the certainty of the evi-
dence has been downgraded to very low.
Compared to IV cyclophosphamide, the use of calcineurin in-
hibitors (tacrolimus and cyclosporin) may be as effective in in-
ducing complete renal remission, while the combination of MMF
and tacrolimus may improve the induction of complete renal re-
mission, and achieving stable kidney function at six months. The
generalisability of these findings may be limited as the two studies
of combination therapy have largely included patients of Asian
ethnicity, and have had serious concerns regarding selection bias
and reporting bias. The safety of these therapies is unclear as the
certainty of evidence is generally low to very low due to substantial
imprecision in treatment effects and a small sample size and event
numbers, limiting the applicability of the findings.
For maintenance therapy, MMF is probably more effective than
azathioprine at preventing renal relapse with less leucopenia but
there may be no difference in other outcomes (major infection,
alopecia, and GI adverse events). The effectiveness and safety of
many other interventions, including biologics (for example, ritux-
imab and abatacept) and cyclosporin, is unclear because of very
low certainty of the evidence, as they have only been trialled in
a small number of studies with low numbers of events and in-
consistent outcome reporting. The clinical role of these therapies
therefore remains unclear and warrants caution.
Overall completeness and applicability of
evidence
Our review was based on a highly sensitive electronic search of
the Cochrane Kidney and Transplant’s Specialised Register, which
includes journal alerts and handsearching of all relevant confer-
ence proceedings, the reporting of existing studies evaluating in-
duction and maintenance therapy of lupus nephritis means there
are considerable gaps in the evidence. While some studies had
moderate periods of follow-up over one to two years, others were
much shorter and inadequately powered to detect events in the
clinically important outcomes. The average time to remission with
cyclophosphamide is about 10 months (Ioannidis 2000); how-
ever, the follow-up in the majority of induction therapy studies
was six months. Furthermore, the risk of adverse events such as
ovarian failure and the development of ESKD increases after six
months, so there is considerable uncertainty in treatment effects
across interventions, which results in an inability of patients and
clinicians to evaluate the benefits and harms of therapy. Health-
related quality of life and fatigue are included in a core set of
outcomes for SLE developed by OMERACT (Strand 2000). Yet,
very few lupus nephritis studies have reported these patient-re-
ported outcomes. No standardised set of outcomes have been de-
veloped specifically for lupus nephritis studies. The development
of a core set of outcomes by all stakeholders, including patients,
with defined measures and definitions of renal remission (Liang
2006; vanVollenhoven 2017)would ease comparisons across stud-
ies and assist with building evidence for the induction and main-
tenance therapy of lupus nephritis. There were limited studies ex-
amining biologics, with sparse outcome data and confidence inter-
vals were frequently very wide, indicating substantial uncertainty.
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Studies may not reflect usual clinical practice due to selection bias,
with rituximab increasingly being used and showing benefit in
patients who have not achieved remission with standard therapies
(Weidenbusch 2013).
The disease spectrum and the proportion of patients within each
class of lupus nephritis differed among studies. Furthermore, pa-
tient demographics varied among studies where environmental,
socioeconomic, as well as clinical and genetic factors have been
thought to play an important role explaining differences in the
outcome of lupus nephritis by ethnicity. Comparing MMF with
cyclophosphamide in induction therapy, six studies included pri-
marily Asian patients (Bao 2008; Chan 2000; Li 2012; Liu 2015;
Ong 2005; Rathi 2016; Sedhain 2016) and two of the largest
studies comparing MMF with cyclophosphamide included higher
proportions of African-American and Hispanic patients (ALMS
2007; Ginzler 2005). Non-Caucasian populations have a higher
risk of relapse, death and CKD compared with Caucasian popu-
lations (Adler 2006; Contreras 2006) and often fail to respond to
cyclophosphamide (Adler 2006; Contreras 2006; Dooley 1997).
Ginzler 2005 included the largest percentage (56%) of patients
of African-American origin. This was the only study that showed
a clear benefit in favour of MMF over IV cyclophosphamide for
induction of remission. The Aspreva Lupus Management Study
(ALMS) data which included 12% African-American and 35%
Hispanic patients, suggested interactions between group interven-
tions and race that were not explained by differences in disease
characteristics (ALMS 2007). ALMS 2007 was the only study to
provide stratified results according to ethnicity and class of lu-
pus in the update, and no studies provided stratified results ac-
cording to severity of kidney impairment reducing the power to
examine potential differences between these groups. Despite the
lack of stratification of results, variation among studies could be
considered a strength as despite clinical differences in population
and histological classification, uniformity of effect demonstrated
in the meta-analysis suggest that the results were valid across race
and class of lupus nephritis.
Quality of the evidence
We graded our confidence in the certainty of the evidence using
the Grading of Recommendations Assessment, Development and
Evaluation (GRADE) approach (GRADE 2011), which consid-
ers study limitations, imprecision, indirectness, inconsistency and
publication bias. Overall, most studies had high or unclear risks
of bias for most domains of study reporting assessed (Figure 2).
The internal validity of the design, conduct and analysis of the
included RCTs was difficult to assess in some studies because of
the omission of important methodological details. No study ade-
quately reported all domains of the risk of bias assessment so that
elements of internal bias may be present in themeta-analysis (Begg
1996; Moher 1999).
Estimated effects on efficacy and safety outcomes were frequently
imprecise with confidence intervals that exhibited both consid-
erable benefit and harm. The generalisability (directness) of the
evidence was limited by the number of available studies on many
treatment comparisons. Additionally, considerable clinical hetero-
geneity in interventions, definitions of remission and renal relapse
and outcome reporting among studies hampered interpretation
and presentation of important outcomes in this review. For exam-
ple, comparing MMF with cyclophosphamide, there was variabil-
ity among studies in therapeutic dosing, route of administration,
definition of outcomes and co-interventions. The small number
of studies for some treatment comparisons limited the power of
statistical testing and important inconsistencies between studies
could not excluded. Publication bias (the effects of small stud-
ies on treatment effects) could not be assessed, new reports from
hand-searching conference proceedings in addition to those al-
ready searched by Cochrane Kidney and Transplant were included
in the meta-analysis to minimise publication bias. Overall, based
on important limitations, we have generally moderate to very low
confidence in the certainty of the evidence for the benefits and
harms of induction and maintenance therapy in people with pro-
liferative lupus nephritis.
Potential biases in the review process
Although this systematic review is reported using Cochrane meth-
ods and includes a comprehensive evidence summary for this topic,
the review has limitations that might be considered. Firstly, the
analysis was limited by the reporting of outcomes in the primary
studies. For example, the definitions of renal remission were vari-
able across studies. While for the analysis of these outcomes, there
was evidence of low heterogeneity, indicating the meta-analysis
was appropriate, the small number of studies for treatment com-
parisons in this review may limit the statistical power to detect
heterogeneity, and as a result it may still be present. Second, in-
complete reporting of outcomes also limits the power of this re-
view to detect differences among interventions. For example, al-
though eight studies with 828 participants compared MMF with
IV cyclophosphamide in induction therapy, only three reported
on ovarian failure and one on doubling of SCr. Finally, differ-
ent treatment effects for patients of different ethnic backgrounds
has been hypothesised and observed (Isenberg 2010), although it
could not be explored in this systematic review because of insuf-
ficient data for ethnicity in the original study reports to perform
meta-regression analyses.
Agreements and disagreements with other
studies or reviews
In contrast to previous meta-analyses (Mak 2009; Moore 2006),
we re-organised interventions according to treatments for induc-
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tion of disease remission or maintenance therapy, which better re-
flects clinical practice. Broad inclusion criteria also helped explore
the totality of evidence available, rather than limiting meta-anal-
ysis by specific immunosuppression regimens as have previously
published systematic reviews (Cao 2015; Deng 2012; Feng 2013;
Hannah 2016;Kamanamool 2010; Lee 2010; Lee 2011; Liu 2012;
Mak 2009; Maneiro 2014; Moore 2006; Radhakrishnan 2010;
Touma 2011; Walsh 2007; Zhang 2016; Zhou 2011; Zhu 2007).
A review of systematic reviews of meta-analyses of RCTs and ob-
servational studies (Chen 2017) also showed that induction ther-
apy with MMF compared to IV cyclophosphamide had a higher
response rate and decreased alopecia. However, in contrast, the
review found that MMF decreased ovarian failure and leucopenia,
and calcineurin inhibitors (tacrolimus) increased complete remis-
sion and decreased ovarian failure and GI adverse events. These
differences may be because the other overview included systematic
reviews of observational studies and did not assess the certainty
of the available evidence, and we included more recent RCTs in
our review. For example, our review included Rathi 2016, which
introduced further uncertainty regarding the outcomes of ovarian
failure and leucopenia for MMF versus cyclophosphamide induc-
tion therapy.
Similar findings between this review and recent network meta-
analysis strengthen the conclusion that there is inconclusive evi-
dence for therapy based on treatment effects on important safety
outcomes and that MMF is the most effective therapy in main-
taining disease remission (Palmer 2017; Tian 2015). While, some
network meta-analyses found similar findings in that there may be
no difference between MMF, calcineurin inhibitors or their com-
bination in inducing renal remission compared to cyclophospha-
mide (Tian 2014; Singh 2016), other network meta-analyses have
found that these therapies may be more effective than cyclophos-
phamide in inducing renal remission (Lee 2015; Palmer 2017). As
there are vast options available for treatment, of which some have
not been directly compared, a network meta-analysis may allow
for greater certainty about all treatment options through the use
of indirect evidence. Although, given the small number of studies,
an imbalance of evidence in the network, particularly tacrolimus
alone or its combination with MMF may affect the power and
reliability for the overall analysis, and also the network meta-anal-
ysis may be underpowered to check for statistical heterogeneity,
leading to incoherence between direct and indirect results. Con-
sidering the apparent lack of evidence and possible incoherency,
the results from the network meta-analysis should be interpreted
with a degree of caution (Mills 2013).
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
In this review, we found thatMMFmay lead to increased complete
disease remission compared to IV cyclophosphamide, although the
certainty of the evidence was low and included the possibility of no
effect, however there was some evidence of better tolerability. The
equivalent remission rates combined with a more favourable side-
effect profile compared to cyclophosphamide support the current
practice of MMF along with corticosteroids as first-line induc-
tion therapy for proliferative lupus nephritis. Numerous published
guidelines concur with our findings, recommending MMF or IV
cyclophosphamide with corticosteroids for induction therapy in
patients with ISN class III/IV lupus nephritis (Tunnicliffe 2015).
The combination of MMF and tacrolimus may be more effective
in inducing renal remission and achieving stable kidney function
but this needs to be interpreted with a degree of caution, as it
has largely been informed by one large study with participants of
mainly Chinese ethnicity.
Although there are few study data on maintenance therapy, meta-
analyses from two recent large RCTs (ALMS 2007; MAINTAIN
Nephritis 2010) showed that MMF is superior to azathioprine in
preventing renal relapse with no difference between the therapies
in death, doubling of SCr, major infection, leucopenia and GI dis-
turbance. The data for newer biologic agents, including rituximab
was very limited, so no conclusions about the relative benefit and
harms of these agents could be made. Until further research be-
comes available, the lack of data on other agents and heterogeneity
of dosing schedules make it difficult to offer recommendations
about other agents and to be more specific about optimal dosing
schedules.
Implications for research
There are four main implications for future research. In no par-
ticular order, firstly for the design of future studies, given the
short duration of studies and imprecision for treatment estimates
for death and ESKD, registry-based RCTs may clarify the risks
and eventual harms of specific treatment regimens, as outcomes,
are captured automatically during routine follow-up with registry
databases. Efficient data linkage between hospital records, national
and state-wide mortality databases and cancer registries may also
help clarify the efficacy and safety of specific therapies. Secondly,
standardisation of the reporting of safety and efficacy outcomes
in studies evaluating therapies for lupus nephritis might facilitate
better comparison and improve our understanding of the bene-
fits and harms of treatment. Thirdly, future studies should fur-
ther examine the long-term safety and efficacy of MMF as main-
tenance therapy to provide guidance around tapering or when to
stop treatment; further studies should also examine the safety and
efficacy of MMF plus tacrolimus as induction therapy in the man-
agement of lupus nephritis across all ethnic groups. Further studies
are needed in patient populations that carry greater disease bur-
den, such as children, African-Americans, Hispanics and Asians,
different histopathological classes of lupus nephritis and patients
presenting with advanced renal impairment.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Abedi 2007
Methods • Study design: parallel RCT
• Study timeframe: not reported
• Duration of follow-up: 18 months
Participants • Country: Iran
• Setting: not reported
• Inclusion criteria: SLE patients with newly diagnosed lupus nephritis, WHO class
III or IV (biopsy proven)
• Number (randomised): 30 (numbers per group not reported)
• Mean age ± SD (years): not reported
• Sex (M/F): not reported
• Exclusion criteria: not reported
Interventions Induction therapy: duration of treatment was 18 months
• Treatment group 1
◦ MMF: 2 g/d
• Treatment group 2
◦ IV CPA: 0.75 to 1 g/month for 6 months then every 3 months for 1 year
• Both groups
◦ Corticosteroids
Outcomes • Complete remission
• Partial remission
• Proteinuria
• Serum albumin
• Hb, ESR, serum complement, urinary activity
• Serious infection
• Leucopenia
• Amenorrhoea
• Diarrhoea
Notes • Abstract-only publication
• Funding source not reported
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Study was described as randomised,
method of randomisation was not reported
Allocation concealment (selection bias) Unclear risk Insufficient information to permit judge-
ment
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Abedi 2007 (Continued)
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Open-label study
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Insufficient information to permit judge-
ment
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Insufficient information to permit judge-
ment
Selective reporting (reporting bias) High risk Data unable to be meta-analysed
Other bias Unclear risk Abstract-only publication; insufficient in-
formation to permit judgement
ACCESS 2014
Methods • Study design: double-blind, parallel RCT
• Study timeframe: November 2008 to June 2012
• Duration of follow-up: 24 and 52 weeks
Participants • Countries: USA and Mexico
• Setting: multicentre (19 sites)
• Inclusion criteria: ≥16 years; diagnosis of SLE (ACR criteria) positive ANA and/
or positive anti-double-stranded DNA (anti-dsDNA) antibody test result at study
entry; active lupus nephritis defined by kidney biopsy findings within the last 12
months of proliferative nephritis (ISN/RPS criteria (class III or class IV with or
without features of class V)) and UPCR of > 1
• Number (randomised/analysed): treatment group (66/66); control group (68/68)
• Mean age ± SD (years): treatment group (32 ± 10.1); control group (32.7 ± 12)
• Sex (M/F): treatment group (8/58); control group (12/56)
• Exclusion criteria: not reported
Interventions Induction therapy: duration of treatment was 6 months
• Treatment group
◦ Abatacept: monthly infusions at doses that were adjusted for body weight
according to the abatacept dose that is recommended for rheumatoid arthritis (for < 60
kg, 500 mg; for 60-100 kg; 750 mg for > 100 kg, 1 g)
• Control group
◦ Placebo
• Both groups
◦ Six IV pulses of 500 mg of CPA at two-week intervals followed by oral AZA
at 2 mg/kg/d based on the ELNT regimen
◦ Oral glucocorticoid treatment was begun at 60 mg/d for 2 weeks in all
subjects, followed by a prescribed taper to 10 mg/d over the next 10 weeks
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ACCESS 2014 (Continued)
Outcomes • Death (all causes)
• Complete response: UPCR of 0.5 based on a 24 h urine collection, SCr level of 1.
2 mg/dL or 125% of baseline, and adherence to the prednisone taper to 10 mg/d by
week 12
• Partial response: UPCR required only 50% improvement from baseline (rather
than a decline to < 0.5 based in complete response) on a 24 h urine collection, SCr
level of 1.2 mg/dL or 125% of baseline, and adherence to the prednisone taper to 10
mg/d by week 12
• Relapse: renal flare was defined as the recurrence of proteinuria of > 1 g/24 h; for
all others, a renal flare was defined as either of the following: SCr level at least 25%
higher than baseline or above the upper limit of normal, plus proteinuria at least 75%
of baseline; or doubling of the UPCR compared with the lowest previous value
• Major infection
Notes • The ACCESS study did not use an initial IV pulse MP, but rather left that decision
to the site investigator’s discretion, unlike Euro-lupus nephritis treatment regimen
• Funding source: NIH National Institute of Allergy and Infectious Diseases
contract N01-AI-15416, protocol number ITN034AI
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Study was described as randomised,
method of randomisation was not reported
Allocation concealment (selection bias) Unclear risk Insufficient information to permit judge-
ment
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Double-blind with identical placebo
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Insufficient information to permit judge-
ment
Incomplete outcome data (attrition bias)
All outcomes
Low risk No missing outcome data
Selective reporting (reporting bias) Low risk Study protocol available and pre-specified
outcomes were reported
Other bias High risk Some authors involved in data acquisition
and analysis are employees of pharmaceu-
tical companies
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ALMS 2007
Methods • Study design: open-label, parallel RCT
• Study timeframe (enrolment): 27 July 2005 to 6 October 2006
• Duration of follow-up (median): 6 months (induction therapy) and 36 months
(maintenance therapy)
Participants • Country: international (countries not reported)
• Setting: multinational (~ 100 sites)
• Inclusion criteria: aged 12 to 75 years with diagnosis of SLE (ACR criteria),
biopsy-proven lupus nephritis (active or chronic) within 6 months before
randomisation, ISN/RPS 2003 class III, IV-S, IV-G, V, III+V, IV+V, class III or V
must have proteinuria > 2 g/d; class III (22); IV (147); III/V (7); IV/V (16); V (35)
• Number (randomised/analysed)
◦ Induction therapy: treatment group 1 (185/185); treatment group 2 (185/
185)
◦ Maintenance therapy: treatment group 1 (116/116); treatment group 2
(111/111)
• Mean age ± SD (years)
◦ Induction therapy: treatment group 1 (32.4 ± 11.2); treatment group 2 (31.
3 ± 10.3)
◦ Maintenance therapy: treatment group 1 (31.8 ± 10.6); treatment group 2
(31 ± 10.8)
• Sex (M/F)
◦ Induction therapy: treatment group 1 (28/157); treatment group 2 (29/156)
◦ Maintenance therapy: treatment group 1 (15/101); treatment group 2 (17/
94)
• Exclusion criteria: treatment with MMF or IV CPA within the previous year;
continuous dialysis for > 2 weeks before randomisation or anticipated duration > 8
weeks; pancreatitis, GI haemorrhage within 6 months or active peptic ulcer within 3
months; severe viral infection; severe cardiovascular disease; bone marrow insufficiency
with cytopenias not attributable to SLE; current infection requiring IV antibiotics
Interventions Induction therapy: duration of therapy was 6 months
• Treatment group 1
◦ Oral MMF: titrated from 0.5 g twice daily in week 1 to 1.0 g twice daily in
week 2, target dose 1.5 g twice daily in week 3
• Treatment group 2
◦ IV CPA: monthly pulses 0.5 to 1.0 g/m2
• Both groups
◦ Oral prednisolone with defined taper, maximum starting dose 60 mg/d
Maintenance therapy: duration of therapy was 36 months
• Treatment group 1
◦ Oral MMF: 2 g/d
◦ AZA placebo
• Treatment group 2
◦ Oral AZA: 2 mg/kg/d
◦ MMF placebo
• Both groups
◦ Oral prednisolone with defined taper, maximum starting dose 10 mg/d
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ALMS 2007 (Continued)
Outcomes Induction therapy
• Death (all causes)
• Stable kidney function: stabilisation ± 25% or improvement in SCr
• Complete renal remission: return to normal creatinine, proteinuria ≤ 0.5 g/d and
inactive urine sediment
• Partial renal remission: prespecified decrease in UPCR (fall in < 3.0 g/d protein if
baseline ≥ 3 or ≥ 50% reduction if < 3 at baseline and stabilisation of SCr ± 25%)
• Major infection
• Systemic disease activity and damage
• Adverse events (reported by > 10% participants)
Maintenance therapy
• Death
• ESKD
• doubling of SCr
• Renal flare: proteinuric or nephritic
• Complete renal remission
• Combined renal and extra-renal remission
Notes • Funding source: Aspreva Pharmaceuticals Corporation as part of the Roche-
Aspreva collaboration agreement
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Participants randomly assigned (1:1, strati-
fied by race and biopsy class, non-blocked)
but sequence of generation is not reported
Allocation concealment (selection bias) Low risk Central, computerised, interactive voice re-
sponse system.Methodwould not allow in-
vestigator/participant to know or influence
intervention group
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Induction therapy - Open-label study;
maintenance therapy - double-blind
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Primary outcome assessed by blinded Clin-
ical EndPoints Committee
Incomplete outcome data (attrition bias)
All outcomes
Low risk No missing outcome data; Induction ther-
apy (group 1: 1 lost to follow-up; group 2:
2 lost to follow-up)
Selective reporting (reporting bias) Low risk Study protocol available and pre-specified
outcomes were reported
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ALMS 2007 (Continued)
Other bias High risk Sponsored by Aspreva Pharmaceuticals
Corporation included in the data analysis
& authorship
APRIL-LN 2012
Methods • Study design: double-blind, double dummy RCT
• Study timeframe: not reported
• Duration of follow-up: 12 months planned
Participants • Country: USA
• Setting: multicentre (4 sites)
• Inclusion criteria: diagnosis of SLE (ACR criteria); positive ANA test (Hep-2
ANA ≥ 1:80) and/or anti-dsDNA ≥ 30 IU/mL); biopsy proven (within the 12
months preceding study entry) class III or IV lupus nephritis (ISN/RPS 2003
classification criteria); active lupus nephritis, defined by proteinuria (UPCR > 1.0 mg/
mg) and haematuria (> 10 RBC/HPF with or without RBC casts)
• Number (randomised): treatment group (4); control group (2)
• Age range 18 to 54 years
• Sex (M/F): 2/4
• Exclusion criteria: causes of haematuria of non-glomerular origin; kidney disease
unrelated to SLE; calculated eGFR ≤ 30 mL/min/1.73 m2 at screening
Interventions Induction therapy: duration of therapy was 12 months
• Treatment group
◦ SC atacicept: 150 mg twice weekly for 4 weeks then 150 mg weekly for a
planned 48 weeks
• Control group
◦ SC placebo
• Both groups
◦ On study Day 14, patients commenced MMF (500 mg, twice daily, orally)
and prednisone or equivalent (the lesser of 0.8 mg/kg/d or 60 mg/d, orally). MMF
dose was increased to 1,000 mg twice daily at Day 7, thereafter up to a maximum of 1.
5 g twice daily by Day 1
Outcomes • Major infection
• Treatment failure
Notes • Follow-up was planned for 12 months
• Early termination of the project
• Funding source: Merck Serono S.A.; ZymoGenetics Inc; EMD Serono Inc
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Study was described as randomised,
method of randomisation was not reported
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APRIL-LN 2012 (Continued)
Allocation concealment (selection bias) Unclear risk Insufficient information to permit judge-
ment
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Double-blind, double-dummy placebo
study
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Insufficient information to permit judge-
ment
Incomplete outcome data (attrition bias)
All outcomes
Low risk No missing outcome data
Selective reporting (reporting bias) High risk Study protocol available and not all pre-
specified outcomes were reported
Other bias High risk Sponsor involved in authorship. The study
was terminated early; there were differences
in characteristics (for example eGFR) be-
tween groups at baseline
AURA-LV 2016
Methods • Study design: double-blind, parallel RCT
• Study timeframe: not reported
• Duration of follow-up: 24 and 48 weeks
Participants • Country: > 20 countries (not reported)
• Setting: multinational (number of sites not reported)
• Inclusion criteria: patients aged 18 to 75 years; diagnosis of SLE (ACR criteria);
biopsy proven classes III, IV-S or IV-G, (A) or (A/C); or Class V, alone or in
combination with Class III or IV (ISN/RPS 2003) (within 6 months prior to screening
(Visit 1); laboratory evidence of active nephritis at screening, defined as Class III, IV-S
or IV-G (confirmed proteinuria ≥ 1,500 mg/24 h, UPCR of ≥ 1.5 mg/mg; Class V
(alone or in combination with Class III or IV: proteinuria ≥ 2,000 mg/24 h, a UPCR
of ≥ 2 mg/mg)
• Number (randomised): 265 patients (numbers not reported for groups)
• Mean age ± SD (years): not reported
• Sex (M/F): not reported
• Exclusion criteria: eGFR of ≤ 45 mL/min/1.73 m2; currently requiring or
expected to require HD or PD during the study period; previous kidney transplant or
planned transplant within study period; in the opinion of the investigator, subject does
not require long-term immunosuppressive treatment (in addition to corticosteroids);
current or medical history of: pancreatitis or GI haemorrhage within 6 months prior to
screening; active unhealed peptic ulcer within 3 months prior to screening; congenital
or acquired immunodeficiency; clinically significant drug or alcohol abuse 2 years prior
to screening; malignancy within 5 years of screening, with the exception of basal and
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AURA-LV 2016 (Continued)
squamous cell carcinomas treated by complete excision; cervical dysplasia that is
cervical intraepithelial neoplasia 1, but have been treated with conization or loop
electrosurgical excision procedure, and have had a normal repeat PAP are allowed;
lymphoproliferative disease or previous total lymphoid irradiation; severe viral
infection (e.g. CMV, HBV, HCV) within 3 months of screening; or known HIV
infection; active TB, or known history of TB; other known clinically significant active
medical conditions, such as severe cardiovascular disease including congestive heart
failure, history of cardiac dysrhythmia or congenital long QT syndrome; liver
dysfunction at screening and confirmed before randomisation; chronic obstructive
pulmonary disease or asthma requiring oral steroids; bone marrow insufficiency
unrelated to active SLE (according to Investigator judgment) with WCC < 2500/mm3 ;
absolute neutrophil count < 1.3 x 103/µL; thrombocytopenia (platelet count < 50,
000/mm3); active bleeding disorders; current infection requiring IV antibiotics; any
overlapping autoimmune condition for which the condition or the treatment of the
condition may affect the study assessments or outcomes; overlapping conditions for
which the condition or treatment is not expected to affect assessments or outcomes are
not excluded; pregnant, breast feeding or, if of childbearing potential, not using
adequate contraceptive precautions
Interventions Induction therapy: duration of therapy was 6 months
• Treatment group 1
◦ Low-dose oral voclosporin: 23.7 mg twice/d
• Treatment group 2
◦ High-dose oral voclosporin: 39.5 mg twice/d
• Control group
◦ Oral placebo
• Both groups
◦ Oral MMF and corticosteroids
Outcomes • Death
• Complete remission
• Major infection
Notes • Abstract-only publications
• Funding source: Aurinia Pharmaceuticals Inc
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Study was described as randomised,
method of randomisation was not reported
Allocation concealment (selection bias) Unclear risk Insufficient information to permit judge-
ment
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Double-blind
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AURA-LV 2016 (Continued)
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Outcome assessor blinded according to
protocol
Incomplete outcome data (attrition bias)
All outcomes
Low risk No missing outcome data
Selective reporting (reporting bias) High risk Not all pre-specified outcomes reported
Other bias High risk Pharma funded; some authors involved are
employees of Aurinia
Balletta 1992
Methods • Study design: parallel RCT
• Study timeframe: not reported
• Duration of follow-up: > 12 months
Participants • Country: Italy
• Setting: not reported
• Inclusion criteria: lupus nephritis shown on biopsy (diffuse proliferative,
mesangioproliferative, membranoproliferative, focal proliferative, diffuse proliferative)
• Number (randomised): treatment group (5); control group (5)
• Mean age ± SD (years): treatment group (25.6 ± 6.2); control group (23.4 ± 3.7)
• Sex (M/F): treatment group (0/5); control group (1/4)
• Exclusion criteria: not reported
Interventions Induction therapy
• Treatment group
◦ Oral CSA: 1.5 mg/kg twice/d
◦ Prednisolone: as per control
• Control group
◦ Prednisolone: pulse, 2 to 3 mg/kg/d for 3 consecutive days, then oral dose 1
mg/kg/d for 2 months and tapered
Outcomes • SCr
• CrCl
• Proteinuria
Notes • 6/10 participants had biopsy
• Funding source: not reported
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Study was described as randomised,
method of randomisation was not reported
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Balletta 1992 (Continued)
Allocation concealment (selection bias) Unclear risk Insufficient information to permit judge-
ment
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Insufficient information to permit judge-
ment
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Insufficient information to permit judge-
ment
Incomplete outcome data (attrition bias)
All outcomes
Low risk No missing outcome data
Selective reporting (reporting bias) High risk Not all expected outcomes are reported
Other bias Low risk The study appears to be free of other
sources of bias
Bao 2008
Methods • Study design: open-label RCT
• Study timeframe: September 2005 to December 2006
• Duration of follow-up: 6 months prolonged to 9 months if complete remission
not achieved within 6 months
Participants • Country: China
• Setting: single centre
• Inclusion criteria: aged 12 to 60 years; diagnosis of SLE (ACR 1997 criteria);
SLEDAI ≥ 12’, biopsy-proven lupus nephritis class IV + V (ISN/RPS 2003) within 3
weeks before enrolment; overt proteinuria (≥ 1.5 g/d) ± active urine sediment
• Number (randomised/analysed): treatment group 1 (20/20); treatment group 2
(20/20)
• Mean age ± SD (years): treatment group 1 (27.2 ± 7.1); treatment group 2 (30.6 ±
4.6)
• Sex (M/F): treatment group 1 (4/16); treatment group 2 (2/18)
• Exclusion criteria: creatinine > 3.0 mg/dL (265.2 µmol/L) or CrCl < 30 mL/min/
1.73 m2 on repeated testing; deranged liver function tests; abnormal glucose; known
hypersensitivity or contraindication to any of the regimens; use of CPA, MMF or TAC
within the past 12 weeks; pregnancy or lactation; cerebral lupus; leflunomide and
methotrexate forbidden
Interventions Induction therapy
• Treatment group 1
◦ MMF: 1.0 g/d twice daily (0.75 g/d twice daily if ≤ 50 kg)
◦ TAC: 4 mg/d twice daily (3 mg/d twice daily if ≤ 50 kg)
• Treatment group 2
◦ IV CPA: 0.75g/m2 of body surface area first month then adjusted to 0.5 to
1.0 g/m2 monthly based on WCC (≤ 2.5)
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Bao 2008 (Continued)
• Both groups
◦ IV MP: 0.5 g/d for 3 days then oral prednisolone (0.6 to 0.8 mg/kg/d for 4
wk) followed by a taper (reduced by 5 mg/d every week to 20 mg/d then 2.5 mg every
week until maintenance dosage of 10 mg/d)
Outcomes • Death (all causes)
• Doubling of SCr
• Deterioration of kidney function
• Stable kidney function (normal value SCr or no more than 15% above baseline)
• Complete remission: proteinuria (< 0.4 g/24 h), normal urine sediment, serum
albumin ≥ 3.5 g/dL, normal SCr or not > 15% from baseline
• Partial remission: resumption of normal or at least 50% improvement in
proteinuria and haematuria, serum albumin ≥ 3.5 g/dL, normal SCr or not > 15%
from baseline
• Major infection
• Herpes zoster virus infection
• Irregular menstruation
• GI syndrome
• Alopecia
• Leucopenia
• Proteinuria
Notes • Funding source: Roche China and Astellas Ireland Co. Ltd
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk A computer-generated randomisation list
was drawn up by a statistician with a block
of every four participants. They enrolled
participants were allocated the next avail-
able number upon entry into the study
Allocation concealment (selection bias) Unclear risk A computer-generated randomisation list
was given to the pharmacy department.
Each patient collected medication directly
from the pharmacy department. Unclear
whether participants and or investigators
might have an opportunity to influence as-
signment
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Open-label study
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Adjudication of primary and key secondary
outcome judged at coordinating centre by
personnel who had no knowledge of the
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Bao 2008 (Continued)
treatment assignment and ratingswere con-
firmed by repeat testing after a 1 month in-
terval
Incomplete outcome data (attrition bias)
All outcomes
Low risk No missing outcome data
Selective reporting (reporting bias) Low risk All expected outcomes were reported
Other bias Low risk Supported byRocheChina andAstellas Ire-
land. Co. Ltd. Partially supported but no
role in design, study or analysis
Barron 1982
Methods • Study design: quasi-RCT
• Study timeframe: 1965 to 1980
• Duration of follow-up: mean follow-up 59 months (range: 7 to 137 months)
Participants • Country: USA
• Setting: single centre
• Inclusion criteria: children with SLE (ACR criteria) and severe biopsy-proven
lupus nephritis, defined by a nephrotic urine sediment and impaired kidney function
with a CrCl between 25 and 80 mL/min. If CrCl > 80 mL/min, the candidate had to
have very active renal histology with crescents or necrosis in more than 25% of
glomeruli; renal biopsies were obtained during the 6 weeks before study entry and were
evaluated by light and electron microscopy
• Number (randomised): treatment group 1 (15); treatment group 2 (7)
• Mean age (at onset) ± SD (years):treatment group 1 (11.9 ± 2.9); treatment group
2 (11.4 ± 3.6)
• Sex (M/F): treatment group 1 (2/13); treatment group 2 (1/6)
• Exclusion criteria: drug-induced SLE
Interventions Induction therapy
• Treatment group 1
◦ High dose oral corticosteroid: prednisone 2 mg/kg/d for 3 to 6 months then
tapered
• Treatment group 2
◦ Pulse MP then oral prednisone: 30 mg/kg body weight (maximum 1 g) IV,
total of 6 treatments every other day; following completion of MP, oral prednisone
2mg/kg/d by then tapered
Outcomes • Death (all causes)
• CrCl
• C3, ANA
• Exacerbations
• Infection
• Aseptic necrosis
66Immunosuppressive treatment for proliferative lupus nephritis (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Barron 1982 (Continued)
Notes • Funding source: not reported
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk Participants were entered in alternating
fashion into one of two treatment groups
Allocation concealment (selection bias) High risk Knowledge of prior allocationdue to lack of
random sequence generation and blinding
Blinding of participants and personnel
(performance bias)
All outcomes
High risk No blinding due to lack of allocation con-
cealment
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Insufficient information to permit judge-
ment
Incomplete outcome data (attrition bias)
All outcomes
High risk Other patients were randomised, but only
those with > 6 months follow-up included
in analysis. It is unclear how many other
patients were randomised
Selective reporting (reporting bias) High risk Not all of the pre-specified primary out-
comes were reported
Other bias Low risk The study appears to be free of other
sources of bias
Belmont 1995
Methods • Study design: parallel RCT (pilot study)
• Study timeframe: not reported
• Duration of follow-up: 18 months
Participants • Country: USA
• Setting: multicentre (number of sites not reported)
• Inclusion criteria: aged 18 to 70 years; SLE (ACR criteria); active kidney disease
(in the absence of infection, at least one of the following: (1) RBC casts, (2) WBC casts
plus either haematuria (> 10/HPF) or pyuria (> 10/HPF), (3) proteinuria at ≥ 3 g, (4)
proteinuria ≥ 1.5 g plus (a) haematuria or (b) pyuria or (c) a 25% decrease in C3 and/
or C4
• Number (randomised): treatment group (7); control group (7)
• Mean age ± SD: 35 ± 2 years
• Sex (M/F): 3/11
• Proliferative lupus nephritis: 7/14
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Belmont 1995 (Continued)
• Exclusion criteria: not reported
Interventions Induction therapy
• Treatment group
◦ Oral misoprostol: 20 µg orally 4 times daily
• Control group
◦ Oral placebo: identical capsule
• Both groups
◦ Oral prednisone: 1 mg/kg, 4 times/d
Outcomes • SCr
• doubling of SCr
• CrCl
• ESKD
• Complete remission of proteinuria
• C3, C4
• Anti-dsDNA
Notes • Funding source: not reported
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Participants randomly assigned but meth-
ods of sequence generation are not de-
scribed
Allocation concealment (selection bias) Unclear risk Insufficient information to permit judge-
ment
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Double-blind study
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Insufficient information to permit judge-
ment
Incomplete outcome data (attrition bias)
All outcomes
Low risk Reasons for missing outcome data unlikely
to be related to true outcome
Selective reporting (reporting bias) Low risk Study protocol available and pre-specified
outcomes were reported
Other bias Low risk The study appears to be free of other
sources of bias
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BELONG 2013
Methods • Study design: double-blind, parallel RCT
• Study timeframe: terminated 19 October 2009
• Duration of follow-up: 48 weeks treatment period extended to 96 week open-label
Participants • Country: 23 countries
• Setting: multinational (123 sites)
• Inclusion criteria: aged ≥ 16 years; SLE (ACR criteria) including a history of anti-
dsDNA positivity and active lupus nephritis (defined as UPCR ≥ 1 with biopsy-
proven (within 6 months prior to randomisation)); Class III or IV with coexisting class
V permitted or class III or IV GN provided that ≤ 50% of glomeruli showed sclerosis
or fibrosis (WHO criteria or ISN/RPS criteria)
• Number (randomised/analysed): treatment group 1 (127/73); treatment group 2
(126/75); control group (125/75)
• Mean age, range (years): treatment group 1 (30.6, 16 to 60); treatment group 2
(31.9, 16 to 69); control group (31.3, 17 to 66)
• Sex (M/F): treatment group 1 (18/109); treatment group 2 (12/114); control
group (19/106)
• Exclusion criteria: lupus class III (C), IV-S(C) and IV-G(C); retinitis; poorly
controlled seizure disorder; acute confusional state; myelitis; stroke or stroke syndrome;
cerebellar ataxia or dementia; severe renal impairment; estimated glomerular filtration
rate <25 mL/min/1.73 m2; ESKD requiring dialysis or transplant; thrombocytopenia;
or experiencing or at high risk of developing clinically significant bleeding or organ
dysfunction
Interventions Induction therapy: duration of treatment 48 weeks
• Treatment group 1
◦ IV ocrelizumab: 1000 mg infusion on days 1 and 15 followed by a single
infusion at week 16 and every 16 weeks
• Treatment group 2
◦ IV ocrelizumab: 400 mg infusion on days 1 and 15 followed by a single
infusion at week 16 and every 16 weeks
• Control group
◦ Placebo
• All groups
◦ Groups were treated with background induction therapy at the discretion of
the investigator MMF (target dose 3 g/d) or CPA (ELNT regimen: 0.5 g IV every 2
weeks). Patients receiving MMF continued to receive MMF, while patients receiving
the ELNT CPA regimen were subsequently treated with azathioprine (AZA; 2 mg/kg
up to 200 mg/d, dose selected by the investigator). IV MP (up to 3 g/d) was also
permitted by day 15, given in divided pulses, and oral steroids (0.5-0.75 mg/kg (60
mg/d)) were allowed with taper to 10 mg over 10 weeks. Before each infusion, patients
were administered IV MP (100 mg), acetaminophen/paracetamol (1 g), and an
antihistamine (50 mg IV diphenhydramine HCl or equivalent)
Outcomes • Complete renal response (normal SCr (25% increase from baseline) and
improvement in UPCR to < 0.5)
• Partial renal response (SCr 25% above baseline, and 50% improvement in UPCR,
and if baseline ratio > 3.0, then UPCR < 3.0)
• Death
• Major infection
69Immunosuppressive treatment for proliferative lupus nephritis (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
BELONG 2013 (Continued)
• Adverse events
• Proteinuria
• CrCl
Notes • Funding source: Genentech and Hoffman-La Roche
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Study was described as randomised,
method of randomisation was not reported
Allocation concealment (selection bias) Unclear risk Insufficient information to permit judge-
ment
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Double-blind, placebo-controlled study
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Insufficient information to permit judge-
ment
Incomplete outcome data (attrition bias)
All outcomes
High risk Study was terminated before completion.
Only 36.8% of patients completed the 48-
week treatment period and were included
in the analysis
Selective reporting (reporting bias) Low risk Study protocol available and pre-specified
outcomes were reported
Other bias High risk Genentech andHoffman-LaRoche funded
the study and were involved in study de-
sign; Conflict of interest of authors re-
lating to the pharmaceutical companies
that funded the study; High drop-out rates
(around 52%) with the early termination
of the study; The 1000 mg ocrelizumab-
treated group had slightly higher propor-
tion of Caucasian patients and a lower pro-
portionofAsianpatients than the other two
groups
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Boedigheimer 2017
Methods • Study design: double-blind, phase 1b, parallel RCT
• Study timeframe: 3 March 2009 to 3 June 2014
• Duration of follow-up: 6 months
Participants • Country: USA, Mexico, France, Malaysia, Hong Kong
• Setting: multinational (11 sites)
• Inclusion criteria: aged 18 to 70 years; SLE (ACR criteria) with the presence of
ANA at least 6 months before randomisation; any concurrent SLE medications (e.g.
MMF, AZA, leflunomide, methotrexate, antimalarials) were at a stable dose for ≥ 30
days before randomisation; concurrent prednisone was 20 mg/d (or equivalent) and for
subjects without lupus nephritis could be increased or decreased once by 5 mg/d within
30 days before randomisation; subjects met current recommendations for
immunisations; subjects with lupus nephritis were required to have biopsy-proven
active disease within 18 months of randomisation according to WHO or ISN/RPS
classification class III or IV; UPCR > 1 or 24 h urine protein > 1 g following ≥ 12
weeks of standard-of-care induction treatment with prednisone plus CPA or MMF,
then maintained on prednisone at 20 mg/d (or equivalent) and MMF or AZA
• Number (randomised/analysed): treatment group (21/21); control group (0/21)
• Mean age ± SD (years): treatment group (30.0 ± 8.1); control group (36.9 ± 11.7)
• Sex (M/F): treatment group (7/7); control group (3/4)
• Ethnicity: treatment group (Caucasian 6, African American 0, Hispanic 12, Asian
3, Other 0); control group (Caucasian 2, African American 0, Hispanic 2, Asian 3,
Other 0)
• Exclusion criteria: any disorder that would interfere with study evaluations
including unstable or severe disease; presence or history of vasculitis or active central
nervous system lupus requiring therapy within 3 years; uncontrolled hypertension; low
CrCl (< 50 mL/min); low Hb levels, thrombocytopenia, neutropenia or low total
WCC; poorly controlled diabetes; evidence of viral, bacterial or fungal infection within
30 days of randomisation or evidence of parasitic infestation; history of repeated
infections or predisposition to infections; receipt of CPA, CSA, TAC, sirolimus, IVIG
or plasmapheresis within 3 months of randomisation; or receipt of an investigational
drug or device within 30 days or 5 half-lives of randomisation
Interventions Induction therapy
• Treatment group
◦ SC AMG 811: 20, 60 or 120 mg administered
• Control group
◦ SC placebo
• Both groups
◦ Concomitant therapy could include prednisone, MMF, AZA, methotrexate
and antimalarials
Outcomes • Death
• Major infection
• Adverse events
• Proteinuria
• Disease activity
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Boedigheimer 2017 (Continued)
Notes • Study included both patients with SLE with and without lupus nephritis, we have
extracted data for patients with lupus nephritis only
• Funding source: Amgen
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Study was described as randomised,
method of randomisation was not reported
Allocation concealment (selection bias) Unclear risk Insufficient information to permit judge-
ment
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Double-blind study
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Insufficient information to permit judge-
ment
Incomplete outcome data (attrition bias)
All outcomes
Low risk No missing outcome data
Selective reporting (reporting bias) High risk Not all expected clinical outcomes reported
Other bias High risk Phase 1b study, study underpowered; study
sponsor involved in data acquisition, data
analysis and reporting of the study
Boletis 1999
Methods • Study design: parallel RCT (pilot study)
• Study timeframe: not reported
• Duration of follow-up: 18 months
Participants • Country: Greece
• Setting: not reported
• Inclusion criteria: lupus nephritis warranting CPA therapy; already received 6
months of CPA (1 g/m2 once a month for 6 months and 0.5 mg/kg daily prednisone)
with satisfactory response (absence of major side-effects requiring interruption of
therapy); inactive or substantially improved urine sediment, and proteinuria of less
than 1 g/d (for patients with baseline proteinuria < 3 g/d) or < 3 g/d (for patients with
baseline proteinuria > 3 g/d)
• Number (randomised/analysed): treatment group 1 (9); treatment group 2 (5)
• Mean age ± SD (years): treatment group 1 (30.4 ± 10.9); treatment group 2 (32.4
± 11.7)
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Boletis 1999 (Continued)
• Sex (M/F): treatment group 1 (3/6); treatment group 2 (2/3)
• Exclusion criteria: previous CPA for more than 6 months, pregnancy, aged < 18
or > 75 years, history of malignant disorders
Interventions Maintenance therapy: duration of treatment was 18 months
• Treatment group 1
◦ IV CPA: every 2 months for 6 months and then every 3 months for 12
months
• Treatment group 2
◦ IVIG: 400 mg/kg monthly for 18 months
Both groups
• Clinicians were allowed to increase the dose of prednisone if relapse or
deterioration of kidney disease
Outcomes • SCr
• CrCl
• Proteinuria
Notes • Funding source: not reported
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Study was described as randomised,
method of randomisation was not reported
Allocation concealment (selection bias) Low risk Randomisation was done with sealed en-
velopes
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Whether participants and investigators
were blinded was not described and treat-
ment options were quite different suggest-
ing that personnel were not blinded
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Insufficient information to permit judge-
ment
Incomplete outcome data (attrition bias)
All outcomes
Low risk No missing outcome data
Selective reporting (reporting bias) Low risk Study protocol available and pre-specified
outcomes were reported
Other bias Low risk The study appears to be free of other
sources of bias
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Boumpas 1992
Methods • Study design: open-label, parallel RCT
• Study timeframe: 1981 to 1986
• Duration of follow-up: 10 years
Participants • Country: USA
• Setting: not reported
• Inclusion criteria: age range 10 to 48 years; SLE (ACR 1982 criteria) and severe
lupus nephritis defined by a nephritic urine sediment and impaired kidney function
with a CrCl between 25 to 80 mL/min; if the CrCl was > 80 mL/min, the candidate
had to have very active renal histology with crescents or necrosis in more than 25% of
glomeruli; renal biopsies were obtained during the 6 weeks before study entry and were
evaluated by light and electron microscopy
• Number (randomised): treatment group 1 (20); treatment group 2 (20); control
group (25)
• Mean age ± SE (years): treatment group 1 (30 ± 2); treatment group 2 (30 ± 2);
control group (31 ± 2)
• Sex (M/F): treatment group 1 (3/17); treatment group 2 (1/19); control group (1/
24)
• Exclusion criteria: pregnancy; received cytotoxic drugs for more than 10 weeks;
active infections; insulin-dependent DM, previous malignancy
Interventions Induction therapy
• Treatment group 1
◦ IV CPA: single doses 0.5 to 1 g/m2 monthly for 6 months
• Treatment group 2
◦ IV CPA: single doses 0.5 to 1 g/m2 monthly for 6 months then 3 monthly
for 18 months
• Control group
◦ IV MP: 3 doses 1 g/m2, then monthly single doses for 6 months
Other/additional treatment
• Patients were treated with prednisone 0.5 mg/kg/d and continuing for 4 weeks
then tapered at a rate of 5 mg every other day but the minimum dose to prevent extra-
renal disease
Outcomes • ESKD
• Doubling of SCr
• Major infection
• Herpes zoster virus
• Malignancy
• Haemorrhagic cystitis
• Premature ovarian failure
• Osteonecrosis
• Relapse
• Stable kidney function
Notes • 2 withdrawals
• Funding source: NIH trial
Risk of bias
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Boumpas 1992 (Continued)
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “Patients were assigned randomly to one of
three treatment groups”. No further details
on randomisation
Allocation concealment (selection bias) Low risk Allocation drawn from a set of masked
cards
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Open-label study
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Insufficient information to permit judge-
ment
Incomplete outcome data (attrition bias)
All outcomes
Low risk No missing outcome data
Selective reporting (reporting bias) Low risk Study protocol available and pre-specified
outcomes were reported
Other bias Low risk The study appears to be free of other
sources of bias
Cade 1973
Methods • Study design: quasi-RCT
• Study timeframe: not reported
• Duration of follow-up: 36 months
Participants • Country: USA
• Setting: single centre
• Inclusion criteria: Diagnosis of SLE; biopsy and functional findings of active
proliferative GN due to SLE; renal biopsy classification as proliferative GN closely
approximates those used by Baldwin 1970
• Number (randomised): treatment group 1 (15); treatment group 2 (13);
treatment group 3 (13); treatment group 4 (13)
• Mean age, range (years): treatment group 1 (26.1, 12 to 51); treatment group 2
(30.5, 11 to 62); treatment group 3 (22.4, 12 to 51); treatment group 4 (24.8, 14 to 51)
• Sex (M/F): treatment group 1 (1/12); treatment group 2 (1/12); treatment group
3 (3/10); treatment group 4 (6/7)
• Exclusion criteria: lupus glomerulitis; focal proliferative disease or predominantly
membranous lupus nephritis
Interventions Induction therapy
• Treatment group 1
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Cade 1973 (Continued)
◦ Oral prednisone: 60 to 100 mg/d for 6 months then slowly tapered to the
lowest dose that controlled the patients symptoms
• Treatment group 2
◦ Oral AZA: started at 1.0 to 1.5 mg/kg/d, increased to 1.5 to 2.0 mg/kg/d
after 6 to 8 weeks if the patient had not improved by clinical or laboratory criteria
• Treatment group 3
◦ Oral prednisone: 60 to 100 mg/d for 6 months then slowly tapered to the
lowest dose that controlled the patients symptoms
◦ Oral AZA: started at 1.0 to 1.5 mg/kg/d, increased to 1.5 to 2.0 mg/kg/d
after 6 to 8 weeks if the patient had not improved by clinical or laboratory criteria
• Treatment group 4
◦ Oral AZA: started at 1.0 to 1.5 mg/kg/d, increased to 1.5 to 2.0 mg/kg/d
after 6 to 8 weeks if the patient had not improved by clinical or laboratory criteria
◦ SC heparin: doses ranging from 20,000 units every 8 hours to 5000 units
every 6 hours
Outcomes • Death (all causes)
• ESKD
• CrCl
Notes • Funding source: not reported
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk Chronological appearance
Allocation concealment (selection bias) High risk Assigned in alternate fashion by division
secretary
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Open-label study
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Insufficient information to permit judge-
ment
Incomplete outcome data (attrition bias)
All outcomes
Low risk Insufficient information to permit judge-
ment
Selective reporting (reporting bias) Low risk All pre-specified outcomes are reported
Other bias Low risk The study appears to be free of other
sources of bias
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Chan 2000
Methods • Study design: parallel RCT
• Study timeframe: November 1996 and October 1998
• Duration of follow-up: median follow-up was 63 months
Participants • Country: Hong Kong
• Setting: multicentre
• Inclusion criteria: diagnosis of SLE (ACR criteria); biopsy-proven diffuse
proliferative lupus nephritis (class IV) (WHO classification), urinary protein excretion
of ≥ 1 g/d, a serum albumin ≤ 3.5 g/dL, SCr < 3.4 mg/dL (300 µmol/L)
• Number (randomised/analysed): treatment group 1 (33/32); treatment group 2
(31/30)
• Mean age ± SD (years): treatment group 1 (38.1 ± 10.2); treatment group 2 (41.8
± 8.9)
• Sex (M/F): treatment group 1 (6/26); treatment group 2 (4/26)
• Exclusion criteria: SCr > 4.2 mg/dL; life-threatening complications; history of
poor compliance; pregnancy; women unwilling to use contraception; CPA in the last 6
months; oral prednisolone 0.4 mg/kg/d for more than 2 weeks
Interventions Induction and maintenance therapy
• Treatment group 1
◦ Oral MMF 1 g twice daily for 6 months then 500 mg twice daily for 6
months followed by AZA 1 to 1.5 mg/kg/d for at least 1 year then tapered. From Jan
2002, protocol changed to reducing dose of MMF to 750 mg twice daily at 6 months
then 500 mg twice daily at 12 months and continued for further 12 months before
tapering
• Treatment group 2
◦ Oral CPA 2.5 mg/kg/d for 6 months followed by AZA 1.5 to 2 mg/kg/d for
6 months then 1 to 1.5 mg/kg/d for at least 1 year before tapering
Other information
• Both groups received prednisolone 0.8 mg/kg/d and tapered to 10 mg/d at 6
months then maintenance dose of 5 to 7.5 mg/kg at 12 to 15 months
• MMF dosing subsequently changed from 2002: MMF 1 g twice daily reduced to
750 mg twice daily after 6 months then 500 mg twice daily for at least 1 year before
tapering
Outcomes • Death
• ESKD
• Doubling of SCr
• Doubling kidney function
• Relapse
• Major infection
• Herpes zoster virus infection
• Ovarian failure
• Bone toxicity
• Alopecia
• GI upset
• Lymphopenia
• Complete remission of proteinuria: < 0.3 g/24 h
• Partial remission of proteinuria: > 50% reduction in proteinuria, proteinuria
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Chan 2000 (Continued)
between 0.3 and 3 g/24 h
• SCr
• CrCl
• Daily proteinuria
Notes • Follow-up: 3585 patient-months (median follow-up 63 months); 2 withdrawals
(1 in each group); 62/64 followed-up
• Funding source: Roche pharmaceuticals supplied MMF
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Participants randomly assigned by drawing
envelopes to one of two treatment groups
in an open-label manner
Allocation concealment (selection bias) Unclear risk Insufficient information to permit judge-
ment
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Insufficient information to permit judge-
ment
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk “...Clinical status was reviewed and cate-
gorised at the coordinating centre by per-
sonnel who had no knowledge of the treat-
ment assignment....”
Incomplete outcome data (attrition bias)
All outcomes
Low risk No missing outcome data
Selective reporting (reporting bias) Low risk Study protocol available and pre-specified
outcomes were reported
Other bias Low risk The study appears to be free of other
sources of bias
Chen 2011
Methods • Study design: open-label, parallel RCT
• Study timeframe: June 2006 to March 2008
• Duration of follow-up: 6 month follow-up; extended median follow-up was 6
months
Participants • Country: China
• Setting: multicentre (9 sites)
• Inclusion criteria: aged 14 to 65 years; diagnosis of SLE (ACR criteria); biopsy-
proven (within 6 months) lupus nephritis class III, IV-S, IV-G, (A) or (A/C), or class V
78Immunosuppressive treatment for proliferative lupus nephritis (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Chen 2011 (Continued)
alone or in combination with class III or IV (ISN/RPS 2003 criteria); laboratory tests
documented the presence of active nephritis, defined as proteinuria (protein excretion
> 1 g/24 h) or increased SCr (> 1.3 mg/dL) with active urinary sediment (any of > 5
RBC/HPF, > 5 WBC/HPF, or RBC casts in the absence of infection or other causes) in
patients with class IV-S or IV-G and significant proteinuria (protein excretion > 2 g/24
h) or increased SCr (> 1.3 mg/dL) in patients with class III or V
• Number (randomised/analysed)
◦ Induction therapy: treatment group 1 (42/39); treatment group 2 (39/34)
◦ Maintenance therapy: treatment group 1 (34/34); treatment group 2 (36/36)
• Mean age ± SD (years)
◦ Induction therapy: treatment group 1 (32.0 ± 10.8); treatment group 2 (31.
9 ± 10.1)
◦ Maintenance therapy: treatment group 1 (30.7 ± 10.2); treatment group 2
(33.1 ± 10.9)
• Sex (M/F)
◦ Induction therapy: treatment group 1 (5/37); treatment group 2 (7/32)
◦ Maintenance therapy: treatment group 1 (5/29); treatment group 2 (4/32)
• Exclusion criteria: SCr > 4 mg/dL; cerebral lupus; severe infection; pregnancy;
women unwilling to use contraception; MMF, CPA, CSA, methotrexate or other
immunosuppression within the 1 month before randomisation
Interventions Induction therapy: duration of therapy was 6 months
• Treatment group 1
◦ Oral TAC: 0.05 mg/kg divided in 2 doses with target trough of 5 to 10 ng/
mL
• Treatment group 2
◦ IV CPA: 750 mg/m2 of body surface area every 4 weeks for a total of 6
pulses (25% decrease in dose if older than 60 years or creatinine > 3.4 mg/dL)
• Both groups
◦ Oral prednisolone: 1 mg/kg/d (maximum 60 mg) tapered by 10 mg/d every
2 weeks to 40 mg, followed by decrease of 5 mg/d every 2 weeks until a dose of 10 mg/
d achieved
Long-term maintenance therapy: duration of therapy was 6 months
• Treatment group 1
◦ Oral TAC: trough blood concentrations were maintained at 4-6 ng/mL.
• Treatment group 2
◦ AZA: 2 mg/kg/d
• Both groups
◦ Oral prednisone: 10 mg/d
Outcomes • Death
• Major infection
• Herpes zoster virus infection
• Ovarian failure
• Alopecia
• GI upset
• Lymphopenia
• Complete renal remission: daily proteinuria < 0.3 g/24 h, normal urinary
sediment, serum albumin ≥ 3.5 g/dL and stable kidney function
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• Partial renal remission: protein excretion of 0.3 to 2.9 g/24 h and a decrease of at
least 50% of baseline level), serum albumin level of at least 3.0 g/dL and stable kidney
function
• Treatment failure: failure to meet complete or partial remission
• SCr
• Daily proteinuria
Notes • Funding source: Scientific and Technologic Committee of Guangdong province,
the Department of Health, Guangzhou city, the Ministry of Education, Peoples’
Republic of China and the 5010 Clinical Program of Sun Yat-sen University. Astellas
Pharmaceutics supplied TAC
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomisation was conducted at a central
office using a computer-based random al-
location sequence table; randomisation not
stratified by centre or baseline characteris-
tic
Allocation concealment (selection bias) Low risk Allocation concealment performed by en-
closing assignments in sequentially num-
bered, opaque, closed envelopes
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Open-label study
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Insufficient information to permit judge-
ment
Incomplete outcome data (attrition bias)
All outcomes
Low risk The primary outcome (complete remis-
sion) and secondary outcomes partial re-
mission and treatment failure were re-
ported on an intention to treat bases. The
attrition rate for secondary safety outcomes
were 92.8%(39/42) for theTACgroup and
87.2% for the IV CPA group
Selective reporting (reporting bias) Low risk Study protocol available and prespecified
outcomes were reported
Other bias Low risk Astellas Pharmaceutics supplied TAC but
had no role in the design or conduct of the
study or analysis or interpretation of results
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Clark 1981
Methods • Study design: open-label RCT
• Study timeframe: from February 1978
• Duration of follow-up: 12 months
Participants • Country: Canada
• Setting: not reported
• Inclusion criteria: Diagnosis of SLE (ACR criteria) and had increased DNA, low
complement; presence of ANA; renal biopsy showing diffuse proliferative GN; CrCl >
30 mL/min at study entry
• Number: treatment group 1 (6); treatment group 2 (6)
• Mean age ± SD (years): not reported
• Sex (M/F): not reported
• Exclusion criteria: not reported
Interventions Induction therapy
• Treatment group 1
◦ Corticosteroids
◦ AZA
• Treatment group 2
◦ Corticosteroids
◦ AZA
◦ Plasmapheresis
Outcomes • Death
• ESKD
• Doubling of SCr
• SCr
• CrCl
• Proteinuria
Notes • Funding source: Physicians’ Services Incorporated Foundation
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Study was described as randomised,
method of randomisation was not reported
Allocation concealment (selection bias) Unclear risk Insufficient information to permit judge-
ment
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Open-label study
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Insufficient information to permit judge-
ment
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Clark 1981 (Continued)
Incomplete outcome data (attrition bias)
All outcomes
Low risk No missing outcome data
Selective reporting (reporting bias) Low risk Study protocol available and pre-specified
outcomes were reported
Other bias Low risk Supported from a grant from Physicians’
Services Incorporated Foundation. The
study appears to be free of other sources of
bias
Clark 1984
Methods • Study design: parallel RCT
• Study timeframe: not reported
• Duration of follow-up: 19 months
Participants • Country: Canada. West Indies
• Setting: multinational (3 sites)
• Inclusion criteria: diagnosis of SLE (ACR criteria) and had at least one episode of
ANA positivity; elevated DNA binding and complement depression; renal biopsy
showing diffuse proliferative GN
• Number (randomised): treatment group 1 (19); treatment group 2 (20)
• Mean age ± SD (years): treatment group 1 (25 ± 2); treatment group 2 (26 ± 2)
• Sex (M/F): treatment group 1 (1/18); treatment group 2 (5/15)
• Exclusion criteria: CrCl < 30 mL/min or SCr > 3 mg/dL
Interventions Induction therapy
• Treatment group 1
◦ Steroids ± cytotoxics
• Treatment group 2
◦ Conventional therapy
◦ PEX: 4 L within the first two weeks, thereafter one 4 L PEX every 3-4 weeks.
In two centres patients received replacement with 5% human serum albumin and in
one centre replacement was with plasma
Outcomes • Death
• ESKD
• Doubling of SCr
• SCr
Notes • Funding source: Physicians’ Services Incorporated Foundation
Risk of bias
Bias Authors’ judgement Support for judgement
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Clark 1984 (Continued)
Random sequence generation (selection
bias)
Unclear risk Study was described as randomised,
method of randomisation was not reported
Allocation concealment (selection bias) Unclear risk “Designated non-medical person at each
Centre who removed a pre-folded slip of
paper from a bowl”
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Open-label study
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Insufficient information to permit judge-
ment
Incomplete outcome data (attrition bias)
All outcomes
Low risk No missing outcome data
Selective reporting (reporting bias) High risk Not all relevant outcomes are reported
Other bias Low risk Supported from a grant from Physicians’
Services Incorporated Foundation. The
study appears to be free of other sources of
bias
Contreras 2004
Methods • Study design: open-label, parallel RCT
• Study timeframe: August 1996 and May 2003
• Duration of follow-up: 72 months
Participants • Country: USA
• Setting: single centre
• Inclusion criteria: diagnosis of SLE (ACR criteria); ≥ 18 years; histologic
diagnosis of proliferative lupus nephritis (WHO class III, IV, or Vb); classes III (12),
IV (46) or Vb (1)
• Number (randomised/analysed): treatment group 1 (19/19); treatment group 2
(20/20); treatment group 3 (20/20)
• Mean age ± SD (years): treatment group 1 (33 ± 10); treatment group 2 (33 ± 12)
; treatment group 3 (32 ± 11)
• Sex (M/F): treatment group 1 (1/19); treatment group 2 (2/18); treatment group
3 (1/19)
• Exclusion criteria: CrCl that was consistently < 20 mL/min; any clinically
significant infection; pregnancy; the receipt of more than seven doses of IV CPA, or the
receipt of AZA for longer than 8 weeks
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Contreras 2004 (Continued)
Interventions Maintenance therapy: duration of therapy 1 to 3 years
• Treatment group 1
◦ IV CPA: 0.5 to 1.0 g/m2 every 3 months
• Treatment group 2
◦ AZA: 1 to 3 mg/kg/d
• Treatment group 3
◦ MMF: 500 to 3000 mg/d
• All groups
◦ Induction therapy of 7 monthly boluses of IV CPA 0.5 to 1.0 g/m2 and
corticosteroids and maintenance therapy included prednisolone (up to 0.5 mg/kg/d)
Outcomes • ESKD
• Death
• Doubling of SCr
• Stable kidney function
• Relapse: doubling of the UPCR (proteinuric) or an increase in SCr level of 50%
or more for more than 1 month (nephritic)
• Major infection
• Herpes zoster virus infection
• Malignancy
• Ovarian failure
Notes • Funding source: Roche
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk “After induction, participants were ran-
domly assigned, in order of enrolment by
means of sealed envelopes (stratified in two
groups: blacks and other participants).” -
consecutive sequence generation
Allocation concealment (selection bias) Low risk Sealed envelopes used
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Open-label study
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Insufficient information to permit judge-
ment
Incomplete outcome data (attrition bias)
All outcomes
Low risk No missing outcome data
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Contreras 2004 (Continued)
Selective reporting (reporting bias) Low risk Study protocol available and pre-specified
outcomes were reported
Other bias High risk Roche pharmaceutical providing research
nurse support and MMF 1999 to 2003.
Authors received fees for lectures and a
grant from Roche Pharmaceuticals
CYCLOFA-LUNE 2010
Methods • Study design: open-label, parallel RCT
• Study timeframe: January 2002 to December 2006
• Duration of follow-up: median extended follow-up 7.7 years (range 5.0 to 10.3
years)
Participants • Country: Czech Republic; Slovakia
• Setting: multinational (8 sites)
• Inclusion criteria: ACR criteria for SLE; biopsy-proven lupus nephritis (WHO or
ISN/RPS criteria) and clinical activity as defined by presence of at least two of the
following: abnormal proteinuria (more than 500 mg/24 h), abnormal microscopic
haematuria, or C3 hypocomplementaemia
• Number (analysed): treatment group 1 (21); treatment group 2 (19)
• Mean age ± SD (years): treatment group 1 (30 ± 9); treatment group 2 (28 ± 5)
• Sex (M/F): treatment group 1 (6/15); treatment group 2 (5/14)
• Exclusion criteria: previous CPA or CSA ever before; treatment with
immunosuppressive drugs or corticosteroids within the last 3 months; persistent
elevation of SCr > 140 µmol/L; pregnancy or lactation; bone marrow insufficiency not
attributable to SLE; severe co-existing conditions such as infection, liver disease, or
active peptic ulcer
Interventions Induction andmaintenance therapy: durationof therapywas 9months induction therapy
and 9 months maintenance therapy
• Treatment group 1
◦ Intermittent IV CPA: 10 mg/kg x 8 over 9 months followed by 4 or 5 oral
pulses (10 mg/d in 6 to 8 week intervals)
• Treatment group 2
◦ Daily oral CSA: 4 to 5 mg/kg/d for 9 months followed by tapering dose of 3.
75 to 1.25 mg/kg/d for further 9 months
• Both groups
◦ MP 0.8 mg/kg/d tapering to 0.2 mg/kg/d over 8 weeks. Additional 1 to 3
doses of MP (15 mg/kg) were administered if felt insufficient control of kidney or
extra-kidney disease, or a 30% to 50% increase in oral steroids with a change in timing
of CPA or increase in dose of CSA was also allowed
Outcomes • Death
• Renal relapse: signs of renal activity
• Major infection
• Herpes zoster virus
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CYCLOFA-LUNE 2010 (Continued)
• Ovarian failure
• Bladder toxicity
• Alopecia
• Lymphopenia
• Complete renal remission: SCr within the normal range with stable or improved
values as compared with baseline (no more than 15% above baseline), AND inactive
urinary sediment, AND normal range proteinuria (< 0.3 g/24 h)
• Partial renal remission: SCr within the normal range with stable or improved
values as compared with baseline (no more than 15% above baseline), AND at least
50% decrease in proteinuria to less than 3 g/d if nephrotic at baseline, or to 0.5 g/d if
baseline non-nephrotic, AND either inactive urinary sediment or at least 25%
improvement in C3 complement (patients with complete remission are counted within
this less strict category as well
• SCr
• Proteinuria
Notes • Funding source: IGA Ministry of Health Czech Republic
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Randomisation 1:1, non-blocked methods
for sequence generation not reported
Allocation concealment (selection bias) Low risk Central computerised system
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Open-label study
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Insufficient information to permit judge-
ment
Incomplete outcome data (attrition bias)
All outcomes
Low risk No missing outcome data
Selective reporting (reporting bias) Low risk Study protocol available and pre-specified
outcomes were reported
Other bias Low risk Research grants from the IGA Ministry of
Health, CzechRepublic. The study appears
to be free of other sources of bias
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Decker 1975
Methods • Study design: open-label, parallel RCT
• Study timeframe: 1969 to 1981
• Duration of follow-up: median 7 years
Participants • Country: USA
• Setting: multicentre (number of sites not reported)
• Inclusion criteria: Diagnosis of SLE (ACR criteria); clinical or histologic evidence
of active lupus GN (mostly proliferative lesions) (WHO classification criteria)
• Number (randomised/analysed): treatment group 1 (30/28); treatment group 2
(20/19); treatment group 3 (18/18); treatment group 4 (23/22); treatment group 5
(20/20)
• Age: median age 27 years (age for individual groups not reported)
• Sex (M/F): 15/92 (sex for individual groups not reported)
• Biopsy-proven lupus nephritis: (60/107)
• Exclusion criteria: CrCl < 20 mL/min; major infection within 2 weeks;
pregnancy; leucocyte count < 2000/mm3 ; cytotoxic therapy within 8 weeks; sensitivity
to study drugs
Interventions Induction therapy: duration of therapy until 18 months of remission had been achieved
or 4 years of protocol therapy
• Treatment group 1
◦ Prednisolone alone: 1 mg/kg for 4 to 8 weeks, then tapering
• Treatment group 2
◦ AZA: up to 4 mg/kg/d
• Treatment group 3
◦ Oral CPA: up to 4 mg/kg/d
• Treatment group 4
◦ CPA and AZA: up to 1 mg/kg/d of each
• Treatment group 4
◦ IV pulse CPA: IV every 3 month 0.5 to 1.0 g/m2
• Additional treatment
◦ Groups 2 to 4 were also treated with low-dose prednisone (up to 0.5 mg/kg/
d)
Outcomes • Death
• ESKD
• Doubling of SCr
• Toxicity
• Stable kidney function
• Herpes zoster virus infection
• Major infection
• Cancer
• Premature ovarian failure
• Haemorrhagic cystitis
Notes • Funding source: NIH trial
Risk of bias
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Decker 1975 (Continued)
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk ”...drawing marked card sequence from a
table of random numbers...”
Allocation concealment (selection bias) Unclear risk Insufficient information to permit judge-
ment
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Insufficient information to permit judge-
ment
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Insufficient information to permit judge-
ment
Incomplete outcome data (attrition bias)
All outcomes
Low risk 3.6% (4/111) of participants excluded as
they did not complete 3 months of treat-
ment
Selective reporting (reporting bias) Low risk All expected outcomes were reported
Other bias High risk Patients were assigned to treatment groups
1, 2 and 3 from the beginning of the study
(1969). Treatment groups 4 and 5 were in-
troduced in January 1973. Pooling of mul-
tiple studies
Deng 2016
Methods • Study design: parallel RCT
• Study timeframe: not reported
• Duration of follow-up: not reported
Participants • Country: China
• Setting: not reported
• Inclusion criteria: biopsy-proven proliferative lupus nephritis
• Number: 30 (numbers not available for groups)
• Mean age ± SD (years): not reported
• Sex (M/F): not reported
• Exclusion criteria: not reported
Interventions Induction therapy: duration of therapy was 6 months
• Treatment group 1
◦ CPA: route of administration and dosage not reported
• Treatment group 2
◦ Leflunomide: route of administration and dosage not reported
• Both groups
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Deng 2016 (Continued)
◦ Prednisone: dosage not reported
Outcomes • Adverse events
• Proteinuria
• Serum albumin
Notes • Abstract-only publication
• Funding source: not reported
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Insufficient information to permit judge-
ment
Allocation concealment (selection bias) Unclear risk Insufficient information to permit judge-
ment
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Insufficient information to permit judge-
ment
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Insufficient information to permit judge-
ment
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Insufficient information to permit judge-
ment
Selective reporting (reporting bias) High risk Not all pre-specified outcomes found on
the protocol are reported; data could not
be meta-analysed
Other bias High risk Primary outcomes identified on clinicaltri-
als.gov page not reported. Focus on p-val-
ues in the results, with no reporting of the
continuous or categorical data
Derksen 1988
Methods • Study design: parallel RCT
• Study timeframe: 1981 to 1985
• Duration of follow-up: 26 weeks
Participants • Country: Netherlands
• Setting: multicentre (5 sites)
• Inclusion criteria: diagnosis of SLE (ARA criteria); presence of active lupus
nephritis, defined by a decreased CrCl, an active urine sediment (> 5 RBC/HPF and
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Derksen 1988 (Continued)
cellular casts) and proteinuria > 0.5 g/24 h; biopsy-proven proliferative lupus nephritis
(class III or IV WHO classification criteria); insufficient response of kidney function to
treatment with corticosteroids alone given in a single daily dose of 1-1.5 mg/kg for at
least 3 weeks
• Number (randomised): treatment group 1 (11); treatment group 2 (9)
• Mean age, range SD (years): treatment group 1 (28, 15 to 55); treatment group 2
(36, 18 to 60)
• Sex (M/F): treatment group 1 (3/8); treatment group 2 (2/7)
• Exclusion criteria: deterioration of kidney function could be explained by other
causes, such as the use of NSAIDs, infection or hypotension; patients with active renal
insufficiency with oliguria/anuria (dialysis indications), and patients with psychiatric
manifestations
Interventions Induction therapy: duration of therapy was 26 weeks
• Treatment group 1
◦ Prednisone ± cytotoxics (oral AZA or CPA 2 mg/kg if kidney function and
haematological functions permitted)
• Treatment group 2
◦ PEX alone: short course
• Both groups
• Daily oral prednisone (1.5 mg/kg) until the time of randomisation, the dose was
gradually reduced (a decrease in daily dose of 10 mg, once a week) until a daily dose of
1 mg/kg was reached
Outcomes • Death
• ESKD
• CrCl
Notes • Funding source: not reported
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Drawing lots from card sequence
Allocation concealment (selection bias) Unclear risk Insufficient information to permit judge-
ment
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Insufficient information to permit judge-
ment
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Insufficient information to permit judge-
ment
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Derksen 1988 (Continued)
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Insufficient information to permit judge-
ment
Selective reporting (reporting bias) High risk Not all expected outcomes are reported
Other bias High risk Pooling interventions in cytotoxic group
Donadio 1972
Methods • Study design: open-label, parallel RCT
• Study timeframe: not reported
• Duration of follow-up: 3 years
Participants • Country: USA
• Setting: single centre
• Inclusion criteria: histologic evidence of kidney disease; one or more of the
following: serositis, arthralgia, and arthritis, skin rash consistent with SLE and
haematological abnormalities that included leukopenia, thrombocytopenia or a
circulating anticoagulant
• Number (randomised): treatment group (7); treatment group (9)
• Age range: 17 to 68 years
• Sex (M/F): 2/14
• Exclusion criteria: received > 7.5 mg prednisone daily in the previous 6 months
(except a dose of 20 mg daily for a maximum of 2 weeks); previous cytotoxic
medication other than antimalarial treatment
Interventions Induction therapy
• Treatment group
◦ Prednisone + AZA (2 mg/kg/body weight for 6 months); average duration of
therapy was 26 months for AZA
• Control group
◦ Prednisone: 60 mg/d for 2 months, 40 mg/d by 3 months, 30 mg/d by 4
months, 25 mg/d by 5 months and 20 mg/d by 6 months
Outcomes • Death
• Complete remission
• Relapse
• Toxicity
• CrCl
• Proteinuria
• Leucopenia (WCC < 3000/mL3)
Notes • Funding source: Mayo Foundation
Risk of bias
Bias Authors’ judgement Support for judgement
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Donadio 1972 (Continued)
Random sequence generation (selection
bias)
Low risk Participants allocated within each category
to treatment groupA or B according to ran-
dom selection. Table of random numbers
used. Each incoming set of 4 participants
assigned to 2 As and 2 Bs in random order
Allocation concealment (selection bias) Unclear risk Insufficient information to permit judge-
ment
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Open-label study
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Insufficient information to permit judge-
ment
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Insufficient information to permit judge-
ment
Selective reporting (reporting bias) High risk One or more reported primary outcomes
were not pre-specified
Other bias Low risk The study appears to be free of other
sources of bias
Donadio 1976
Methods • Study design: open-label, parallel RCT
• Study timeframe: commenced December 1971
• Duration of follow-up: 4 years
Participants • Country: USA
• Setting: single centre
• Inclusion criteria: SLE fulfilled 4 or more criteria used for the classification of the
disease; a positive LE-cell preparation or rosettes of neutrophils or nucleolysis; a
positive antinuclear-antibody test in titres ≥ 1:32 or elevated levels of anti-nDNA;
CrCl < 80 mL/min/1.73 m2 or a reduction of 25% in the CrCl as compared with the
initial clearance of a maximal period of three months; and adequate renal biopsy
showing diffuse proliferative GN
• Number (randomised): treatment group (24); control group (26)
• Mean age, range (years): treatment group (30.2, 16 to 60); control group (32.3,
17 to 50)
• Sex (M/F): treatment group (5/19); control group (4/22)
• Exclusion criteria: Previous CPA or immunosuppressive drugs in the last 6 months
Interventions Induction therapy
• Treatment group
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Donadio 1976 (Continued)
◦ Oral CPA: 2 mg/kg/d for 6 months
◦ Maintenance dose of prednisone to control other systemic manifestations
• Control group
◦ Prednisone: 60 mg/d tapered after 1 to 3 months
Outcomes • ESKD
• Death
• Toxicity
• Major infection
• Treatment failure: ESKD or final CrCl increased by 25%
• Relapse: reappearance of systematic features, reductions in CrCl, increased
proteinuria and changes in anti-nDNA and CH50 levels
• Current status on kidney function
• Proteinuria
• Avascular necrosis
Notes • Funding source: Mayo Foundation and Constance Belden Memorial Fund
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Random number tables used
Allocation concealment (selection bias) Unclear risk Insufficient information to permit judge-
ment
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Open-label study
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Insufficient information to permit judge-
ment
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Insufficient information to permit judge-
ment
Selective reporting (reporting bias) Low risk All expected outcomes are reported
Other bias Low risk The study appears to be free of other
sources of bias
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Doria 1994
Methods • Study design: parallel RCT
• Study timeframe: 1988 to 1993
• Duration of follow-up: every 4 weeks for 24 months and then every 8 weeks
thereafter
Participants • Country: Italy
• Setting: single centre
• Inclusion criteria: SLE (1982 ACR criteria); biopsy-proven class IV lupus
nephritis (WHO classification criteria); normal kidney function (SCr ≤ 1.2 mg/dL)
• Number (randomised): treatment group 1 (7); treatment group 2 (5); control
group (6)
• Mean age, range (years): treatment group 1 (30, 20 to 55); treatment group 2 (23,
15 to 32); control group (25, 15 to 46)
• Sex (M/F): 2/16 (not reported for individual groups)
• Exclusion criteria: Pregnancy; aged < 15 and > 80 years; infections; insulin-
dependent DM; history of malignancy; immunosuppressive therapy within a 6 month
period prior to renal biopsy
Interventions Induction therapy
• Treatment group
◦ Standard therapy
◦ PEX: 3 x times weekly for 1 week then twice a week for 2 weeks then once a
week for 2 months then once a fortnight for 3 months. 50% of the patient’s plasma
volume was removed and replaced with a 4% human albumin solution
• Treatment group 2
◦ Standard therapy
◦ IV MP: 500 mg daily for 3 consecutive days
• Control group
◦ Standard therapy
⋄ Prednisone: 2 mg/kg/d for 4 weeks with slow tapering (5 mg every 10
days)
⋄ AZA: 2 mg/kg/d
Outcomes • Death
• ESKD
• Doubling of SCr
• 24 h urinary protein
• Partial remission
• Complete remission
• Herpes zoster virus
• Leucopenia
Notes • Funding source: not reported
Risk of bias
Bias Authors’ judgement Support for judgement
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Doria 1994 (Continued)
Random sequence generation (selection
bias)
Unclear risk Study was described as randomised,
method of randomisation was not reported
Allocation concealment (selection bias) Unclear risk Insufficient information to permit judge-
ment
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Open-label study
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Insufficient information to permit judge-
ment
Incomplete outcome data (attrition bias)
All outcomes
Low risk No missing outcome data
Selective reporting (reporting bias) Low risk All relevant outcomes reported
Other bias Low risk The study appears to be free of other
sources of bias
Dyadyk 2001
Methods • Study design: parallel RCT
• Study timeframe: not reported
• Duration of follow-up: 19 years
Participants • Country: Ukraine
• Setting: not reported
• Inclusion criteria: diffuse proliferative lupus nephritis class IV (WHO
classification criteria)
• Number (randomised/analysed): treatment group 1 (21/21); treatment group 2
(38/38)
• Mean age: 36 years (not reported for groups)
• Sex (M/F): treatment group 1 (4/17); treatment group 2 (5/33)
• Exclusion criteria: not reported
Interventions Induction therapy
• Treatment group 1
◦ AZA: 1.5 to 2.0 mg/kg/d; mean total duration of therapy (18.9 months)
• Treatment group 2
◦ CPA: 1.5 to 3.5 mg/kg/d; mean total duration of therapy (21.7 months)
Outcomes • Death (all causes)
• Complete remission
• Partial remission
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Dyadyk 2001 (Continued)
Notes • Abstract-only publications
• 5 and 10 year survival follow-up
• Funding source: not reported
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Study was described as randomised,
method of randomisation was not reported
Allocation concealment (selection bias) Unclear risk Insufficient information to permit judge-
ment
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Open-label study
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Insufficient information to permit judge-
ment
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Insufficient information to permit judge-
ment
Selective reporting (reporting bias) High risk Not all relevant reported outcomes are re-
ported
Other bias Low risk The study appears to be free of other
sources of bias
El-Sehemy 2006
Methods • Study design: parallel RCT
• Study timeframe: commenced January 2004
• Duration of follow-up: 6 months
Participants • Country: Egypt
• Setting: single centre
• Inclusion criteria: all SLE patients; class III (1), class IV (10), class Vc (5), class Va
or b (4), class V (1), unclassified (1)
• Number (randomised/analysed): treatment group 1 (7/7); treatment group 2 (7/
7); treatment group 3 (8/8)
• Age range (years): treatment group 1 (18 to 29); treatment group 2 (19 to 24);
treatment group 3 (18 to 27)
• Sex (M/F): all female
• Exclusion criteria: uncontrolled infection; CNS manifestations; known neoplastic
disease; intention to become pregnant; previous immunosuppressive drugs < 3 months
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El-Sehemy 2006 (Continued)
prior to study
Interventions Induction therapy: duration of therapy not reported
• Treatment group 1
◦ CPA: 0.75 mg/m2
• Treatment group 2
◦ CSA: 1 to 2 mg/kg/d
• Treatment group 3
◦ AZA: 1 to 2 mg/kg/d
• All groups
◦ MP 500 to 1000 mg/kg/d for 3 to 5 days then oral prednisolone 0.5 mg/kg/
d for 4 weeks then tapered dose
Outcomes • Major infection
• Ovarian failure
• Proteinuria
• CrCl
Notes • Three participants from group 1 and one participant from group 3 shifted to
group II due to side effects or no response
• Funding source: not reported
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Study was described as randomised,
method of randomisation was not reported
Allocation concealment (selection bias) Unclear risk Insufficient information to permit judge-
ment
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Insufficient information to permit judge-
ment
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Insufficient information to permit judge-
ment
Incomplete outcome data (attrition bias)
All outcomes
Low risk No missing outcome data
Selective reporting (reporting bias) High risk Not all expected patient outcomes reported
Other bias High risk Baseline kidney function highly different
between groups. Reported outcomes with
patients transferred to different groups
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El-Shafey 2010
Methods • Study design: open label, RCT
• Study timeframe: February 2006 to December 2008
• Duration of follow-up: 24 weeks
Participants • Country: Egypt
• Setting: single centre
• Inclusion criteria: diagnosis of SLE (ACR criteria); newly diagnoses active
proliferative class III or IV lupus nephritis (WHO classification criteria); ≥15 years
• Number (randomised/analysed/completed 24 week induction phase): treatment
group 1 (24/24/20); treatment group 2 (23/23/19)
• Mean age ± SD (years): treatment group 1 (22.8 ± 5.8); treatment group 2 (23.8 ±
5.6)
• Sex (M/F): treatment group 1 (1/23); treatment group 2 (1/22)
• Exclusion criteria: eGFR < 30 mL/min, SCr > 200 µmol/L, WCC < 3.5 x 109/L,
major infection, history of cancer, alcohol or substance abuse, active peptic ulcer
disease, pregnant or lactating women, allergy to MMF or CPA and use of study drugs
in preceding 6 months
Interventions Induction therapy: duration of therapy was 6 months
• Treatment group 1
◦ MMF: 1 g twice daily for 6 months
• Treatment group 2
◦ IV CPA: 0.5 to 1.0 g/m2 for 6 months, median monthly dose 0.75 g/m2
• Both groups
◦ Prednisolone: 60 mg/d for 4 to 6 weeks, then 40 mg/d for 2 weeks followed
by tapering dose to 5 to 10 mg/d
Outcomes • Death (all causes)
• ESKD
• Remission: combined complete and partial remission at 6 months
• Complete renal remission: normal SCr, proteinuria < 0.5 g/d and urine RBC < 5
per HPF, without RBC cast
• Partial renal remission: improvement of 50% in all abnormal renal measurements
without deterioration (within 20%) of any measurement
• Major infection
• Herpes zoster virus
• Menstrual irregularities
• Diarrhoea
• Lymphopenia
• SCr
• eGFR
• Proteinuria
Notes • Funding source: not reported
Risk of bias
Bias Authors’ judgement Support for judgement
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El-Shafey 2010 (Continued)
Random sequence generation (selection
bias)
Unclear risk Study was described as randomised,
method of randomisation was not reported
Allocation concealment (selection bias) Unclear risk Insufficient information to permit judge-
ment
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Open-label study
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Insufficient information to permit judge-
ment
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Insufficient information to permit judge-
ment
Selective reporting (reporting bias) Low risk Study protocol available and pre-specified
outcomes were reported
Other bias Low risk The study appears to be free of other
sources of bias
Florez-Suarez 2004
Methods • Study design: parallel RCT
• Study timeframe: not reported
• Duration of follow-up: 1year
Participants • Country: Mexico
• Setting: not reported
• Inclusion criteria: lupus nephritis patients type IV and V
• Number (randomised): 20 (numbers per group not reported)
• Mean age ± SD (years): not reported
• Sex (M/F): not reported
• Exclusion criteria: not reported
Interventions Induction therapy: duration of treatment was 12 months
• Treatment group 1
◦ MMF: up to 2 g/d
• Treatment group 2
◦ IV CPA: monthly (does not reported)
• Both groups
◦ Prednisone
Outcomes • Complete remission
• Partial remission
• Treatment failure
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Florez-Suarez 2004 (Continued)
• Death
Notes • Abstract-only publication; authors contact - no reply
• Funding source: Roche Mexico
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Study was described as randomised,
method of randomisation was not reported
Allocation concealment (selection bias) Unclear risk Insufficient information to permit judge-
ment
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Open-label study
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Insufficient information to permit judge-
ment
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Insufficient information to permit judge-
ment
Selective reporting (reporting bias) High risk Data unable to be meta-analysed
Other bias High risk abstract-only publication; funded by
Roche Mexico
Fries 1973
Methods • Study design: open-label, RCT
• Study timeframe: not reported
• Duration of follow-up: 40 months
Participants • Country: USA
• Setting: single centre
• Inclusion criteria: SLE with antinuclear antibodies; involvement of two or more
organs
• Number (randomised/lupus nephritis): treatment group (10/5); control group
(12/5)
• Mean age ± SD (years): not reported
• Sex (M/F): not reported
• Exclusion criteria: not reported
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Fries 1973 (Continued)
Interventions Induction therapy
• Treatment group
◦ CPA: adjusted on the basis of weekly WCC, attempting to maintain a WCC
between 3500 and 4000 cells/cu mm
• Control group
◦ Prednisone: 1 mg/kg/d
Outcomes • Relapse
• Failure or response of treatment
Notes • Significant cross-over
• Funding source: Clinical Research centre Grant RR-70 and Biotechnology
Resources Branch of the National Institutes of Health RR00311-04
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Study was described as randomised,
method of randomisation was not reported
Allocation concealment (selection bias) Unclear risk Insufficient information to permit judge-
ment
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Open-label study
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Insufficient information to permit judge-
ment
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Insufficient information to permit judge-
ment
Selective reporting (reporting bias) High risk Not all relevant reported outcomes are re-
ported
Other bias High risk Heavy cross-over between groups
Fu 1997
Methods • Study design: parallel RCT
• Study timeframe: July 1994 to December 1995
• Duration of follow-up: 1 year
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Fu 1997 (Continued)
Participants • Country: Taiwan
• Setting: single centre
• Inclusion criteria: diagnosis of SLE (ACR 1982 revised criteria); class III-IV lupus
nephritis proven by biopsy (WHO classification criteria) with heavy proteinuria and
normal SCr
• Number (randomised): treatment group 1 (20); treatment group 2 (20)
• Mean age ± SD (years): treatment group 1 (10.2 ± 3.4); treatment group 2 (10.4 ±
3.1)
• Sex (M/F): not reported
• Exclusion criteria: not reported
Interventions Maintenance therapy: duration of treatment was 12 months
• Treatment group 1
◦ Oral CPA: 2 mg/kg/d
◦ Prednisolone: 2 mg/kg/d
• Treatment group 2
◦ CSA: 5 mg/kg/d every 12 h
• Both groups
◦ Oral prednisolone 2 mg/kg/d for 4 weeks ± pulsed MP (if unresponsive).
Dose of prednisolone tapered to 0.5 to 1 mg/kg as maintenance therapy for > 1 year
before randomisation
Outcomes • Proteinuria
• SCr
• CrCl
• Height velocity
• Height SDS
Notes • Funding source: not reported
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Participants randomly assigned (1:1, strati-
fied by race and biopsy class, non-blocked)
by a central computerised, interactive voice
response system random number table
Allocation concealment (selection bias) Low risk Used sealed, completely opaque, envelopes
numbered in sequence according to a table
of random numbers
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Open-label study
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Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Insufficient information to permit judge-
ment
Incomplete outcome data (attrition bias)
All outcomes
Low risk No missing outcome data
Selective reporting (reporting bias) High risk Not all of the study’s prespecified primary
outcomes were reported
Other bias Low risk Funding source not declared. The study ap-
pears to be free of other sources of bias
Furie 2014
Methods • Study design: double-blind, parallel RCT
• Study timeframe: not reported
• Duration of follow-up: 12 months
Participants • Countries: North America, Europe, South America, Asia, Australia, India, South
Africa, Turkey
• Setting: multinational (85 sites)
• Inclusion criteria: aged ≥ 18 years; diagnosis of SLE (ACR criteria); class III or IV
GN (ISN/RPS 2003 criteria or WHO 1982 classification), complement C3 or C4
levels below the lower limit of normal or elevated anti-dsDNA antibody titres at the
time of screening were further requirements for eligibility as were UPCR of ≥ 0.44
mg/mg (50 mg/mmol) at the time of screening and active urinary sediment (> 5 RBC
or >8 WBC/HPF or cylinduria at time of screening or the current flare
• Number (randomised/analysed): treatment group 1 (99/99); treatment group 2
(99/99); control group (100/100)
• Mean age ± SD (years): treatment group 1 (30.5 ± 10.6); treatment group 2 (31 ±
9.5); control group (31.8 ± 9)
• Sex (M/F): treatment group 1 (13/86); treatment group 2 (15/84); control group
(19/81)
• Exclusion criteria: evidence of severe, rapidly advancing kidney failure (i.e.
increase in SCr levels of ≥ 1 mg/dL within 1 month prior to screening or a SCr level of
> 3 mg/dL); evidence of severe unstable and or progressive central nervous system
lupus; use of immunosuppressive or immunomodulatory agents during the study
except for antimalarial agents and protocol defined MMF and glucocorticoids
Interventions Induction therapy: duration of therapy was 12 months
• Treatment group 1
◦ Abatacept 10/10 regimen: weight tiered (500 mg for patients weighing < 60
kg, 750 mg for patients 60-100 kg, 1,000 mg for patients >1 00 kg) on days 1, 15, 29,
57, 85, 113, 141, 169, 197, 225, 253, 281, 309, and 337
• Treatment group 2
• Abatacept 30/10 regimen: 30 mg/kg on days 1, 15, 29, and 57, followed by
abatacept approximating 10 mg/kg (weight tiered: 500 mg for patients weighing <60
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kg, 750 mg for patients 60-100 kg, 1,000 mg for patients >100 kg) on days 85, 113,
141, 169, 197, 225, 253, 281, 309, and 337
• Control group
◦ Placebo: consisted of dextrose 5% in water or normal saline on days 1, 15,
29, 57, 85, 113, 141, 169, 197, 225, 253, 281, 309, and 337
• All groups
◦ MMF (dosage based on race and prior treatment) and prednisone (or
prednisone equivalent), followed by adjustment or taper
Outcomes • Death (all causes)
• ESKD
• Complete response: 1) eGFR 90% of screening level if normal at screening visit,
or eGFR 90% of 6-month, pre-flare value if abnormal at screening, 2) UPCR 0.26 g/g
(30 mg/mmol), and 3) inactive urinary sediment (RBC and WBC/HPF within normal
limits of central laboratory assessments; no RBC or WBC casts)
• Partial response: SCr level normal or 125% of baseline; UPCR 50% of baseline
and 3.0 g/g (339 mg/mmol) if nephrotic, or 1.0 g/g (133 mg/mmol) if non-nephrotic;
urinary sediment inactive or 50% reduction in RBC/HPF from baseline; for
confirmation, assessed on day 337 and confirmed on day 365
• Major infection
• Herpes zoster virus
Notes • Funding source: Bristol Myers Squibb
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Study was described as randomised,
methodof randomisationwas not reported,
however patients were stratified according
to prior treatment
Allocation concealment (selection bias) Unclear risk Insufficient information to permit judge-
ment
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Double-blind, double dummy placebo
study
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Insufficient information to permit judge-
ment
Incomplete outcome data (attrition bias)
All outcomes
Low risk Not all relevant reported outcomes are re-
ported
Selective reporting (reporting bias) Low risk Study protocol available and pre-specified
outcomes were reported
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Other bias High risk Sponsor included in data analysis/author-
ship
Ginzler 1976
Methods • Study design: cross-over RCT
• Study timeframe: not reported
• Duration of follow-up: 4 months then crossed over
Participants • Country: USA
• Setting: single centre
• Inclusion criteria: diagnosis of SLE (ARA criteria); active kidney disease as
manifested by either 1) the new appearance of hypocomplementaemia, azotaemia (SCr
> 1.2 mg%), urinary protein excretion >200 mg/24 h; cellular casts or more than 10
RBC/HPF in the urine sediment, or hypertension, or 2) deterioration in renal status in
a patient with previously known renal disease, including either the new development of
any of the above manifestations, or a 50% increase in SCr, or a 200% increase in
urinary protein excretion; a renal biopsy demonstrating diffuse proliferative or
membranous GN
• Number (randomised): treatment group 1 (8); treatment group 2 (6)
• Mean age ± SD (years): treatment group 1 (28.2 ± 8.5); treatment group 2 (25.8 ±
6.2)
• Sex (M/F): not reported
• Exclusion criteria: SCr > 3 mg/dL, previous exposure to cytotoxic drugs
Interventions Induction therapy: duration of treatment was 4 months
• Treatment group 1
◦ Oral AZA: 1.25 mg/kg/d
◦ CPA: 1.25 mg/kg/d
• Treatment group 2
◦ AZA: 2.5 mg/kg/d
• Both groups
◦ Prednisone prior to randomisation (minimum dose of 1 mg/kg/d for 3
weeks); steroid dose was tapered throughout the study by a maximum of 5 mg
decrements at each clinic visit, in accordance with parameters of clinical disease activity
Outcomes • Death
• ESKD
• Toxicity
• Proteinuria
• CrCl
• Ovarian failure
• Infection
Notes • Funding source: Supported by a grant from Lupus Erythematosus Foundation
Risk of bias
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Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Study was described as randomised,
method of randomisation was not reported
Allocation concealment (selection bias) Unclear risk Insufficient information to permit judge-
ment
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Double-blind with a cross-over to other
treatment under certain conditions (prede-
termined therapeutic failures)
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Insufficient information to permit judge-
ment
Incomplete outcome data (attrition bias)
All outcomes
Low risk No missing outcome data
Selective reporting (reporting bias) Low risk Study protocol available and prespecified
outcomes were reported
Other bias High risk Cross-over design and reporting of results,
difficult to separate treatment effects
Ginzler 2005
Methods • Study design: open-label, non-inferiority RCT
• Study timeframe: December 1999 to October 2003
• Duration of follow-up: 24 weeks
Participants • Country: USA
• Setting: multicentre (19 sites)
• Inclusion criteria: diagnosis of SLE (ACR criteria), biopsy-proven lupus nephritis
class III, IV or V, clinical activity defined by one of; incident decrease in kidney
function, proteinuria (> 0.5 g/24 h), microscopic haematuria (> 5 RBC/HPF);
participants with class III or V required to have SCr > 1.0 mg/dL or proteinuria > 2 g/
24 h
• Number (randomised/analysed): treatment group 1 (71/71); treatment group 2
(69/69)
◦ 113 had diffuse proliferative lupus nephritis; 27 had pure membranous
• Mean age ± SD (years): treatment group 1 (32.5 ± 10); treatment group 2 (31.0 ±
9.0)
• Sex (M/F): treatment group 1 (10/61); treatment group 2 (4/65)
• Ethnicity (Black/white/Hispanic/Asian/other): treatment group 1(43/12/10/6/0);
treatment group 2 (36/12/18/2/1)
• Exclusion criteria: CrCl < 30 mL/min, SCr > 3.0 mg/dL; severe co-existing
conditions precluding immunosuppression or requiring IV antibiotics; prior treatment
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with MMF; treatment with IV CPA in last 12 months; treatment within last 30 days;
pregnancy or lactation
Interventions Induction therapy: duration of therapy was 24 weeks
• Treatment group 1
◦ MMF: 0.5 g twice daily to increase to max 1 g 3 times/d
• Treatment group 2
◦ IV CPA: 0.5 g/m2 BSA increased to 1.0 g/m2
• Both groups
◦ Prednisone at a dose of 1 mg/kg/d, with tapering by 10 to 20% at 1 week or
2 week intervals, on the basis of clinical improvement
◦ The new appearance or worsening of manifestations of extrarenal disease
could be treated with one 3-day pulse of IV MP or increased dose of prednisone to a
maximum of 2 mg/kg/d
Outcomes • Death
• ESKD
• Doubling of SCr
• Relapse
• Stable kidney function
• Major infection
• Herpes zoster
• Ovarian failure
• GI upset
• Diarrhoea
• Lymphopenia (< 800 lymphocytes/mm3)
• Complete remission in proteinuria
• Partial remission in proteinuria
• Complete renal remission: defined at 24 weeks as return to within 10% of normal
values of SCr levels, proteinuria, and urine sediment
• Partial renal remission: defined at 24 weeks as improvement of 50% in all
abnormal renal measurements, without worsening (within 10 percent) of any
measurement
• Treatment failure: patients in whom treatment failed included all those without
complete or partial remission at 24 weeks, plus those who stopped treatment for any
reason
• SCr
• Daily proteinuria
Notes • 1 participant on MMF crossed-over to CPA and 2 participants on IV CPA
crossed over to MMF
• Funding source: FDA’s Orphan Products Development program and a
supplemental grant from Roche Laboratories
Risk of bias
Bias Authors’ judgement Support for judgement
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Random sequence generation (selection
bias)
Low risk Treatment assigned at central site with the
use of sealed envelopes
Allocation concealment (selection bias) Low risk Sealed envelopes used
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Open-label study
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Insufficient information to permit judge-
ment
Incomplete outcome data (attrition bias)
All outcomes
Low risk No missing outcome data
Selective reporting (reporting bias) High risk Due to early termination, primary outcome
as per protocol not reported; Not all ex-
pected outcomes reported
Other bias High risk The study was terminated early and there
was heavy cross-over between study arms.
Funding provided by a supplemental grant
from Roche laboratories
Gourley 1996
Methods • Study design: open-label, parallel RCT
• Study timeframe: from mid 1990
• Duration of follow-up: > 5 years
Participants • Country: USA
• Setting: single centre
• Inclusion criteria: SLE; GN was defined as a sediment on 2 or more urinalysis
that showed either 10 or more RBC/HPF or erythrocyte or leukocyte casts (without
evidence of infection) or both plus biopsy-proven active proliferative lupus GN (within
3 months of study entry); 79/82 class III/IV on biopsy; 3/82 no biopsy
• Number (randomised): treatment group 1 (27); treatment group 2 (28); control
group (27)
• Mean age (years): treatment group 1 (30); treatment group 2 (31); control group
(30)
• Sex (M/F): treatment group 1 (6/21); treatment group 2 (3/25); control group (5/
22)
• Exclusion criteria: cytotoxic drug treatment > 2 weeks and with 6 weeks of start
date; 10 weeks of CPA therapy; pulse therapy of corticosteroids within 6 weeks of start
of study; oral corticosteroids > 0.5 mg/kg/d; active or chronic infection; pregnancy;
insulin-dependent DM; allergy to study medication
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Interventions Induction therapy
• Treatment group 1
◦ IV CPA: 0.75 g/m2 boluses monthly for 6 months then 3 monthly for at
least 2 years
• Treatment group 2
◦ IV MP: as per control group
◦ IV CPA: as per treatment group 1
• Control group
◦ IV MP: 3 doses (1 g/m2) over 3 consecutive days then one dose monthly for
12 months
• All groups
◦ Initially given oral prednisone (0.5 mg/kg/d) for 4 weeks. The prednisone
dose was then tapered by 5 mg every other day each week to the minimal dose required
to control extrarenal disease or 0.25 mg/kg every other day, whichever was greater
◦ For severe extrarenal flares of lupus, patients were permitted to receive
prednisone, 1.0 mg/kg per day for 2 weeks
Outcomes • Death
• ESKD
• Doubling of SCr
• Renal remission
• Treatment failure: ≥ 10 RBC/HPF, cellular casts, proteinuria (>1 g of protein/d)
• Relapse: reactivation of renal disease after 6 or more months of remission
• One or more infections
• Herpes zoster virus infection
• Amenorrhoea
• Avascular necrosis
Notes • 2 participants lost to follow-up
• Funding source: Arthritis Foundation
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Masked cards from table of random num-
bers
Allocation concealment (selection bias) Unclear risk Using masked card but no description
methods of allocation concealment
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Open-label study
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Outcome data with the exception of ad-
verse events, were collected in a blinded
manner
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Incomplete outcome data (attrition bias)
All outcomes
Low risk No missing outcome data; participants at
endpoints censored but considered in final
analysis
Selective reporting (reporting bias) Low risk Study protocol available and prespecified
outcomes were reported
Other bias Low risk The study appears to be free of other
sources of bias
Grootscholten 2006
Methods • Study design: parallel RCT
• Study timeframe: September 1995 to September 2001
• Duration of follow-up: median follow-up 5.7 years (interquartile range 4.1 to 7.2
years); unintentional skewed distribution (resulting from stratification per centre and
small contribution of some centres). Median extended follow-up was 9.6 years (range
0.1 to 13.2 years)
Participants • Country: Netherlands
• Setting: multicentre (number of sites not reported)
• Inclusion criteria: biopsy-proven lupus nephritis (PALGA), diagnosis of SLE
(ACR criteria); 18 to 60 years; CrCl > 25 mL/min; if already known to have
proliferative lupus nephritis, renal biopsy < 1 year before; WHO class IV or Vd must
have signs of active nephritis or deterioration of kidney function; class III or Vc lupus
nephritis had to meet both criteria
• Number (randomised/analysed): treatment group 1 (50/50); treatment group 2
(37/37)
• Mean age, range (years): treatment group 1 (30, 24 to 47); treatment group 2 (33,
26 to 39)
• Sex (M/F): treatment group 1 (6/44); treatment group 2 (9/28)
• Exclusion criteria: decline in kidney function (> 30% increase in SCr) in month
before inclusion; active infection; malignancy < 5 years before randomisation;
pregnancy or no contraceptives during first 2.5 years of treatment; hepatitis or cirrhosis
of liver; active peptic ulcer; leucocytopenia (< 3 x 109/L) or thrombocytopenia (< 100 x
109/L with suppressed bone marrow; allergy to AZA or CPA
Interventions Induction and maintenance therapy
• Treatment group 1
◦ IV CPA: 750 mg/m2, 13 pulses in 2 years, oral prednisolone cumulative
corticosteroid dose (11 g)
• Treatment group 2
◦ Oral AZA: 2 mg/kg/d in 2 years, IV MP (3 x 3 pulses of 1000 mg) and oral
prednisolone (initially 1 mg/kg/d for 4 weeks, 0.75 mg/kg/d for 4 weeks, 0.50 mg/kg/d
for 4 weeks and thereafter tapered by 5mg every 4 weeks to a final dose of 10 mg daily
after 6 months)
• Both groups
◦ Switched to long-term AZA (2 mg/kg) plus prednisolone (10 mg/d) after 2
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years
Outcomes • Death
• ESKD
• Doubling of SCr
• Deterioration of kidney function
• major infection
• Ovarian failure
• Daily proteinuria
• Renal relapse: could occur after week 12, and was defined as doubling of the
lowest obtained SCr so far and/ or development of either a nephrotic syndrome
(proteinuria > 3.5 g/d and serum albumin < 30 g/L), while the lowest protein excretion
so far had been ≤ 2.0 g/d repeatedly, or proteinuria < 1.5 g/d without other causes, in a
previously non-proteinuric patient
Notes • 8/87 class III or Vc class IV or Vd 79/97 13/87 given previous cytotoxics IV CPA:
7/50 (14%) AZA: 6/37 (16%) If 1y failure (DSC) switched to other arm of study 1
lost to follow-up in each group
• Funding source: Dutch Kidney Foundation, Dutch League against Rheumatism
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomisation performed at a central of-
fice with a computer program, using the
minimisation determinants: centre, SCr (<
150 or > 150 µmol/L), WHO class III or
IV, previous treatment with immunosup-
pressive medication for lupus nephritis
Allocation concealment (selection bias) Unclear risk Central officewith computer program.Not
sufficiently clear to determine risk
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Open-label study
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Insufficient information to permit judge-
ment
Incomplete outcome data (attrition bias)
All outcomes
Low risk No missing outcome data
Selective reporting (reporting bias) Low risk Study protocol available and pre-specified
outcomes were reported
111Immunosuppressive treatment for proliferative lupus nephritis (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Grootscholten 2006 (Continued)
Other bias Low risk Funding from Dutch Kidney Foundation
and Dutch League against Rheumatism.
One author disclosed speaking fees from
Novartis. The study appears to be free of
other sources of bias
Hahn 1975
Methods • Study design: open-label, RCT
• Study timeframe: not reported
• Duration of follow-up: 2 years
Participants • Country: USA
• Setting: single centre
• Inclusion criteria: SLE diagnosed using established specific criteria (positive
antinuclear antibodies, a score of severe points or more on major-minor criteria scale;
all patients also met the preliminary criteria for SLE (ARA); active life-threatening
disease (severe nephritis, central nervous system involvement, haemolytic anaemia,
thrombocytopenia, myocarditis, lupus crisis)
• Number (randomised): treatment group (11); control group (13)
• Mean age ± SD (years): treatment group (33.5 ± 13.2); control group (31.7 ± 13.
9)
• Sex (M/F): treatment group (2/9); control group (2/11)
• Exclusion criteria: prior treatment with cytotoxic drugs; 20 mg prednisone/d
during the preceding 6 weeks
Interventions Induction therapy: duration of therapy was 24 months
• treatment group
◦ Oral AZA: 3 to 4 mg/kg/d
◦ Prednisone: as per control group
• Control group
◦ Prednisone: daily oral dose of 40 to 60 mg was maintained for 4 to 6
months. After prednisone was maintained at 40 to 60 mg daily for 6 months in both
groups, it was tapered slowly (by 5 mg increments every 2 weeks to a level of 30 mg
daily, then by 2.5 mg increments every 2 weeks)
Outcomes • Death
• Toxicity
• Major infection
• Infection
• Proteinuria
• Remission of proteinuria
• CrCl
• SCr
Notes • 2/24 lost to follow-up
• Funding source: US Public Health Service grants AM17469 and AM05548 and
Public Health Service Research grant FR-36 from the General Clinical Research centre
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Branch, Division of Research Facilities and Resources; and the Arthritis Foundation
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Slips of paper bearing letters A or B sealed
in envelopes then placed in a drawer. On
randomising patient, envelopes drawn ran-
domly from drawer
Allocation concealment (selection bias) Low risk Sealed envelopes used in randomisation
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Open-label study
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Insufficient information to permit judge-
ment
Incomplete outcome data (attrition bias)
All outcomes
Low risk No missing outcome data
Selective reporting (reporting bias) High risk Not all expected clinical outcomes were re-
ported
Other bias Low risk The study appears to be free of other
sources of bias
Hong 2007
Methods • Study design: open-label, parallel RCT
• Study timeframe: not reported
• Duration of follow-up: 6 months
Participants • Country: China
• Setting: not reported
• Inclusion criteria: diffuse proliferative lupus nephritis on renal biopsy; all > 2 g/d
proteinuria and SCr < 3 mg/dL
• Number (randomised/analysed): treatment group 1 (13/13); treatment group 2
(12/12)
• Mean age ± SD: 30.7± 5.1 years
• Sex (M/F): 2/23
• Exclusion criteria: not reported
Interventions Induction therapy
• Treatment group 1
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◦ Oral FK506 (TAC): 0.1 mg/kg/d
• Treatment group 2
◦ IV CPA: 0.5 to 0.75g/m2 monthly
• Both groups
◦ Prednisolone: 0.8 mg/kg/d
Outcomes • Stable kidney function
• No response
• Infection
• Complete remission (urinary protein excretion < 0.4 g/24 h, no active urinary
sediment (urinary RBC < 10×104/mL), serum albumin > 35 g/L, SCr in normal ranges)
• Partial remission (between complete remission and no response - referred to
urinary protein excretion > 2 g or the reduction less than the baseline value, serum
albumin < 30 g/L, or increment of SCr > 50% of the baseline value)
• Proteinuria
Notes • Abstract-only publication
• Funding source: not reported
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Insufficient information to permit judge-
ment
Allocation concealment (selection bias) Unclear risk Insufficient information to permit judge-
ment
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Open-label study
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Insufficient information to permit judge-
ment
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Insufficient information to permit judge-
ment
Selective reporting (reporting bias) High risk Not all expected outcomes reported
Other bias Unclear risk Abstract-only publication; insufficient in-
formation to permit judgement
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Methods • Study design: RCT
• Study timeframe: September 1996 to September 2000
• Duration of follow-up: 10 years
Participants • Country: Europe (countries not reported)
• Setting: multinational (19 sites)
• Inclusion criteria: diagnosis of SLE (ACR criteria); age ≥ 14 years; biopsy-proven
proliferative lupus GN (WHO class III, IV, Vc, or Vd); proteinuria 500 mg/24 h; 69/
90 class IV or Vc/Vd
• Number (randomised): treatment group 1 (46); treatment group 2 (44)
• Mean age ± SD (years): treatment group 1 (30 ± 11); treatment group 2 (33 ± 12)
• Sex (M/F): treatment group 1 (3/43); treatment group 2 (3/41)
• Exclusion criteria: CPA or AZA in previous year; > 15 mg/d prednisolone during
preceding month; renal thrombotic microangiopathy; pre-existing CKD; pregnancy;
previous malignancy - except skin or cervical intraepithelial neoplasia’s; DM; severe
toxicity or immunosuppressive drugs; anticipated poor compliance
Interventions Induction and maintenance therapy
• Treatment group 1
◦ High dose IV CPA: received 8 pulses within a year (6 monthly pulses
followed by 2 quarterly pulses. The initial IV CPA dose was 0.5 g/m2 of body surface
area; subsequent doses were increased by 250 mg according to the WBC count nadir
measured on day 14, with a maximum of 1,500 mg per pulse
• Treatment group 2
◦ Low dose IV CPA: received 6 fortnightly IV CPA pulses at a fixed dose of
500 mg
• Both groups
◦ All patients received 3 daily pulses of 750 mg of IV MP, followed by oral
prednisolone (or equivalent) at an initial dosage of 0.5 mg/kg/d for 4 weeks. A dosage
of 1 mg/kg/d was allowed in critically ill patients (those with renal impairment or
severe extrarenal disease), glucocorticoid therapy (5-7.5 mg of prednisolone per day)
was maintained at least until month 30 after inclusion; after 4 weeks, prednisolone (or
equivalent) dosages were tapered by 2.5 mg every 2 weeks.
◦ Both treatment arms, AZA (2 mg/kg/d) was started 2 weeks after the last
CPA injection and continued at least until month 30 after study inclusion
Outcomes • Death
• ESKD
• Renal remission: defined as 10 RBC/HPF and a 24-hour urinary protein level < 1
g, in the absence of a doubling of the SCr level; and the number of severe flares
• Treatment failure: defined as any of the following 3 features: 1. Absence of a
primary response A. For patients with a baseline SCr ≥ 1.3 mg/dL but ≤ 2.6 mg/dL,
absence of a primary response was defined as failure of the SCr to decrease to < 1.3 mg/
dL at 6 months; B. For patients with a baseline SCr > 2.6 mg/dL, absence of a primary
response was defined as failure of the SCr level to improve by 50% at 6 months; C. For
patients with nephrotic syndrome at baseline (serum albumin level < 3.5 g/dL and 24-
hour urinary protein level ≥ 3 g/d), but without renal impairment (SCr < 1.3 mg/dL),
absence of a primary response was defined as the persistence of nephrotic syndrome at
6 months; 2. A glucocorticoid-resistant flare (defined as a severe flare that did not
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respond to a 1-month increase in the glucocorticoid dosage); 3. A doubling of the SCr
over the lowest value reached at any time during the follow-up and confirmed on 2
consecutive visits 1 month apart
• Doubling of SCr
• Relapse: severe renal flare was defined as 1 of the following 3 features: renal
impairment, increase in proteinuria, or severe systemic disease. Renal impairment was
defined as an SLE-related increase of 33% in the SCr within a 1-month period; An
increase in proteinuria defined as recurrence or appearance of nephrotic syndrome
(albuminaemia ≤ 3.5 g/dL and proteinuria ≥ 3 g/24 h); In patients with low-grade
proteinuria at baseline (≥ 0.5 g but ≤1 g in 24 h); a 3-fold increase in 24-hour urinary
protein levels within a 3-month period was also considered a severe flare, provided that
it was accompanied by microscopic haematuria and a 33% reduction of serum C3
levels within a 3-month period
• Toxicity
• Proteinuria
• Infection
• Herpes zoster virus
• Ovarian failure
• Leucopenia: ≤ 4000/µL
Notes • Follow-up: median 41 month follow-up; 1 patient lost to follow-up. 73 month
follow-up; 5 participants lost to follow-up, 10 year follow-up
• Funding source: supported by the European League against Rheumatism
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomisation by minimisation
Allocation concealment (selection bias) Unclear risk Insufficient information to permit judge-
ment
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Insufficient information to permit judge-
ment
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Insufficient information to permit judge-
ment
Incomplete outcome data (attrition bias)
All outcomes
Low risk No missing outcome data
Selective reporting (reporting bias) Low risk Study protocol available and pre-specified
outcomes were reported
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Other bias Low risk Supported by the European League Against
Rheumatism. The study appears to be free
of other sources of bias
Jayne 2013
Methods • Study design: double-blind double-dummy RCT
• Study timeframe: not reported
• Duration of follow-up: 6 months
Participants • Country: not reported
• Setting: multicentre (number of sites not reported)
• Inclusion criteria: active lupus nephritis
• Number (randomised): treatment group 1 (16); treatment group 2 (16); control
group (15)
• Mean age ± SD (years): not reported
• Sex (M/F): not reported
• Exclusion criteria: not reported
Interventions Induction therapy: duration of treatment was 6 months
• Treatment group 1
◦ High-dose laquinimod: oral 1 mg/d
• Treatment group 2
◦ Low-dose laquinimod: oral 0.5 mg/d
• Control group
◦ Placebo
• All groups
◦ All patients received MMF and prednisone (or equivalent)
Outcomes • Death
• Remission
• Kidney function
• Adverse events
Notes • Abstract-only publication
• Funding source: not reported
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Insufficient information to permit judge-
ment
Allocation concealment (selection bias) Unclear risk Insufficient information to permit judge-
ment
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Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Double-blind, double dummy placebo
study
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Insufficient information to permit judge-
ment
Incomplete outcome data (attrition bias)
All outcomes
Low risk No missing outcome data
Selective reporting (reporting bias) High risk Not all prespecified outcomes were re-
ported
Other bias Unclear risk Abstract-only publication; insufficient in-
formation to permit judgement
Kaballo 2016
Methods • Study design: parallel RCT
• Study timeframe: March 2008 to August 2011
• Duration of follow-up: 36 months
Participants • Country: Sudan
• Setting: multicentre (2 sites)
• Inclusion criteria: aged 12 to 75 years and have been diagnosed with SLE (ACR
revised criteria); lupus nephritis criteria included persistent proteinuria > 0.5 g/d and
presence of active urine sediment; renal biopsies were performed at presentation, only
patients who had a histological diagnosis of severe proliferative Class III and IV and/or
membranous Class V lupus nephritis (ISN/RPS 2003 classification) were enrolled
• Number (randomised): treatment group 1 (41); treatment group 2 (40)
• Mean age ± SD (years): treatment group 1 (27.1 ± 9.8); treatment group 2 (29.4 ±
11.6)
• Sex (M/F): treatment group 1 (3/38); treatment group 2 (3/37)
• Exclusion criteria: ESKD; malignancy; severe cardiovascular or liver disease; severe
infection
Interventions Maintenance therapy
• Treatment group 1
◦ Oral MMF: 22 mg/kg/d, range 1000 to 3000 mg/d. The dosages remained
unchanged within the 1st year, and then they were reduced by 25% in stable patients
after the 1st year and continued for at least another year before further tapering
• Treatment group 2
◦ Oral AZA: 2 mg/kg/d. The dosages remained unchanged within the 1st year,
and then they were reduced by 25% in stable patients after the 1st year and continued
for at least another year before further tapering
• Both groups
◦ All patients underwent induction therapy using IV pulse CPA (500 mg/m2
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of body surface area with a maximum dose ≤ 500 mg) monthly for six months, plus 3
consecutive pulses of IV MP (15 mg/kg/d maximum 500 mg). All patients initially
received oral prednisone (1 mg/kg)
Outcomes • Death
• ESKD
• Complete remission: defined as reduction in proteinuria to ≤0.2 g/d with normal
SCr
• Partial remission: defined as a reduction of proteinuria from nephrotic range to a
range between 0.2 and 2.0 g/d or reduction of proteinuria more than 50% with normal
SCr
• Relapse: patients in complete or partial remission, defined by an increase in SCr
levels 50% or more over the last value besides a nephritic urinary sediment and
generally increased proteinuria (nephritic flare) or by an increase in proteinuria without
modification of SCr (proteinuric flare). Proteinuria had to increase by at least 2 g/d if
the basal proteinuria was <3.0 g/d, or double if the patient had already nephrotic range
proteinuria
• Doubling of SCr
• Major infection
• Alopecia
• Leucopenia
• Nausea
• Vomiting
• Diarrhoea
• Proteinuria
Notes • Funding source: not reported
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Patients stratified by block randomisation
(stratification factors were gender, age and
weight)
Allocation concealment (selection bias) Unclear risk Insufficient information to permit judge-
ment
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Insufficient information to permit judge-
ment
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Insufficient information to permit judge-
ment
Incomplete outcome data (attrition bias)
All outcomes
Low risk No missing outcome data
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Selective reporting (reporting bias) Low risk Trial registration was not reported, all ex-
pected outcomes were reported
Other bias Low risk The study appears to be free of other
sources of bias
Kamanamool 2017
Methods • Study design: open-label, parallel RCT
• Study timeframe: 1 April 2012 to 31 March 2016
• Duration of follow-up: 12 months
Participants • Country: Thailand
• Setting: multicentre (number of sites not reported)
• Inclusion criteria: patients with active, biopsy-proven lupus nephritis Class III, IV
or V (ISN/RPS) 2003 criteria within 24 weeks of randomisation and who were ANA
(ANA) or anti-double stranded DNA (anti-dsDNA) positive
• Number (randomised/analysed): treatment group 1 (42/42); treatment group 2
(41/41)
◦ Treatment group 1: class III or IV (29), class V or III/IV + V (13)
◦ Treatment group 2: class III or IV (28), class V or III/IV + V (13)
• Mean age ± SD (years): treatment group 1 (34.1 ± 11.1); treatment group 2 (31.7
± 10.5)
• Sex (M/F): treatment group 1 (1/40); treatment group 2 (3/38)
• Exclusion criteria: Severe extra-renal manifestations; previous therapy with
calcineurin inhibitor or MMF or CPA within the previous four months before
randomisation; allergy to macrolide antibiotics; uncontrolled hypertension (SBP > 160
mm Hg or DBP > 100 mm Hg); severely deteriorated kidney function or rapid
progressive crescentic GN; severe myocarditis or cardiomyopathy; requiring
plasmapheresis or IVIG; severe infection or active TB; active hepatitis and evidence of
chronic liver disease; HIV infection; MD; pregnancy; hypersensitivity or
contraindication to MMF, mycophenolic acid, TAC, corticosteroids or any
components of these drug products
Interventions Induction therapy
• Treatment group 1
◦ Oral MMF: initiated at a dose of 500 mg twice daily (patients > 50 kg and
eGFR > 60 mL/min) for 2 weeks. It was then advanced to 750 mg twice daily in lupus
nephritis patients weighing less than 50 kg, or 1000 mg twice daily in lupus nephritis
patients weighing 50 kg or more. Dosage of MMF was prescribed according to the
ACR recommendations, which suggest MMF 2 g/d for Asians
• Treatment group 2
◦ Oral TAC: started at a dosage of 0.1 mg/kg/d divided into two daily doses at
12-hour intervals, and the dosage was titrated to achieve trough blood concentrations
of 6-10 ng/mL in the first and second month and then 4-8 ng/mL thereafter
• Both groups
◦ All patients received prednisone at a dose of 0.5 to 0.7 mg/kg/d (maximum
60 mg/d), with tapering by 5 to 10 mg/d every two weeks until a dose of 5 mg/d had
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been achieved, and this dosage was maintained until the end of 24 weeks
◦ All patients who had remission received AZA 1 to 2 mg/kg/d for 24 weeks as
standard treatment. For patients who did not respond to the induction therapy,
treatment depended on physician decision
Outcomes • Death
• Complete remission
• SCr
• Disease activity
Notes • Funding source: Astellas Pharma (Thailand) Co., Ltd provided study drug and
budget
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “We stratified patients into two strata ac-
cording to the classification of renal pathol-
ogy (Class III-IV LN or Class V III/IV LN)
. Patients were randomly assigned 1:1 to a
TAC group or an MMF group.”
Allocation concealment (selection bias) Low risk To preserve the allocation concealment, the
generation of blocks of four to six randomi-
sation lists was electronically produced at
Ramathibodi Hospital and web-based ran-
domizations was used
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Open-label study
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Insufficient information to permit judge-
ment
Incomplete outcome data (attrition bias)
All outcomes
Low risk No missing outcome data
Selective reporting (reporting bias) Low risk Study protocol available and pre-specified
outcomes were reported
Other bias Low risk “Astellas Pharma (Thailand) Co., Ltd. pro-
vided study drug and funded the study but
had no role in study design, data collection,
data analysis, data interpretation or conclu-
sions.” The study appears to be free of other
sources of bias
121Immunosuppressive treatment for proliferative lupus nephritis (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Lewis 1992
Methods • Study design: open-label, parallel RCT
• Study timeframe: 1 April 1981 to 30 September 1986
• Duration of follow-up: mean follow-up 2.5 years with termination of study
Participants • Country: USA
• Setting: multicentre
• Inclusion criteria: ≥ 16 years; SLE (ARA criteria); qualifying biopsy; 35
participants with class IV disease
• Number (randomised): treatment group 1 (40); treatment group 2 (46)
• Mean age ± SD (years): treatment group 1 (31 ± 11); treatment group 2 (33 ± 14)
• Sex (M/F): treatment group 1 (7/33); treatment group 2 (7/39)
• Exclusion criteria: pregnancy; SCr > 6 mg/dL; previous plasmapheresis; history of
primary myocardial disease; cancer within last 5 years; prednisone-associated psychosis;
peptic ulcer; active liver disease
Interventions Induction therapy
• Treatment group 1
◦ Oral CPA
◦ Corticosteroids
◦ PEX: 3 x weekly for 4 weeks
• Treatment group 2
◦ Oral CPA
◦ Corticosteroids
Outcomes • Death
• ESKD
• Remission: SCr ≤ 1.2 mg/dL and a 24-hour urinary protein of ≤ 0.2 g/d
• Toxicity
• Infection
• Herpes zoster virus infection
• SCr
• Proteinuria
Notes • Funding source: Public health service
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Stratified according to clinic by central co-
ordination centre
Allocation concealment (selection bias) Low risk Generated by Biostatistical Coordinating
centre which issued treatment assignments
by telephone after confirmation of patient
eligibility
Blinding of participants and personnel
(performance bias)
High risk Open-label study
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All outcomes
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Insufficient information to permit judge-
ment
Incomplete outcome data (attrition bias)
All outcomes
Low risk Nomissing outcome data; 1 patient lost-to
follow-up
Selective reporting (reporting bias) Low risk Study protocol available and pre-specified
outcomes were reported
Other bias High risk The study was terminated early
Li 2009c
Methods • Study design: open-label, pilot RCT
• Study timeframe: not reported
• Duration of follow-up: 48 weeks
Participants • Country: Hong Kong
• Setting: single centre
• Inclusion criteria: diagnosis of SLE (revised ACR criteria); biopsy-proven lupus
nephritis class III or IV (WHO classification criteria), clinical activity index ≥ 6/24,
proteinuria ≥ 1.5 g/24 h, albumin ≤ 35 g/L; 3/19 participants with class IV disease
• Number (randomised/analysed): treatment group 1 (9/9); treatment group 2 (10/
10)
• Mean age ± SD (years): treatment group 1 (40.3 ± 13.9); treatment group 2 (39.6
± 8.6)
• Sex (M/F): treatment group 1 (0/9); treatment group 2 (1/9)
• Exclusion criteria: severe infection in last 3 months; HIV; HBV or HCV; active
TB; pregnancy; on oral/IV CPA, AZA or MMF within 8 weeks or prednisolone ≥ 0.5
mg/kg/d within 4 weeks; history of cancer; DM or kidney failure leading to dialysis
Interventions Induction therapy
• Treatment group 1
◦ RTX: 1000 mg, treatment repeated on day 15
• Treatment group 2
◦ RTX: 1000 mg, 250 mg MP day 1, followed by IV CPA 750 mg, treatment
repeated once on day 15
• Both groups
◦ All participants received 250 mg IV MP on day 1, oral prednisolone 30 mg/
d from day 2 to day 5, then 0.5 mg/kg for 4 weeks, then dose reduction 5 mg every 2
weeks
◦ Patients were pre-medicated with chlorpheniramine (10 mg IV) and
paracetamol (1 g orally) 30 min before IV infusions
◦ All participants on ACEi before the study and continued on same dose
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Outcomes • Major infection
• Herpes zoster virus infection
• Complete response: if the baseline (at week 0) SLEDAI scores were greater than 0
and the follow-up score was equal to 0
• Partial response: if the baseline SLEDAI scores were greater than the follow-up
score but the follow-up score was not equal to 0
• Treatment failure: worse disease activity
• CrCl
• Proteinuria
Notes • Funding source: Roche provided the study drug
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomisation according to a randomisa-
tion table kept by a third party
Allocation concealment (selection bias) Low risk Randomisation table kept by a third party
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Open-label study
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Insufficient information to permit judge-
ment
Incomplete outcome data (attrition bias)
All outcomes
Low risk No missing outcome data
Selective reporting (reporting bias) High risk Not all expected outcomes were reported
Other bias Low risk “...Roche provided study drug but had no
role in study design, data collection, data
analysis, data interpretation or writing of
the report...” The study appears to be free
of other sources of bias
Li 2012
Methods • Study design: open-label, parallel RCT
• Study timeframe:
• Duration of follow-up:
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Participants • Country: China
• Setting: single centre
• Inclusion criteria: aged 8 to 65 years; diagnosis of SLE (1997 revised ARA
criteria); biopsy-proven classes III, IV-S or IV-G, V, V + III or V + IV lupus nephritis
(2003 ISN/ RPS classification criteria) 6 months before randomisation, chronic index
≤ 3 and urinary protein excretion of ≥ 1.0 g/24 h, and/or a recent deterioration in
kidney function; 60 participants with classes III, IV and V disease; 35 participants with
class IV disease
• Number (randomised/analysed): treatment group 1 (20/20); treatment group 2
(20/20); treatment group 3 (20/20)
• Median age, range (years): treatment group 1 (26.5, 16 to 62); treatment group 2
(29, 17 to 50); treatment group 3 (22, 17 to 64)
• Sex (M/F): treatment group 1 (3/17); treatment group 2 (3/17); treatment group
3 (2/19)
• Exclusion criteria: treatment with MMF, TAC, CSA or CPA within the previous
year; SCr concentration > 5.0 mg/dL; life-threatening complications such as cerebral
lupus, pancreatitis, GI haemorrhage, within 6 months or active peptic ulcer within 3
months, severe infection, severe cardiovascular disease, bone marrow insufficiency with
cytopenia not attributable to SLE or poor drug compliance
Interventions Induction therapy: duration of treatment was 6 months
• Treatment group 1
◦ Oral MMF: 1.5 to 2.0 g/d
• Treatment group 2
◦ Oral TAC: 0.08 to 0.1 mg/kg/d, target 12 hour trough 6 to 8 ng/mL
• Treatment group 3
◦ IV CPA: 0.5 to 0.75 g/1.73 m2
• All groups
◦ All patients received corticosteroids 0.8 to 1 mg/kg/d (max dose 60 mg/d).
Reduced by 10 mg every 2 weeks until at 40 mg/d, then reduced by 5 mg/d every 2
weeks to maintenance dose of 10 mg/d
Outcomes • Death
• Stable kidney function
• Major infection
• Leucopenia
• Complete renal remission: urinary protein excretion < 0.3 g/24 h with normal
urine sediment, serum albumin concentration > 35 g/L and SCr above baseline values
by ≤ 15%
• Partial renal remission: urinary protein excretion between 0.3 to 2.9 g/24 h,
having decreased by at least 50% from baseline values, with a serum albumin
concentration of at least 30 g/L and relative stabilisation (± 30%) in SCr
• Complete remission in proteinuria
• Doubling of SCr
• Proteinuria
• Serum albumin
Notes • Funding source: Shanghai Institutes of Health and Chinese National Natural
Science Foundation
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Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Study was described as randomised,
method of randomisation was not reported
Allocation concealment (selection bias) Unclear risk Insufficient information to permit judge-
ment
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Open-label study
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Insufficient information to permit judge-
ment
Incomplete outcome data (attrition bias)
All outcomes
Low risk No missing outcome data
Selective reporting (reporting bias) Low risk Study protocol available and pre-specified
outcomes were reported
Other bias Low risk The study appears to be free of other
sources of bias
Liou 2007
Methods • Study design: open-label, parallel RCT
• Study timeframe: not reported
• Duration of follow-up: 18 months
Participants • Country: China
• Setting: single centre
• Inclusion criteria: biopsy-proven lupus nephritis
• Number (randomised): treatment group 1 (19); treatment group 2 (21)
• Mean age ± SD (years): not reported
• Sex (M/F): not reported
• Exclusion criteria: not reported
Interventions Induction and maintenance therapy: 6 months induction therapy and 12 months main-
tenance therapy
• Treatment group 1
◦ Oral leflunomide: 30 mg/d; after 6 months of induction therapy,
leflunomide was reduced to 20 mg/d
• Treatment group 2
◦ IV CPA: 1g per month; after 6 months IV CPA was given 1g/3 months for
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maintenance therapy
• Both groups
◦ All patients received prednisolone 0.8 to 1 mg/kg/d tapered to 10 mg/d
Outcomes • Complete renal remission (not defined)
• Herpes zoster virus infection
• Proteinuria
• Serum albumin
• SCr
Notes • Abstract-only publication
• Only induction therapy (6 months) reported
• Funding source: not reported
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Insufficient information to permit judge-
ment
Allocation concealment (selection bias) Unclear risk Insufficient information to permit judge-
ment
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Open-label study
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Insufficient information to permit judge-
ment
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Insufficient information to permit judge-
ment
Selective reporting (reporting bias) High risk Not all expected clinical outcomes are re-
ported
Other bias Unclear risk Abstract-only publication; insufficient in-
formation to permit judgement
Liu 2015
Methods • Study design: open-label, parallel RCT
• Study timeframe: April 2009 to June 2011
• Duration of follow-up: 24 weeks
127Immunosuppressive treatment for proliferative lupus nephritis (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Liu 2015 (Continued)
Participants • Country: China
• Setting: multicentre (number of sites not reported)
• Inclusion criteria: patients aged 18 to 65 years; diagnosis of SLE (ACR criteria);
biopsy-proven class III, IV, V, III+V, and IV+V lupus nephritis (ISN/RPS 2003
classification criteria) within 6 months before study entry; proteinuria (≥1.5 g/d) with
a SCr ≤ 3.0 mg/dL)
• Number (randomised/analysed): treatment group 1 (181/175); treatment group 2
(181/181)
◦ Treatment group 1: class III (10), class IV (74), class V (32); class III+IV or
IV+V (65)
◦ Treatment group 2: class III (9), class IV (76), class V (37); class III+IV or
IV+V (52)
• Median age, IQR (years): treatment group 1 (33.6, 24.2 to 41.5); treatment
group 2 (30.3, 23.3 to 38.6)
• Sex (M/F): treatment group 1 (20/161); treatment group 2 (13/168)
• Exclusion criteria: treatment with MMF, CPA, TAC, or high-dose MP; current
RRT; plasmapheresis, or IVIG within the 12 weeks before randomisation; abnormal
liver function or serum glucose test results; and pathologic chronicity index > 3
Interventions Induction therapy: duration of therapy was 6 months
• Treatment group 1
◦ IV CPA: initiated at a dose of 0.75 g/m2 body surface area and then adjusted
to a dose of 0.5 to 1.0 g/m2 body surface area every 4 weeks for 6 doses
• Treatment group 2
◦ Oral MMF: 0.5 g twice/d
◦ Oral TAC: 2 mg twice/d
• Both groups
◦ IV MP pulse therapy (0.5 g/d) for 3 days, followed by oral prednisone (0.6
mg/kg/d) every morning for 4 weeks. The daily dose of prednisone was tapered by 5
mg/d every 2 weeks to 20 mg/d and then by 2.5 mg/d every 2 weeks to a maintenance
dose of 10 mg/d
Outcomes • Death
• Complete remission: 24 h urinary protein excretion ≤ 0.4 g, the absence of active
urine sediments, serum albumin level ≥ 35 g/L, and normal SCr
• Partial remission: ≥ 50% reduction in proteinuria and urine protein < 3.5 g/24 h,
serum albumin level≥30 g/L, and normal or ≤ 25% increase in SCr level from baseline
• Doubling of SCr
• Major infection
• Herpes zoster virus infection
• Menstrual disorder
• Avascular necrosis
• Alopecia
• Leucopenia
• Upper GI symptoms
• Diarrhoea
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Notes • Funding source: National Basic Research Program of China (973 Program, No.
2012CB517600, No. 2012CB517606), National Key Technology R&D Program
(2011BAI10B04, 2013BAI09B04).
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomisation list, stratified by centre was
created by Rundo International Pharma-
ceutical Research & Development (Shang-
hai) Co. Ltd. by using computer generated
random-number sequences
Allocation concealment (selection bias) Low risk Sequentially numbered, concealed en-
velopes containing group assignment were
provided to the investigators. After eligible
patients provided written informed con-
sent, the envelopes were opened in se-
quence and patients were randomly as-
signed, in a 1:1 ratio, to the multi-target
regimen or IV CPA
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Open-label study
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk The outcomes were adjudicated by the
Clinical Endpoints Committee, blinded to
treatment regimen
Incomplete outcome data (attrition bias)
All outcomes
High risk Unclear why 6 patients (3%) in the IVCPA
group were not given therapy and not in-
cluded in the analysis and why patients in
the IV CPA group were seen at twice the
follow-up rate then patients in the multi-
target therapy group
Selective reporting (reporting bias) High risk Not all prespecified outcomes were re-
ported
Other bias Low risk This study appears to be free of other
sources of bias
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Loo 2010
Methods • Study design: open-label, parallel RCT
• Study timeframe: not reported
• Duration of follow-up: 6 months
Participants • Country: Malaysia
• Setting: single centre
• Inclusion criteria: aged ≥ 12 years; diagnosis of SLE (ARA 1982 criteria) and
biopsy proven severe classes III or IV ± V lupus nephritis (ISN/RPS 2003 classification
criteria)
• Number (randomised/analysed): treatment group 1 (14/14); treatment group 2
(14/14)
• Mean age ± SD (years): treatment group 1 (31.9 ± 11.6); treatment group 2 (30.2
± 7.5)
• Sex (M/F): treatment group 1 (4/10); treatment group 2 (0/14)
• Ethnicity: treatment group 1 (Chinese (5), Malay (7), Indian (2)); treatment
group 2 (Chinese (5), Malay (7), Indian (2))
• Exclusion criteria: not reported
Interventions Induction therapy: duration of therapy was 6 months
• Treatment group 1
◦ PEX: 3 sessions (3L per session) following MP treatment. For PEX, the
plasma removed was replaced with 2 litres of human albumin 5% and the balance with
Hartman’s solution
• Treatment group 2
◦ Immunoadsorption: 3 sessions carried out on a daily or every other day basis
for 3 days. Three litres of plasma or 1 plasma volume, whichever was greater was
processed at each session
• Both groups
◦ All patients received standard induction IV pulse MP at 250 mg/d for 3 days
followed by PEX or immunoadsorption. Followed by IVIG 10 g/d for 3 days. Patients
subsequently proceed to the consolidation phase with pulse IV CPA at 10 to 12 mg/
kg/dose 2-weekly for 4 doses, then monthly for four more doses. Patients were then
randomised to receive maintenance therapy with either oral CSA or MMF in
conjunction with low dose steroid, for a further 12 to 18 months
Outcomes • Relapse: nephrotic syndrome
Notes • Funding source: not reported
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk Consecutive enrolment
Allocation concealment (selection bias) Unclear risk Insufficient information to permit judge-
ment
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Blinding of participants and personnel
(performance bias)
All outcomes
High risk Open-label study
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Insufficient information to permit judge-
ment
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Insufficient information to permit judge-
ment
Selective reporting (reporting bias) High risk Not all expected outcomes were reported
Other bias High risk Marked differences (demographics and
clinical characteristics) between groups at
baseline
Lui 1997
Methods • Study design: parallel RCT
• Study timeframe: not reported
• Duration of follow-up: 12 months
Participants • Country: Hong Kong
• Setting: not reported
• Inclusion criteria: class IV disease
• Number (randomised/analysed): treatment group 1 (17/17); treatment group 2
(17/17)
• Mean age ± SD (years): not reported
• Sex (M/F): not reported
• Exclusion criteria: not reported
Interventions Induction therapy
• Treatment group 1
◦ Oral CSA: 5 mg/kg/d, reduced to 2.5 mg/kg/d
• Treatment group 2
◦ Oral CPA: 1 mg/kg/d
• Both groups
◦ All patients received prednisolone (0.5 mg/kg/d) and AZA (1 mg/kg/d)
Outcomes • Failure to respond
• Partial response
• Complete response
• Proteinuria
• CrCl
• Infection
• Herpes zoster virus infection
• Leucopenia
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• Amenorrhoea
Notes • Abstract-only publication
• Funding source: not reported
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Insufficient information to permit judge-
ment
Allocation concealment (selection bias) Unclear risk Insufficient information to permit judge-
ment
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Open-label study
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Insufficient information to permit judge-
ment
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Insufficient information to permit judge-
ment
Selective reporting (reporting bias) Unclear risk Insufficient information to permit judge-
ment
Other bias Unclear risk Abstract-only publication; insufficient in-
formation to permit judgement
LUNAR 2012
Methods • Study design: phase III, double-blind double-dummy RCT
• Study timeframe: January 2006 to January 2008
• Duration of follow-up: 12 months
Participants • Countries: USA, Latin America
• Setting: multinational (52 sites)
• Inclusion criteria: aged 16 to 75 years of age; diagnosis of SLE (ACR criteria);
history of ANA positivity; diagnosis of class III or IV lupus nephritis (ISN/RPS 2003
Classification) with either active or active chronic disease; proteinuria (urine
polymerase chain reaction > 1.0); If the biopsy was performed > 3 months before
screening; an active urinary sediment (> 10 RBC/HPF or the presence of RBC casts)
• Number (randomised/analysed): treatment group (72/72); control group (72/72)
• Mean age ± SD (years): treatment group (31.8 ± 9.6); control group (29.4 ± 9.3)
• Sex (M/F): treatment group (9/63); control group (5/67)
• Exclusion criteria: active infection; recurrent or chronic infection,; CPA or CNI
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treatment within 90 days prior to screening; MMF > 2 g daily > 90 d prior to screening;
use of prednisolone >20 mg/d > 14 days prior to screening; previous treatment with
CAMPATH-1H; B-cell targeted therapy; pregnancy or lactation; history of cancer
Interventions Induction therapy: duration of therapy was 12 months
• Treatment group
◦ IV RTX: 1000 mg (days 1, 15, 168, 182)
• Control group
◦ Placebo
• Both groups
◦ MMF: initial dosage of 1.5 g/d in 3 divided doses, and the dosage was
increased to 3 g/d by week 4
◦ IV MP: 1,000 mg was administered 30-60 minutes prior to the
administration of study drug on day 1 and again within 3 days.
◦ Oral prednisone: 0.75 mg/kg/d (maximum 60 mg) was administered until
day 16 and tapered to 10 mg/d by week 16
Outcomes • Death (all causes)
• Stable creatinine
• Major infection
• Herpes zoster virus infection
• Complete response: SCr ≤ 115% of baseline if it was normal at baseline; inactive
urinary sediment (< 5 RBC/HPF and absence of RBC casts); and UPCR < 0.5
• Partial response: SCr ≤ 115% of baseline; RBCs/HPF ≤ 50% above baseline and
no RBC casts; and at least a 50% decrease in the UPCR to < 1.0 (if the baseline UPCR
was ≤ 3.0) or to ≤ 3.0 (if the baseline UPCR was > 3.0)
• Treatment failure (if criteria for complete response or partial response were not
met, for early termination from the study or inability to assess the end point due to
missing data, or for initiation of a new immunosuppressant agent prior to week 52
• Complete response in proteinuria
• Partial response in proteinuria
• Serious adverse events
• Nausea
• Diarrhoea
Notes • Funding source: Genentech and Biogen Idec
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Study was described as randomised,
method of randomisation was not reported
Allocation concealment (selection bias) Unclear risk Insufficient information to permit judge-
ment
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Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Double-blind, double-dummy placebo
study
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Insufficient information to permit judge-
ment
Incomplete outcome data (attrition bias)
All outcomes
Low risk No missing outcome data
Selective reporting (reporting bias) Low risk Study protocol available and pre-specified
outcomes were reported
Other bias High risk Some authors declared grants/research sup-
port from Genentech and Aspreva, and
sponsor included in data analysis and au-
thorship
MAINTAIN Nephritis 2010
Methods • Study design: open-label, parallel RCT
• Study timeframe: July 2002 and March 2006
• Duration of follow-up: median follow-up 53 months; extended median follow-up
was 9.16 years (range 1.5 to 13 years)
Participants • Country: European (countries not reported)
• Setting: multinational (27 sites)
• Inclusion criteria: SLE ≥ 14 years, diagnosis of SLE (ACR criteria), proteinuria ≥
0.5 g/d, biopsy-proven lupus nephritis Class III, IV, Vc or Vd lupus nephritis (WHO
classification criteria)
• Number (randomised/analysed): treatment group 1 (52/52); treatment group 2
(53/53)
• Mean age ± SD (years): treatment group 1 (33 ± 11); treatment group 2 (33 ± 10)
• Sex (M/F): treatment group 1 (4/48); treatment group 2 (5/48)
• Exclusion criteria: recent treatment with high dose corticosteroids or
immunosuppressive drugs; non-lupus related renal disease (such as microthrombotic
disease associated with antiphospholipid syndrome); pre-existing chronic kidney failure
(defined as a SCr value above the upper normal value for the local laboratory) due to a
previous episode of lupus nephritis or other cause; pregnancy or breast feeding;
previous malignancy (except skin and cervical intraepithelial neoplasia’s); DM;
previously documented severe toxicity of immunosuppressants, anticipated non-
compliance with the protocol
Interventions Maintenance therapy
• Treatment group 1
◦ AZA: 2 mg/kg/d
• Treatment group 2
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◦ MMF: 2 g/d
• Both groups
◦ Induction therapy of 3 x 750 mg IV MP followed by oral glucocorticoids 0.5
mg/kg/d and 6 fortnightly pulses IV CPA 500 mg
◦ Maintenance treatment started in both groups at week 12
Outcomes • Death
• ESKD
• Relapse: (i) recurrence or the development of nephrotic syndrome (serum albumin
≤ 3.5 g/dL and proteinuria ≥ 3 g/24 h); (ii) renal impairment (≥ 33% increase of SCr
within a 1-month period directly attributed to lupus nephritis and confirmed 1 week
later; flare referred to as ‘renal impairment’) or (iii) a threefold increase of 24 h
proteinuria within a 3-month period accompanied by microscopic haematuria (defined
as a number of RBC/HPF superior to upper normal limit for the local laboratory) and
≥ 33% reduction of serum C3 level within a 3-month period (this definition of renal
flare was only applicable to those patients with low-grade baseline 24 h proteinuria (≥
0.5 g and < 1 g); this type of renal flare is further referred to as ‘proteinuria increase’
• Time to renal flare
• Doubling of SCr
• Number of withdrawals due to toxicity
• Number of treatment failures
• Major infection
• Herpes zoster virus infection
• Avascular necrosis
• Malignancy
• Alopecia
• Leucopenia
• Kidney function over time
• 24 hour proteinuria over time
Notes • Funding source: no external funding
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Randomisation by minimisation
Allocation concealment (selection bias) Unclear risk Insufficient information to permit judge-
ment
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Open-label study
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Insufficient information to permit judge-
ment
135Immunosuppressive treatment for proliferative lupus nephritis (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
MAINTAIN Nephritis 2010 (Continued)
Incomplete outcome data (attrition bias)
All outcomes
Low risk No missing outcome data
Selective reporting (reporting bias) Low risk Study protocol available and pre-specified
outcomes were reported
Other bias Low risk Nocompeting interests declared.The study
appears to be free of other sources of bias
Mehra 2018
Methods • Study design: open-label, parallel RCT
• Study timeframe: December 2015 to December 2016
• Duration of follow-up: 12 months
Participants • Country: India
• Setting: single centre
• Inclusion criteria: diagnosis of SLE (ACR criteria); aged > 16 years; proteinuria ≥
500 mg/24 h and/or urine routine microscopy showing active cellular casts/sediments
(> 5 RBC/HPF and > 5 WBC/HPF and cellular casts); biopsy-proven proliferative
class III, IV lupus GN (ISN/RPS) criteria
• Number (randomised/analysed): treatment group 1 (37/37); treatment group 2
(38/38)
◦ Treatment group 1: class III (11), class IV (26); had crescents (14; 38%)
◦ Treatment group 2: class III (17), class IV (21); had crescents (8; 21%)
• Mean age ± SD (years): not reported
• Sex (M/F): treatment group 1 (3/34); treatment group 2 (4/34)
• Exclusion criteria: ever treated previously with IV or oral cyclophosphamide,
MMF, cyclosporine or steroids > 15 mg/d in the last 3 months; renal thrombotic
microangiopathy, pre-existing chronic kidney failure, previous malignancy (except skin
and cervical intraepithelial neoplasia); DM or coronary heart disease; previously
documented severe toxicity to immunosuppressive drugs; patients with active acute or
chronic infections; pregnancy
Interventions Induction therapy
• Treatment group 1
◦ High dose IV CPA: four weekly six cycles of 750 mg/m2 with a maximum of
1.5 g per pulse.
• Treatment group 2
◦ Low dose IV CPA: six fortnightly IV CPA cycles at a fixed dose of 500 mg
• Both groups
◦ All participants received 3 daily pulses of 1 g IV MP followed by 1 mg/kg/d
of prednisolone for 4 weeks tapered by 5 mg every 2 weeks to reach a dose of 5-7.5 mg/
d until completion of 52 weeks. After completion of induction, oral AZA 2 mg/kg was
started two weeks after the last CPA dose. For patients with AZA-related toxicity, the
dosage was reduced to 1 mg/kg/d
◦ All patients received hydroxychloroquine during the study (5 to 6 mg/kg,
400 mg/d maximum) after normal baseline fundus evaluation
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◦ Hypertension (DBP > 90 mm Hg) was treated with ACEi (unless
contraindicated) and other appropriate drugs
◦ Atorvastatin was started for patients with LDL cholesterol > 100 mg/dL
Outcomes • Death
• Complete remission: UPCR < 0.5 g and normal GFR (> 90 mL/ min) or stable (<
10% deterioration from baseline if GFR was previously abnormal) kidney function and
inactive urinary sediments.
• Partial remission: ≥ 50% reduction in proteinuria to sub-nephrotic levels, normal
GFR (> 90 mL/ min) or stable (< 10%) deterioration from baseline if GFR was
previously abnormal
• Renal relapse (not defined)
• Treatment failure
• Major infection
• Herpes zoster virus infection
• Ovarian failure
• Bone toxicity: avascular necrosis
• Alopecia
• Leucopenia
• GI disturbance
• CrCl
Notes • Funding source: Investigator initiated
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “Patients were randomised, using block
randomization, eight blocks of 10 patients
each with 1:1 random allocation was per-
formed using a computer generated ran-
dom number table.”
Allocation concealment (selection bias) Low risk “Fellow researcher had given random block
and number to patients sequentially, who
was unaware of treatment allocation and
had no other role in the study.”
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Open-label study
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Insufficient information to permit judge-
ment
Incomplete outcome data (attrition bias)
All outcomes
Low risk No missing outcome data
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Selective reporting (reporting bias) High risk Not all expected outcomes were reported
and partial remission listed in protocol not
reported
Other bias Low risk The study appears to be free of other
sources of bias
Mendonca 2017
Methods • Study design: open-label, parallel RCT
• Study timeframe: November 2014 to November 2015
• Duration of follow-up: 6 months
Participants • Country: India
• Setting: single centre
• Inclusion criteria: SLE according to the SLICC 2012 and the ACR criteria; all
biopsy-proven class III, IV or III/IV +V lupus nephritis was diagnosed based on biopsy
findings as per the ISN/RPS
• Number (randomised/analysed): treatment group 1 (18/17); treatment group 2
(23/23)
◦ Treatment group 1: class III (1); class IV (11); class V (2); class III+V or class
IV+V (3)
◦ Treatment group 2: class III (1); class IV (15); class V (3); class III+V or class
IV+V (4)
• Mean age ± SD (years): treatment group 1 (26.0 ± 10.8); treatment group 2 (25.7
± 10.3)
• Sex (M/F): treatment group 1 (3/14); treatment group 2 (5/18)
• Exclusion criteria: CKD stage-3 and above; crescentic lupus nephritis;
pancreatitis, GI haemorrhage within six months or active peptic ulcer disease within
last three months; ongoing infection; bone marrow insufficiency with cytopenias not
attributable to SLE; and prior treatment with CPA or MM
Interventions Induction therapy
• Treatment group 1
◦ Oral MMF: twice daily, titrated from 750 mg twice daily in the 1st week,
and 1.0 g twice daily in the 2nd week, to a target dosage of 1.5 g twice daily, if
required, based on the disease activity and response. Reduction was permitted to 2 g/d
in response to any adverse events
• Treatment group 2
◦ Low dose IV CPA: Pulse CPA (750 mg/m2), which was adjusted to 500 to
1000 mg/m2 every 4 weeks to maintain a nadir leukocyte count of 2.5 to 4.0 × 109/L
for a total of 6 pulses. A 25% decrease in dosage for age older than 60 years, and SCr >
3.4 mg/dL was followed
• Both groups
◦ All participants had received unified concomitant corticosteroid therapy
according to protocol that consisted of three doses of IV pulse MP 500 mg followed by
oral prednisone (or equivalent) at an initial dose of 0.5 mg/kg/d. Prednisolone dosage
was tapered by a decrease of 5 mg/d every two weeks until a dose of 10 mg/day was
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achieved, and this dosage was maintained till the end of six months.
◦ Doses of ACEi and/or ARB had been unchanged during the 6 month
follow-up period
◦ Target blood pressure was kept at 130/80 mm Hg
◦ Hyperlipidaemia was treated using statins and/or fibric acid derivatives as
required
Outcomes • Death
• Complete remission: urinary protein excretion < 0.3 g/24 h was accomplished
with normal serum albumin levels and/or an improvement in the baseline SCr levels of
> 50%
• Partial remission: improvement of > 50% from baseline proteinuria, serum
albumin levels of at least 30 g/L, and SCr level of ≥ 25% from baseline or stable SCr
level within 25% of the baseline
• Treatment failure
• Major infection
• Herpes zoster virus infection
• Diarrhoea
• Nausea
• Vomiting
• CrCl
• SCr
• Daily proteinuria
Notes • Funding source: not reported
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Study was described as randomised,
method of randomisation was not reported
Allocation concealment (selection bias) Unclear risk Insufficient information to permit judge-
ment
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Open-label study
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Insufficient information to permit judge-
ment
Incomplete outcome data (attrition bias)
All outcomes
Low risk No missing outcome data
Selective reporting (reporting bias) High risk No protocol available, some expected out-
comes not reported
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Other bias Low risk The study appears to be free of other
sources of bias
Mitwalli 2011
Methods • Study design: double-blind, parallel RCT
• Study timeframe: December 1997 to January 2007
• Duration of follow-up: mean follow-up 6.77 ± 3.3 years
Participants • Country: Saudi Arabia
• Setting: single centre
• Inclusion criteria: adult patients with newly diagnosed biopsy-proven lupus
nephritis (WHO class IV)
• Number (randomised/analysed): treatment group 1 (73/73); treatment group 2
(44/44)
• Mean age ± SD (years): treatment group 1 (36.4 ± 12.7); treatment group 2 (30.3
± 10.4)
• Sex (M/F): treatment group 1 (12/61); treatment group 2 (5/39)
• Exclusion criteria: not reported
Interventions Induction therapy
• Treatment group 1
◦ IV CPA: 10 mg/kg monthly for 6 months then 2 monthly for 12 months
• Treatment group 2
◦ IV CPA: 5 mg/kg monthly for 6 months then 2 monthly for 36 months
• Both groups
◦ Oral prednisolone: 1 mg/kg/d for 4 weeks followed by taper to 0.2 mg/kg/d
alternate days for 24 months
Maintenance therapy both (groups)
• Hydroxychloroquine: 200 mg/d for 24 months
• AZA: 1 mg/kg/d for 24 months
Outcomes • Death
• Doubling of SCr
• Stable kidney function
• Major infection
• Ovarian failure
• Malignancy
• Lymphopenia
• Complete remission of proteinuria: < 0.3 g/24 h with normal serum albumin
levels and/or an improvement in the baseline SCr levels of > 50%
• Partial remission of proteinuria: > 50% reduction in proteinuria, serum albumin
levels≥ 30 g/L, and SCr ≥ 25% from baseline or stable SCr level within 25% of the
baseline
• SCr
• Daily proteinuria
Notes • Funding source: not reported
140Immunosuppressive treatment for proliferative lupus nephritis (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Mitwalli 2011 (Continued)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Study was described as randomised,
method of randomisation was not reported
Allocation concealment (selection bias) Unclear risk Insufficient information to permit judge-
ment
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Double-blind study
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Outcome assessor was blinded according to
the protocol
Incomplete outcome data (attrition bias)
All outcomes
Low risk No missing outcome data
Selective reporting (reporting bias) Low risk All outcomes on clinicaltrials.gov are re-
ported
Other bias High risk Marked differences in clinical characteris-
tics between the groups - median cumula-
tive dose of CPA between the groups, high
rates of leucopenia in the low dose com-
pared to the high dose CPA group at base-
line
Mok 2016
Methods • Study design: open-label, parallel RCT
• Study timeframe: 2005 to 2012
• Duration of follow-up: median 30 months
Participants • Countries: Hong Kong, China
• Setting: multicentre (number of centres not reported)
• Inclusion criteria: aged ≥ 18 years; diagnosis of SLE (ACR criteria); biopsy-
proven active lupus class III/IV/ V(ISN/RPS 2003 classification) within 4 weeks; SCr <
2.3 mg/dL
• Number (randomised/analysed): treatment group 1 (74/74); treatment group 2
(76/76)
• Mean age ± SD (years): treatment group 1 (36.2 ± 14); treatment group 2 (36.1 ±
13.1)
• Sex (M/F): treatment group 1 (4/70); treatment group 2 (8/68)
• Exclusion criteria: refusal to be randomised; preference for treatment with
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conventional regimens such as CPA; planning for pregnancy within 12 months after
randomisation
Interventions Induction therapy and maintenance therapy
• Treatment group 1
◦ TAC: initial dosage 0.1 mg/kg/d in two divided doses, reduced to 0.06 mg/
kg/d if clinical response was satisfactory at month in two divided doses for 6 months
• Treatment group 2
◦ MMF: 2 g/d initially, augmented to up to 3 g/d if clinical response was
suboptimal in two divided doses for 6 months
• Both groups
◦ Prednisolone: 0.6 mg/kg/d for 6 weeks then tapered by 5 mg/d every week to
< 10 mg/d. At end of intervention, if complete clinical response or good partial
response, changed to AZA (2 mg/kg/d) for maintenance. Poor responders re-induced
with oral CPA 2 mg/kg/d
Outcomes • Death
• ESKD
• Doubling of SCr
• Stable kidney function
• Relapse
• Major infection
• Herpes zoster virus
• Diarrhoea
• Nausea
• Complete renal remission: stabilisation (within 25%) or improvement in SCr
with reduction of proteinuria to < 1 g/d (or UPCR < 1.0), resolution of urinary
sediment abnormalities (urine RBC < 5/HPF and absence of cellular casts) and
persistent improvement in C3 and anti-dsDNA levels
• Partial renal remission: stabilisation (within 25%) or improvement in SCr with
persistent reduction of proteinuria (if nephrotic range at baseline, a ≥ 50% decrease in
proteinuria but < 3 g/d (or UPCR < 3.0); if non-nephrotic at baseline, a decrease to ≤
50% of the pre-treatment value but > 1 g/d (or UPCR > 1.0) and improvement in
urinary sediment abnormalities (≥ 50% reduction in haematuria and urine RBC <10/
HPF)
• Treatment failure: deterioration of SCr (> 25%), an increase in proteinuria, or a
reduction in proteinuria but not to the extent of complete renal remission or partial
renal remission)
• Renal flare: proteinuric flare - an increase in proteinuria to more than 2g/d (or
UPCR >2.0), with or without deterioration in SCr (< 30%), after a complete remission;
or doubling of proteinuria (or UPCR), with or without deterioration in SCr (<30%),
in patients who achieved partial remission. Nephrotic flare - an increase or recurrence
of active urinary sediments (RBC ≥10/HPF or active cellular casts) with a concomitant
increase in proteinuria (or UPCR) or deterioration in SCr (≥30%) after excluding
other causes (e.g. sepsis, over diuresis, nephrotoxic agents, renal vein thrombosis)
• Alopecia
• Proteinuria
• CrCl
• Serum albumin
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Notes • Funding source: no support from any organisation including industry (Roche and
Astella)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Participants were randomised by com-
puter-generated blocks of four in a 1:1 ra-
tio
Allocation concealment (selection bias) Unclear risk Central research assistant was responsible
for treatment allocation
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Open-label study
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Insufficient information to permit judge-
ment
Incomplete outcome data (attrition bias)
All outcomes
Low risk No missing outcome data
Selective reporting (reporting bias) Low risk Study protocol available and pre-specified
outcomes were reported
Other bias Low risk The study appears to be free of other
sources of bias
Moroni 2006
Methods • Study design: open label, parallel RCT
• Study timeframe (recruitment): March 1999 to March 2001
• Duration of follow-up: a least 1 year follow-up, invited to continue to 4 years
Participants • Country: Italy
• Setting: multicentre
• Inclusion criteria: aged at least 16 years; diagnosis of SLE (ACR criteria) and
biopsy-proven class IV, Vc or Vd lupus nephritis with a chronicity index of ≤ 4 (WHO
classification); patients with a new diagnosis of lupus nephritis or were experiencing a
new flare of a previously quiescent disease were enrolled if they had active urine
sediment (≥ 5 RBC/HPF); proteinuria > 1 g/d in case of new diagnosis or > 2 g if new
renal flare; SCr < 4 mg/dL; after induction therapy those with no major extrarenal
signs or symptoms of lupus requiring aggressive therapy; SCr ≤ 1.5 mg/dL, proteinuria
> 0.5 g/d; CrCl > 60 mL/min; diastolic BP < 90 mm Hg with a maximum of two
antihypertensive drugs and the oral prednisone dose ≤ 0.5 mg/kg/d
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• Number (randomised/analysed): treatment group 1 (36/36); treatment group 2
(33/33)
• Mean age ± SD (years): treatment group 1 (31.7 ± 9.1); treatment group 2 (31.2 ±
11.7)
• Sex (M/F): treatment group 1 (3/33); treatment group 2 (4/29)
• Exclusion criteria: potential silent nephritis; renal diseases unrelated to SLE;
treatment with CSA or AZA in the 6 months preceding the screening visit; cumulative
CPA dose > 200 mg/kg; any contraindication to the study drugs; previous malignancy
Interventions Maintenance therapy: duration of therapy was 24 months
• Treatment group 1
◦ CSA: 4 mg/kg/d and reduced to maintenance dose (2.5 to 3.0 mg/kg/d) if
proteinuria < 1 g/d, if proteinuria was higher the dose was reduced more slowly
• Treatment group 2
◦ AZA: 2 mg/kg/d optional reduction at 1 month to 1.5 mg/kg/d if
proteinuria < 1 g/d and SCr stable
• Both groups
◦ Induction therapy: 3 x IV MP 0.5 g if ≤ 50 kg and 1 g if > 50 kg. followed
by prednisolone 1 mg/kg/d for 10 to 15 days then tapered
◦ During maintenance therapy both groups received oral prednisone which
had to be reduced from 0.5 to 0.2 mg/kg/d by the end of the 6 months, in the case of
normal levels of SCr and proteinuria of < 0.5 g/d and in absence of extrarenal
symptoms. A further reduction or complete withdrawal could be attempted at the
investigators discretion
Outcomes 1. Death
2. ESKD
3. Major infection
4. Lymphopenia
5. GI disorders
6. Complete remission proteinuria
7. Proteinuria at 2 and 4 years
8. CrCl at 2 and 4 years
9. 24 hour proteinuria
10. Renal flare
Notes • Funding source: educational grant from Novartis Pharma AG
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomisation according to a coin-based
design
Allocation concealment (selection bias) Low risk Stratified by centre and performed cen-
trally. Phone calls to randomisation centre-
computer program assigned participants
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Blinding of participants and personnel
(performance bias)
All outcomes
High risk Open-label study
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Blinded endpoint study
Incomplete outcome data (attrition bias)
All outcomes
Low risk No missing outcome data
Selective reporting (reporting bias) Low risk Study protocol available and pre-specified
outcomes were reported
Other bias High risk Sponsor included in data management and
analysis: Novartis Pharma and authorship
Mulic-Bacic 2008
Methods • Study design: open-label, parallel RCT
• Study timeframe: not reported
• Duration of follow-up: 24 weeks
Participants • Country: Bosnia Herzegovina
• Setting: not reported
• Inclusion criteria: active lupus nephritis class III, IV or V (WHO classification
criteria)
• Number (randomised/analysed): treatment group 1 (20/20); treatment group 2
(25/25)
• Mean age ± SD (years): not reported
• Sex (M/F): not reported
• Exclusion criteria: not reported
Interventions Induction therapy: duration of therapy was 24 months
• Treatment group 1
◦ MMF: 2 g/d for 6 months then 1 g/d for 18 months, administer orally
• Treatment group 2
◦ IV CPA: 0.5 g/m2 monthly
• Both groups
◦ Prednisolone: 0.75 to 1 mg/kg/d with determined tapering
Outcomes • Death
• Stable kidney function
• Complete remission proteinuria
• Partial remission proteinuria
• Complete remission: normalisation of abnormal renal measurements and
maintenance of baseline normal measurements
• Partial remission
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Notes • Abstract-only publication
• Funding source: not reported
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Study was described as randomised,
method of randomisation was not reported
Allocation concealment (selection bias) Unclear risk Insufficient information to permit judge-
ment
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Open-label study
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Insufficient information to permit judge-
ment
Incomplete outcome data (attrition bias)
All outcomes
Low risk No missing outcome data
Selective reporting (reporting bias) High risk Not all expected clinical outcomes reported
and no protocol available; abstract-only
publication
Other bias Unclear risk Abstract-only publication; insufficient in-
formation to permit judgement
MyLupus 2011
Methods • Study design: open-label, parallel RCT
• Study timeframe: February 2007 to November 2009
• Duration of follow-up: 6 months
Participants • Countries: France, Germany, Italy, Spain, UK, Hungary, Greece, Colombia,
Taiwan
• Setting: multinational (19 sites)
• Inclusion criteria: aged ≥ 18 years, (i) diagnosis of SLE (ACR criteria); biopsy-
proven (within previous 24 months) proliferative lupus nephritis (class III or IV) (ISN/
RPS 2003 classification criteria); proteinuria defined as UPCR > 0.5 at screening and
baseline; and clinical activity defined by one or more of the following: SCr > 1 mg/dL;
microscopic haematuria (> 5 RBC/HPF) and presence of cellular casts
• Number (randomised/analysed): treatment group 1 (42/42); treatment group 2
(39/39)
• Mean age ± SD (years): treatment group 1 (32.2 ± 8.5); treatment group 2 (34.2 ±
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10.7)
• Sex (M/F): treatment group 1 (5/37); treatment group 2 (10/29)
• Exclusion criteria: CrCl < 30 mL/min; IV glucocorticoids, oral or IV CPA or
MMF during the previous 3 months; antibody therapy within the previous 6 months
Interventions Induction therapy: duration of therapy was 6 months
• Treatment group 1
◦ Standard dose EC-MPS
◦ Prednisolone: 1 mg/kg/d
• Treatment group 2
• Reduced dose EC-MPS
• Prednisolone: 0.5 mg/kg/d
• Both groups
◦ MP: 0.5 g IV/d for 3 days
◦ EC-MPS started at 1440 mg/d for first 2 weeks then 2160 mg in remaining
22 weeks
◦ Prednisolone tapered in both groups according to guidelines
Outcomes • Death
• Infection
• Herpes zoster virus infection
• Vomiting
• Diarrhoea
• Complete remission: UPCR < 0.5 with normalised urine sediment and SCr
within 10% of normal value
• Partial remission: reduction in UPCR of 50% compared with baseline, and SCr
improved or stable (i.e. within 10% of baseline value)
• Renal flare: A mild SLE flare was diagnosed if SLE increased after partial or
complete response, defined as the presence of 1 or 2 BILAG B scores and no A scores
and intention by the investigator to increase the glucocorticoid dose; a moderate to
severe SLE flare was diagnosed if increased lupus activity after partial or complete
response resulted in 1 BILAG A score or 3 BILAG B scores
• UPCR
• Creatinine
Notes • Funding source: Novartis Pharma AG
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Study was described as randomised,
method of randomisation was not reported
Allocation concealment (selection bias) High risk Insufficient information to permit judge-
ment
147Immunosuppressive treatment for proliferative lupus nephritis (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
MyLupus 2011 (Continued)
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Open-label study
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Insufficient information to permit judge-
ment
Incomplete outcome data (attrition bias)
All outcomes
Low risk No missing outcome data
Selective reporting (reporting bias) High risk Not all expected outcomes were reported
Other bias High risk Novartis Pharma AG funded. Sponsor in-
volved in authorship, Disclosure of con-
sulting fees fromNovartis Pharma, Amgen,
BMS and Roche
Nakamura 2002e
Methods • Study design: open-label, parallel RCT
• Study timeframe: not reported
• Duration of follow-up: 6 months
Participants • Country: Japan
• Setting: not reported
• Inclusion criteria: diagnosis of SLE (ACR criteria); biopsy-proven diffuse
proliferative, class IV lupus nephritis (WHO classification criteria); oral corticosteroid
with or without cytotoxic drugs for at least 6 months with treatment resistance
• Number (randomised): treatment group 1 (10); treatment group 2 (10)
• Mean age (years): treatment group 1 (30.5); treatment group 2 (29.5)
• Sex (M/F): treatment group 1 (2/8); treatment group 2 (2/8)
• Exclusion criteria: not reported
Interventions Induction therapy: duration of therapy was 6 months
• Treatment group 1
◦ PEX: double filtration 1 to 2 weekly
• Treatment group 2
◦ IV CPA: 0.75 to 1.0 g/m2 once a month for 6 months
• Both groups
• Oral prednisone (or equivalent): 1 mg/kg/d tapered to the minimum dose needed
to control extrarenal diseases
Outcomes • Proteinuria
• Urinary podocyte number
Notes • Funding source: not reported
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Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Study was described as randomised,
method of randomisation was not reported
Allocation concealment (selection bias) Unclear risk Insufficient information to permit judge-
ment
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Open-label study
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Insufficient information to permit judge-
ment
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Insufficient information to permit judge-
ment
Selective reporting (reporting bias) High risk Not all expected outcomes were reported
Other bias Low risk The study appears to be free of other
sources of bias
Ong 2005
Methods • Study design: open-label, parallel RCT
• Study timeframe: January 2001 to December 2002
• Duration of follow-up: 6 months
Participants • Country: Malaysia
• Setting: multicentre (8 sites)
• Inclusion criteria: aged > 16 years; diagnosis of SLE (ACR criteria); class III or IV
lupus nephritis (WHO classification criteria)
• Number (randomised/analysed): treatment group 1 (28/25); treatment group 2
(26/19)
• Mean age ± SD (years): treatment group 1 (30.5 ± 8.7); treatment group 2 (31.3 ±
9.9)
• Sex (M/F): treatment group 1 (3/23); treatment group 2 (4/15)
• Exclusion criteria: SCr > 200 µmol/L, WCC < 3.5 x 109/L; major infection;
history of cancer; alcohol or substance misuse; pregnancy; active peptic ulcer disease;
allergy to MMF or CPA; use of study drugs in preceding 6 months
Interventions Induction therapy: duration of therapy was 6 months
• Treatment group 1
◦ IV CPA: 0.75 to 1 g/m2 monthly for 6 months
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• Treatment group 2
◦ MMF: 1 g orally twice daily for 6 months
• Both groups
◦ Prednisolone: 60 mg/d for 4 to 6 weeks then tapering dose to 5 to 10 mg/d
Outcomes • Death
• ESKD
• Stable kidney function
• Major infection
• Herpes zoster virus
• Leucopenia (< 3.5 x 109/L)
• Oligomenorrhoea
• GI side effects
• Complete renal remission: stabilisation or improvement in kidney function, RCC
< 10, proteinuria < 3 g
• Combined partial remission: stabilisation or improvement in kidney function,
RCC < 10, proteinuria < 3 g if was > 3 g or at least 50% reduction or < 1.0 g if
subnephrotic
• Proteinuria
Notes • Funding source: not reported; MMF supplied by Roche Malaysia
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomisation code generated separately
for each centre using random permutated
blockmethodwith randomly varying block
size (1:1)
Allocation concealment (selection bias) Low risk Randomisation performed centrally
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Open-label study
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Insufficient information to permit judge-
ment
Incomplete outcome data (attrition bias)
All outcomes
Low risk No missing outcome data
Selective reporting (reporting bias) Low risk Study protocol available and pre-specified
outcomes were reported
Other bias Low risk The study appears to be free of other
sources of bias
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Methods • Study design: open-label, parallel RCT
• Study timeframe: not reported
• Duration of follow-up: not reported
Participants • Country: India
• Setting: not reported
• Inclusion criteria: lupus nephritis class III and IV or III/IV + V
• Number (randomised/analysed): 58 (number per group not reported)
• Mean age ± SD (years): not reported
• Sex (M/F): not reported
• Exclusion criteria: not reported
Interventions Induction therapy: duration of therapy not reported
• Treatment group 1
◦ Oral TAC: 0.75 mg/kg
◦ Oral AZA: 2 mg/kg
• Treatment group 2
◦ IV CPA: 500 mg/m2 monthly
• Both groups
◦ MP: 3 pulsed doses and subsequently, prednisolone was given at doses of 0.5
mg/kg/d for the next 1 month and then tapered as tolerated to 10 mg or less by 3
months
Outcomes • Complete renal remission
• Partial renal remission
• Daily proteinuria
• Adverse events
• Disease activity
Notes • Abstract-only publication
• Funding source: not reported
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Study was described as randomised,
method of randomisation was not reported
Allocation concealment (selection bias) Unclear risk Insufficient information to permit judge-
ment
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Likely to be an open-label study
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Insufficient information to permit judge-
ment
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Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Insufficient information to permit judge-
ment
Selective reporting (reporting bias) High risk Not all expected outcomes have been re-
ported
Other bias Unclear risk Abstract-only publication; insufficient in-
formation to permit judgement
Rathi 2016
Methods • Study design: open-label, proof-of-concept RCT
• Study timeframe: not reported
• Duration of follow-up: 6 months
Participants • Country: India
• Setting: single centre
• Inclusion criteria: aged 12 to 65 years; diagnosis of SLE (ACR criteria); biopsy-
proven class III, IV, V, III+V, or IV+V lupus nephritis (ISN/RPS 2003 classification
criteria)
• Number (randomised/analysed): treatment group 1 (50/50); treatment group 2
(50/50)
• Mean age ± SD (years): treatment group 1 (30.6 ± 9.5); treatment group 2 (28.3 ±
9.5)
• Sex (M/F): treatment group 1 (5/45); treatment group 2 (3/47)
• Exclusion criteria: crescentic lupus nephritis (> 50% crescents in biopsy); SCr of >
265 µmol/L; neurological or pulmonary lupus; ongoing infection; pregnancy; prior
treatment with CPA or MMF
Interventions Induction therapy
• Treatment group 1
◦ IV CPA: 6 fixed doses 0.5 g administered fortnightly; duration of therapy
was 3 months
• Treatment group 2
◦ Oral MMF: initiated at a dose of 0.5 g twice a day and increased every 2
weeks to achieve a target dose of 1.5-3.0 g/d; duration of therapy was 6 months
• Both groups
• IV MP: 3 daily boluses (0.75 g each) at the beginning of treatment followed by
oral prednisolone (1 mg/kg/d) for 8 weeks and subsequent tapering
• Hydroxychloroquine: 6 mg/kg, single daily dose
• ACEi or ARB
Maintenance therapy
• At the end of induction therapy patients received maintenance therapy AZA (2
mg/kg) and prednisolone (5 to 7.5 mg/d)
Outcomes • Death
• Complete remission: return to normal SCr along with proteinuria ≤ 0.5 g/d and
inactive urine sediment
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Rathi 2016 (Continued)
• Partial remission: defined as treatment response, as a decrease in the UPCR to < 3
in subjects with a baseline ratio ≥ 3 or a decrease in UPCR by ≥ 50% in those with a
baseline ratio < 3, along with stabilisation or improvement in SCr (a 24-week SCr level
within 25% of baseline).
• Herpes zoster virus infection
• Ovarian failure
• Alopecia
• Leucopenia
Notes • Funding source: not reported
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Study was described as randomised,
method of randomisation was not reported
Allocation concealment (selection bias) Unclear risk Insufficient information to permit judge-
ment
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Open-label study
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Insufficient information to permit judge-
ment
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Insufficient information to permit judge-
ment
Selective reporting (reporting bias) Low risk Study protocol available from Indian clin-
ical trials registry and pre-specified out-
comes were reported
Other bias High risk High dropout rate; baseline characteris-
tics different between the two groups with
UPCR significantly higher in the CPA
group
Rovin 2016
Methods • Study design: double-blind, parallel, proof-of-concept RCT
• Study timeframe: not reported
• Duration of follow-up: placebo mean 40.1 weeks; sirukumab mean 36.1 weeks
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Participants • Countries: 6 (countries not reported)
• Setting: multinational (18 sites)
• Inclusion criteria: adults (18 to 70 years); diagnosis of SLE (ACR or SLICC
criteria), including seropositivity for ANA and/or anti-ds DNA autoantibodies; biopsy-
proven (within 14 months of randomisation) Class III or IV lupus nephritis (ISN/RPS
2003 classification criteria), and persistently active (proteinuria > 0.5 g/d or at least one
of the following criteria: haematuria (≥ 5 RBC/HPF), anti-dsDNA-positive test, or C3
or C4 complement levels below the lower limit of normal; plus disease despite
standard-of-care induction and maintenance immunosuppressive treatment
• Number (randomised/analysed): treatment group (21/21); control group (4/4)
◦ Treatment group: class III (7); class IV (14)
◦ Control group: class III (2); class IV (2)
• Mean age ± SD (years): treatment group (30.6 ± 7.7); control group (37.8 ± 11.4)
• Sex (M/F): treatment group (4/17); control group (0/4)
• Exclusion criteria: received CPA within 3 months of randomisation; unless
intolerant, patients were required to be on a stable dose of an ACEi and/or an ARB;
poorly controlled hypertension (mean SBP >150 mm Hg) or a pattern of worsening or
unstable kidney disease during the 8-week screening period
Interventions Induction therapy: duration of therapy was 6 months
• Treatment group
◦ Sirukumab (IL-6 antibody): 10 mg/kg administered IV every 4 weeks
• Control group
◦ Placebo: administered IV every 4 weeks
• Both groups
◦ MMF (1 to 3 g/d; or the equivalent dose of mycophenolic acid/
mycophenolate sodium) or AZA (1 to 3 mg/kg/d), with or without oral corticosteroids
(≤ 20 mg/d prednisone or equivalent)
Outcomes • Death
• Major infection
• Malignancy
• Diarrhoea
• Kidney function
Notes • Funding source: Janssen Research & development LLC
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Study was described as randomised,
method of randomisation was not reported
Allocation concealment (selection bias) Unclear risk Insufficient information to permit judge-
ment
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Rovin 2016 (Continued)
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Double-blind, placebo-controlled study
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Insufficient information to permit judge-
ment
Incomplete outcome data (attrition bias)
All outcomes
Low risk No missing outcome data
Selective reporting (reporting bias) High risk Not all pre-specified outcomes were re-
ported
Other bias High risk Marked differences (demographics and
clinical characteristics) between groups at
baseline. Sponsor involved in authorship
Sabry 2009
Methods • Study design: quasi-RCT
• Study timeframe: not reported
• Duration of follow-up: 1 year
Participants • Country: Egypt
• Setting: single centre
• Inclusion criteria: ACR criteria for SLE; ≥ 18 years; biopsy-proven proliferative
lupus nephritis (WHO class IV), urine protein > 0.5 g/d
• Number (randomised/analysed): treatment group 1 (26/26); treatment group 2
(20/20)
• Mean age ± SD (years): treatment group 1 (26.4 ± 9); treatment group 2 (25.7 ± 7)
• Sex (M/F): treatment group 1 (4/22); treatment group 2 (2/18)
• Exclusion criteria: CSA or AZA in previous year or > 15 mg/d prednisolone in
previous month; renal thrombotic microangiopathy; pre-existing CKD; pregnancy;
previous malignancy; DM, documented toxicity; anticipated poor compliance
Interventions Induction therapy: duration of therapy was 12 months
• Treatment group 1
◦ High dose CPA: 6 x monthly pulses + 2 x quarterly pulses. Initial dose (0.5
g/1.73 m2) then dose increased by 250 mg according to WCC on day 14 with final
increment to maximum dose of 1 g/1.73m2
• Treatment group 2
◦ Low dose CPA: 6 x monthly pulses + 2 x quarterly pulses fixed dose of 0.5 g/d
• Both groups
◦ Prednisolone (0.5 mg/kg) and AZA (2 mg/kg/d) given in both treatment
arms. Prednisolone given at high dose for 4 weeks then given alternate days after being
tapered by 5 mg each week to minimal dose to control extrarenal SLE manifestations
or 0.25 mg/kg/d. AZA started 2 weeks after last infusion and continued until the end
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of the study
Outcomes • Death
• ESKD
• Doubling of SCr
• Relapse: defined by a doubling of the urinary protein excretion or by an increase
in the SCr level by 50% or more for more than 1 month
• Treatment failure: defined as urinary protein excretion ≥ 3 g/24 h; and/or
doubling of SCr or severe flare that was resistant to increased glucocorticoid dose;
patients who did not meet complete or partial remission criteria were considered as
having treatment failure
• Major infection
• Ovarian failure
• Anaemia
• Leucopenia
• GI side effects
• Proteinuria
• SCr
• Serum albumin
Notes • Six participants with most severe form of lupus nephritis allocated to high-dose
arm
• Funding source: not reported
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk All participants meeting inclusion criteria
randomised. Manual randomisation to al-
locate every other patient to either group
and then assigned to one of 2 regimens. Six
participants with most severe form of lupus
nephritis allocated to high dose arm
Allocation concealment (selection bias) High risk Use of alternation to allocate
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Insufficient information to permit judge-
ment
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Insufficient information to permit judge-
ment
Incomplete outcome data (attrition bias)
All outcomes
Low risk No missing outcome data
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Selective reporting (reporting bias) Unclear risk No study protocol available, all expected
outcomes were reported
Other bias Unclear risk Differences in baseline characteristics be-
tween the groups (more severe proteinuria
and lower serum albumin in high doseCPA
Sedhain 2016
Methods • Study design: open-label, parallel RCT
• Study timeframe: January 2014 to June 2015
• Duration of follow-up: 6 months
Participants • Country: Nepal
• Setting: single centre
• Inclusion criteria: biopsy-proven proliferative lupus nephritis
• Number (randomised/analysed): 49/42; treatment group 1 (21); treatment group
2 (21)
• Mean age ± SD (years): not reported
• Sex (M/F): not reported
• Exclusion criteria: not reported
Interventions Induction therapy: duration of therapy was 6 months
• Treatment group 1
◦ MMF: administered orally daily
• Treatment group 2
◦ IV CPA: administered monthly
Outcomes • Complete remission: normal SCr and proteinuria ≤ 0.5 g/d
• Partial remission
• Treatment failure: no response to therapy
• Proteinuria
Notes • Abstract-only publication
• Funding source: not reported
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Study was described as randomised,
method of randomisation was not reported
Allocation concealment (selection bias) Unclear risk Insufficient information to permit judge-
ment
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Blinding of participants and personnel
(performance bias)
All outcomes
High risk Open-label study
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Insufficient information to permit judge-
ment
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Insufficient information to provide judge-
ment
Selective reporting (reporting bias) Unclear risk Insufficient information to provide judge-
ment
Other bias High risk Characteristics of the six patients unable to
complete the study period are not provided
and these patients were not included in the
analysis; abstract-only publication
Sesso 1994a
Methods • Study design: parallel RCT
• Study timeframe: September 1990 to December 1992
• Duration of follow-up: 15 months
Participants • Country: Brazil
• Setting: single centre
• Inclusion criteria: aged ≥ 16 years; diagnosis of SLE (ARA criteria); severe lupus
nephritis (defined as nephritic urine sediment or urinary protein of > 3.0 g/d and
impaired kidney function (CrCl < 80 mL/min or a recent reduction of at least 30%); if
CrCl was stable the patient had to have histology of diffuse proliferative GN (WHO
classification criteria); 23/29 diffuse proliferative lupus nephritis
• Number (randomised): treatment group 1 (14); treatment group 2 (15)
• Mean age ± SE (years): treatment group 1 (30.0 ± 2.7); treatment group 2 (24.3 ±
1.5)
• Sex (M/F): treatment group 1 (2/12); treatment group 2 (2/13)
• Exclusion criteria: CrCl < 20 mL/min; SCr > 6 mg/dL; major infection within 2
weeks of study entry; pregnancy; low leucocyte count; pulse MP or CPA within 1 year
Interventions Induction therapy: duration of therapy was 10 months
• Treatment group 1
◦ IV CPA: 0.5 to 1.0 g/m2, monthly pulse for 4 months, bimonthly for 4
months then quarterly for 6 months
• Treatment group 2
◦ IV MP: 10 to 20 mg/kg; max 1.0 g x 3 daily, then monthly for 4 months,
bimonthly for 4 months then quarterly for 6 months
• Both groups
◦ Low dose oral prednisolone: 0.5 mg/kg/d initially then tapered to control
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extra-renal manifestations
Outcomes • Death
• ESKD
• Doubling of SCr
• Bone toxicity
• Bladder toxicity
• Malignancy
• Major infection
• Proteinuria
• Complete remission: improvement of SCr and of urine sediment or proteinuria
• Partial remission: trend of improvement of SCr and of urine sediment or
proteinuria
• Relapse: worsening of urine sediment, proteinuria and kidney function after
having reached initial improvement with therapy, requiring reinstitution of therapy
Notes • 2 participants lost to follow-up
• Funding source: Instituto Paulista de Estudos e Pesquisas em Nefrologia e
Hipertensao
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Study was described as randomised,
method of randomisation was not reported
Allocation concealment (selection bias) Unclear risk Insufficient information to permit judge-
ment
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Insufficient information to permit judge-
ment
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Insufficient information to permit judge-
ment
Incomplete outcome data (attrition bias)
All outcomes
Low risk No missing outcome data
Selective reporting (reporting bias) Low risk All expected outcomes were reported
Other bias High risk Proteinuria between groups at baseline was
different
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Methods • Study design: double-blind, pilot RCT
• Study timeframe: not reported
• Duration of follow-up: 36 months
Participants • Country: Canada
• Setting: single-centre
• Inclusion criteria: aged ≥ 18 years; had a history of SLE according to ACR
criteria; class III or class IV or class III/IV + V lupus nephritis by the ISN/RPS
classification criteria; must have had an index biopsy within the 3 years previous to
study enrolment, and could have been induced with CPA, MMF or another
immunosuppressant as seen as appropriate by their physician; to be in at least partial
remission at the time of randomisation, defined as having a) 0.3 to 2.9 g/d proteinuria,
b) serum albumin at least 30 g/L and c) stable kidney function), be receiving between 5
and 20 mg/d of prednisone and provide informed consent
• Number (randomised/analysed): treatment group 1 (7/7); treatment group 2 (8/8)
◦ Treatment group 1: class III (1), class IV (6), class V (5)
◦ Treatment group 2: class III (3), class IV (4), class V (3)
• Mean age ± SD (years): treatment group 1 (28.4 ± 5.6); treatment group 2 (39.2 ±
12.8)
• Sex (M/F): treatment group 1 (0/7); treatment group 2 (2/6)
• Exclusion criteria: pregnant; required prednisone for treatment of another
medical condition other than SLE; were receiving or expected to receive RRT within
the next 6 months
Interventions Maintenance therapy: duration of therapy was 36 months
• Treatment group 1
◦ Prednisone withdrawal: tapered the dose of prednisone contained in the
capsules at a rate of 5 mg/d every 2 weeks until the dose was 10 mg/d, then by 2.5 mg/
d every 2 weeks until the dose was 5 mg/d and then by 1 mg/d every 2 weeks until no
prednisone and only placebo was contained in the capsules. A capsule containing
placebo only was then continued for the duration of the study.
• Treatment group 2
◦ Prednisone: Low-dose maintenance glucocorticoids were tapered from their
steroid dose at the time of randomisation, if necessary, to a target dose of 7.5 mg/d
using the same algorithm as the prednisone withdrawal group. Patients who were
already on 5 to 7.5 mg/d of prednisone therapy were maintained on their current dose
with no changes made to the dose
• Both groups
◦ Hydroxychloroquine, and antihypertensives, NSAIDs and statins were left to
the discretion of the patient’s usual care providers. Vitamin D and calcium were
recommended for all patients in the study as osteoporosis prophylaxis
Outcomes • Relapse (composite of renal and major non-renal flare)
◦ Renal flare: defined as the occurrence of any one of the three following
events: (1) Increased proteinuria, measured by either 24 hour urine collection or by a
urine protein to creatinine ratio, by at least a) 1 g/d if the baseline proteinuria was less
than 0.2 g/d or, b) 2 g/d if the baseline proteinuria was between 0.2 and 1 g/d
(inclusive), or c) more than double the baseline proteinuria if the baseline proteinuria
was greater than 1 g/d; (2) A sustained (i.e. for two consecutive measures) increase in
SCr by at least 30% over baseline that was not due to institution of antihypertensive
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therapy or angiotensin converting enzyme inhibitor therapy and with new haematuria
attributable to active SLE; (3) New sustained haematuria attributable to active SLE,
and exclusive of menses, infection or medications, that was associated with an increase
in proteinuria by at least 0.8 g/d)
◦ Major non-renal flare
• Major infection
• Quality of life: SF-36
Notes • 2 participants lost to follow-up
• Funding source: centre for Advancement of Health, Calgary
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “Patients were randomly allocated to either
the prednisone or placebo group using a
random number list generated by an in-
dependent statistician. Randomization was
blocked and stratified according to the du-
ration of steroid treatment at the time of
enrollment (≤12 months or >12 months)
and remission status (partial or complete).
”
Allocation concealment (selection bias) Low risk “Allocation was concealed using sealed,
opaque, sequentially numbered envelopes
maintained by an independent physician.
When a participant was randomised, the
independent physician faxed the study
number and assigned treatment to the
study pharmacy.”
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Double-blind study “Patients, investiga-
tors, care providers and data analysts
remained blinded to study treatment
throughout the trial.”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk “Patients, investigators, care providers and
data analysts remained blinded to study
treatment throughout the trial.”
Incomplete outcome data (attrition bias)
All outcomes
Low risk No missing outcome data
Selective reporting (reporting bias) High risk All prespecified outcomes are reported, but
not all expected outcomes are reported
161Immunosuppressive treatment for proliferative lupus nephritis (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
SIMPL 2014 (Continued)
Other bias High risk Pilot study - underpowered
Steinberg 1971
Methods • Study design: double-blind, parallel RCT
• Study timeframe: not reported
• Duration of follow-up: 10 weeks
Participants • Country: USA
• Setting: single centre
• Inclusion criteria: diagnosis of SLE (ARA criteria); a positive lupus erythematosus
cell test in the course of the disease; kidney disease unaccounted for by other
pathological processes, with at least one of the following: RBC casts in a fresh
centrifuged urine sediment; cellular casts and either haematuria (≥ 20 RBC/HPF) or
pyuria (e≥ 20 WBC/HPF); proteinuria ≥ 1 g/24 h; CrCl < 50 mL/min; 8/15 diffuse
proliferative lupus nephritis
• Number (randomised/analysed): treatment group (7/9); control group (6/6)
• Mean age, range (years): treatment group (23, 11 to 36); control group (23, 11 to
36)
• Sex (M/F): treatment group (0/7); control group (2/6)
• Exclusion criteria: major infection within the preceding 2 weeks; pregnancy;
granulocyte count < 1500/mm3 , immunosuppressive therapy within 3 months; severe
liver disease
Interventions Induction therapy: duration of treatment was 10 weeks
• Treatment group
◦ Oral CPA: initial dose of 3 mg/kg/d could be increased to 4 mg/kg/d after 2
weeks
◦ Prednisone: 30 mg/d
• Control group
◦ Prednisone: 30 mg/d
• Both groups
◦ Aspirin: 30 mg/d
Outcomes • Death
• Toxicity
• Alopecia
• Complete remission of proteinuria
• Relapse: major SLE flare (criteria not reported)
• Proteinuria
• CrCl
Notes • 2 participants crossed-over to CPA therapy following placebo treatment period
and were included in the analysis for CPA
• Funding source: Drug and placebo were supplied through the kindness of Dr
Martin E. Vancif, Mead Johnson Laboratories, Evansville, Ind
Risk of bias
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Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Used consecutively numbered envelopes,
each containing a randomly assigned pre-
scription for placebo or CPA
Allocation concealment (selection bias) Low risk As each patient entered the study, the
next sequential envelope was opened in the
pharmacy
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Double-blind study
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Insufficient information to permit judge-
ment
Incomplete outcome data (attrition bias)
All outcomes
Low risk No missing outcome data
Selective reporting (reporting bias) Low risk Study protocol available and pre-specified
outcomes were reported
Other bias High risk Cross-over of two participants from the
placebo to CPA arm were included in the
analysis
Sun 2015
Methods • Study design: open-label, parallel RCT
• Study timeframe: September 2007 to February 2012
• Duration of follow-up: 6 months
Participants • Country: China
• Setting: single centre
• Inclusion criteria: aged 14 to 60 years; SLEDAI ≥ 12; renal-biopsy-proven diffuse
segment or global (IV-s of IV-G) lupus nephritis (ISN/RPS 2003 classification criteria)
• Number (randomised/analysed): treatment group 1 (40/40); treatment group 2
(42/42)
• Mean age ± SD (years): treatment group 1 (33.3 ± 11); treatment group 2 (31.9 ±
8.7)
• Sex (M/F): treatment group 1 (3/37); treatment group 2 (4/38)
• Exclusion criteria: complicated by uncontrolled severe infections or
neuropsychiatric SLE; abnormal liver or kidney function (defined as > 2 times of the
normal values of transaminases or > 265.2 µmol/L of SCr level); patients with < 3×10
9/L of WBC or < 50×109/L of platelets; patients who received any cytotoxic or
immunosuppressive drugs like CPA, TAC, MMF, or CSA within 3 months; pregnant
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or lactating women; patients with cerebrovascular disease, glucose metabolism disorder,
or severe cardiopulmonary dysfunction
Interventions Induction therapy: duration of therapy was 6 months
• Treatment group 1
◦ IV CPA: monthly dose of 0.75 g/m2
• Treatment group 2
◦ IV CPA: monthly dose of 0.4 g/m2
◦ Oral MMF: 1.0 g/d
• Both groups
• Prednisolone was started at a daily dose of 1.0 mg/kg for both groups, and then
the dose was reduced gradually after 4 to 8 weeks until completion of the treatment
Outcomes 1. Death
2. Major infection
3. Leucopenia: WCC < 4000/mm3
4. Complete remission: < 0.3 g/24 h proteinuria with ≥ 35 g/L of serum albumin
and normal SCr level
5. Partial remission: proteinuria range 0.3 to 2.9 g/24 h with an albumin
concentration of ≥ 30 g/L, stable or improved kidney function with reduction of
proteinuria by > 50%
6. Serum albumin
7. Proteinuria
Notes • Funding source: This study was in part supported by the Natural Science
Foundation of Hunan Province (No. 13JJ3033)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Study was described as randomised,
method of randomisation was not reported
Allocation concealment (selection bias) Unclear risk Insufficient information to permit judge-
ment
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Open-label study
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Insufficient information to permit judge-
ment
Incomplete outcome data (attrition bias)
All outcomes
Low risk No missing outcome data
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Selective reporting (reporting bias) Low risk No study protocol available but expected
outcomes are reported
Other bias Low risk The study appears to be free of other
sources of bias
Wallace 1998
Methods • Study design: open-label, parallel RCT
• Study timeframe: not reported
• Duration of follow-up: > 24 months
Participants • Country: USA
• Setting: single centre
• Inclusion criteria: diagnosis of SLE (ACR criteria); aged ≥ 16 years; class III or IV
lupus nephritis on renal biopsy and chronicity index < 6; 2/19 class IV
• Number (randomised): treatment group 1 (9); treatment group 2 (9)
• Mean age ± SD (years): treatment group 1 (33.0 ± 10.0); treatment group 2 (32.0
± 14.0)
• Sex (M/F): treatment group 1 (1/8); treatment group 2 (0/9)
• Exclusion criteria: SCr > 3 mg/dL; renal biopsy chronicity index ≥ 6; pregnancy;
< 16 years; immunosuppression in last 3 months
Interventions Induction therapy: duration of treatment was 8 months
• Treatment group 1
◦ PEX: 3 x daily preceding CPA
◦ IV CPA: (750 mg/m2 x 6)
• Treatment group 2
• IV CPA: 750 mg/m2 x 6 over 8 months
• Both groups
◦ Prednisolone: 1 mg/kg/d for 6 weeks then tapering dose
Outcomes • Death
• ESKD
• Complete remission: SCr < 1.4 mg/dL, a 24-h urine protein < 500 mg, absence of
urinary casts; normal BP and serum albumin > 4.0 mg/dL
• SCr
• Serum albumin
• Proteinuria
Notes • 1 patient lost to follow-up
• Funding source: not reported
Risk of bias
Bias Authors’ judgement Support for judgement
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Random sequence generation (selection
bias)
Unclear risk Study was described as randomised,
method of randomisation was not reported
Allocation concealment (selection bias) Unclear risk Insufficient information to permit judge-
ment
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Open-label study
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Insufficient information to permit judge-
ment
Incomplete outcome data (attrition bias)
All outcomes
Low risk No missing outcome data
Selective reporting (reporting bias) High risk Not all expected outcomes were reported
Other bias Low risk The study appears to be free of other
sources of bias
Yap 2017
Methods • Study design: parallel RCT
• Study timeframe: not reported
• Duration of follow-up: 6 months
Participants • Country: Hong Kong
• Setting: not reported
• Inclusion criteria: active lupus nephritis
• Number (randomised): treatment group 1 (7); treatment group 2 (7)
• Mean age ± SD (years): not reported
• Sex (M/F): not reported
• Exclusion criteria: not reported
Interventions Induction therapy: duration of treatment was 6 months
• Treatment group 1
◦ MMF: no details provided
• Treatment group 2
◦ CPA: no details provided
• Both groups
◦ Prednisone or prednisone equivalent: no details provided
Outcomes • Immunological function
Notes • Funding source: Bristol Myers Squibb
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Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Study was described as randomised,
method of randomisation was not reported
Allocation concealment (selection bias) Unclear risk Insufficient information to permit judge-
ment
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Insufficient information to permit judge-
ment
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Insufficient information to permit judge-
ment
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Insufficient information to permit judge-
ment
Selective reporting (reporting bias) High risk Not all relevant clinical outcomes reported
Other bias Unclear risk Insufficient information to permit judge-
ment; abstract-only publication
Yee 2004
Methods • Study design: open label, parallel RCT
• Study timeframe: June 1992 to May 1996
• Duration of follow-up: intended to be 5 to 10 years
Participants • Countries: Austria, Czech Republic, Lithuania, Slovenia, Sweden, UK
• Setting: multinational (8 sites)
• Inclusion criteria: diagnosis of SLE (ACR criteria); biopsy-proven proliferative
lupus nephritis (WHO classification criteria), aged 16 to 65 years
• Number (randomised/analysed): treatment group 1 (16/13); treatment group 2
(16/16)
◦ Treatment group 1: class III (6), class IV (10)
◦ Treatment group 2: class III (5), class IV (8)
• Mean age ± SD (years): treatment group 1 (42.4 ± 11.8); treatment group 2 (32.2
± 11.7)
• Sex (M/F): treatment group 1 (2/11); treatment group 2 (2/14)
• Exclusion criteria: previous CPA or AZA in preceding 3 weeks; pure membranous
or mesangial proliferative GN on biopsy; previous treatment with CPA for > 3 months;
allergy to study drugs; previous malignancy; primary immunodeficiency (except
complement components); non-lupus-related kidney disease
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Interventions Induction therapy: duration of treatment was 24 months
• Treatment group 1
◦ Intermittent IV CPA: 10 mg/kg 3 x/wk, max 1 g for 4 doses, then orally
(same dose split over 2/7) 4 weekly for 9 months and 6 weekly for 12 months
◦ IV MP 6.6 mg/kg before each pulse of CPA then orally at same dose split
over 2 days before each oral dose plus oral prednisolone 0.3 mg/kg/d reducing to 0.1
mg/kg/d to maintenance dose of 0.05 to 0.1 mg/kg/d
• Treatment group 2
◦ Oral CPA: 2 mg/kg/d for 3 months then 1.5 mg/kg/d
◦ Oral prednisolone: 0.85 mg/kg/d (max dose 60 mg) reducing to 0.11 mg/
kg/d by week 53
• Both groups
◦ H2 receptor antagonist (ranitidine 150 mg at night or cimetidine 400 mg at
night) and amphotericin lozenges (10 mg four times a day) as prophylaxis while on
daily CPA and for two weeks with each pulse of CPA
Outcomes • Death
• ESKD
• Doubling of SCr
• Major infection
• Ovarian failure
• Malignancy
• Bladder toxicity
• Nausea/vomiting
• Treatment failure: failure to respond to treatment
Notes • Study terminated after 4 years due to poor recruitment and high withdrawal rate
• Funding source: European League Against Rheumatism (EULAR) Standing
Committee on International Clinical Studies including Therapeutic Trials (ESCIST);
Lupus UK; and the Swedish Medical Research Council (grant 13489).
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Participants were stratified according to the
presence of kidney failure and underwent
block randomisation to either therapy
Allocation concealment (selection bias) Unclear risk Insufficient information to permit judge-
ment
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Open-label study
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Insufficient information to permit judge-
ment
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Incomplete outcome data (attrition bias)
All outcomes
Low risk No missing outcome data
Selective reporting (reporting bias) High risk Not all pre-specified outcomes reported:
alopecia
Other bias High risk Study was terminated after four years as
patient recruitment was disappointing and
many patients had been withdrawn; Many
physicians became reluctant to enter pa-
tients because of concerns that the oral reg-
imen was slower to work and more toxic
than the pulse regimen, following develop-
ment of severe neutropenia in the contin-
uous group; This led to the premature ter-
mination of the study
Zhang 1995a
Methods • Study design: open-label, parallel RCT
• Study timeframe: not reported
• Duration of follow-up: 12 to 39 months
Participants • Country: China
• Setting: single centre
• Inclusion criteria: biopsy-proven active lupus nephritis
• Number (randomised): 36 (numbers per group not reported)
• Mean age ± SD (years): not reported
• Sex (M/F): not reported
• Exclusion criteria: not reported
Interventions Induction therapy
• Treatment group 1
◦ CPA: monthly pulse 0.5 to 0.8 g/m2 until remission
• Treatment group 2
◦ CPA: monthly pulse 0.5 to 0.8 g/m2 for 1 year
• Both groups
◦ Minimum necessary dose of steroids
Outcomes • Remission
• Relapse
• Urinalysis
• Serology
Notes • Abstract-only publications
• Funding source: not reported
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Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Study was described as randomised,
method of randomisation was not reported
Allocation concealment (selection bias) Unclear risk Insufficient information to permit judge-
ment
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Open-label study
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Insufficient information to permit judge-
ment
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Insufficient information to permit judge-
ment
Selective reporting (reporting bias) High risk Data unable to be meta-analysed
Other bias Unclear risk Abstract-only publication; insufficient in-
formation to permit judgement
ACEi - angiotensin-converting enzyme inhibitor; ACR - American College of Rheumatology; ANA - antinuclear antibody; ARA
- American Rheumatology Association; ARB - angiotensin receptor blocker; AZA - azathioprine; BILAG - British Isles Lupus
Assessment Group; CKD - chronic kidney disease; CMV - cytomegalovirus; CNI - calcineurin; CNS - central nervous system;
CPA - cyclophosphamide; CrCl - creatinine clearance; CSA - cyclosporin A; DM - diabetes mellitus; EC-MPS - enteric-coated
mycophenolate sodium; eGFR - estimated glomerular filtration rate; ELNT - Euro-lupus nephritis treatment; ESKD - end-stage
kidney disease; GI - gastrointestinal: GN - glomerulonephritis; Hb - haemoglobin; HBV - hepatitis B virus; HCV - hepatitis C
virus; HIV - human immunodeficiency virus; HPF - high power field; IA - immunoadsorption; ISN/RPS - International Society
of Nephrology/Renal Pathology Society; IV - intravenous; IVIG - intravenous immunoglobulin; M/F - male/female; MMF -
mycophenolate mofetil; MP - methylprednisolone; NSAID/s - nonsteroidal anti-inflammatory drug/s; PEX - plasma exchange or
plasmapheresis; PALGA - Dutch Pathology Registry; RBC - red blood cell/s; RCC - red cell count; RCT - randomised controlled
trial; RTX - rituximab; SC - subcutaneous; SCr - serum creatinine; SD - standard deviation; SDS - standard deviation score; SLE
- systemic lupus erythematosus; SLEDAI - SLE Disease Activity Index; SLICC - Systemic Lupus Collaborating Clinics; TAC -
tacrolimus; TB - tuberculosis;WHO -WorldHealthOrganization; ISN/RPS - International Society ofNephrology/ Renal Pathology
Society; UPCR - urine protein-to-creatinine ratio; WBC - white blood cell/s; WCC - white cell count
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Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Andrade-Ortega 2010 Wrong population: not biopsy-proven lupus nephritis
Antunes 2001 Wrong intervention: not comparing immunosuppression
ASPEN 2008 Wrong population: not biopsy-proven lupus nephritis
ATLAS 2016 Wrong population: diagnosis of biopsy-proven proliferative lupus nephritis at randomisation unclear
Austin 2009 Wrong population: not biopsy-proven lupus nephritis but membranous
Balow 1981 Wrong population: not biopsy-proven lupus nephritis
Balow 1984 No relevant outcomes
Ble 2011 Wrong intervention: not immunosuppressive intervention
Chanchairujira 2009 No relevant clinical outcomes
Clark 1993 Wrong population: not biopsy-proven lupus nephritis
Clark 2001a Wrong population: not biopsy-proven lupus nephritis
CONTROL 2016 Wrong population: diagnosis of biopsy-proven proliferative lupus nephritis at randomisation was unclear
Davis 1999 Wrong population and intervention: not biopsy-proven lupus nephritis or comparing immunosuppression
Daza 2005 Wrong intervention: not comparing immunosuppression
Deng 2017a Wrong intervention: not comparing immunosuppression
Feng 2014 Wrong population: not biopsy-proven lupus nephritis
Frutos 1997 Insufficient information to determine if the study is randomised
Hebert 1987 Wrong population: not biopsy-proven lupus nephritis
Khajehdehi 2012 Wrong intervention: not immunosuppressive intervention
Kuo 2001 Wrong intervention: not comparing immunosuppression
Li 2005 Insufficient information to determine if the study is randomised
Li 2014a Wrong intervention: not immunosuppressive intervention
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LJP 394-90-05 2003 Wrong population: not biopsy-proven lupus nephritis
LJP 394-90-09 2005 Wrong population: not biopsy-proven lupus nephritis
Lu 2002 Wrong population: not biopsy-proven lupus nephritis
Miyasaka 2009 Wrong population: included class II and class V lupus nephritis
NCT00001212 Wrong population: membranous lupus nephritis
NCT00404157 The study has been terminated
NCT00429377 The recruitment status of this study is unknown (registered 2007). The completion date of this study has
passed and the status has not been verified in more than two years
NCT00436438 Study terminated early for administrative reasons
NCT00539799 This study was withdrawn prior to enrolment, as the local pharmacy were unwilling to comply with the
study protocol
NCT00659217 The recruitment status of this study is unknown (registered 2008). The completion date of this study has
passed and the status has not been verified in more than two years
NCT01299922 This study was withdrawn prior to recruitment
NCT01342016 This study has been terminated due to safety concerns of active control drug
NCT01930890 Study was terminated because results from previous studies did not demonstrate sufficient efficacy
NCT02176486 Study was terminated, insufficient enrolment
Pierucci 1989 Wrong population: not comparing immunosuppression
Schaumann 1992 Unclear if biopsy-proven lupus nephritis
Su 2007 Wrong population: not biopsy-proven lupus nephritis
Sztejnbok 1971 Wrong population: not biopsy-proven lupus nephritis
Wallace 2006 Wrong population: not biopsy-proven lupus nephritis
Wang 2007 Wrong population: non-invasive necrotising vasculopathy-severe variant not usually responsive to standard
therapy
Witte 1993 Unclear if biopsy-proven lupus nephritis
Yap 2012 Wrong population: not biopsy-proven lupus nephritis
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Ye 2001 Wrong population: not biopsy-proven lupus nephritis
Yoshida 1996 Wrong intervention: not comparing immunosuppression
Zhang 2015c Wrong population: biopsy-proven proliferative lupus nephritis were excluded
Zheng 2005a Unclear if biopsy-proven lupus nephritis
Characteristics of ongoing studies [ordered by study ID]
2nd Dutch Lupus Trial
Trial name or title Comparison of short course cyclophosphamide followed by mycophenolate mofetil versus long course cyclo-
phosphamide in the treatment of proliferative lupus nephritis
Methods Multicentre RCT
Participants Adult, proliferative lupus nephritis, biopsy-proven, active urinary sediment, proteinuria
Interventions 6 months IV CPA induction followed by either 3 monthly IV CPA or MMF for 18 months, then 2 years
AZA in both arms
Outcomes Renal relapse
Starting date January 2003
Contact information Marc Bijl, University Medical Centre Groningen
Notes
ChiCTR-TRC-09000587
Trial name or title The intensive therapy of severe lupus nephritis: a multicenter, randomised, controlled prospective clinical
trial
Methods Multicentre, randomised controlled
Participants Adult, SLE according to ACR criteria, renal biopsy-proven lupus nephritis: 24 hours proteinuria (≥ 3.0g/d
or +++), erythrocyturia > 5/HPF, leucocyturia or cast (RBC, Hb, tubuli or mixed); SLEDAI score ≥10
Interventions 1. NIH IV CPA standard program (Induction period, follow-up once every four weeks; consolidation
therapy: follow-up once every twelve weeks, maintenance therapy: follow-up once every twelve weeks.
2. Intensive group: mini-pulse of CPA, hydroxychloroquine and another immunosuppressive agent, such
as MMF, leflunomide, AZA or methotrexate
Outcomes Serum albumin, SCr, SLEDAI, liver function, adverse events
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ChiCTR-TRC-09000587 (Continued)
Starting date September 2009
Contact information Zhanguo Li, The department of rheumatology and immunology, People’sHospital, Peking university, Beijing,
China
Notes
ChiCTR-TRC-10000931
Trial name or title Treatment of severe lupus nephritis with tacrolimus (FK 506) based immunosuppression
Methods Multicentre RCT
Participants Adult; SLE (ACR criteria); SLEDAI > 10 points; biopsy-proven lupus nephritis severe type III, IV type, V+III
type and V+IV-type lupus nephritis (WHO2004 criteria), heavy-III, with severe segmental lesions that have
loop necrosis or crescent formation of the III-type lupus nephritis); significant renal disease, proteinuria ≥ 2
g/24 h, with active urine sediment (urine RBC > 400,000/mL, tube urine, leukocytes in urine), SCr < 3mg/
dL (265 µmol/L)
Interventions Tacrolimus (0.5 mg and 1 mg)
Outcomes Serum albumin, SCr, proteinuria, immunological function, renal biopsy, adverse events
Starting date 2009
Contact information Changlin Mei, Shanghai Changzheng Hospital, Beijing China
Notes Sponsor - Astellas Pharma China Inc.
CTRI/2016/01/006488
Trial name or title Comparison of two steroid dose regimen in lupus nephritis: a randomised controlled trial
Methods RCT
Participants 12 to 70 years of age, SLE (ACR criteria); biopsy-proven lupus nephritis (ISN/RPS class III, IV, III+V or
IV+V)
Interventions 1. Low dose oral prednisolone (0.5 mg/kg/d)
2. Oral prednisolone (1 mg/kg/d)
Patients in both groups will receive IV MP (750 mg) for 3 days, followed by oral prednisolone for a period
of 8 weeks followed by a taper. All patients will receive MMF
Outcomes Complete remission, partial remission, SELENA-SLEDAI, quality of life, immunological function, adverse
events
Starting date January 2016
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Contact information Krishan Lal Gupta, Department of nephrology, Postgraduate Institute of Medical Education and Research,
Chandigarh, India
Notes
CTRI/2017/05/008697
Trial name or title Randomised controlled trial of multi-targetted therapy versus low-dose intravenous cyclophosphamide in the
treatment of lupus nephritis
Methods Parallel RCT
Participants Adults, SLE ACR criteria; lupus nephritis class III, IV, V, a combination of III+V or IV+V; SCr < 3.0 mg/dL
Interventions 1. MMF: 1 g/d in 2 divided doses and TAC 0.1 mg/kg/d to target a trough level of 4 to 7 ng/mL. MMF
and TAC will be taken morning and evening, before meals, and with a glass of water
2. CPA: Euro-lupus Nephritis trial group regimen of six fortnightly IV infusions of a fixed dose of 500
mg CPA
• All the patients will be given 3 IV infusion of MP (750 mg) followed by 1 mg/kg/d of oral
prednisolone for a period of 8 weeks followed by taper to 7.5 mg/d at the end of 6 months
• All the patients will be given maintenance treatment after completion of induction treatment, in the
form of AZA (2 mg/kg) plus low-dose steroids
Outcomes 1. Decrease in 24 h proteinuria, defined as decrease in the UPCR to 3 in subjects with baseline nephrotic
range proteinuria (≥ 3 UPCR) or decrease in the UPCR by ≥ 50% in subjects with sub-nephrotic
proteinuria (3 UPCR)
2. Stabilization of SCr (i.e., a week 24 SCr level ± 25% of baseline) or improvement
Starting date July 2016
Contact information KrishanLalGupta,Department ofNephrology,NehruHospital, PostGraduate Institute ofMedical Education
and Research, Chandigarh, India
Notes Follow-up: 6 months
ISRCTN66475575
Trial name or title Enteric coatmycophenolate sodium versus intravenous cyclophosphamide for severe paediatric lupus nephritis
Methods Multicentre RCT
Participants Paediatric lupus nephritis
Interventions 1. EC-MPS (myfortic®): 720 to 860 mg/m2/d, oral twice daily + oral steroid
2. CPA: 750 to 1000 mg/m2/d (maximum dose 1000 mg/d), IV monthly for 6 months then every 3
months + oral steroid
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Outcomes 1. Death
2. ESKD
3. Complete remission
4. Partial remission
5. Relapse (renal and non-renal)
6. Disease activity: SLEDAI
7. Infection
8. GI symptoms
Starting date July 2009
Contact information Wattana Chartapisak, Department of Pediatrics, Chiang Mai, Thailand
Notes
NCT00302549
Trial name or title To compare the efficacy and safety of FK506 vs IVC in the treatment of class III-IV lupus nephritis
Methods Multicentre RCT
Participants Adult (18 to 65 years) female patients with SLE according to ACR criteria, SLEDAI > 10; biopsy-proven
class III or IV lupus nephritis according to theWHOclassification criteria within 3month and have significant
active pathological lesion; proteinuria ≥ 2 g/24 h, and an active urine sediment (haematuria with white cells
and casts in urine)
Interventions 1. TAC: 0.1 mg/kg/d
2. IV CPA
Outcomes Safety and efficacy
Starting date May 2004
Contact information Lei-shi Li, Research Institute of Nephrology, Jinling Hospital, Nanjing University School of Medicine, Nan-
jing, Jiangsu, China
Notes Study was registered over 10 years ago and it is unlikely the study will be published
NCT00705367
Trial name or title A single centre, randomised, placebo-controlled, double blind, parallel group study to evaluate the tolerability
of a single dose of Abatacept 30 mg/kg via intravenous infusion in Chinese SLE subjects with lupus nephritis
Methods Single-centre, double blind and open-label extension RCT
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Participants Adult; ≥ 18 years of age; SLE and with lupus nephritis currently stable for the last 3 months without change
in treatment for lupus nephritis; stable renal disease; no flaring of other organ systems in a minimum of the
last 3 months
Interventions 1. Abatacept: IV 30 mg/kg, single dose at day 1 and IV 10 mg/kg on days 15 and 29 followed by doses
every 4 weeks until the end of the study
2. Placebo: IV
Outcomes 1. Death
2. Adverse events
3. Clinical characteristics: e.g. blood pressure, heart rate
Starting date August 2008
Contact information Bristol-Myers Squibb
Notes Study includes short-term follow-up period and long-term extension period
NCT00881309
Trial name or title To compare the efficacy and safety of tripterygium vs azathioprine in the maintenance therapy for lupus
nephritis
Methods RCT
Participants Adults, class III-V lupus nephritis (biopsy-proven)
Interventions Induction with MMF, CPA, TAC or multi-target therapy followed by randomisation to either AZA mainte-
nance therapy or tripterygium 90 mg once/d
Outcomes Complete remission
Starting date March 2009
Contact information Weixin Hu, Nanjing University School of Medicine, China
Notes
NCT01056237
Trial name or title Long-term study of multi-target therapy as maintenance treatment for lupus nephritis
Methods Open-label RCT
Participants Adults (18 to 65 years); SLE; diagnosed class , , + , + or lupus nephritis (ISN/RPS 2003 criteria) by
renal biopsy; all patients had received induction therapy for 6 months with multi-therapy (FK506 +MMF) or
IV CPA pulses. Patients were recruited when received partial remission or complete remission after 6 months
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induction therapy
Interventions 1. Multi-target therapy: TAC (1 to 3 mg/d) and MMF (0.5 to 0.75 g/d)
2. AZA: 1.0 to 2.0 mg/kg/d
Outcomes Safety and efficacy
Starting date February 2010
Contact information Zhi-Hong Liu, Nanjing University School of Medicine
Notes 18 month duration
NCT01172002
Trial name or title Leflunomide versus AZA for maintenance therapy of lupus nephritis
Methods Open-label RCT
Participants Adults, biopsy-proven proliferative lupus nephritis
Interventions Leflunomide versus AZA (maintenance therapy)
Outcomes Lupus nephritis flare
Starting date March 2010
Contact information Bao Chun De, Renji Hospital
Notes
NCT01284725
Trial name or title Weaning of Immunosuppression in Nephritis of Lupus
Methods Open-label RCT
Participants Adult, biopsy-proven proliferative lupus nephritis
Interventions Immunosuppressive treatment discontinuation versus continuation of MMF or AZA
Outcomes Discontinuation of maintenance immunosuppressive therapy
Starting date January 2011
Contact information Noemie Jourde Chiche, Assistance Publique hôpitaux de Marseille
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Notes
NCT01639339
Trial name or title A phase 3, randomised, double-blind, placebo-controlled study to evaluate the efficacy and safety of Beli-
mumab plus standard of care versus placebo plus standard of care in adult subjects with active lupus nephritis
Methods Double-blind, placebo controlled RCT
Participants Adult, diagnosis of SLE (ACR criteria), biopsy-proven lupus nephritis, clinically active lupus nephritis, au-
toantibody positive
Interventions Belimumab versus placebo and standard therapy
Outcomes Renal response, complete renal response, adverse events
Starting date July 2012
Contact information GlaxoSmithKline
Notes
NCT01714817
Trial name or title A phase 3 randomised, double-blind, placebo-controlled study to evaluate the efficacy and safety of BMS-
188667 (Abatacept) or placeboon abackgroundofmycophenolatemofetil and corticosteroids in the treatment
of subjects with active class III or IV lupus nephritis
Methods Double-blind RCT
Participants Age > 16 years; biopsy-proven class III or IV lupus nephritis within 12 months; UPCR ≥ 1; SCr ≤ 3 mg/dL
(i.e., ≤ 265 µmol/L); active disease within 3 months - based on one of the following (1) worsening of lupus
nephritis - UPCR ≥ 3 (2) active urine sediment (3) biopsy within 3 months indicating active class III or IV
Inclusion criteria for the long-term extension period: achieved complete or partial renal response after com-
pleting 2 years of double-blind treatment
Interventions 1. BMS-188667 + MMF + Prednisone: BMS-188667 30 mg/kg injection by IV on days 1, 15, 29, and
57, followed by a weight-tiered dose approximating 10 mg/kg injection by IV every 4 weeks, MMF 1.5 g
tablet by mouth and prednisone up to 60 mg tablet by mouth daily for 104 weeks
2. Placebo matching with BMS-188667 injection by IV on Days 1, 15, 29, and 57, followed by every 4
weeks, MMF 1.5 g tablet by mouth and prednisone up to 60 mg tablet by mouth daily for 104 weeks
Outcomes Renal response
Starting date January 2013
Contact information Bristol-Myers Squibb
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Notes
NCT01845740
Trial name or title A phase Ib study of milatuzumab administered subcutaneously in patients with active systemic lupus Erythe-
matosus
Methods Double-blind RCT
Participants Adult ≥ 18 years; SLE (ACR criteria); positive ANA (titre ≥ 1:80); at least 1 BILAG A or 2 BILAG B scores
in any organ/body system and ≥ 6 SELENA-SLEDAI score; receiving at least 5.0 mg/d oral prednisone
(or equivalent) at stable doses for at least 4 weeks prior to study entry If receiving immunosuppressives or
antimalarial agents, at stable doses for at least 4 weeks prior to study entry
Interventions 1. High dose milatuzumab SC 250 mg
2. Low dose milatuzumab SC 150 mg
3. Placebo SC
Outcomes Safety and efficacy
Starting date January 2015
Contact information Heather Horne, Cedars Sinai Medical Center-Wallace Rheumatic Study centre, California, United States of
America
Notes
NCT01861561
Trial name or title Efficacy and infectious complications of induction therapy with low-dose versus high-dose intravenous cy-
clophosphamide for proliferative lupus nephritis in children
Methods Open-label RCT
Participants Children (≤ 15 years), diagnosis of SLE (ACR 1997 criteria), biopsy-proven class III or IV lupus nephritis
(ISN/RPS 2003 classification criteria)
Interventions High-dose IV CPA versus low-dose IV CPA (induction therapy)
Outcomes Complete renal response, partial renal response, infection, quality of life, disease activity
Starting date May 2013
Contact information Nuntawan Piyaphanee, Siriraj Hospital, Thailand
Notes
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NCT02226341
Trial name or title Open-label prospective randomised study to determine the efficacy and safety of two dosing regimens of
ACTHar in the treatment of proliferative lupus nephritis
Methods Open-label RCT
Participants ≥ 16 years, diagnosis of SLE (ACR/SLICC criteria), biopsy-proven class III or IV ±V lupus nephritis (ISN/
RPS 2003 classification criteria)
Interventions CellCept daily & ACTHar gel biweekly versus CellCept daily & ACTHar gel every other day
Outcomes Complete response, partial response, renal flares, adverse events, cortisol levels, urinary lymphocytes
Starting date October 2014
Contact information Anca D Askanase, Columbia University, USA
Notes
NCT02256150
Trial name or title A multi-center, randomised, controlled, open-label clinical study to evaluate the efficacy and safety of mi-
zoribine in comparison with cyclophosphamide in the treatment of lupus nephritis
Methods Open-label RCT
Participants Adult, diagnosis of SLE (ACR 1997 criteria), biopsy-proven class III, III+V, IV, IV+V or V (ISN/RPS 2003
classification criteria), proteinuria > 1 g/d, SLEDAI > 8, patient body weight 40-80kg at screening
Interventions Mizoribine versus CPA
Outcomes Complete remission, partial remission, treatment failure, ESKD, doubling of SCr, SCr, eGFR, C3, anti-
dsDNA, anti-phospholipid, anti-Sm, SLEDAI
Starting date November 2014
Contact information Asahi Kasei Pharma Corporation
Notes
NCT02260934
Trial name or title Rituximab plus cyclophosphamide followed by belimumab for the treatment of lupus nephritis (ITN055AI)
Methods Open-label RCT
Participants Adult, diagnosis of SLE (ACR criteria), biopsy-proven proliferative lupus nephritis (ISN/RPS classification
criteria), > 5 RBC/HPF in absence of menses and infection, > WBC/HPF in absence of infection or cellular
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NCT02260934 (Continued)
casts, UPCR > 1
Interventions RTX, CPA and belimumab versus RTX and CPA
Outcomes Major infection, hypogammaglobulinaemia, complete response, partial response, treatment failure, relapse
anti-dsDNA, C3 and C4, death, leucopenia, ovarian failure, malignancy, thrombocytopenia, adverse advents
Starting date October 2014
Contact information Betty Diamond, Feinstein Institute for Medical Research: centre for Autoimmune and Musculoskeletal Dis-
eases, USA
Notes
NCT02457221
Trial name or title A phase III, randomised, open, parallel-controlled, multi-center study to compare the efficacy and safety of
tacrolimus capsules and cyclophosphamide injection in treatment of lupus nephritis
Methods Open-label RCT
Participants 18-60 years, 18.5 ≤ BMI < 27, diagnosis of SLE (ACR 1997 criteria), biopsy-proven class III, IV, V, III+V,
IV+V lupus nephritis (ISN/RPS 2003 classification criteria) within 24 weeks of study entry, proteinuria > 1.
5 g/d, SCr < 3 mg/dL
Interventions TAC versus CPA (induction therapy)
Outcomes Complete remission, partial remission, proteinuria, serum albumin, SCr, eGFR, anti-dsDNA and ANA,
SLEDAI, C3 and C4, renal biopsy active index and chronic index
Starting date March 2015
Contact information Astellas Pharma China, Inc.
Notes
NCT02547922
Trial name or title A multicentre, randomised, double-blind, placebo-controlled, phase 2 study evaluating the efficacy and safety
of Anifrolumab in adult subjects with active proliferative lupus nephritis
Methods Double-blind RCT
Participants 18 to 70 years, fulfil four or more of the ACR 1982 criteria which must include positive ANA, elevated anti-
dsDNA, anti-Smith; biopsy-proven class III±V, IV±V, UPCR 1g/d, eGFR ≥ 35 mL/min/1.73 m2, women
of childbearing potential must have negative serum beta-hCG
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NCT02547922 (Continued)
Interventions High-dose anifrolumab, low-dose anifrolumab versus placebo
Outcomes Complete renal response, partial renal response, eGFR, proteinuria, urine sediment, adverse events
Starting date November 2015
Contact information AstraZeneca Clinical Study Information centre
Notes
NCT02550652
Trial name or title A randomised, double-blind, placebo-controlled, multi-center study to evaluate the safety and efficacy of
Obinutuzumab in patients with ISN/RPS 2003 Class III or IV lupus nephritis
Methods Double-blind, placebo-controlled RCT
Participants Age 18-75 years, diagnosis of SLE (ACR criteria), biopsy-proven class III or IV lupus nephritis (ISN/RPS
2003 classification criteria), proteinuria UPCR > 1.0 g, premenopausal female participants agree to refraining
from getting pregnant 18 months, male participants agree to use contraception for 12 month
Interventions Obinutuzumab versus placebo
Outcomes Complete renal response, partial renal response, anti-dsDNA, C3 and C4, disease activity, immune cells (CD-
19 B-cells, T-cells, neutrophil), adverse events
Starting date November, 2015
Contact information Hoffmann-La Roche
Notes
NCT02630628
Trial name or title A randomised open-label study to evaluate the efficacy and safety of tacrolimus and corticosteroids in com-
parison with mycophenolate mofetil and corticosteroids in subjects with class III/IV±V Lupus nephritis
Methods Open-label RCT
Participants Adult, biopsy-proven lupus nephritis Class III/IV±V (ISN/RPS 2003 classification criteria), positive anti-
dsDNA, UPCR > 1.0 g or 24 h urine protein > 1.0 g/d at baseline), with or without haematuria, new or
flaring patients
Interventions TAC versus MMF
Outcomes Renal response
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NCT02630628 (Continued)
Starting date September 2015
Contact information Tak-Mao Daniel Chan, The University of Hong Kong
Notes
NCT02770170
Trial name or title A double-blind, randomised, placebo-controlled trial evaluating the effect of BI 655064 administered as sub-
cutaneous injections, on renal response after one year treatment in patients with lupus nephritis
Methods Double-blind, placebo-controlled RCT
Participants 18-70 years, diagnosis of SLE (ACR criteria), biopsy-proven class III or IV lupus nephritis (ISN/RPS 2003
classification criteria), proteinuria ≥ 1.0 g/d (UPCR ≥ 100 mg/mmol)
Interventions BI 655064 (anti-CD-40 antibody) versus placebo
Outcomes Complete renal response, partial response
Starting date January 2016
Contact information Boehringer Ingelheim
Notes
NCT02936375
Trial name or title Iguratimod as treatment for active lupus nephritis
Methods Open-label RCT
Participants Diagnosis of SLE (ACR criteria), biopsy-proven class III, IV, V, III+IV or IV+V active lupus nephritis,
proteinuria 1g/d, body weight ≥ 40 kg, SLEDAI-2K ≥ 8, agreement of contraception
Interventions Iguratimod versus CPA and AZA
Outcomes Renal remission, renal flare, adverse events, disease activity (SLEDAI-2K, BILAG), patient general assessment
Starting date March 2017
Contact information Chunde Bao, RenJi Hospital
Notes
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NCT02954939
Trial name or title The effect of mycophenolate mofetil and cyclophosphamide on the lymphocyte subsets in patients With
proliferative Lupus nephritis
Methods Open-label RCT
Participants 18 to 80 years , biopsy-proven class III or IV±V lupus nephritis lupus nephritis (ISN/RPS 2003 classification
criteria), active lupus nephritis indicated by proteinuria >1 g/d and/or rise in SCr by 15%
Interventions MMF (induction and maintenance therapy) versus CPA (induction therapy) and AZA (maintenance therapy)
Outcomes Lymphocyte subset profile (CD8+ T cells, CD4+ Th1, Th2, Th17 & Treg), Naïve &memory B cells, plasma
cells, serum cytokine profile (IL-2, IL-5, IL-6, IL-7, IL-10, IL-17, IL-21, IL-23, IFN-alpha, IFN-gamma,
TGF-beta)
Starting date March 2012
Contact information Desmond Yap, Queen Mary Hospital, Hong Kong
Notes
NCT03021499
Trial name or title A randomised, controlled double-blind study comparing the efficacy and safety of voclosporin (23.7 mg twice
daily) with placebo in achieving renal response in subjects with active lupus nephritis
Methods Double-blind RCT
Participants Subjects with evidence of active nephritis, defined as follows: Kidney biopsy result within 2 years prior to
screening indicating Class III, IV-S, IV-G (alone or in combination with Class V), or Class V lupus nephritis
with a doubling or greater increase of UPCR within the last 6 months to a minimum of ≥ 1.5 mg/mg
for Class III/IV or to a minimum of ≥ 2 mg/mg for Class V at screening. Biopsy results over 6 months
prior to screening must be reviewed with a medical monitor to confirm eligibility. Or kidney biopsy result
within 6 months prior to screening indicating Class III, IV-S or IV-G (alone or in combination with Class
V) lupus nephritis with a UPCR of ≥ 1.5 mg/mg at screening. Or kidney biopsy result within 6 months
prior to screening indicating Class V lupus nephritis and a UPCR of ≥ 2 mg/mg at screening. Women of
childbearing potential must have a negative serum pregnancy test at screening and a negative urine pregnancy
test at baseline
Interventions 1. Voclosporin oral, 23.7 mg BID
2. Voclosporin placebo, oral, 3 capsules BID
Outcomes 1. Renal response
2. Partial renal response
3. kidney function
4. Disease activity - SELENA-SLEDAI
5. Quality of life
Starting date May 2017
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NCT03021499 (Continued)
Contact information Mary Anne Dooley, University of North Carolina
Notes Sponsor - Aurinia Pharmaceuticals Inc.
NCT03214731
Trial name or title Efficacy and safety of artesunate plus standard of care in active lupus nephritis (AURORA)
Methods Multicentre, double-blind RCT
Participants 14 to 65 years; SLE (ACR criteria); renal biopsy within 6 months prior to randomisation with a histological
diagnosis (ISN/RPS 2003 classification of lupus nephritis) - class III, IV, V, III+V and IV+V (excluding Class
III(C), IV-S(C), and IV-G(C)); class IV or IV+V lupus nephritis: proteinuria ≥ 1 g/24 h (or UPCR ≥ 1.0)
or SCr > 1.3 mg/dL, with active urinary sediment (> 5 RBC/HPF or > 5 WBC/HPF (or within the reference
range of the laboratory) in absence of menses and genitourinary tract infection, or presence of cellular casts
(RBC or WBC casts)); Class III, III+V or V lupus nephritis: proteinuria≥ 2 g/24 h (or UPCR≥ 2.0) or SCr
> 1.3 mg/dL; Provision of written informed consent by subject or guardian
Interventions 1. High-dose artesunate: 50 mg
2. Low-dose artesunate: 25 mg
3. Placebo
• All patients received standard of care
Outcomes 1. Complete remission
2. Partial remission
Starting date September 2017
Contact information Xue Qing Yu, The 1st Affiliated Hospital, Sun Yet-sen University, Guangzhou, Guangdong, China
Notes
PER-062-15
Trial name or title A multicentre, randomised, double-blind, placebo-controlled, phase 3 study evaluating the efficacy and safety
of two doses of anifrolumab in adult subjects with active systemic lupus erythematosus
Methods Multicentre, double-blind RCT
Participants Aged 18 - 70 years; weight ≥ 40.0 kg; adequate peripheral venous access; SLE (ACR criteria); currently
receiving at least 1 of the following: (a) a dose of oral prednisone (≤ 40 mg/d) for a minimum of 2 weeks,
the dose of oral prednisone the subject is taking must be stable for a minimum of 2 weeks prior to Week 0
(Day 1) (b) Any of the following medications administered for a minimum of 12 weeks prior to signing the
informed consent, and at a stable dose for a minimum of 8 weeks prior to Day 1
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PER-062-15 (Continued)
Interventions 1. High-dose anifrolumab (MEDI-546) - 150 mg IV administration
2. Low-dose anifrolumab (MEDI-546) - 300 mg IV administration
3. Placebo IV
• Investigational product will be administered every 4 weeks from Week 0 to Week 48 for a total of 13
doses.
Outcomes 1. SLE Responder Index
2. Disease activity - SLEDAI, BILAG
3. Cutaneous Lupus Erythematosus Disease Area and Severity Index (CLASI) activity
4. Immunological function
Starting date May 2015
Contact information Luis Fernando Bellatin Vargas, Hogar Clínica, San Juan De Dios-Arequipa
Notes
RING 2015
Trial name or title RING, an investigator-initiated trial aimed at testing the efficacy of rituximab in refractory lupus nephritis:
Rationale, trial design and call for participation (abstract)
Methods RCT
Participants SLE, age > 15 years old, ISN/RPS Class III, IV or V lupus nephritis (biopsy within 24 months), refractory
lupus nephritis with previous treatment with Euro-lupus/NIH CPA or AZA or MMF, maximum 10 mg
prednisolone/d, UPCR > 1 (mg/mg), and female patients on contraception
Interventions 1. RTX
2. Standard of care
Outcomes Complete response (UPCR ≤ 0.5 (expressed in mg/mg) measured in a 24 h urine collection; and eGFR ≥
60 mL/min or, if < 60 mL/min at screening, not fallen by > 20% compared to screening; and no increase
of glucocorticoids throughout the study (except for two limited courses as per protocol; vide infra); and no
introduction of another immunosuppressant.)
Starting date August 2012
Contact information Frédéric A. Houssiau, Université Catholique de Louvain, Belgium
Notes
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RITUXILUP 2013
Trial name or title Phase 3 open label randomised multicentre controlled trial of rituximab and mycophenolate mofetil without
oral steroids for the treatment of lupus nephritis
Methods Open-label RCT
Participants 12 to 75 years, biopsy-proven lupus nephritis (ISN/RPS 2003 classification criteria), active lupus nephritis
UPCR > 1000 mg/mmol, not planning pregnancy during study period
Interventions RTX versus prednisolone
Outcomes Complete renal response, major infections, serious adverse and adverse events, disease activity scores, renal
flare, serum C3, C4, anti-dsDNA, quality of life
Starting date April 2015
Contact information Liz Lightstone, Hammersmith Hospital, Imperial College Healthcare NHS Trust, United Kingdom
Notes
ACEi - angiotensin-converting enzyme inhibitor; ACR - American College of Rheumatology; ARA - American Rheumatology Associa-
tion; ARB - angiotensin receptor blocker; AZA - azathioprine; BILAG - British Isles Lupus Assessment Group; CKD - chronic kidney
disease; CMV - cytomegalovirus; CNI - calcineurin; CNS - central nervous system; CPA - cyclophosphamide; CrCl - creatinine clear-
ance; CSA - cyclosporin A; DM - diabetes mellitus; EC-MPS - enteric-coated mycophenolate sodium; eGFR - estimated glomerular
filtration rate; ELNT - Euro-lupus nephritis treatment; ESKD - end-stage kidney disease; ESR - erythrocyte sedimentation rate; GI
- gastrointestinal: GN - glomerulonephritis; HBV - hepatitis B virus; HCV - hepatitis C virus; HIV - human immunodeficiency
virus; HPF - high power field; IA - immunoadsorption; ISN/RPS - International Society of Nephrology/Renal Pathology Society; IV
- intravenous; IVIG - intravenous immunoglobulin; M/F - male/female;MMF - mycophenolate mofetil; MP - methylprednisolone;
NSAID/s - nonsteroidal anti-inflammatory drug/s; PEX - plasma exchange or plasmapheresis; PLAGA - Dutch Pathology Registry;
RBC - red blood cell/s; RCC - red cell count; RCT - randomised controlled trial; RTX - rituximab; SC - subcutaneous; SCr - serum
creatinine; SD - standard deviation; SELENA - Safety of Estrogens in Lupus Erythematosus National Assessment; SLE - systemic
lupus erythematosus; SLEDAI - SLE Disease Activity Index; SLICC - Systemic Lupus Collaborating Clinics; TAC - tacrolimus;
TB - tuberculosis; WHO - World Health Organization; ISN/RPS - International Society of Nephrology/ Renal Pathology Society;
UPCR - urine protein-to-creatinine ratio; WBC - white blood cell/s; WCC - white cell count
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D A T A A N D A N A L Y S E S
Comparison 1. Mycophenolate mofetil (MMF) versus IV cyclophosphamide (CPA)
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Death 8 826 Risk Ratio (M-H, Random, 95% CI) 1.12 [0.61, 2.06]
2 Remission 9 Risk Ratio (M-H, Random, 95% CI) Subtotals only
2.1 Complete renal remission:
MMF versus IV CPA
9 868 Risk Ratio (M-H, Random, 95% CI) 1.17 [0.97, 1.42]
2.2 Partial renal remission:
MMF versus IV CPA
9 868 Risk Ratio (M-H, Random, 95% CI) 1.02 [0.89, 1.18]
2.3 Complete remission in
proteinuria: MMF versus IV
CPA
6 686 Risk Ratio (M-H, Random, 95% CI) 1.16 [0.85, 1.58]
2.4 Partial remission in
proteinuria: MMF versus IV
CPA
6 744 Risk Ratio (M-H, Random, 95% CI) 1.03 [0.91, 1.18]
3 Adverse renal outcomes 4 Risk Ratio (M-H, Random, 95% CI) Subtotals only
3.1 ESKD 3 231 Risk Ratio (M-H, Random, 95% CI) 0.71 [0.27, 1.84]
3.2 Renal relapse 1 140 Risk Ratio (M-H, Random, 95% CI) 0.97 [0.39, 2.44]
3.3 Doubling of serum
creatinine
1 40 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
4 Stable kidney function 6 641 Risk Ratio (M-H, Random, 95% CI) 1.05 [0.94, 1.17]
5 Ovarian failure 3 539 Risk Ratio (M-H, Random, 95% CI) 0.36 [0.06, 2.18]
6 Menstrual irregularities 2 87 Risk Ratio (M-H, Random, 95% CI) 0.33 [0.07, 1.59]
7 Infection 7 1452 Risk Ratio (M-H, Random, 95% CI) 1.13 [0.81, 1.58]
7.1 Major infection 6 699 Risk Ratio (M-H, Random, 95% CI) 1.02 [0.67, 1.54]
7.2 Herpes zoster virus 6 753 Risk Ratio (M-H, Random, 95% CI) 1.39 [0.78, 2.46]
8 Malignancy 1 364 Risk Ratio (M-H, Random, 95% CI) 0.65 [0.11, 3.86]
9 Leucopenia 6 753 Risk Ratio (M-H, Random, 95% CI) 0.59 [0.33, 1.08]
10 Bladder toxicity 1 364 Risk Ratio (M-H, Random, 95% CI) 0.33 [0.01, 7.95]
11 Alopecia 3 622 Risk Ratio (M-H, Random, 95% CI) 0.29 [0.19, 0.46]
12 Gastrointestinal (GI) adverse
events
4 Risk Ratio (M-H, Random, 95% CI) Subtotals only
12.1 Diarrhoea 4 609 Risk Ratio (M-H, Random, 95% CI) 2.42 [1.64, 3.58]
12.2 Vomiting 3 562 Risk Ratio (M-H, Random, 95% CI) 0.48 [0.24, 0.97]
12.3 Nausea 3 562 Risk Ratio (M-H, Random, 95% CI) 0.48 [0.23, 0.98]
12.4 GI upset 3 569 Risk Ratio (M-H, Random, 95% CI) 0.91 [0.78, 1.06]
13 Daily proteinuria 4 271 Mean Difference (IV, Random, 95% CI) -0.08 [-0.43, 0.26]
14 Serum creatinine 6 759 Mean Difference (IV, Random, 95% CI) 2.14 [-3.09, 7.37]
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Comparison 2. Mycophenolate mofetil (MMF) versus oral cyclophosphamide (CPA)
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Death 1 62 Risk Ratio (M-H, Random, 95% CI) 0.19 [0.01, 3.76]
2 Remission 1 Risk Ratio (M-H, Random, 95% CI) Subtotals only
2.1 Complete remission in
proteinuria
1 62 Risk Ratio (M-H, Random, 95% CI) 0.98 [0.74, 1.30]
2.2 Partial remission in
proteinuria
1 62 Risk Ratio (M-H, Random, 95% CI) 1.07 [0.44, 2.59]
3 Adverse renal outcomes 1 Risk Ratio (M-H, Random, 95% CI) Subtotals only
3.1 ESKD 1 62 Risk Ratio (M-H, Random, 95% CI) 0.19 [0.01, 3.76]
3.2 Renal relapse 1 62 Risk Ratio (M-H, Random, 95% CI) 1.15 [0.55, 2.37]
3.3 Doubling of serum
creatinine
1 62 Risk Ratio (M-H, Random, 95% CI) 0.63 [0.11, 3.48]
4 Ovarian failure 1 53 Risk Ratio (M-H, Random, 95% CI) 0.10 [0.01, 0.73]
5 Infection 1 Risk Ratio (M-H, Random, 95% CI) Subtotals only
5.1 Major infection 1 62 Risk Ratio (M-H, Random, 95% CI) 0.21 [0.05, 0.89]
5.2 Herpes zoster virus 1 62 Risk Ratio (M-H, Random, 95% CI) 0.38 [0.08, 1.79]
6 Leucopenia 1 62 Risk Ratio (M-H, Random, 95% CI) 0.06 [0.00, 0.92]
7 Bone toxicity 1 62 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
8 Alopecia 1 62 Risk Ratio (M-H, Random, 95% CI) 0.05 [0.00, 0.81]
9 Gastrointestinal (GI) adverse
events
1 Risk Ratio (M-H, Random, 95% CI) Subtotals only
9.1 GI upset 1 62 Risk Ratio (M-H, Random, 95% CI) 2.81 [0.31, 25.58]
10 Daily proteinuria 1 42 Mean Difference (IV, Random, 95% CI) 0.3 [-0.19, 0.79]
Comparison 3. Mycophenolate mofetil (MMF) + tacrolimus (TAC) versus IV cyclophosphamide (CPA)
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Death 2 402 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
2 Remission 2 Risk Ratio (M-H, Random, 95% CI) Subtotals only
2.1 Complete renal remission 2 402 Risk Ratio (M-H, Random, 95% CI) 2.38 [1.07, 5.30]
2.2 Partial renal remission 2 402 Risk Ratio (M-H, Random, 95% CI) 1.0 [0.78, 1.28]
2.3 Complete remission in
proteinuria
2 402 Risk Ratio (M-H, Random, 95% CI) 2.38 [1.07, 5.30]
2.4 Partial remission in
proteinuria
2 402 Risk Ratio (M-H, Random, 95% CI) 0.98 [0.76, 1.26]
3 Adverse renal outcomes 2 Risk Ratio (M-H, Random, 95% CI) Subtotals only
3.1 Doubling of serum
creatinine
2 402 Risk Ratio (M-H, Random, 95% CI) 0.98 [0.10, 9.23]
4 Stable kidney function 2 402 Risk Ratio (M-H, Random, 95% CI) 1.78 [1.40, 2.26]
5 Ovarian failure 1 34 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
6 Menstrual irregularities 1 323 Risk Ratio (M-H, Random, 95% CI) 0.28 [0.06, 1.35]
7 Infection 2 Risk Ratio (M-H, Random, 95% CI) Subtotals only
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7.1 Major infection 2 402 Risk Ratio (M-H, Random, 95% CI) 1.65 [0.11, 24.44]
7.2 Herpes zoster virus 2 402 Risk Ratio (M-H, Random, 95% CI) 0.80 [0.22, 2.94]
8 Leucopenia 2 402 Risk Ratio (M-H, Random, 95% CI) 0.23 [0.04, 1.44]
9 Bone toxicity 1 362 Risk Ratio (M-H, Random, 95% CI) 3.0 [0.12, 73.16]
10 Alopecia 2 402 Risk Ratio (M-H, Random, 95% CI) 0.78 [0.36, 1.72]
11 Gastrointestinal (GI) adverse
events
2 Risk Ratio (M-H, Random, 95% CI) Subtotals only
11.1 Diarrhoea 1 362 Risk Ratio (M-H, Random, 95% CI) 2.33 [0.92, 5.94]
11.2 GI upset 2 402 Risk Ratio (M-H, Random, 95% CI) 0.21 [0.10, 0.41]
12 Daily proteinuria 1 40 Mean Difference (IV, Random, 95% CI) -1.69 [-2.81, -0.57]
Comparison 4. Mycophenolate mofetil (MMF) + IV cyclophosphamide (CPA) versus IV CPA
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Death 1 82 Risk Ratio (M-H, Random, 95% CI) 0.95 [0.06, 14.72]
2 Remission 1 Risk Ratio (M-H, Random, 95% CI) Subtotals only
2.1 Complete renal remission 1 82 Risk Ratio (M-H, Random, 95% CI) 1.22 [0.78, 1.89]
2.2 Partial renal remission 1 82 Risk Ratio (M-H, Random, 95% CI) 1.03 [0.55, 1.90]
3 Menstrual irregularities 1 75 Risk Ratio (M-H, Random, 95% CI) 0.49 [0.16, 1.48]
4 Infection 1 82 Risk Ratio (M-H, Random, 95% CI) 0.37 [0.14, 0.93]
4.1 Major infection 1 82 Risk Ratio (M-H, Random, 95% CI) 0.37 [0.14, 0.93]
5 Leucopenia 1 82 Risk Ratio (M-H, Random, 95% CI) 0.63 [0.11, 3.60]
6 Daily proteinuria 1 77 Mean Difference (IV, Random, 95% CI) -0.54 [-1.12, 0.04]
Comparison 5. Mycophenolate mofetil (MMF) versus tacrolimus (TAC)
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Death 3 273 Risk Ratio (M-H, Random, 95% CI) 1.10 [0.44, 2.77]
2 Remission 3 Risk Ratio (M-H, Random, 95% CI) Subtotals only
2.1 Complete renal remission 3 273 Risk Ratio (M-H, Random, 95% CI) 1.02 [0.83, 1.26]
2.2 Partial renal remission 2 190 Risk Ratio (M-H, Random, 95% CI) 0.83 [0.51, 1.36]
2.3 Complete remission in
proteinuria
1 40 Risk Ratio (M-H, Random, 95% CI) 1.0 [0.50, 1.98]
2.4 Partial remission in
proteinuria
2 190 Risk Ratio (M-H, Random, 95% CI) 0.90 [0.79, 1.03]
3 Adverse renal outcomes 1 Risk Ratio (M-H, Random, 95% CI) Subtotals only
3.1 ESKD 1 150 Risk Ratio (M-H, Random, 95% CI) 1.22 [0.51, 2.91]
3.2 Renal relapse 1 150 Risk Ratio (M-H, Random, 95% CI) 0.67 [0.48, 0.93]
3.3 Renal relapse (nephritic
flare)
1 152 Risk Ratio (M-H, Random, 95% CI) 0.68 [0.36, 1.28]
3.4 Renal relapse (proteinuric
flare)
1 150 Risk Ratio (M-H, Random, 95% CI) 0.67 [0.41, 1.12]
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3.5 Deterioration in kidney
function
1 150 Risk Ratio (M-H, Random, 95% CI) 0.54 [0.27, 1.09]
4 Stable kidney function 1 40 Risk Ratio (M-H, Random, 95% CI) 1.0 [0.50, 1.98]
5 Menstrual irregularities 1 40 Risk Ratio (M-H, Random, 95% CI) 3.0 [0.13, 69.52]
6 Infection 2 Risk Ratio (M-H, Random, 95% CI) Subtotals only
6.1 Major infection 2 190 Risk Ratio (M-H, Random, 95% CI) 2.14 [0.93, 4.92]
6.2 Herpes zoster virus 1 150 Risk Ratio (M-H, Random, 95% CI) 6.82 [1.60, 28.96]
7 Leucopenia 1 40 Risk Ratio (M-H, Random, 95% CI) 1.0 [0.07, 14.90]
8 Alopecia 1 150 Risk Ratio (M-H, Random, 95% CI) 0.07 [0.00, 1.31]
9 Daily proteinuria (at 24 weeks) 1 150 Mean Difference (IV, Random, 95% CI) 0.18 [-0.25, 0.61]
10 Disease activity 2 Mean Difference (IV, Random, 95% CI) Subtotals only
10.1 Renal SLEDAI 2 233 Mean Difference (IV, Random, 95% CI) -0.21 [-2.05, 1.63]
10.2 Extrarenal SLEDAI 2 233 Mean Difference (IV, Random, 95% CI) -0.26 [-0.74, 0.22]
11 Serum creatinine 1 83 Mean Difference (IV, Random, 95% CI) -0.01 [-0.16, 0.14]
12 Creatinine clearance 1 40 Mean Difference (IV, Random, 95% CI) -1.93 [-7.77, 3.91]
Comparison 6. Calcineurin inhibitors (CNI) versus IV cyclophosphamide (CPA)
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Death 3 Risk Ratio (M-H, Random, 95% CI) Subtotals only
1.1 Death 3 153 Risk Ratio (M-H, Random, 95% CI) 0.41 [0.06, 2.69]
1.2 Death: extended follow-
up
1 38 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
2 Remission 4 Risk Ratio (M-H, Random, 95% CI) Subtotals only
2.1 Complete renal remission 4 178 Risk Ratio (M-H, Random, 95% CI) 1.35 [0.94, 1.93]
2.2 Partial renal remission 4 178 Risk Ratio (M-H, Random, 95% CI) 0.88 [0.61, 1.26]
2.3 Complete remission in
proteinuria
3 105 Risk Ratio (M-H, Random, 95% CI) 1.71 [1.08, 2.70]
3 Adverse renal outcomes 2 Risk Ratio (M-H, Random, 95% CI) Subtotals only
3.1 ESKD: extended follow-
up
1 38 Risk Ratio (M-H, Random, 95% CI) 1.0 [0.07, 14.85]
3.2 Doubling of serum
creatinine
1 40 Risk Ratio (M-H, Random, 95% CI) 0.33 [0.01, 7.72]
3.3 Doubling of serum
creatinine: extended follow-up
1 38 Risk Ratio (M-H, Random, 95% CI) 1.0 [0.16, 6.38]
4 Stable kidney function 4 186 Risk Ratio (M-H, Random, 95% CI) 1.11 [0.61, 2.00]
5 Ovarian failure 2 Risk Ratio (M-H, Random, 95% CI) Subtotals only
5.1 Ovarian failure 2 113 Risk Ratio (M-H, Random, 95% CI) 0.25 [0.03, 2.18]
5.2 Premature ovarian failure:
extended follow-up
1 27 Risk Ratio (M-H, Random, 95% CI) 0.31 [0.01, 7.02]
6 Menstrual irregularities 2 54 Risk Ratio (M-H, Random, 95% CI) 0.41 [0.04, 4.05]
7 Infection 4 Risk Ratio (M-H, Random, 95% CI) Subtotals only
7.1 Major infection 3 138 Risk Ratio (M-H, Random, 95% CI) 0.73 [0.33, 1.63]
7.2 Herpes zoster virus 2 113 Risk Ratio (M-H, Random, 95% CI) 1.41 [0.38, 5.20]
8 Malignancy: extended follow-up 1 38 Risk Ratio (M-H, Random, 95% CI) 5.0 [0.26, 97.70]
9 Leucopenia 3 153 Risk Ratio (M-H, Random, 95% CI) 0.44 [0.13, 1.49]
10 Alopecia 2 113 Risk Ratio (M-H, Random, 95% CI) 0.21 [0.02, 1.76]
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11 Gastrointestinal (GI) adverse
events
1 73 Risk Ratio (M-H, Random, 95% CI) 0.35 [0.12, 1.01]
12 Daily proteinuria 2 156 Mean Difference (IV, Random, 95% CI) -0.37 [-0.67, -0.07]
12.1 At 9 months 1 40 Mean Difference (IV, Random, 95% CI) -0.83 [-1.37, -0.29]
12.2 At 12 months 1 38 Mean Difference (IV, Random, 95% CI) -0.27 [-0.43, -0.11]
12.3 At 18 months 1 40 Mean Difference (IV, Random, 95% CI) -1.0 [-2.26, 0.26]
12.4 Extended follow-up 1 38 Mean Difference (IV, Random, 95% CI) -0.10 [-0.49, 0.29]
13 Creatinine clearance 3 Mean Difference (IV, Random, 95% CI) Subtotals only
13.1 At 6 months 1 150 Mean Difference (IV, Random, 95% CI) 11.70 [1.61, 21.79]
13.2 At 9 months 1 40 Mean Difference (IV, Random, 95% CI) 14.90 [1.35, 28.45]
13.3 At 12 months 1 38 Mean Difference (IV, Random, 95% CI) -15.70 [-23.71, -7.
69]
13.4 At 18 months 1 40 Mean Difference (IV, Random, 95% CI) -1.40 [-17.25, 14.
45]
14 Serum creatinine 1 Mean Difference (IV, Random, 95% CI) Subtotals only
14.1 At 9 months 1 40 Mean Difference (IV, Random, 95% CI) 12.70 [1.88, 23.52]
14.2 At 18 months 1 40 Mean Difference (IV, Random, 95% CI) 2.70 [-11.50, 16.90]
14.3 Extended follow-up 1 38 Mean Difference (IV, Random, 95% CI) -8.0 [-20.35, 4.35]
Comparison 7. Cyclophosphamide (CPA) versus azathioprine (AZA)
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Death 2 Risk Ratio (M-H, Random, 95% CI) Subtotals only
1.1 At 5 years 2 146 Risk Ratio (M-H, Random, 95% CI) 1.39 [0.25, 7.77]
1.2 At 10 years 1 59 Risk Ratio (M-H, Random, 95% CI) 1.93 [1.22, 3.06]
2 Remission in proteinuria 1 Risk Ratio (M-H, Random, 95% CI) Subtotals only
2.1 Complete remission 1 59 Risk Ratio (M-H, Random, 95% CI) 2.03 [0.64, 6.46]
2.2 Partial remission 1 59 Risk Ratio (M-H, Random, 95% CI) 1.80 [0.67, 4.81]
3 Adverse renal outcomes 2 Risk Ratio (M-H, Random, 95% CI) Subtotals only
3.1 ESKD 2 144 Risk Ratio (M-H, Random, 95% CI) 0.40 [0.15, 1.07]
3.2 ESKD at 9.6 years
(median)
1 100 Risk Ratio (M-H, Random, 95% CI) 1.0 [0.15, 6.82]
3.3 Renal relapse 1 87 Risk Ratio (M-H, Random, 95% CI) 0.15 [0.03, 0.64]
3.4 Renal relapse at 9.6 years
(median)
1 87 Risk Ratio (M-H, Random, 95% CI) 0.26 [0.10, 0.67]
3.5 Doubling of serum
creatinine
2 144 Risk Ratio (M-H, Random, 95% CI) 0.48 [0.24, 0.95]
3.6 Deterioration of kidney
function
1 30 Risk Ratio (M-H, Random, 95% CI) 0.67 [0.18, 2.42]
4 Stable kidney function 1 57 Risk Ratio (M-H, Random, 95% CI) 1.32 [0.86, 2.01]
5 Ovarian failure 2 126 Risk Ratio (M-H, Random, 95% CI) 2.11 [0.59, 7.53]
6 Menstrual irregularities 1 15 Risk Ratio (M-H, Random, 95% CI) 1.90 [0.69, 5.23]
7 Infection 1 Risk Ratio (M-H, Random, 95% CI) Subtotals only
7.1 Major infection 1 57 Risk Ratio (M-H, Random, 95% CI) 1.25 [0.27, 5.86]
7.2 Herpes zoster virus 1 57 Risk Ratio (M-H, Random, 95% CI) 2.75 [0.68, 11.18]
8 Malignancy 2 Risk Ratio (M-H, Random, 95% CI) Subtotals only
8.1 CPA versus AZA 2 144 Risk Ratio (M-H, Random, 95% CI) 0.59 [0.13, 2.63]
8.2 10 year follow-up 1 87 Risk Ratio (M-H, Random, 95% CI) 0.74 [0.11, 5.01]
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9 Bone toxicity 1 87 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
10 Bladder toxicity 2 144 Risk Ratio (M-H, Random, 95% CI) 3.59 [0.19, 66.14]
Comparison 8. Rituximab (RTX) + mycophenolate mofetil (MMF) versus placebo + MMF
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Death 1 144 Risk Ratio (M-H, Random, 95% CI) 5.0 [0.24, 102.35]
2 Remission 1 Risk Ratio (M-H, Random, 95% CI) Subtotals only
2.1 Complete renal response 1 144 Risk Ratio (M-H, Random, 95% CI) 0.86 [0.51, 1.45]
2.2 Partial renal response 1 144 Risk Ratio (M-H, Random, 95% CI) 2.0 [1.05, 3.82]
2.3 Complete remission in
proteinuria
1 144 Risk Ratio (M-H, Random, 95% CI) 0.87 [0.63, 1.21]
3 Stable kidney function 1 144 Risk Ratio (M-H, Random, 95% CI) 1.24 [0.90, 1.71]
4 Infection 1 Risk Ratio (M-H, Random, 95% CI) Subtotals only
4.1 Major infection 1 144 Risk Ratio (M-H, Random, 95% CI) 1.0 [0.48, 2.08]
4.2 Herpes zoster virus 1 144 Risk Ratio (M-H, Random, 95% CI) 0.82 [0.36, 1.85]
5 Leucopenia 1 144 Risk Ratio (M-H, Random, 95% CI) 3.0 [0.85, 10.63]
Comparison 9. Rituximab (RTX) + cyclophosphamide (CPA) versus RTX
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Remission 1 Risk Ratio (M-H, Random, 95% CI) Subtotals only
1.1 Complete renal response 1 19 Risk Ratio (M-H, Random, 95% CI) 0.9 [0.16, 5.13]
1.2 Partial renal response 1 19 Risk Ratio (M-H, Random, 95% CI) 0.75 [0.35, 1.62]
2 Infection 1 38 Risk Ratio (M-H, Random, 95% CI) 0.57 [0.08, 4.20]
2.1 Major infection 1 19 Risk Ratio (M-H, Random, 95% CI) 0.9 [0.07, 12.38]
2.2 Herpes zoster virus 1 19 Risk Ratio (M-H, Random, 95% CI) 0.30 [0.01, 6.62]
3 Daily proteinuria 1 19 Mean Difference (IV, Random, 95% CI) -0.30 [-2.29, 1.69]
4 Creatinine clearance 1 19 Mean Difference (IV, Random, 95% CI) -17.20 [-50.66, 16.
26]
5 Serum creatinine 1 19 Mean Difference (IV, Random, 95% CI) 35.00 [-27.14, 97.
14]
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Comparison 10. Abatacept + other immunosuppressive agent (IS) + versus placebo + other IS
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Death 2 Risk Ratio (M-H, Random, 95% CI) Subtotals only
1.1 Abatacept versus placebo 2 432 Risk Ratio (M-H, Random, 95% CI) 0.29 [0.10, 0.91]
1.2 High dose abatacept
versus placebo
1 199 Risk Ratio (M-H, Random, 95% CI) 0.29 [0.06, 1.36]
1.3 Low dose abatacept versus
placebo
1 199 Risk Ratio (M-H, Random, 95% CI) 0.29 [0.06, 1.36]
2 Remission 2 Risk Ratio (M-H, Random, 95% CI) Subtotals only
2.1 Complete remission:
abatacept versus placebo
2 432 Risk Ratio (M-H, Random, 95% CI) 1.13 [0.74, 1.71]
2.2 Complete remission: high
dose abatacept versus placebo
1 199 Risk Ratio (M-H, Random, 95% CI) 1.14 [0.46, 2.83]
2.3 Complete remission: low
dose abatacept versus placebo
1 199 Risk Ratio (M-H, Random, 95% CI) 1.39 [0.58, 3.31]
2.4 Partial remission:
abatacept versus placebo
2 432 Risk Ratio (M-H, Random, 95% CI) 0.88 [0.58, 1.33]
2.5 Partial remission: high
dose abatacept versus placebo
1 199 Risk Ratio (M-H, Random, 95% CI) 1.01 [0.51, 2.01]
2.6 Partial remission: low dose
abatacept versus placebo
1 199 Risk Ratio (M-H, Random, 95% CI) 0.65 [0.29, 1.43]
3 Adverse renal outcomes 2 Risk Ratio (M-H, Random, 95% CI) Subtotals only
3.1 ESKD: Abatacept versus
placebo
1 298 Risk Ratio (M-H, Random, 95% CI) 0.84 [0.21, 3.45]
3.2 ESKD: high dose
abatacept versus placebo
1 199 Risk Ratio (M-H, Random, 95% CI) 1.01 [0.21, 4.88]
3.3 ESKD: low dose abatacept
versus placebo
1 199 Risk Ratio (M-H, Random, 95% CI) 0.67 [0.11, 3.94]
3.4 Renal relapse: abatacept
versus placebo
1 134 Risk Ratio (M-H, Random, 95% CI) 1.03 [0.22, 4.92]
4 Major Infection 2 Risk Ratio (M-H, Random, 95% CI) Subtotals only
4.1 Abatacept versus placebo 2 432 Risk Ratio (M-H, Random, 95% CI) 1.29 [0.81, 2.04]
4.2 High dose abatacept
versus placebo
1 199 Risk Ratio (M-H, Random, 95% CI) 1.37 [0.78, 2.40]
4.3 Low dose abatacept versus
placebo
1 199 Risk Ratio (M-H, Random, 95% CI) 1.07 [0.59, 1.95]
5 Herpes zoster virus 1 Risk Ratio (M-H, Random, 95% CI) Subtotals only
5.1 Abatacept versus placebo 1 298 Risk Ratio (M-H, Random, 95% CI) 9.64 [0.57, 164.02]
5.2 High dose abatacept
versus placebo
1 199 Risk Ratio (M-H, Random, 95% CI) 7.07 [0.37, 135.11]
5.3 Low dose abatacept versus
placebo
1 199 Risk Ratio (M-H, Random, 95% CI) 13.13 [0.75, 229.99]
6 Health-related quality of life 1 Mean Difference (IV, Random, 95% CI) Subtotals only
6.1 Physical component 1 134 Mean Difference (IV, Random, 95% CI) 0.0 [-3.73, 3.73]
6.2 Mental component 1 134 Mean Difference (IV, Random, 95% CI) -0.60 [-4.50, 3.30]
7 Disease activity (BILAG) 1 134 Mean Difference (IV, Random, 95% CI) -0.40 [-1.23, 0.43]
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Comparison 11. Laquinimod + other immunosuppressive agent (IS) versus placebo + other IS
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Death 1 Risk Ratio (M-H, Random, 95% CI) Subtotals only
1.1 Laquinimod versus
placebo
1 46 Risk Ratio (M-H, Random, 95% CI) 1.5 [0.06, 34.79]
1.2 High dose laquinimod
versus placebo
1 30 Risk Ratio (M-H, Random, 95% CI) 3.0 [0.13, 68.26]
1.3 Low dose laquinimod
versus placebo
1 31 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
2 Complete remission 1 Risk Ratio (M-H, Random, 95% CI) Subtotals only
2.1 Complete remission:
laquinimod versus placebo
1 46 Risk Ratio (M-H, Random, 95% CI) 1.55 [0.70, 3.42]
2.2 Complete remission: high
dose laquinimod versus placebo
1 30 Risk Ratio (M-H, Random, 95% CI) 1.2 [0.47, 3.09]
2.3 Complete remission: low
dose laquinimod versus placebo
1 31 Risk Ratio (M-H, Random, 95% CI) 1.88 [0.83, 4.22]
Comparison 12. Ocrelizumab + other immunosuppressive agent (IS) versus placebo + other IS
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Death 1 Risk Ratio (M-H, Random, 95% CI) Subtotals only
1.1 Ocrelizumab versus
placebo
1 379 Risk Ratio (M-H, Random, 95% CI) 0.66 [0.23, 1.85]
1.2 High dose ocrelizumab
versus placebo
1 253 Risk Ratio (M-H, Random, 95% CI) 0.81 [0.25, 2.60]
1.3 Low dose ocrelizumab
versus placebo
1 251 Risk Ratio (M-H, Random, 95% CI) 0.50 [0.13, 1.94]
2 Remission 1 Risk Ratio (M-H, Random, 95% CI) Subtotals only
2.1 Complete remission:
ocrelizumab versus placebo
1 223 Risk Ratio (M-H, Random, 95% CI) 1.07 [0.74, 1.56]
2.2 Complete remission:
high dose ocrelizumab versus
placebo
1 148 Risk Ratio (M-H, Random, 95% CI) 0.91 [0.57, 1.44]
2.3 Complete remission:
low dose ocrelizumab versus
placebo
1 150 Risk Ratio (M-H, Random, 95% CI) 1.23 [0.82, 1.85]
2.4 Partial remission:
ocrelizumab versus placebo
1 223 Risk Ratio (M-H, Random, 95% CI) 1.49 [0.89, 2.49]
2.5 Partial remission: high
dose ocrelizumab versus
placebo
1 148 Risk Ratio (M-H, Random, 95% CI) 1.78 [1.03, 3.08]
2.6 Partial remission: low dose
ocrelizumab versus placebo
1 150 Risk Ratio (M-H, Random, 95% CI) 1.2 [0.65, 2.20]
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3 Major Infection 1 Risk Ratio (M-H, Random, 95% CI) Subtotals only
3.1 Ocrelizumab versus
placebo
1 378 Risk Ratio (M-H, Random, 95% CI) 1.14 [0.95, 1.36]
3.2 High dose ocrelizumab
versus placebo
1 252 Risk Ratio (M-H, Random, 95% CI) 1.05 [0.85, 1.30]
3.3 Low dose ocrelizumab
versus placebo
1 251 Risk Ratio (M-H, Random, 95% CI) 1.22 [1.00, 1.48]
Comparison 13. Sirukumab + other immunosuppressive agent (IS) versus placebo + other IS
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Death 1 25 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
2 Infection 1 25 Risk Ratio (M-H, Random, 95% CI) 0.93 [0.66, 1.32]
2.1 Major infection 1 25 Risk Ratio (M-H, Random, 95% CI) 0.93 [0.66, 1.32]
3 Malignancy 1 25 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
4 Gastrointestinal (GI) adverse
events
1 Risk Ratio (M-H, Random, 95% CI) Subtotals only
4.1 Diarrhoea 1 25 Risk Ratio (M-H, Random, 95% CI) 1.59 [0.10, 26.15]
Comparison 14. IV versus oral cyclophosphamide (CPA)
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Death 2 67 Risk Ratio (M-H, Random, 95% CI) 0.80 [0.20, 3.24]
2 Adverse renal outcomes 2 Risk Ratio (M-H, Random, 95% CI) Subtotals only
2.1 ESKD 2 67 Risk Ratio (M-H, Random, 95% CI) 0.23 [0.04, 1.28]
2.2 Doubling of serum
creatinine
2 67 Risk Ratio (M-H, Random, 95% CI) 0.67 [0.23, 1.98]
2.3 Deterioration of kidney
function
1 38 Risk Ratio (M-H, Random, 95% CI) 0.72 [0.23, 2.27]
3 Stable kidney function 1 38 Risk Ratio (M-H, Random, 95% CI) 1.11 [0.77, 1.59]
4 Ovarian failure 2 56 Risk Ratio (M-H, Random, 95% CI) 0.70 [0.37, 1.30]
5 Infection 2 Risk Ratio (M-H, Random, 95% CI) Subtotals only
5.1 Major infection 2 67 Risk Ratio (M-H, Random, 95% CI) 1.16 [0.47, 2.90]
5.2 Herpes zoster virus 1 38 Risk Ratio (M-H, Random, 95% CI) 0.75 [0.28, 2.04]
6 Malignancy 2 67 Risk Ratio (M-H, Random, 95% CI) 1.43 [0.41, 4.96]
7 Bladder toxicity 2 67 Risk Ratio (M-H, Random, 95% CI) 0.22 [0.03, 1.83]
8 Gastrointestinal (GI) adverse
events
1 Risk Ratio (M-H, Random, 95% CI) Subtotals only
8.1 GI upset 1 29 Risk Ratio (M-H, Random, 95% CI) 3.69 [0.43, 31.43]
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Comparison 15. Low versus high dose cyclophosphamide (CPA)
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Death 4 Risk Ratio (M-H, Random, 95% CI) Subtotals only
1.1 At 6 months 1 117 Risk Ratio (M-H, Random, 95% CI) 1.81 [0.19, 16.85]
1.2 At 12 months 2 121 Risk Ratio (M-H, Random, 95% CI) 0.97 [0.14, 6.56]
1.3 At 5 years 1 85 Risk Ratio (M-H, Random, 95% CI) 0.13 [0.01, 2.51]
1.4 At 10 years 1 90 Risk Ratio (M-H, Random, 95% CI) 0.38 [0.08, 1.87]
2 Remission 3 Risk Ratio (M-H, Random, 95% CI) Subtotals only
2.1 Complete renal remission 3 267 Risk Ratio (M-H, Random, 95% CI) 1.09 [0.63, 1.86]
2.2 Partial renal remission 3 267 Risk Ratio (M-H, Random, 95% CI) 0.88 [0.69, 1.14]
3 Adverse renal outcomes 3 Risk Ratio (M-H, Random, 95% CI) Subtotals only
3.1 ESKD 2 135 Risk Ratio (M-H, Random, 95% CI) 0.49 [0.05, 5.20]
3.2 ESKD at 5 years 1 85 Risk Ratio (M-H, Random, 95% CI) 2.80 [0.30, 25.81]
3.3 ESKD at 10 years 1 90 Risk Ratio (M-H, Random, 95% CI) 1.91 [0.37, 9.92]
3.4 Renal relapse 3 211 Risk Ratio (M-H, Random, 95% CI) 2.75 [0.47, 15.98]
3.5 Doubling of serum
creatinine
2 135 Risk Ratio (M-H, Random, 95% CI) 0.33 [0.04, 3.02]
3.6 Doubling of serum
creatinine at 5 years
1 85 Risk Ratio (M-H, Random, 95% CI) 0.13 [0.02, 1.04]
3.7 Doubling of serum
creatinine at 10 years
1 90 Risk Ratio (M-H, Random, 95% CI) 0.80 [0.26, 2.42]
4 Stable kidney function 1 Risk Ratio (M-H, Random, 95% CI) Subtotals only
4.1 At 3 years 1 89 Risk Ratio (M-H, Random, 95% CI) 0.72 [0.50, 1.03]
4.2 At 5 years 1 85 Risk Ratio (M-H, Random, 95% CI) 0.96 [0.77, 1.20]
5 Ovarian failure 4 299 Risk Ratio (M-H, Random, 95% CI) 1.73 [0.70, 4.31]
6 Infection 4 Risk Ratio (M-H, Random, 95% CI) Subtotals only
6.1 Major infection 4 327 Risk Ratio (M-H, Random, 95% CI) 1.44 [0.83, 2.49]
6.2 Herpes zoster virus 3 281 Risk Ratio (M-H, Random, 95% CI) 1.58 [0.41, 6.05]
7 Malignancy 2 206 Risk Ratio (M-H, Random, 95% CI) 1.44 [0.09, 23.31]
8 Leucopenia 3 281 Risk Ratio (M-H, Random, 95% CI) 0.82 [0.13, 5.15]
9 Bone toxicity 2 164 Risk Ratio (M-H, Random, 95% CI) 2.93 [0.48, 18.02]
10 Alopecia 1 75 Risk Ratio (M-H, Random, 95% CI) 0.28 [0.06, 1.25]
11 Gastrointestinal (GI) adverse
events
1 Risk Ratio (M-H, Random, 95% CI) Subtotals only
11.1 GI disturbance 1 75 Risk Ratio (M-H, Random, 95% CI) 0.11 [0.01, 1.94]
12 Daily proteinuria 3 242 Mean Difference (IV, Random, 95% CI) -0.10 [-0.65, 0.46]
13 Creatinine clearance 1 117 Mean Difference (IV, Random, 95% CI) -12.60 [-23.63, -1.
57]
14 Serum creatinine 3 247 Mean Difference (IV, Random, 95% CI) 2.85 [-7.61, 13.31]
15 Disease activity (SLEDAI) 1 75 Mean Difference (IV, Random, 95% CI) -1.50 [-3.04, 0.04]
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Comparison 16. Standard versus reduced dose oral corticosteroids
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Death 1 81 Risk Ratio (M-H, Random, 95% CI) 4.65 [0.23, 93.95]
2 Remission 1 Risk Ratio (M-H, Random, 95% CI) Subtotals only
2.1 Complete renal remission 1 81 Risk Ratio (M-H, Random, 95% CI) 0.93 [0.39, 2.23]
2.2 Partial renal remission 1 81 Risk Ratio (M-H, Random, 95% CI) 1.33 [0.78, 2.24]
3 Relapse 1 50 Risk Ratio (M-H, Random, 95% CI) 2.38 [0.10, 55.72]
4 Infection 1 Risk Ratio (M-H, Random, 95% CI) Subtotals only
4.1 Major infection 1 81 Risk Ratio (M-H, Random, 95% CI) 4.64 [0.57, 38.00]
4.2 Herpes zoster virus 1 81 Risk Ratio (M-H, Random, 95% CI) 13.95 [0.82, 236.48]
5 Gastrointestinal (GI) adverse
events
1 Risk Ratio (M-H, Random, 95% CI) Subtotals only
5.1 Diarrhoea 1 81 Risk Ratio (M-H, Random, 95% CI) 1.16 [0.51, 2.64]
5.2 Vomiting 1 81 Risk Ratio (M-H, Random, 95% CI) 0.93 [0.25, 3.46]
5.3 Nausea 1 81 Risk Ratio (M-H, Random, 95% CI) 2.79 [0.30, 25.67]
6 Creatinine clearance 1 74 Mean Difference (IV, Random, 95% CI) -5.80 [-21.08, 9.48]
7 Serum creatinine 1 81 Mean Difference (IV, Random, 95% CI) -2.40 [-15.98, 11.
18]
Comparison 17. IV versus oral corticosteroids
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Death 1 22 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
2 Adverse renal outcomes 1 Risk Ratio (M-H, Random, 95% CI) Subtotals only
2.1 Renal relapse 1 22 Risk Ratio (M-H, Random, 95% CI) 0.95 [0.44, 2.04]
Comparison 18. Cyclophosphamide (CPA) + corticosteroids versus corticosteroids
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Death 5 226 Risk Ratio (M-H, Random, 95% CI) 0.98 [0.53, 1.82]
2 Complete remission of
proteinuria
1 13 Risk Ratio (M-H, Random, 95% CI) 2.63 [0.13, 54.64]
3 Adverse renal outcomes 5 Risk Ratio (M-H, Random, 95% CI) Subtotals only
3.1 ESKD 5 278 Risk Ratio (M-H, Random, 95% CI) 0.63 [0.39, 1.03]
3.2 Renal relapse 2 84 Risk Ratio (M-H, Random, 95% CI) 0.23 [0.08, 0.62]
3.3 Doubling serum creatinine 4 228 Risk Ratio (M-H, Random, 95% CI) 0.59 [0.40, 0.88]
4 Deterioration of kidney function 5 179 Risk Ratio (M-H, Random, 95% CI) 0.78 [0.52, 1.18]
5 Stable kidney function 5 278 Risk Ratio (M-H, Random, 95% CI) 1.20 [1.00, 1.45]
6 Ovarian failure 3 147 Risk Ratio (M-H, Random, 95% CI) 2.18 [1.10, 4.34]
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7 Infection 6 Risk Ratio (M-H, Random, 95% CI) Subtotals only
7.1 Major infection 6 291 Risk Ratio (M-H, Random, 95% CI) 0.87 [0.50, 1.51]
7.2 Herpes zoster virus 3 199 Risk Ratio (M-H, Random, 95% CI) 1.77 [0.63, 4.99]
8 Malignancy 2 117 Risk Ratio (M-H, Random, 95% CI) 0.82 [0.07, 9.90]
9 Bone toxicity 3 197 Risk Ratio (M-H, Random, 95% CI) 0.84 [0.40, 1.75]
10 Bladder toxicity 2 65 Risk Ratio (M-H, Random, 95% CI) 2.66 [0.33, 21.68]
11 Daily proteinuria 3 92 Mean Difference (IV, Random, 95% CI) 0.15 [-0.23, 0.54]
12 Serum creatinine 1 29 Mean Difference (IV, Random, 95% CI) -52.0 [-111.39, 7.
39]
13 Creatinine clearance 2 63 Mean Difference (IV, Random, 95% CI) 12.23 [-0.13, 24.58]
Comparison 19. Cyclophosphamide (CPA) + azathioprine (AZA) + corticosteroids versus corticosteroids alone
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Death 1 29 Risk Ratio (M-H, Random, 95% CI) 0.53 [0.17, 1.68]
2 Adverse renal outcomes 1 Risk Ratio (M-H, Random, 95% CI) Subtotals only
2.1 ESKD 1 29 Risk Ratio (M-H, Random, 95% CI) 0.21 [0.04, 1.02]
2.2 Doubling of serum
creatinine
1 29 Risk Ratio (M-H, Random, 95% CI) 0.16 [0.04, 0.69]
3 Stable kidney function 1 29 Risk Ratio (M-H, Random, 95% CI) 1.59 [0.83, 3.06]
4 Ovarian failure 1 27 Risk Ratio (M-H, Random, 95% CI) 7.32 [0.49, 108.96]
5 Infection 1 Risk Ratio (M-H, Random, 95% CI) Subtotals only
5.1 Major infection 1 29 Risk Ratio (M-H, Random, 95% CI) 0.48 [0.10, 2.30]
5.2 Herpes zoster virus 1 29 Risk Ratio (M-H, Random, 95% CI) 5.22 [0.33, 81.40]
6 Bladder toxicity 1 29 Risk Ratio (M-H, Random, 95% CI) 2.43 [0.14, 42.17]
Comparison 20. Azathioprine (AZA) + corticosteroids versus corticosteroids alone
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Death 3 78 Risk Ratio (M-H, Random, 95% CI) 0.60 [0.36, 0.99]
2 Complete remission of
proteinuria
2 37 Risk Ratio (M-H, Random, 95% CI) 0.95 [0.54, 1.69]
3 Adverse renal outcomes 3 Risk Ratio (M-H, Random, 95% CI) Subtotals only
3.1 ESKD 2 54 Risk Ratio (M-H, Random, 95% CI) 0.66 [0.17, 2.55]
3.2 Renal relapse 1 16 Risk Ratio (M-H, Random, 95% CI) 0.78 [0.22, 2.74]
3.3 Doubling of serum
creatinine
1 26 Risk Ratio (M-H, Random, 95% CI) 0.98 [0.36, 2.68]
4 Stable kidney function 1 26 Risk Ratio (M-H, Random, 95% CI) 1.01 [0.48, 2.14]
5 Ovarian failure 1 24 Risk Ratio (M-H, Random, 95% CI) 2.58 [0.15, 43.86]
6 Infection 2 Risk Ratio (M-H, Random, 95% CI) Subtotals only
6.1 Herpes zoster virus 2 42 Risk Ratio (M-H, Random, 95% CI) 3.56 [0.46, 27.79]
7 Malignancy 1 26 Risk Ratio (M-H, Random, 95% CI) 2.0 [0.11, 37.22]
8 Bone toxicity 1 24 Risk Ratio (M-H, Random, 95% CI) 3.55 [0.43, 29.42]
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9 Creatinine clearance 1 24 Mean Difference (IV, Random, 95% CI) 5.0 [-3.14, 13.14]
Comparison 21. Cyclosporin (CSA) + corticosteroids versus corticosteroids alone
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Daily proteinuria 1 10 Mean Difference (IV, Random, 95% CI) -1.8 [-2.59, -1.01]
2 Serum creatinine 1 10 Mean Difference (IV, Random, 95% CI) -31.90 [-73.63, 9.
83]
3 Creatinine clearance 1 10 Mean Difference (IV, Random, 95% CI) -42.5 [-85.02, 0.02]
Comparison 22. Misoprostol + corticosteroids versus corticosteroids alone
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Adverse renal outcomes 1 Risk Ratio (M-H, Random, 95% CI) Subtotals only
1.1 Doubling of serum
creatinine
1 14 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
Comparison 23. Plasma exchange (PE) + immunosuppression (IS) versus IS alone
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Death 2 125 Risk Ratio (M-H, Random, 95% CI) 1.62 [0.64, 4.09]
2 Adverse renal outcomes 4 251 Risk Ratio (M-H, Random, 95% CI) 0.89 [0.51, 1.55]
2.1 ESKD 3 143 Risk Ratio (M-H, Random, 95% CI) 1.24 [0.60, 2.57]
2.2 Doubling of serum
creatinine
2 51 Risk Ratio (M-H, Random, 95% CI) 0.17 [0.02, 1.26]
2.3 Deterioration of kidney
function
2 57 Risk Ratio (M-H, Random, 95% CI) 0.53 [0.06, 4.83]
3 Stable kidney function 3 75 Risk Ratio (M-H, Random, 95% CI) 1.10 [0.94, 1.30]
4 Infection 3 Risk Ratio (M-H, Random, 95% CI) Subtotals only
4.1 Major infection 2 125 Risk Ratio (M-H, Random, 95% CI) 0.69 [0.35, 1.37]
4.2 Herpes zoster virus 2 104 Risk Ratio (M-H, Random, 95% CI) 1.69 [0.10, 29.42]
5 Leucopenia 1 18 Risk Ratio (M-H, Random, 95% CI) 2.60 [0.20, 34.07]
6 Daily proteinuria 2 30 Mean Difference (IV, Random, 95% CI) -0.56 [-5.23, 4.11]
7 Serum creatinine 3 69 Mean Difference (IV, Random, 95% CI) -17.90 [-23.41, -12.
39]
8 Creatinine clearance 1 12 Mean Difference (IV, Random, 95% CI) 26.0 [-17.60, 69.60]
9 Disease activity (SLAM) 1 18 Mean Difference (IV, Random, 95% CI) 0.67 [-3.47, 4.81]
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Comparison 24. Plasma exchange (PE) versus immunosuppression (IS)
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Adverse renal outcomes 1 Risk Ratio (M-H, Random, 95% CI) Subtotals only
1.1 ESKD 1 20 Risk Ratio (M-H, Random, 95% CI) 0.24 [0.01, 4.44]
2 Infection 1 Risk Ratio (M-H, Random, 95% CI) Subtotals only
2.1 Major infection 1 20 Risk Ratio (M-H, Random, 95% CI) 0.4 [0.02, 8.78]
2.2 Herpes zoster virus 1 20 Risk Ratio (M-H, Random, 95% CI) 0.24 [0.01, 4.44]
3 Leucopenia 1 20 Risk Ratio (M-H, Random, 95% CI) 0.24 [0.01, 4.44]
4 Alopecia 1 20 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
5 Daily proteinuria 1 20 Mean Difference (IV, Random, 95% CI) -0.10 [-0.45, 0.25]
6 Creatinine clearance 1 20 Mean Difference (IV, Random, 95% CI) 15.30 [-5.40, 36.00]
Comparison 25. Long versus short duration cyclophosphamide (CPA)
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Adverse renal outcomes 1 Risk Ratio (M-H, Random, 95% CI) Subtotals only
1.1 ESKD 1 40 Risk Ratio (M-H, Random, 95% CI) 0.4 [0.09, 1.83]
1.2 Doubling of serum
creatinine
1 40 Risk Ratio (M-H, Random, 95% CI) 0.43 [0.13, 1.43]
1.3 Deterioration of kidney
function
1 40 Risk Ratio (M-H, Random, 95% CI) 0.43 [0.13, 1.43]
2 Stable kidney function 1 40 Risk Ratio (M-H, Random, 95% CI) 1.31 [0.90, 1.89]
3 Ovarian failure 1 29 Risk Ratio (M-H, Random, 95% CI) 2.05 [0.60, 7.02]
4 Infection 1 Risk Ratio (M-H, Random, 95% CI) Subtotals only
4.1 Major infection 1 40 Risk Ratio (M-H, Random, 95% CI) 1.0 [0.07, 14.90]
4.2 Herpes zoster virus 1 40 Risk Ratio (M-H, Random, 95% CI) 0.5 [0.05, 5.08]
5 Malignancy 1 40 Risk Ratio (M-H, Random, 95% CI) 3.0 [0.13, 69.52]
6 Bone toxicity 1 40 Risk Ratio (M-H, Random, 95% CI) 1.33 [0.34, 5.21]
7 Bladder toxicity 1 40 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
Comparison 26. Maintenance: azathioprine (AZA) versus mycophenolate mofetil (MMF)
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Death 4 Risk Ratio (M-H, Random, 95% CI) Subtotals only
1.1 At end of treatment
duration or follow-up
4 451 Risk Ratio (M-H, Random, 95% CI) 1.15 [0.34, 3.87]
1.2 At 10 years 1 87 Risk Ratio (M-H, Random, 95% CI) 0.62 [0.11, 3.54]
2 Renal relapse 4 Risk Ratio (M-H, Random, 95% CI) Subtotals only
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2.1 At end of treatment
duration or follow-up
4 452 Risk Ratio (M-H, Random, 95% CI) 1.75 [1.20, 2.55]
2.2 At 10 years 1 87 Risk Ratio (M-H, Random, 95% CI) 1.08 [0.69, 1.69]
3 End-stage kidney disease 4 Risk Ratio (M-H, Random, 95% CI) Subtotals only
3.1 At end of treatment
duration or follow-up
4 452 Risk Ratio (M-H, Random, 95% CI) 1.70 [0.52, 5.54]
3.2 At 10 years 1 87 Risk Ratio (M-H, Random, 95% CI) 0.31 [0.03, 2.88]
4 Doubling of serum creatinine 4 452 Risk Ratio (M-H, Random, 95% CI) 2.19 [1.03, 4.66]
5 Ovarian failure 2 177 Risk Ratio (M-H, Random, 95% CI) 0.77 [0.17, 3.42]
6 Infection 3 Risk Ratio (M-H, Random, 95% CI) Subtotals only
6.1 Major infection 3 412 Risk Ratio (M-H, Random, 95% CI) 1.08 [0.60, 1.96]
6.2 Herpes zoster virus 1 105 Risk Ratio (M-H, Random, 95% CI) 1.27 [0.36, 4.48]
7 Malignancy 3 Risk Ratio (M-H, Random, 95% CI) Subtotals only
7.1 At end of treatment
duration or follow-up
3 370 Risk Ratio (M-H, Random, 95% CI) 4.04 [0.45, 36.07]
7.2 At 10 years 1 87 Risk Ratio (M-H, Random, 95% CI) 1.87 [0.18, 19.84]
8 Leucopenia 3 412 Risk Ratio (M-H, Random, 95% CI) 5.61 [1.68, 18.72]
9 Bone toxicity 1 105 Risk Ratio (M-H, Random, 95% CI) 3.06 [0.13, 73.36]
10 Alopecia 3 412 Risk Ratio (M-H, Random, 95% CI) 0.95 [0.46, 1.95]
11 Gastrointestinal (GI) adverse
events
3 Risk Ratio (M-H, Random, 95% CI) Subtotals only
11.1 GI symptoms 1 105 Risk Ratio (M-H, Random, 95% CI) 1.02 [0.41, 2.51]
11.2 Nausea 2 307 Risk Ratio (M-H, Random, 95% CI) 1.08 [0.65, 1.80]
11.3 Diarrhoea 2 307 Risk Ratio (M-H, Random, 95% CI) 0.74 [0.31, 1.73]
11.4 Vomiting 2 307 Risk Ratio (M-H, Random, 95% CI) 0.81 [0.18, 3.62]
12 Daily proteinuria 1 81 Mean Difference (IV, Random, 95% CI) 0.40 [-0.53, 1.33]
Comparison 27. Maintenance: azathioprine (AZA) versus cyclosporin (CSA)
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Death 1 69 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
2 Adverse renal outcomes 1 Risk Ratio (M-H, Random, 95% CI) Subtotals only
2.1 ESKD 1 69 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
2.2 Renal relapse 1 69 Risk Ratio (M-H, Random, 95% CI) 1.25 [0.51, 3.06]
3 Infection 1 Risk Ratio (M-H, Random, 95% CI) Subtotals only
3.1 Major infection 1 69 Risk Ratio (M-H, Random, 95% CI) 2.18 [1.01, 4.73]
4 Leucopenia 1 69 Risk Ratio (M-H, Random, 95% CI) 2.73 [0.95, 7.86]
5 Gastrointestinal (GI) adverse
events
1 Risk Ratio (M-H, Random, 95% CI) Subtotals only
5.1 GI disturbance 1 69 Risk Ratio (M-H, Random, 95% CI) 0.30 [0.09, 0.97]
6 Daily proteinuria 1 69 Mean Difference (IV, Random, 95% CI) 0.15 [-0.23, 0.53]
7 Disease activity (SLEDAI) 1 69 Mean Difference (IV, Random, 95% CI) -3.20 [-5.77, -0.63]
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Comparison 28. Maintenance: azathioprine (AZA) versus cyclophosphamide (CPA)
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Death 1 39 Risk Ratio (M-H, Random, 95% CI) 0.12 [0.01, 2.03]
2 Adverse renal outcomes 1 Risk Ratio (M-H, Random, 95% CI) Subtotals only
2.1 ESKD 1 39 Risk Ratio (M-H, Random, 95% CI) 0.35 [0.04, 3.09]
2.2 Renal relapse 1 39 Risk Ratio (M-H, Random, 95% CI) 0.79 [0.34, 1.85]
2.3 Doubling of serum
creatinine
1 39 Risk Ratio (M-H, Random, 95% CI) 0.79 [0.34, 1.85]
3 Bladder toxicity 1 39 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
4 Creatinine clearance 1 38 Mean Difference (IV, Random, 95% CI) -15.70 [-23.71, -7.
69]
Comparison 29. Maintenance: azathioprine (AZA) versus tacrolimus (TAC)
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Adverse renal outcomes 1 Risk Ratio (M-H, Random, 95% CI) Subtotals only
1.1 Renal relapse 1 70 Risk Ratio (M-H, Random, 95% CI) 6.62 [0.35, 123.63]
2 Infection 1 Risk Ratio (M-H, Random, 95% CI) Subtotals only
2.1 Major infection 1 70 Risk Ratio (M-H, Random, 95% CI) 1.26 [0.30, 5.22]
3 Gastrointestinal (GI) adverse
events
1 Risk Ratio (M-H, Random, 95% CI) Subtotals only
3.1 GI disturbance 1 70 Risk Ratio (M-H, Random, 95% CI) 1.89 [0.18, 19.89]
Comparison 30. Maintenance: prednisone withdrawal versus prednisone continuation
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Relapse 1 Risk Ratio (M-H, Random, 95% CI) Subtotals only
1.1 Renal relapse 1 15 Risk Ratio (M-H, Random, 95% CI) 0.38 [0.05, 2.88]
1.2 Non-renal relapse 1 15 Risk Ratio (M-H, Random, 95% CI) 0.38 [0.02, 7.96]
2 Major infection 1 15 Risk Ratio (M-H, Random, 95% CI) 0.57 [0.06, 5.03]
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Comparison 31. Maintenance: intravenous immunoglobulin (IVIG) versus intravenous cyclophosphamide (IV
CPA)
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Creatinine clearance 1 13 Mean Difference (IV, Random, 95% CI) 2.20 [-37.85, 42.25]
2 Daily proteinuria 1 13 Mean Difference (IV, Random, 95% CI) -0.08 [-0.95, 0.79]
3 Serum creatinine 1 14 Mean Difference (IV, Random, 95% CI) -35.40 [-128.90, 58.
10]
Analysis 1.1. Comparison 1 Mycophenolate mofetil (MMF) versus IV cyclophosphamide (CPA), Outcome 1
Death.
Review: Immunosuppressive treatment for proliferative lupus nephritis
Comparison: 1 Mycophenolate mofetil (MMF) versus IV cyclophosphamide (CPA)
Outcome: 1 Death
Study or subgroup MMF CPA Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
El-Shafey 2010 0/24 1/23 3.8 % 0.32 [ 0.01, 7.48 ]
Mulic-Bacic 2008 1/20 0/25 3.8 % 3.71 [ 0.16, 86.55 ]
Ong 2005 1/19 1/25 5.1 % 1.32 [ 0.09, 19.71 ]
Mendonca 2017 1/17 1/23 5.1 % 1.35 [ 0.09, 20.13 ]
Li 2012 1/20 2/20 7.0 % 0.50 [ 0.05, 5.08 ]
Rathi 2016 5/50 2/50 14.8 % 2.50 [ 0.51, 12.29 ]
Ginzler 2005 4/71 8/69 28.1 % 0.49 [ 0.15, 1.54 ]
ALMS 2007 9/185 5/185 32.4 % 1.80 [ 0.61, 5.27 ]
Total (95% CI) 406 420 100.0 % 1.12 [ 0.61, 2.06 ]
Total events: 22 (MMF), 20 (CPA)
Heterogeneity: Tau2 = 0.0; Chi2 = 5.40, df = 7 (P = 0.61); I2 =0.0%
Test for overall effect: Z = 0.36 (P = 0.72)
Test for subgroup differences: Not applicable
0.005 0.1 1 10 200
Less with MMF Less with CPA
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Analysis 1.2. Comparison 1 Mycophenolate mofetil (MMF) versus IV cyclophosphamide (CPA), Outcome 2
Remission.
Review: Immunosuppressive treatment for proliferative lupus nephritis
Comparison: 1 Mycophenolate mofetil (MMF) versus IV cyclophosphamide (CPA)
Outcome: 2 Remission
Study or subgroup MMF CPA Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Complete renal remission: MMF versus IV CPA
Ong 2005 5/19 3/25 2.2 % 2.19 [ 0.60, 8.06 ]
Ginzler 2005 16/71 4/69 3.4 % 3.89 [ 1.37, 11.05 ]
El-Shafey 2010 6/24 5/23 3.5 % 1.15 [ 0.41, 3.25 ]
Li 2012 9/20 6/20 5.5 % 1.50 [ 0.66, 3.43 ]
ALMS 2007 16/185 15/185 8.3 % 1.07 [ 0.54, 2.09 ]
Mendonca 2017 9/17 11/23 9.8 % 1.11 [ 0.60, 2.06 ]
Mulic-Bacic 2008 14/20 15/25 20.3 % 1.17 [ 0.76, 1.79 ]
Sedhain 2016 14/21 14/21 20.5 % 1.00 [ 0.65, 1.53 ]
Rathi 2016 27/50 25/50 26.4 % 1.08 [ 0.74, 1.57 ]
Subtotal (95% CI) 427 441 100.0 % 1.17 [ 0.97, 1.42 ]
Total events: 116 (MMF), 98 (CPA)
Heterogeneity: Tau2 = 0.0; Chi2 = 7.69, df = 8 (P = 0.46); I2 =0.0%
Test for overall effect: Z = 1.60 (P = 0.11)
2 Partial renal remission: MMF versus IV CPA
Sedhain 2016 6/21 4/21 1.6 % 1.50 [ 0.49, 4.56 ]
Li 2012 6/20 6/20 2.2 % 1.00 [ 0.39, 2.58 ]
Mulic-Bacic 2008 5/20 10/25 2.5 % 0.63 [ 0.25, 1.53 ]
El-Shafey 2010 8/24 7/23 2.8 % 1.10 [ 0.47, 2.53 ]
Mendonca 2017 6/17 9/23 3.0 % 0.90 [ 0.40, 2.05 ]
Ong 2005 6/19 10/25 3.0 % 0.79 [ 0.35, 1.79 ]
Ginzler 2005 21/71 17/69 6.7 % 1.20 [ 0.69, 2.07 ]
Rathi 2016 37/50 37/50 37.0 % 1.00 [ 0.79, 1.26 ]
ALMS 2007 88/185 83/185 41.2 % 1.06 [ 0.85, 1.32 ]
Subtotal (95% CI) 427 441 100.0 % 1.02 [ 0.89, 1.18 ]
Total events: 183 (MMF), 183 (CPA)
Heterogeneity: Tau2 = 0.0; Chi2 = 2.59, df = 8 (P = 0.96); I2 =0.0%
0.05 0.2 1 5 20
More with CPA More with MMF
(Continued . . . )
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(. . . Continued)
Study or subgroup MMF CPA Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Test for overall effect: Z = 0.33 (P = 0.74)
3 Complete remission in proteinuria: MMF versus IV CPA
Ginzler 2005 16/71 4/69 7.4 % 3.89 [ 1.37, 11.05 ]
El-Shafey 2010 6/24 5/23 7.4 % 1.15 [ 0.41, 3.25 ]
Li 2012 9/20 6/20 10.7 % 1.50 [ 0.66, 3.43 ]
Ong 2005 11/19 15/25 21.0 % 0.96 [ 0.59, 1.59 ]
Mulic-Bacic 2008 14/20 15/25 24.4 % 1.17 [ 0.76, 1.79 ]
ALMS 2007 (1) 44/185 50/185 29.1 % 0.88 [ 0.62, 1.25 ]
Subtotal (95% CI) 339 347 100.0 % 1.16 [ 0.85, 1.58 ]
Total events: 100 (MMF), 95 (CPA)
Heterogeneity: Tau2 = 0.05; Chi2 = 8.15, df = 5 (P = 0.15); I2 =39%
Test for overall effect: Z = 0.93 (P = 0.35)
4 Partial remission in proteinuria: MMF versus IV CPA
Mulic-Bacic 2008 5/20 10/25 2.1 % 0.63 [ 0.25, 1.53 ]
El-Shafey 2010 8/24 7/23 2.4 % 1.10 [ 0.47, 2.53 ]
Ginzler 2005 21/71 17/69 5.7 % 1.20 [ 0.69, 2.07 ]
Sedhain 2016 14/21 14/21 9.3 % 1.00 [ 0.65, 1.53 ]
Rathi 2016 37/50 37/50 31.5 % 1.00 [ 0.79, 1.26 ]
ALMS 2007 104/185 98/185 49.1 % 1.06 [ 0.88, 1.28 ]
Subtotal (95% CI) 371 373 100.0 % 1.03 [ 0.91, 1.18 ]
Total events: 189 (MMF), 183 (CPA)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.69, df = 5 (P = 0.89); I2 =0.0%
Test for overall effect: Z = 0.48 (P = 0.63)
0.05 0.2 1 5 20
More with CPA More with MMF
(1) Complete remission defined as <0.5g/24 hours
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Analysis 1.3. Comparison 1 Mycophenolate mofetil (MMF) versus IV cyclophosphamide (CPA), Outcome 3
Adverse renal outcomes.
Review: Immunosuppressive treatment for proliferative lupus nephritis
Comparison: 1 Mycophenolate mofetil (MMF) versus IV cyclophosphamide (CPA)
Outcome: 3 Adverse renal outcomes
Study or subgroup MMF CPA Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 ESKD
El-Shafey 2010 2/24 1/23 17.0 % 1.92 [ 0.19, 19.73 ]
Ong 2005 1/19 2/25 17.1 % 0.66 [ 0.06, 6.73 ]
Ginzler 2005 4/71 7/69 65.9 % 0.56 [ 0.17, 1.81 ]
Subtotal (95% CI) 114 117 100.0 % 0.71 [ 0.27, 1.84 ]
Total events: 7 (MMF), 10 (CPA)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.87, df = 2 (P = 0.65); I2 =0.0%
Test for overall effect: Z = 0.71 (P = 0.48)
2 Renal relapse
Ginzler 2005 8/71 8/69 100.0 % 0.97 [ 0.39, 2.44 ]
Subtotal (95% CI) 71 69 100.0 % 0.97 [ 0.39, 2.44 ]
Total events: 8 (MMF), 8 (CPA)
Heterogeneity: not applicable
Test for overall effect: Z = 0.06 (P = 0.95)
3 Doubling of serum creatinine
Li 2012 0/20 0/20 Not estimable
Subtotal (95% CI) 20 20 Not estimable
Total events: 0 (MMF), 0 (CPA)
Heterogeneity: not applicable
Test for overall effect: not applicable
0.05 0.2 1 5 20
Less with MMF Less with CPA
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Analysis 1.4. Comparison 1 Mycophenolate mofetil (MMF) versus IV cyclophosphamide (CPA), Outcome 4
Stable kidney function.
Review: Immunosuppressive treatment for proliferative lupus nephritis
Comparison: 1 Mycophenolate mofetil (MMF) versus IV cyclophosphamide (CPA)
Outcome: 4 Stable kidney function
Study or subgroup MMF CPA Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Li 2012 9/20 6/20 1.8 % 1.50 [ 0.66, 3.43 ]
Ong 2005 11/19 13/25 4.3 % 1.11 [ 0.65, 1.91 ]
Sedhain 2016 14/21 14/21 6.8 % 1.00 [ 0.65, 1.53 ]
Mulic-Bacic 2008 16/20 14/25 7.4 % 1.43 [ 0.95, 2.15 ]
Rathi 2016 27/50 25/50 8.8 % 1.08 [ 0.74, 1.57 ]
ALMS 2007 130/185 130/185 70.9 % 1.00 [ 0.88, 1.14 ]
Total (95% CI) 315 326 100.0 % 1.05 [ 0.94, 1.17 ]
Total events: 207 (MMF), 202 (CPA)
Heterogeneity: Tau2 = 0.0; Chi2 = 3.55, df = 5 (P = 0.62); I2 =0.0%
Test for overall effect: Z = 0.79 (P = 0.43)
Test for subgroup differences: Not applicable
0.2 0.5 1 2 5
More with CPA More with MMF
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Analysis 1.5. Comparison 1 Mycophenolate mofetil (MMF) versus IV cyclophosphamide (CPA), Outcome 5
Ovarian failure.
Review: Immunosuppressive treatment for proliferative lupus nephritis
Comparison: 1 Mycophenolate mofetil (MMF) versus IV cyclophosphamide (CPA)
Outcome: 5 Ovarian failure
Study or subgroup MMF CPA Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Ginzler 2005 0/65 2/61 25.2 % 0.19 [ 0.01, 3.84 ]
Rathi 2016 2/50 1/50 34.5 % 2.00 [ 0.19, 21.36 ]
ALMS 2007 1/157 8/156 40.3 % 0.12 [ 0.02, 0.98 ]
Total (95% CI) 272 267 100.0 % 0.36 [ 0.06, 2.18 ]
Total events: 3 (MMF), 11 (CPA)
Heterogeneity: Tau2 = 0.98; Chi2 = 3.26, df = 2 (P = 0.20); I2 =39%
Test for overall effect: Z = 1.11 (P = 0.27)
Test for subgroup differences: Not applicable
0.005 0.1 1 10 200
Less with MMF Less with CPA
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Analysis 1.6. Comparison 1 Mycophenolate mofetil (MMF) versus IV cyclophosphamide (CPA), Outcome 6
Menstrual irregularities.
Review: Immunosuppressive treatment for proliferative lupus nephritis
Comparison: 1 Mycophenolate mofetil (MMF) versus IV cyclophosphamide (CPA)
Outcome: 6 Menstrual irregularities
Study or subgroup MMF CPA Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
El-Shafey 2010 1/24 2/23 44.8 % 0.48 [ 0.05, 4.93 ]
Li 2012 1/20 4/20 55.2 % 0.25 [ 0.03, 2.05 ]
Total (95% CI) 44 43 100.0 % 0.33 [ 0.07, 1.59 ]
Total events: 2 (MMF), 6 (CPA)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.17, df = 1 (P = 0.68); I2 =0.0%
Test for overall effect: Z = 1.37 (P = 0.17)
Test for subgroup differences: Not applicable
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Analysis 1.7. Comparison 1 Mycophenolate mofetil (MMF) versus IV cyclophosphamide (CPA), Outcome 7
Infection.
Review: Immunosuppressive treatment for proliferative lupus nephritis
Comparison: 1 Mycophenolate mofetil (MMF) versus IV cyclophosphamide (CPA)
Outcome: 7 Infection
Study or subgroup MMF CPA Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Major infection
Mendonca 2017 1/17 3/23 2.4 % 0.45 [ 0.05, 3.97 ]
Ginzler 2005 1/83 6/75 2.6 % 0.15 [ 0.02, 1.22 ]
El-Shafey 2010 2/24 2/23 3.2 % 0.96 [ 0.15, 6.25 ]
Ong 2005 3/19 3/25 5.1 % 1.32 [ 0.30, 5.81 ]
Li 2012 8/20 8/20 19.6 % 1.00 [ 0.47, 2.14 ]
ALMS 2007 22/185 18/185 32.6 % 1.22 [ 0.68, 2.20 ]
Subtotal (95% CI) 348 351 65.5 % 1.02 [ 0.67, 1.54 ]
Total events: 37 (MMF), 40 (CPA)
Heterogeneity: Tau2 = 0.0; Chi2 = 4.33, df = 5 (P = 0.50); I2 =0.0%
Test for overall effect: Z = 0.07 (P = 0.94)
2 Herpes zoster virus
Rathi 2016 2/50 1/50 2.0 % 2.00 [ 0.19, 21.36 ]
El-Shafey 2010 2/24 3/23 3.9 % 0.64 [ 0.12, 3.48 ]
Ong 2005 3/19 3/25 5.1 % 1.32 [ 0.30, 5.81 ]
Mendonca 2017 3/17 3/23 5.2 % 1.35 [ 0.31, 5.90 ]
Ginzler 2005 3/83 4/75 5.3 % 0.68 [ 0.16, 2.93 ]
ALMS 2007 14/184 6/180 12.9 % 2.28 [ 0.90, 5.81 ]
Subtotal (95% CI) 377 376 34.5 % 1.39 [ 0.78, 2.46 ]
Total events: 27 (MMF), 20 (CPA)
Heterogeneity: Tau2 = 0.0; Chi2 = 2.92, df = 5 (P = 0.71); I2 =0.0%
Test for overall effect: Z = 1.12 (P = 0.26)
Total (95% CI) 725 727 100.0 % 1.13 [ 0.81, 1.58 ]
Total events: 64 (MMF), 60 (CPA)
Heterogeneity: Tau2 = 0.0; Chi2 = 7.91, df = 11 (P = 0.72); I2 =0.0%
Test for overall effect: Z = 0.72 (P = 0.47)
Test for subgroup differences: Chi2 = 0.74, df = 1 (P = 0.39), I2 =0.0%
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Analysis 1.8. Comparison 1 Mycophenolate mofetil (MMF) versus IV cyclophosphamide (CPA), Outcome 8
Malignancy.
Review: Immunosuppressive treatment for proliferative lupus nephritis
Comparison: 1 Mycophenolate mofetil (MMF) versus IV cyclophosphamide (CPA)
Outcome: 8 Malignancy
Study or subgroup MMF CPA Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
ALMS 2007 2/184 3/180 100.0 % 0.65 [ 0.11, 3.86 ]
Total (95% CI) 184 180 100.0 % 0.65 [ 0.11, 3.86 ]
Total events: 2 (MMF), 3 (CPA)
Heterogeneity: not applicable
Test for overall effect: Z = 0.47 (P = 0.64)
Test for subgroup differences: Not applicable
0.1 0.2 0.5 1 2 5 10
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Analysis 1.9. Comparison 1 Mycophenolate mofetil (MMF) versus IV cyclophosphamide (CPA), Outcome 9
Leucopenia.
Review: Immunosuppressive treatment for proliferative lupus nephritis
Comparison: 1 Mycophenolate mofetil (MMF) versus IV cyclophosphamide (CPA)
Outcome: 9 Leucopenia
Study or subgroup MMF CPA Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Li 2012 1/20 1/20 4.3 % 1.00 [ 0.07, 14.90 ]
El-Shafey 2010 4/24 3/23 12.2 % 1.28 [ 0.32, 5.10 ]
Rathi 2016 7/50 5/50 16.4 % 1.40 [ 0.48, 4.12 ]
Ginzler 2005 5/83 14/75 18.2 % 0.32 [ 0.12, 0.85 ]
Ong 2005 7/19 13/25 23.8 % 0.71 [ 0.35, 1.43 ]
ALMS 2007 11/184 38/180 25.1 % 0.28 [ 0.15, 0.54 ]
Total (95% CI) 380 373 100.0 % 0.59 [ 0.33, 1.08 ]
Total events: 35 (MMF), 74 (CPA)
Heterogeneity: Tau2 = 0.26; Chi2 = 10.41, df = 5 (P = 0.06); I2 =52%
Test for overall effect: Z = 1.70 (P = 0.088)
Test for subgroup differences: Not applicable
0.05 0.2 1 5 20
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Analysis 1.10. Comparison 1 Mycophenolate mofetil (MMF) versus IV cyclophosphamide (CPA), Outcome
10 Bladder toxicity.
Review: Immunosuppressive treatment for proliferative lupus nephritis
Comparison: 1 Mycophenolate mofetil (MMF) versus IV cyclophosphamide (CPA)
Outcome: 10 Bladder toxicity
Study or subgroup MMF CPA Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
ALMS 2007 0/184 1/180 100.0 % 0.33 [ 0.01, 7.95 ]
Total (95% CI) 184 180 100.0 % 0.33 [ 0.01, 7.95 ]
Total events: 0 (MMF), 1 (CPA)
Heterogeneity: not applicable
Test for overall effect: Z = 0.69 (P = 0.49)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Less with MMF Less with CPA
Analysis 1.11. Comparison 1 Mycophenolate mofetil (MMF) versus IV cyclophosphamide (CPA), Outcome
11 Alopecia.
Review: Immunosuppressive treatment for proliferative lupus nephritis
Comparison: 1 Mycophenolate mofetil (MMF) versus IV cyclophosphamide (CPA)
Outcome: 11 Alopecia
Study or subgroup MMF CPA Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Rathi 2016 0/50 1/50 2.0 % 0.33 [ 0.01, 7.99 ]
Ginzler 2005 0/83 8/75 2.5 % 0.05 [ 0.00, 0.91 ]
ALMS 2007 20/184 64/180 95.5 % 0.31 [ 0.19, 0.48 ]
Total (95% CI) 317 305 100.0 % 0.29 [ 0.19, 0.46 ]
Total events: 20 (MMF), 73 (CPA)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.50, df = 2 (P = 0.47); I2 =0.0%
Test for overall effect: Z = 5.37 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 1.12. Comparison 1 Mycophenolate mofetil (MMF) versus IV cyclophosphamide (CPA), Outcome
12 Gastrointestinal (GI) adverse events.
Review: Immunosuppressive treatment for proliferative lupus nephritis
Comparison: 1 Mycophenolate mofetil (MMF) versus IV cyclophosphamide (CPA)
Outcome: 12 Gastrointestinal (GI) adverse events
Study or subgroup MMF CPA Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Diarrhoea
El-Shafey 2010 5/24 2/23 6.5 % 2.40 [ 0.52, 11.14 ]
Ginzler 2005 15/83 2/75 7.4 % 6.78 [ 1.60, 28.66 ]
Mendonca 2017 5/17 3/23 9.2 % 2.25 [ 0.62, 8.17 ]
ALMS 2007 (1) 52/184 23/180 76.9 % 2.21 [ 1.42, 3.45 ]
Subtotal (95% CI) 308 301 100.0 % 2.42 [ 1.64, 3.58 ]
Total events: 77 (MMF), 30 (CPA)
Heterogeneity: Tau2 = 0.0; Chi2 = 2.20, df = 3 (P = 0.53); I2 =0.0%
Test for overall effect: Z = 4.43 (P < 0.00001)
2 Vomiting
Mendonca 2017 2/17 10/23 17.0 % 0.27 [ 0.07, 1.08 ]
Ginzler 2005 23/83 25/75 40.5 % 0.83 [ 0.52, 1.33 ]
ALMS 2007 25/184 68/180 42.5 % 0.36 [ 0.24, 0.54 ]
Subtotal (95% CI) 284 278 100.0 % 0.48 [ 0.24, 0.97 ]
Total events: 50 (MMF), 103 (CPA)
Heterogeneity: Tau2 = 0.26; Chi2 = 7.83, df = 2 (P = 0.02); I2 =74%
Test for overall effect: Z = 2.04 (P = 0.041)
3 Nausea
Mendonca 2017 3/17 11/23 21.9 % 0.37 [ 0.12, 1.12 ]
Ginzler 2005 23/83 25/75 37.9 % 0.83 [ 0.52, 1.33 ]
ALMS 2007 27/184 82/180 40.1 % 0.32 [ 0.22, 0.47 ]
Subtotal (95% CI) 284 278 100.0 % 0.48 [ 0.23, 0.98 ]
Total events: 53 (MMF), 118 (CPA)
0.02 0.1 1 10 50
Less with MMF Less with CPA
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(. . . Continued)
Study or subgroup MMF CPA Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Heterogeneity: Tau2 = 0.30; Chi2 = 9.62, df = 2 (P = 0.01); I2 =79%
Test for overall effect: Z = 2.01 (P = 0.045)
4 GI upset
El-Shafey 2010 4/24 5/23 1.6 % 0.77 [ 0.23, 2.50 ]
Ginzler 2005 (2) 7/83 10/75 2.7 % 0.63 [ 0.25, 1.58 ]
ALMS 2007 113/184 120/180 95.7 % 0.92 [ 0.79, 1.07 ]
Subtotal (95% CI) 291 278 100.0 % 0.91 [ 0.78, 1.06 ]
Total events: 124 (MMF), 135 (CPA)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.76, df = 2 (P = 0.68); I2 =0.0%
Test for overall effect: Z = 1.24 (P = 0.22)
0.02 0.1 1 10 50
Less with MMF Less with CPA
(1) 24 week follow-up
(2) defined as either recurrent or chrinoc upper GI symptoms including nausea, vomiting, bloating, epigastric pain or persistant diarrhoea
Analysis 1.13. Comparison 1 Mycophenolate mofetil (MMF) versus IV cyclophosphamide (CPA), Outcome
13 Daily proteinuria.
Review: Immunosuppressive treatment for proliferative lupus nephritis
Comparison: 1 Mycophenolate mofetil (MMF) versus IV cyclophosphamide (CPA)
Outcome: 13 Daily proteinuria
Study or subgroup MMF CPA
Mean
Difference Weight
Mean
Difference
N Mean(SD)[g/24 h] N Mean(SD)[g/24 h] IV,Random,95% CI IV,Random,95% CI
Ginzler 2005 71 2.03 (2.79) 69 1.46 (1.27) 15.2 % 0.57 [ -0.14, 1.28 ]
Ong 2005 19 1.1 (0.6) 25 1.9 (1.5) 17.2 % -0.80 [ -1.45, -0.15 ]
Mendonca 2017 17 0.47 (0.3) 23 0.53 (0.6) 33.7 % -0.06 [ -0.34, 0.22 ]
El-Shafey 2010 24 0.68 (0.5) 23 0.72 (0.48) 33.9 % -0.04 [ -0.32, 0.24 ]
Total (95% CI) 131 140 100.0 % -0.08 [ -0.43, 0.26 ]
Heterogeneity: Tau2 = 0.07; Chi2 = 8.02, df = 3 (P = 0.05); I2 =63%
Test for overall effect: Z = 0.48 (P = 0.63)
Test for subgroup differences: Not applicable
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Analysis 1.14. Comparison 1 Mycophenolate mofetil (MMF) versus IV cyclophosphamide (CPA), Outcome
14 Serum creatinine.
Review: Immunosuppressive treatment for proliferative lupus nephritis
Comparison: 1 Mycophenolate mofetil (MMF) versus IV cyclophosphamide (CPA)
Outcome: 14 Serum creatinine
Study or subgroup MMF CPA
Mean
Difference Weight
Mean
Difference
N
Mean(SD)[
mol/L] N
Mean(SD)[
mol/L] IV,Random,95% CI IV,Random,95% CI
Ong 2005 19 109.5 (168.4) 25 94.4 (61.5) 0.4 % 15.10 [ -64.37, 94.57 ]
Mendonca 2017 17 78.68 (44.2) 23 69.84 (44.2) 3.6 % 8.84 [ -18.87, 36.55 ]
El-Shafey 2010 24 81.68 (29.7) 23 92.95 (24.6) 11.3 % -11.27 [ -26.83, 4.29 ]
ALMS 2007 185 130 (70.3) 185 125 (67.6) 13.9 % 5.00 [ -9.05, 19.05 ]
Rathi 2016 50 80.9 (35.5) 50 82.6 (22.4) 20.2 % -1.70 [ -13.34, 9.94 ]
Ginzler 2005 83 80.4 (22.1) 75 75.1 (24.8) 50.6 % 5.30 [ -2.06, 12.66 ]
Total (95% CI) 378 381 100.0 % 2.14 [ -3.09, 7.37 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 4.46, df = 5 (P = 0.48); I2 =0.0%
Test for overall effect: Z = 0.80 (P = 0.42)
Test for subgroup differences: Not applicable
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Analysis 2.1. Comparison 2 Mycophenolate mofetil (MMF) versus oral cyclophosphamide (CPA), Outcome
1 Death.
Review: Immunosuppressive treatment for proliferative lupus nephritis
Comparison: 2 Mycophenolate mofetil (MMF) versus oral cyclophosphamide (CPA)
Outcome: 1 Death
Study or subgroup MMF CPA Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Chan 2000 0/32 2/30 100.0 % 0.19 [ 0.01, 3.76 ]
Total (95% CI) 32 30 100.0 % 0.19 [ 0.01, 3.76 ]
Total events: 0 (MMF), 2 (CPA)
Heterogeneity: not applicable
Test for overall effect: Z = 1.09 (P = 0.27)
Test for subgroup differences: Not applicable
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Analysis 2.2. Comparison 2 Mycophenolate mofetil (MMF) versus oral cyclophosphamide (CPA), Outcome
2 Remission.
Review: Immunosuppressive treatment for proliferative lupus nephritis
Comparison: 2 Mycophenolate mofetil (MMF) versus oral cyclophosphamide (CPA)
Outcome: 2 Remission
Study or subgroup MMF CPA Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Complete remission in proteinuria
Chan 2000 24/32 23/30 100.0 % 0.98 [ 0.74, 1.30 ]
Subtotal (95% CI) 32 30 100.0 % 0.98 [ 0.74, 1.30 ]
Total events: 24 (MMF), 23 (CPA)
Heterogeneity: not applicable
Test for overall effect: Z = 0.15 (P = 0.88)
2 Partial remission in proteinuria
Chan 2000 8/32 7/30 100.0 % 1.07 [ 0.44, 2.59 ]
Subtotal (95% CI) 32 30 100.0 % 1.07 [ 0.44, 2.59 ]
Total events: 8 (MMF), 7 (CPA)
Heterogeneity: not applicable
Test for overall effect: Z = 0.15 (P = 0.88)
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Analysis 2.3. Comparison 2 Mycophenolate mofetil (MMF) versus oral cyclophosphamide (CPA), Outcome
3 Adverse renal outcomes.
Review: Immunosuppressive treatment for proliferative lupus nephritis
Comparison: 2 Mycophenolate mofetil (MMF) versus oral cyclophosphamide (CPA)
Outcome: 3 Adverse renal outcomes
Study or subgroup MMF CPA Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 ESKD
Chan 2000 0/32 2/30 100.0 % 0.19 [ 0.01, 3.76 ]
Subtotal (95% CI) 32 30 100.0 % 0.19 [ 0.01, 3.76 ]
Total events: 0 (MMF), 2 (CPA)
Heterogeneity: not applicable
Test for overall effect: Z = 1.09 (P = 0.27)
2 Renal relapse
Chan 2000 11/32 9/30 100.0 % 1.15 [ 0.55, 2.37 ]
Subtotal (95% CI) 32 30 100.0 % 1.15 [ 0.55, 2.37 ]
Total events: 11 (MMF), 9 (CPA)
Heterogeneity: not applicable
Test for overall effect: Z = 0.37 (P = 0.71)
3 Doubling of serum creatinine
Chan 2000 (1) 2/32 3/30 100.0 % 0.63 [ 0.11, 3.48 ]
Subtotal (95% CI) 32 30 100.0 % 0.63 [ 0.11, 3.48 ]
Total events: 2 (MMF), 3 (CPA)
Heterogeneity: not applicable
Test for overall effect: Z = 0.54 (P = 0.59)
0.005 0.1 1 10 200
Less with MMF Less with oral CPA
(1) 4/5 had abnormal serum creatinine and chronicity score >5 at baseline
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Analysis 2.4. Comparison 2 Mycophenolate mofetil (MMF) versus oral cyclophosphamide (CPA), Outcome
4 Ovarian failure.
Review: Immunosuppressive treatment for proliferative lupus nephritis
Comparison: 2 Mycophenolate mofetil (MMF) versus oral cyclophosphamide (CPA)
Outcome: 4 Ovarian failure
Study or subgroup MMF CPA Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Chan 2000 1/28 9/25 100.0 % 0.10 [ 0.01, 0.73 ]
Total (95% CI) 28 25 100.0 % 0.10 [ 0.01, 0.73 ]
Total events: 1 (MMF), 9 (CPA)
Heterogeneity: not applicable
Test for overall effect: Z = 2.27 (P = 0.023)
Test for subgroup differences: Not applicable
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Analysis 2.5. Comparison 2 Mycophenolate mofetil (MMF) versus oral cyclophosphamide (CPA), Outcome
5 Infection.
Review: Immunosuppressive treatment for proliferative lupus nephritis
Comparison: 2 Mycophenolate mofetil (MMF) versus oral cyclophosphamide (CPA)
Outcome: 5 Infection
Study or subgroup MMF CPA Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Major infection
Chan 2000 2/32 9/30 100.0 % 0.21 [ 0.05, 0.89 ]
Subtotal (95% CI) 32 30 100.0 % 0.21 [ 0.05, 0.89 ]
Total events: 2 (MMF), 9 (CPA)
Heterogeneity: not applicable
Test for overall effect: Z = 2.12 (P = 0.034)
2 Herpes zoster virus
Chan 2000 2/32 5/30 100.0 % 0.38 [ 0.08, 1.79 ]
Subtotal (95% CI) 32 30 100.0 % 0.38 [ 0.08, 1.79 ]
Total events: 2 (MMF), 5 (CPA)
Heterogeneity: not applicable
Test for overall effect: Z = 1.23 (P = 0.22)
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Analysis 2.6. Comparison 2 Mycophenolate mofetil (MMF) versus oral cyclophosphamide (CPA), Outcome
6 Leucopenia.
Review: Immunosuppressive treatment for proliferative lupus nephritis
Comparison: 2 Mycophenolate mofetil (MMF) versus oral cyclophosphamide (CPA)
Outcome: 6 Leucopenia
Study or subgroup MMF CPA Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Chan 2000 0/32 8/30 100.0 % 0.06 [ 0.00, 0.92 ]
Total (95% CI) 32 30 100.0 % 0.06 [ 0.00, 0.92 ]
Total events: 0 (MMF), 8 (CPA)
Heterogeneity: not applicable
Test for overall effect: Z = 2.02 (P = 0.043)
Test for subgroup differences: Not applicable
0.002 0.1 1 10 500
Less with MMF Less with oral CPA
Analysis 2.7. Comparison 2 Mycophenolate mofetil (MMF) versus oral cyclophosphamide (CPA), Outcome
7 Bone toxicity.
Review: Immunosuppressive treatment for proliferative lupus nephritis
Comparison: 2 Mycophenolate mofetil (MMF) versus oral cyclophosphamide (CPA)
Outcome: 7 Bone toxicity
Study or subgroup MMF CPA Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Chan 2000 0/32 0/30 Not estimable
Total (95% CI) 32 30 Not estimable
Total events: 0 (MMF), 0 (CPA)
Heterogeneity: not applicable
Test for overall effect: not applicable
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
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Analysis 2.8. Comparison 2 Mycophenolate mofetil (MMF) versus oral cyclophosphamide (CPA), Outcome
8 Alopecia.
Review: Immunosuppressive treatment for proliferative lupus nephritis
Comparison: 2 Mycophenolate mofetil (MMF) versus oral cyclophosphamide (CPA)
Outcome: 8 Alopecia
Study or subgroup MMF CPA Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Chan 2000 0/32 9/30 100.0 % 0.05 [ 0.00, 0.81 ]
Total (95% CI) 32 30 100.0 % 0.05 [ 0.00, 0.81 ]
Total events: 0 (MMF), 9 (CPA)
Heterogeneity: not applicable
Test for overall effect: Z = 2.10 (P = 0.035)
Test for subgroup differences: Not applicable
0.002 0.1 1 10 500
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Analysis 2.9. Comparison 2 Mycophenolate mofetil (MMF) versus oral cyclophosphamide (CPA), Outcome
9 Gastrointestinal (GI) adverse events.
Review: Immunosuppressive treatment for proliferative lupus nephritis
Comparison: 2 Mycophenolate mofetil (MMF) versus oral cyclophosphamide (CPA)
Outcome: 9 Gastrointestinal (GI) adverse events
Study or subgroup MMF CPA Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 GI upset
Chan 2000 3/32 1/30 100.0 % 2.81 [ 0.31, 25.58 ]
Subtotal (95% CI) 32 30 100.0 % 2.81 [ 0.31, 25.58 ]
Total events: 3 (MMF), 1 (CPA)
Heterogeneity: not applicable
Test for overall effect: Z = 0.92 (P = 0.36)
Test for subgroup differences: Not applicable
0.02 0.1 1 10 50
Less with MMF Less with oral CPA
Analysis 2.10. Comparison 2 Mycophenolate mofetil (MMF) versus oral cyclophosphamide (CPA), Outcome
10 Daily proteinuria.
Review: Immunosuppressive treatment for proliferative lupus nephritis
Comparison: 2 Mycophenolate mofetil (MMF) versus oral cyclophosphamide (CPA)
Outcome: 10 Daily proteinuria
Study or subgroup MMF CPA
Mean
Difference Weight
Mean
Difference
N Mean(SD)[g/24 h] N Mean(SD)[g/24 h] IV,Random,95% CI IV,Random,95% CI
Chan 2000 21 0.5 (1.1) 21 0.2 (0.3) 100.0 % 0.30 [ -0.19, 0.79 ]
Total (95% CI) 21 21 100.0 % 0.30 [ -0.19, 0.79 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.21 (P = 0.23)
Test for subgroup differences: Not applicable
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Analysis 3.1. Comparison 3 Mycophenolate mofetil (MMF) + tacrolimus (TAC) versus IV cyclophosphamide
(CPA), Outcome 1 Death.
Review: Immunosuppressive treatment for proliferative lupus nephritis
Comparison: 3 Mycophenolate mofetil (MMF) + tacrolimus (TAC) versus IV cyclophosphamide (CPA)
Outcome: 1 Death
Study or subgroup MMF+TAC CPA Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Bao 2008 0/20 0/20 Not estimable
Liu 2015 0/181 0/181 Not estimable
Total (95% CI) 201 201 Not estimable
Total events: 0 (MMF+TAC), 0 (CPA)
Heterogeneity: not applicable
Test for overall effect: not applicable
Test for subgroup differences: Not applicable
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Analysis 3.2. Comparison 3 Mycophenolate mofetil (MMF) + tacrolimus (TAC) versus IV cyclophosphamide
(CPA), Outcome 2 Remission.
Review: Immunosuppressive treatment for proliferative lupus nephritis
Comparison: 3 Mycophenolate mofetil (MMF) + tacrolimus (TAC) versus IV cyclophosphamide (CPA)
Outcome: 2 Remission
Study or subgroup MMF+TAC CPA Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Complete renal remission
Bao 2008 13/20 3/20 31.5 % 4.33 [ 1.45, 12.91 ]
Liu 2015 83/181 46/181 68.5 % 1.80 [ 1.34, 2.42 ]
Subtotal (95% CI) 201 201 100.0 % 2.38 [ 1.07, 5.30 ]
Total events: 96 (MMF+TAC), 49 (CPA)
Heterogeneity: Tau2 = 0.22; Chi2 = 2.33, df = 1 (P = 0.13); I2 =57%
Test for overall effect: Z = 2.12 (P = 0.034)
2 Partial renal remission
Bao 2008 8/20 8/20 10.9 % 1.00 [ 0.47, 2.14 ]
Liu 2015 68/181 68/181 89.1 % 1.00 [ 0.77, 1.30 ]
Subtotal (95% CI) 201 201 100.0 % 1.00 [ 0.78, 1.28 ]
Total events: 76 (MMF+TAC), 76 (CPA)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.0, df = 1 (P = 1.00); I2 =0.0%
Test for overall effect: Z = 0.0 (P = 1.0)
3 Complete remission in proteinuria
Bao 2008 (1) 13/20 3/20 31.5 % 4.33 [ 1.45, 12.91 ]
Liu 2015 83/181 46/181 68.5 % 1.80 [ 1.34, 2.42 ]
Subtotal (95% CI) 201 201 100.0 % 2.38 [ 1.07, 5.30 ]
Total events: 96 (MMF+TAC), 49 (CPA)
Heterogeneity: Tau2 = 0.22; Chi2 = 2.33, df = 1 (P = 0.13); I2 =57%
Test for overall effect: Z = 2.12 (P = 0.034)
4 Partial remission in proteinuria
Bao 2008 (2) 6/20 8/20 8.7 % 0.75 [ 0.32, 1.77 ]
Liu 2015 68/181 68/181 91.3 % 1.00 [ 0.77, 1.30 ]
Subtotal (95% CI) 201 201 100.0 % 0.98 [ 0.76, 1.26 ]
Total events: 74 (MMF+TAC), 76 (CPA)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.39, df = 1 (P = 0.53); I2 =0.0%
Test for overall effect: Z = 0.19 (P = 0.85)
0.05 0.2 1 5 20
More with CPA More with MMF+TAC
(1) 9 months, CR: proteinuria < 0.4 g/24 h
(2) 9 months, PR: resumption of normal or at least 50% improvement in proteinuria
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Analysis 3.3. Comparison 3 Mycophenolate mofetil (MMF) + tacrolimus (TAC) versus IV cyclophosphamide
(CPA), Outcome 3 Adverse renal outcomes.
Review: Immunosuppressive treatment for proliferative lupus nephritis
Comparison: 3 Mycophenolate mofetil (MMF) + tacrolimus (TAC) versus IV cyclophosphamide (CPA)
Outcome: 3 Adverse renal outcomes
Study or subgroup MMF+TAC CPA Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Doubling of serum creatinine
Liu 2015 1/181 0/181 49.2 % 3.00 [ 0.12, 73.16 ]
Bao 2008 0/20 1/20 50.8 % 0.33 [ 0.01, 7.72 ]
Subtotal (95% CI) 201 201 100.0 % 0.98 [ 0.10, 9.23 ]
Total events: 1 (MMF+TAC), 1 (CPA)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.92, df = 1 (P = 0.34); I2 =0.0%
Test for overall effect: Z = 0.02 (P = 0.99)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Less with MMF+TAC Less with IV CPA
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Analysis 3.4. Comparison 3 Mycophenolate mofetil (MMF) + tacrolimus (TAC) versus IV cyclophosphamide
(CPA), Outcome 4 Stable kidney function.
Review: Immunosuppressive treatment for proliferative lupus nephritis
Comparison: 3 Mycophenolate mofetil (MMF) + tacrolimus (TAC) versus IV cyclophosphamide (CPA)
Outcome: 4 Stable kidney function
Study or subgroup MMF+TAC CPA Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Bao 2008 19/20 11/20 34.3 % 1.73 [ 1.15, 2.60 ]
Liu 2015 83/181 46/181 65.7 % 1.80 [ 1.34, 2.42 ]
Total (95% CI) 201 201 100.0 % 1.78 [ 1.40, 2.26 ]
Total events: 102 (MMF+TAC), 57 (CPA)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.03, df = 1 (P = 0.86); I2 =0.0%
Test for overall effect: Z = 4.71 (P < 0.00001)
Test for subgroup differences: Not applicable
0.2 0.5 1 2 5
More with IV CPA More with MMF+TAC
Analysis 3.5. Comparison 3 Mycophenolate mofetil (MMF) + tacrolimus (TAC) versus IV cyclophosphamide
(CPA), Outcome 5 Ovarian failure.
Review: Immunosuppressive treatment for proliferative lupus nephritis
Comparison: 3 Mycophenolate mofetil (MMF) + tacrolimus (TAC) versus IV cyclophosphamide (CPA)
Outcome: 5 Ovarian failure
Study or subgroup MMF+TAC CPA Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Bao 2008 0/16 0/18 Not estimable
Total (95% CI) 16 18 Not estimable
Total events: 0 (MMF+TAC), 0 (CPA)
Heterogeneity: not applicable
Test for overall effect: not applicable
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Less with MMF+TAC Less with IV CPA
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Analysis 3.6. Comparison 3 Mycophenolate mofetil (MMF) + tacrolimus (TAC) versus IV cyclophosphamide
(CPA), Outcome 6 Menstrual irregularities.
Review: Immunosuppressive treatment for proliferative lupus nephritis
Comparison: 3 Mycophenolate mofetil (MMF) + tacrolimus (TAC) versus IV cyclophosphamide (CPA)
Outcome: 6 Menstrual irregularities
Study or subgroup MMF+TAC CPA Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Liu 2015 2/162 7/161 100.0 % 0.28 [ 0.06, 1.35 ]
Total (95% CI) 162 161 100.0 % 0.28 [ 0.06, 1.35 ]
Total events: 2 (MMF+TAC), 7 (CPA)
Heterogeneity: not applicable
Test for overall effect: Z = 1.59 (P = 0.11)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Less with MMF+TAC Less with IV CPA
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Analysis 3.7. Comparison 3 Mycophenolate mofetil (MMF) + tacrolimus (TAC) versus IV cyclophosphamide
(CPA), Outcome 7 Infection.
Review: Immunosuppressive treatment for proliferative lupus nephritis
Comparison: 3 Mycophenolate mofetil (MMF) + tacrolimus (TAC) versus IV cyclophosphamide (CPA)
Outcome: 7 Infection
Study or subgroup MMF+TAC CPA Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Major infection
Liu 2015 7/181 1/181 45.2 % 7.00 [ 0.87, 56.32 ]
Bao 2008 3/20 6/20 54.8 % 0.50 [ 0.14, 1.73 ]
Subtotal (95% CI) 201 201 100.0 % 1.65 [ 0.11, 24.44 ]
Total events: 10 (MMF+TAC), 7 (CPA)
Heterogeneity: Tau2 = 3.05; Chi2 = 4.99, df = 1 (P = 0.03); I2 =80%
Test for overall effect: Z = 0.36 (P = 0.72)
2 Herpes zoster virus
Bao 2008 1/20 1/20 23.1 % 1.00 [ 0.07, 14.90 ]
Liu 2015 3/181 4/181 76.9 % 0.75 [ 0.17, 3.30 ]
Subtotal (95% CI) 201 201 100.0 % 0.80 [ 0.22, 2.94 ]
Total events: 4 (MMF+TAC), 5 (CPA)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.03, df = 1 (P = 0.85); I2 =0.0%
Test for overall effect: Z = 0.33 (P = 0.74)
0.01 0.1 1 10 100
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Analysis 3.8. Comparison 3 Mycophenolate mofetil (MMF) + tacrolimus (TAC) versus IV cyclophosphamide
(CPA), Outcome 8 Leucopenia.
Review: Immunosuppressive treatment for proliferative lupus nephritis
Comparison: 3 Mycophenolate mofetil (MMF) + tacrolimus (TAC) versus IV cyclophosphamide (CPA)
Outcome: 8 Leucopenia
Study or subgroup MMF+TAC CPA Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Liu 2015 1/181 12/181 44.1 % 0.08 [ 0.01, 0.63 ]
Bao 2008 2/20 4/20 55.9 % 0.50 [ 0.10, 2.43 ]
Total (95% CI) 201 201 100.0 % 0.23 [ 0.04, 1.44 ]
Total events: 3 (MMF+TAC), 16 (CPA)
Heterogeneity: Tau2 = 0.94; Chi2 = 2.09, df = 1 (P = 0.15); I2 =52%
Test for overall effect: Z = 1.57 (P = 0.12)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Less with MMF+TAC Less wiyh IV CPA
Analysis 3.9. Comparison 3 Mycophenolate mofetil (MMF) + tacrolimus (TAC) versus IV cyclophosphamide
(CPA), Outcome 9 Bone toxicity.
Review: Immunosuppressive treatment for proliferative lupus nephritis
Comparison: 3 Mycophenolate mofetil (MMF) + tacrolimus (TAC) versus IV cyclophosphamide (CPA)
Outcome: 9 Bone toxicity
Study or subgroup MMF+TAC CPA Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Liu 2015 1/181 0/181 100.0 % 3.00 [ 0.12, 73.16 ]
Total (95% CI) 181 181 100.0 % 3.00 [ 0.12, 73.16 ]
Total events: 1 (MMF+TAC), 0 (CPA)
Heterogeneity: not applicable
Test for overall effect: Z = 0.67 (P = 0.50)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Less with MMF+TAC Less with IV CPA
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Analysis 3.10. Comparison 3 Mycophenolate mofetil (MMF) + tacrolimus (TAC) versus IV
cyclophosphamide (CPA), Outcome 10 Alopecia.
Review: Immunosuppressive treatment for proliferative lupus nephritis
Comparison: 3 Mycophenolate mofetil (MMF) + tacrolimus (TAC) versus IV cyclophosphamide (CPA)
Outcome: 10 Alopecia
Study or subgroup MMF+TAC CPA Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Bao 2008 4/20 4/20 40.0 % 1.00 [ 0.29, 3.45 ]
Liu 2015 6/181 9/181 60.0 % 0.67 [ 0.24, 1.83 ]
Total (95% CI) 201 201 100.0 % 0.78 [ 0.36, 1.72 ]
Total events: 10 (MMF+TAC), 13 (CPA)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.25, df = 1 (P = 0.62); I2 =0.0%
Test for overall effect: Z = 0.61 (P = 0.54)
Test for subgroup differences: Not applicable
0.1 0.2 0.5 1 2 5 10
Less with MMF+TAC Less with IV CPA
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Analysis 3.11. Comparison 3 Mycophenolate mofetil (MMF) + tacrolimus (TAC) versus IV
cyclophosphamide (CPA), Outcome 11 Gastrointestinal (GI) adverse events.
Review: Immunosuppressive treatment for proliferative lupus nephritis
Comparison: 3 Mycophenolate mofetil (MMF) + tacrolimus (TAC) versus IV cyclophosphamide (CPA)
Outcome: 11 Gastrointestinal (GI) adverse events
Study or subgroup MMF+TAC CPA Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Diarrhoea
Liu 2015 14/181 6/181 100.0 % 2.33 [ 0.92, 5.94 ]
Subtotal (95% CI) 181 181 100.0 % 2.33 [ 0.92, 5.94 ]
Total events: 14 (MMF+TAC), 6 (CPA)
Heterogeneity: not applicable
Test for overall effect: Z = 1.78 (P = 0.075)
2 GI upset
Bao 2008 2/20 7/20 22.6 % 0.29 [ 0.07, 1.21 ]
Liu 2015 7/181 37/181 77.4 % 0.19 [ 0.09, 0.41 ]
Subtotal (95% CI) 201 201 100.0 % 0.21 [ 0.10, 0.41 ]
Total events: 9 (MMF+TAC), 44 (CPA)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.24, df = 1 (P = 0.62); I2 =0.0%
Test for overall effect: Z = 4.48 (P < 0.00001)
0.02 0.1 1 10 50
Less with MMF+TAC Less with IV CPA
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Analysis 3.12. Comparison 3 Mycophenolate mofetil (MMF) + tacrolimus (TAC) versus IV
cyclophosphamide (CPA), Outcome 12 Daily proteinuria.
Review: Immunosuppressive treatment for proliferative lupus nephritis
Comparison: 3 Mycophenolate mofetil (MMF) + tacrolimus (TAC) versus IV cyclophosphamide (CPA)
Outcome: 12 Daily proteinuria
Study or subgroup MMF+TAC CPA
Mean
Difference Weight
Mean
Difference
N Mean(SD)[g/24 h] N Mean(SD)[g/24 h] IV,Random,95% CI IV,Random,95% CI
Bao 2008 20 -3.79 (2.12) 20 -2.1 (1.41) 100.0 % -1.69 [ -2.81, -0.57 ]
Total (95% CI) 20 20 100.0 % -1.69 [ -2.81, -0.57 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.97 (P = 0.0030)
Test for subgroup differences: Not applicable
-4 -2 0 2 4
Lower with MMF+TAC Lower with IV CPA
Analysis 4.1. Comparison 4 Mycophenolate mofetil (MMF) + IV cyclophosphamide (CPA) versus IV CPA,
Outcome 1 Death.
Review: Immunosuppressive treatment for proliferative lupus nephritis
Comparison: 4 Mycophenolate mofetil (MMF) + IV cyclophosphamide (CPA) versus IV CPA
Outcome: 1 Death
Study or subgroup MMF+CPA CPA Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Sun 2015 1/42 1/40 100.0 % 0.95 [ 0.06, 14.72 ]
Total (95% CI) 42 40 100.0 % 0.95 [ 0.06, 14.72 ]
Total events: 1 (MMF+CPA), 1 (CPA)
Heterogeneity: not applicable
Test for overall effect: Z = 0.03 (P = 0.97)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Less with MMF + IV CPA Less with IV CPA
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Analysis 4.2. Comparison 4 Mycophenolate mofetil (MMF) + IV cyclophosphamide (CPA) versus IV CPA,
Outcome 2 Remission.
Review: Immunosuppressive treatment for proliferative lupus nephritis
Comparison: 4 Mycophenolate mofetil (MMF) + IV cyclophosphamide (CPA) versus IV CPA
Outcome: 2 Remission
Study or subgroup MMF+CPA CPA Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Complete renal remission
Sun 2015 23/42 18/40 100.0 % 1.22 [ 0.78, 1.89 ]
Subtotal (95% CI) 42 40 100.0 % 1.22 [ 0.78, 1.89 ]
Total events: 23 (MMF+CPA), 18 (CPA)
Heterogeneity: not applicable
Test for overall effect: Z = 0.88 (P = 0.38)
2 Partial renal remission
Sun 2015 14/42 13/40 100.0 % 1.03 [ 0.55, 1.90 ]
Subtotal (95% CI) 42 40 100.0 % 1.03 [ 0.55, 1.90 ]
Total events: 14 (MMF+CPA), 13 (CPA)
Heterogeneity: not applicable
Test for overall effect: Z = 0.08 (P = 0.94)
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Analysis 4.3. Comparison 4 Mycophenolate mofetil (MMF) + IV cyclophosphamide (CPA) versus IV CPA,
Outcome 3 Menstrual irregularities.
Review: Immunosuppressive treatment for proliferative lupus nephritis
Comparison: 4 Mycophenolate mofetil (MMF) + IV cyclophosphamide (CPA) versus IV CPA
Outcome: 3 Menstrual irregularities
Study or subgroup MMF+CPA CPA Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Sun 2015 4/38 8/37 100.0 % 0.49 [ 0.16, 1.48 ]
Total (95% CI) 38 37 100.0 % 0.49 [ 0.16, 1.48 ]
Total events: 4 (MMF+CPA), 8 (CPA)
Heterogeneity: not applicable
Test for overall effect: Z = 1.27 (P = 0.20)
Test for subgroup differences: Not applicable
0.1 0.2 0.5 1 2 5 10
Less with MMF+IV CPA Less with IV CPA
Analysis 4.4. Comparison 4 Mycophenolate mofetil (MMF) + IV cyclophosphamide (CPA) versus IV CPA,
Outcome 4 Infection.
Review: Immunosuppressive treatment for proliferative lupus nephritis
Comparison: 4 Mycophenolate mofetil (MMF) + IV cyclophosphamide (CPA) versus IV CPA
Outcome: 4 Infection
Study or subgroup MMF+CPA CPA Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Major infection
Sun 2015 5/42 13/40 100.0 % 0.37 [ 0.14, 0.93 ]
Total (95% CI) 42 40 100.0 % 0.37 [ 0.14, 0.93 ]
Total events: 5 (MMF+CPA), 13 (CPA)
Heterogeneity: not applicable
Test for overall effect: Z = 2.10 (P = 0.035)
Test for subgroup differences: Not applicable
0.1 0.2 0.5 1 2 5 10
Less with MMF+IV CPA Less with IV CPA
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Analysis 4.5. Comparison 4 Mycophenolate mofetil (MMF) + IV cyclophosphamide (CPA) versus IV CPA,
Outcome 5 Leucopenia.
Review: Immunosuppressive treatment for proliferative lupus nephritis
Comparison: 4 Mycophenolate mofetil (MMF) + IV cyclophosphamide (CPA) versus IV CPA
Outcome: 5 Leucopenia
Study or subgroup MMF+CPA CPA Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Sun 2015 2/42 3/40 100.0 % 0.63 [ 0.11, 3.60 ]
Total (95% CI) 42 40 100.0 % 0.63 [ 0.11, 3.60 ]
Total events: 2 (MMF+CPA), 3 (CPA)
Heterogeneity: not applicable
Test for overall effect: Z = 0.51 (P = 0.61)
Test for subgroup differences: Not applicable
0.1 0.2 0.5 1 2 5 10
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Analysis 4.6. Comparison 4 Mycophenolate mofetil (MMF) + IV cyclophosphamide (CPA) versus IV CPA,
Outcome 6 Daily proteinuria.
Review: Immunosuppressive treatment for proliferative lupus nephritis
Comparison: 4 Mycophenolate mofetil (MMF) + IV cyclophosphamide (CPA) versus IV CPA
Outcome: 6 Daily proteinuria
Study or subgroup MMF+CPA CPA
Mean
Difference Weight
Mean
Difference
N Mean(SD)[g/24 h] N Mean(SD)[g/24 h] IV,Random,95% CI IV,Random,95% CI
Sun 2015 40 0.54 (1.17) 37 1.08 (1.41) 100.0 % -0.54 [ -1.12, 0.04 ]
Total (95% CI) 40 37 100.0 % -0.54 [ -1.12, 0.04 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.82 (P = 0.069)
Test for subgroup differences: Not applicable
-2 -1 0 1 2
Lower with MMF+IV CPA Lower with CPA
Analysis 5.1. Comparison 5 Mycophenolate mofetil (MMF) versus tacrolimus (TAC), Outcome 1 Death.
Review: Immunosuppressive treatment for proliferative lupus nephritis
Comparison: 5 Mycophenolate mofetil (MMF) versus tacrolimus (TAC)
Outcome: 1 Death
Study or subgroup MMF TAC Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Li 2012 1/20 1/20 11.6 % 1.00 [ 0.07, 14.90 ]
Kamanamool 2017 2/42 2/41 23.3 % 0.98 [ 0.14, 6.61 ]
Mok 2016 6/76 5/74 65.1 % 1.17 [ 0.37, 3.66 ]
Total (95% CI) 138 135 100.0 % 1.10 [ 0.44, 2.77 ]
Total events: 9 (MMF), 8 (TAC)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.03, df = 2 (P = 0.98); I2 =0.0%
Test for overall effect: Z = 0.20 (P = 0.84)
Test for subgroup differences: Not applicable
0.05 0.2 1 5 20
Less with MMF Less with TAC
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Analysis 5.2. Comparison 5 Mycophenolate mofetil (MMF) versus tacrolimus (TAC), Outcome 2 Remission.
Review: Immunosuppressive treatment for proliferative lupus nephritis
Comparison: 5 Mycophenolate mofetil (MMF) versus tacrolimus (TAC)
Outcome: 2 Remission
Study or subgroup MMF TAC Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Complete renal remission
Li 2012 9/20 9/20 9.3 % 1.00 [ 0.50, 1.98 ]
Kamanamool 2017 24/42 19/41 24.7 % 1.23 [ 0.81, 1.88 ]
Mok 2016 45/76 46/74 65.9 % 0.95 [ 0.74, 1.23 ]
Subtotal (95% CI) 138 135 100.0 % 1.02 [ 0.83, 1.26 ]
Total events: 78 (MMF), 74 (TAC)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.06, df = 2 (P = 0.59); I2 =0.0%
Test for overall effect: Z = 0.18 (P = 0.85)
2 Partial renal remission
Li 2012 6/20 6/20 26.9 % 1.00 [ 0.39, 2.58 ]
Mok 2016 16/76 20/74 73.1 % 0.78 [ 0.44, 1.38 ]
Subtotal (95% CI) 96 94 100.0 % 0.83 [ 0.51, 1.36 ]
Total events: 22 (MMF), 26 (TAC)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.20, df = 1 (P = 0.66); I2 =0.0%
Test for overall effect: Z = 0.73 (P = 0.47)
3 Complete remission in proteinuria
Li 2012 9/20 9/20 100.0 % 1.00 [ 0.50, 1.98 ]
Subtotal (95% CI) 20 20 100.0 % 1.00 [ 0.50, 1.98 ]
Total events: 9 (MMF), 9 (TAC)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
4 Partial remission in proteinuria
Li 2012 6/20 6/20 2.0 % 1.00 [ 0.39, 2.58 ]
Mok 2016 61/76 66/74 98.0 % 0.90 [ 0.78, 1.03 ]
Subtotal (95% CI) 96 94 100.0 % 0.90 [ 0.79, 1.03 ]
Total events: 67 (MMF), 72 (TAC)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.06, df = 1 (P = 0.81); I2 =0.0%
Test for overall effect: Z = 1.49 (P = 0.13)
0.1 0.2 0.5 1 2 5 10
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Analysis 5.3. Comparison 5 Mycophenolate mofetil (MMF) versus tacrolimus (TAC), Outcome 3 Adverse
renal outcomes.
Review: Immunosuppressive treatment for proliferative lupus nephritis
Comparison: 5 Mycophenolate mofetil (MMF) versus tacrolimus (TAC)
Outcome: 3 Adverse renal outcomes
Study or subgroup MMF TAC Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 ESKD
Mok 2016 10/76 8/74 100.0 % 1.22 [ 0.51, 2.91 ]
Subtotal (95% CI) 76 74 100.0 % 1.22 [ 0.51, 2.91 ]
Total events: 10 (MMF), 8 (TAC)
Heterogeneity: not applicable
Test for overall effect: Z = 0.44 (P = 0.66)
2 Renal relapse
Mok 2016 31/76 45/74 100.0 % 0.67 [ 0.48, 0.93 ]
Subtotal (95% CI) 76 74 100.0 % 0.67 [ 0.48, 0.93 ]
Total events: 31 (MMF), 45 (TAC)
Heterogeneity: not applicable
Test for overall effect: Z = 2.39 (P = 0.017)
3 Renal relapse (nephritic flare)
Mok 2016 13/76 19/76 100.0 % 0.68 [ 0.36, 1.28 ]
Subtotal (95% CI) 76 76 100.0 % 0.68 [ 0.36, 1.28 ]
Total events: 13 (MMF), 19 (TAC)
Heterogeneity: not applicable
Test for overall effect: Z = 1.18 (P = 0.24)
4 Renal relapse (proteinuric flare)
Mok 2016 18/76 26/74 100.0 % 0.67 [ 0.41, 1.12 ]
Subtotal (95% CI) 76 74 100.0 % 0.67 [ 0.41, 1.12 ]
Total events: 18 (MMF), 26 (TAC)
Heterogeneity: not applicable
Test for overall effect: Z = 1.52 (P = 0.13)
5 Deterioration in kidney function
Mok 2016 10/76 18/74 100.0 % 0.54 [ 0.27, 1.09 ]
0.1 0.2 0.5 1 2 5 10
Less with MMF Less with TAC
(Continued . . . )
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(. . . Continued)
Study or subgroup MMF TAC Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Subtotal (95% CI) 76 74 100.0 % 0.54 [ 0.27, 1.09 ]
Total events: 10 (MMF), 18 (TAC)
Heterogeneity: not applicable
Test for overall effect: Z = 1.71 (P = 0.087)
Test for subgroup differences: Chi2 = 2.12, df = 4 (P = 0.71), I2 =0.0%
0.1 0.2 0.5 1 2 5 10
Less with MMF Less with TAC
Analysis 5.4. Comparison 5 Mycophenolate mofetil (MMF) versus tacrolimus (TAC), Outcome 4 Stable
kidney function.
Review: Immunosuppressive treatment for proliferative lupus nephritis
Comparison: 5 Mycophenolate mofetil (MMF) versus tacrolimus (TAC)
Outcome: 4 Stable kidney function
Study or subgroup MMF TAC Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Li 2012 9/20 9/20 100.0 % 1.00 [ 0.50, 1.98 ]
Total (95% CI) 20 20 100.0 % 1.00 [ 0.50, 1.98 ]
Total events: 9 (MMF), 9 (TAC)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
Test for subgroup differences: Not applicable
0.2 0.5 1 2 5
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Analysis 5.5. Comparison 5 Mycophenolate mofetil (MMF) versus tacrolimus (TAC), Outcome 5 Menstrual
irregularities.
Review: Immunosuppressive treatment for proliferative lupus nephritis
Comparison: 5 Mycophenolate mofetil (MMF) versus tacrolimus (TAC)
Outcome: 5 Menstrual irregularities
Study or subgroup MMF TAC Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Li 2012 1/20 0/20 100.0 % 3.00 [ 0.13, 69.52 ]
Total (95% CI) 20 20 100.0 % 3.00 [ 0.13, 69.52 ]
Total events: 1 (MMF), 0 (TAC)
Heterogeneity: not applicable
Test for overall effect: Z = 0.69 (P = 0.49)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Less with MMF Less with TAC
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Analysis 5.6. Comparison 5 Mycophenolate mofetil (MMF) versus tacrolimus (TAC), Outcome 6 Infection.
Review: Immunosuppressive treatment for proliferative lupus nephritis
Comparison: 5 Mycophenolate mofetil (MMF) versus tacrolimus (TAC)
Outcome: 6 Infection
Study or subgroup MMF TAC Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Major infection
Mok 2016 7/76 4/74 49.5 % 1.70 [ 0.52, 5.58 ]
Li 2012 8/20 3/20 50.5 % 2.67 [ 0.82, 8.62 ]
Subtotal (95% CI) 96 94 100.0 % 2.14 [ 0.93, 4.92 ]
Total events: 15 (MMF), 7 (TAC)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.28, df = 1 (P = 0.60); I2 =0.0%
Test for overall effect: Z = 1.78 (P = 0.074)
2 Herpes zoster virus
Mok 2016 14/76 2/74 100.0 % 6.82 [ 1.60, 28.96 ]
Subtotal (95% CI) 76 74 100.0 % 6.82 [ 1.60, 28.96 ]
Total events: 14 (MMF), 2 (TAC)
Heterogeneity: not applicable
Test for overall effect: Z = 2.60 (P = 0.0093)
Test for subgroup differences: Chi2 = 1.85, df = 1 (P = 0.17), I2 =46%
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Analysis 5.7. Comparison 5 Mycophenolate mofetil (MMF) versus tacrolimus (TAC), Outcome 7
Leucopenia.
Review: Immunosuppressive treatment for proliferative lupus nephritis
Comparison: 5 Mycophenolate mofetil (MMF) versus tacrolimus (TAC)
Outcome: 7 Leucopenia
Study or subgroup MMF TAC Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Li 2012 1/20 1/20 100.0 % 1.00 [ 0.07, 14.90 ]
Total (95% CI) 20 20 100.0 % 1.00 [ 0.07, 14.90 ]
Total events: 1 (MMF), 1 (TAC)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Less with MMF Less with TAC
Analysis 5.8. Comparison 5 Mycophenolate mofetil (MMF) versus tacrolimus (TAC), Outcome 8 Alopecia.
Review: Immunosuppressive treatment for proliferative lupus nephritis
Comparison: 5 Mycophenolate mofetil (MMF) versus tacrolimus (TAC)
Outcome: 8 Alopecia
Study or subgroup MMF TAC Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Mok 2016 0/76 6/74 100.0 % 0.07 [ 0.00, 1.31 ]
Total (95% CI) 76 74 100.0 % 0.07 [ 0.00, 1.31 ]
Total events: 0 (MMF), 6 (TAC)
Heterogeneity: not applicable
Test for overall effect: Z = 1.78 (P = 0.076)
Test for subgroup differences: Not applicable
0.002 0.1 1 10 500
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Analysis 5.9. Comparison 5 Mycophenolate mofetil (MMF) versus tacrolimus (TAC), Outcome 9 Daily
proteinuria (at 24 weeks).
Review: Immunosuppressive treatment for proliferative lupus nephritis
Comparison: 5 Mycophenolate mofetil (MMF) versus tacrolimus (TAC)
Outcome: 9 Daily proteinuria (at 24 weeks)
Study or subgroup MMF TAC
Mean
Difference Weight
Mean
Difference
N Mean(SD)[g/24 h] N Mean(SD)[g/24 h] IV,Random,95% CI IV,Random,95% CI
Mok 2016 76 1.23 (1.3) 74 1.05 (1.4) 100.0 % 0.18 [ -0.25, 0.61 ]
Total (95% CI) 76 74 100.0 % 0.18 [ -0.25, 0.61 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.82 (P = 0.41)
Test for subgroup differences: Not applicable
-1 -0.5 0 0.5 1
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Analysis 5.10. Comparison 5 Mycophenolate mofetil (MMF) versus tacrolimus (TAC), Outcome 10 Disease
activity.
Review: Immunosuppressive treatment for proliferative lupus nephritis
Comparison: 5 Mycophenolate mofetil (MMF) versus tacrolimus (TAC)
Outcome: 10 Disease activity
Study or subgroup MMF TAC
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Renal SLEDAI
Kamanamool 2017 42 3.9 (3.8) 41 5.2 (4.3) 42.5 % -1.30 [ -3.05, 0.45 ]
Mok 2016 76 3.9 (3.1) 74 3.3 (3.1) 57.5 % 0.60 [ -0.39, 1.59 ]
Subtotal (95% CI) 118 115 100.0 % -0.21 [ -2.05, 1.63 ]
Heterogeneity: Tau2 = 1.28; Chi2 = 3.43, df = 1 (P = 0.06); I2 =71%
Test for overall effect: Z = 0.22 (P = 0.82)
2 Extrarenal SLEDAI
Kamanamool 2017 42 1.5 (1.6) 41 1.9 (2.4) 30.1 % -0.40 [ -1.28, 0.48 ]
Mok 2016 76 1.7 (1.9) 74 1.9 (1.7) 69.9 % -0.20 [ -0.78, 0.38 ]
Subtotal (95% CI) 118 115 100.0 % -0.26 [ -0.74, 0.22 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.14, df = 1 (P = 0.71); I2 =0.0%
Test for overall effect: Z = 1.06 (P = 0.29)
Test for subgroup differences: Chi2 = 0.00, df = 1 (P = 0.96), I2 =0.0%
-4 -2 0 2 4
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Analysis 5.11. Comparison 5 Mycophenolate mofetil (MMF) versus tacrolimus (TAC), Outcome 11 Serum
creatinine.
Review: Immunosuppressive treatment for proliferative lupus nephritis
Comparison: 5 Mycophenolate mofetil (MMF) versus tacrolimus (TAC)
Outcome: 11 Serum creatinine
Study or subgroup MMF TAC
Mean
Difference Weight
Mean
Difference
N
Mean(SD)[
mol/L] N
Mean(SD)[
mol/L] IV,Random,95% CI IV,Random,95% CI
Kamanamool 2017 42 0.85 (0.32) 41 0.86 (0.37) 100.0 % -0.01 [ -0.16, 0.14 ]
Total (95% CI) 42 41 100.0 % -0.01 [ -0.16, 0.14 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.13 (P = 0.90)
Test for subgroup differences: Not applicable
-1 -0.5 0 0.5 1
Lower with MMF Lower with TAC
Analysis 5.12. Comparison 5 Mycophenolate mofetil (MMF) versus tacrolimus (TAC), Outcome 12
Creatinine clearance.
Review: Immunosuppressive treatment for proliferative lupus nephritis
Comparison: 5 Mycophenolate mofetil (MMF) versus tacrolimus (TAC)
Outcome: 12 Creatinine clearance
Study or subgroup MMF TAC
Mean
Difference Weight
Mean
Difference
N Mean(SD)[mL/min] N Mean(SD)[mL/min] IV,Random,95% CI IV,Random,95% CI
Mendonca 2017 17 91.4 (9.6) 23 93.33 (8.9) 100.0 % -1.93 [ -7.77, 3.91 ]
Total (95% CI) 17 23 100.0 % -1.93 [ -7.77, 3.91 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.65 (P = 0.52)
Test for subgroup differences: Not applicable
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Analysis 6.1. Comparison 6 Calcineurin inhibitors (CNI) versus IV cyclophosphamide (CPA), Outcome 1
Death.
Review: Immunosuppressive treatment for proliferative lupus nephritis
Comparison: 6 Calcineurin inhibitors (CNI) versus IV cyclophosphamide (CPA)
Outcome: 1 Death
Study or subgroup CNI IV CPA Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Death
CYCLOFA-LUNE 2010 0/19 0/21 Not estimable
Chen 2011 0/39 1/34 34.9 % 0.29 [ 0.01, 6.93 ]
Li 2012 1/20 2/20 65.1 % 0.50 [ 0.05, 5.08 ]
Subtotal (95% CI) 78 75 100.0 % 0.41 [ 0.06, 2.69 ]
Total events: 1 (CNI), 3 (IV CPA)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.07, df = 1 (P = 0.79); I2 =0.0%
Test for overall effect: Z = 0.92 (P = 0.36)
2 Death: extended follow-up
CYCLOFA-LUNE 2010 0/19 0/19 Not estimable
Subtotal (95% CI) 19 19 Not estimable
Total events: 0 (CNI), 0 (IV CPA)
Heterogeneity: not applicable
Test for overall effect: not applicable
Test for subgroup differences: Not applicable
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Analysis 6.2. Comparison 6 Calcineurin inhibitors (CNI) versus IV cyclophosphamide (CPA), Outcome 2
Remission.
Review: Immunosuppressive treatment for proliferative lupus nephritis
Comparison: 6 Calcineurin inhibitors (CNI) versus IV cyclophosphamide (CPA)
Outcome: 2 Remission
Study or subgroup CNI IV CPA Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Complete renal remission
Hong 2007 6/13 3/12 10.0 % 1.85 [ 0.59, 5.79 ]
CYCLOFA-LUNE 2010 5/19 5/21 11.3 % 1.11 [ 0.38, 3.23 ]
Li 2012 9/20 6/20 19.1 % 1.50 [ 0.66, 3.43 ]
Chen 2011 22/39 15/34 59.5 % 1.28 [ 0.80, 2.04 ]
Subtotal (95% CI) 91 87 100.0 % 1.35 [ 0.94, 1.93 ]
Total events: 42 (CNI), 29 (IV CPA)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.54, df = 3 (P = 0.91); I2 =0.0%
Test for overall effect: Z = 1.61 (P = 0.11)
2 Partial renal remission
Hong 2007 4/13 2/12 5.7 % 1.85 [ 0.41, 8.32 ]
Li 2012 6/20 6/20 14.4 % 1.00 [ 0.39, 2.58 ]
CYCLOFA-LUNE 2010 8/19 11/21 29.1 % 0.80 [ 0.41, 1.57 ]
Chen 2011 16/39 17/34 50.8 % 0.82 [ 0.50, 1.36 ]
Subtotal (95% CI) 91 87 100.0 % 0.88 [ 0.61, 1.26 ]
Total events: 34 (CNI), 36 (IV CPA)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.17, df = 3 (P = 0.76); I2 =0.0%
Test for overall effect: Z = 0.70 (P = 0.48)
3 Complete remission in proteinuria
Hong 2007 6/13 3/12 16.0 % 1.85 [ 0.59, 5.79 ]
Li 2012 9/20 6/20 30.6 % 1.50 [ 0.66, 3.43 ]
CYCLOFA-LUNE 2010 13/19 8/21 53.4 % 1.80 [ 0.96, 3.36 ]
Subtotal (95% CI) 52 53 100.0 % 1.71 [ 1.08, 2.70 ]
Total events: 28 (CNI), 17 (IV CPA)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.14, df = 2 (P = 0.93); I2 =0.0%
Test for overall effect: Z = 2.29 (P = 0.022)
Test for subgroup differences: Chi2 = 5.55, df = 2 (P = 0.06), I2 =64%
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Analysis 6.3. Comparison 6 Calcineurin inhibitors (CNI) versus IV cyclophosphamide (CPA), Outcome 3
Adverse renal outcomes.
Review: Immunosuppressive treatment for proliferative lupus nephritis
Comparison: 6 Calcineurin inhibitors (CNI) versus IV cyclophosphamide (CPA)
Outcome: 3 Adverse renal outcomes
Study or subgroup CNI IV CPA Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 ESKD: extended follow-up
CYCLOFA-LUNE 2010 1/19 1/19 100.0 % 1.00 [ 0.07, 14.85 ]
Subtotal (95% CI) 19 19 100.0 % 1.00 [ 0.07, 14.85 ]
Total events: 1 (CNI), 1 (IV CPA)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
2 Doubling of serum creatinine
Li 2012 0/20 1/20 100.0 % 0.33 [ 0.01, 7.72 ]
Subtotal (95% CI) 20 20 100.0 % 0.33 [ 0.01, 7.72 ]
Total events: 0 (CNI), 1 (IV CPA)
Heterogeneity: not applicable
Test for overall effect: Z = 0.69 (P = 0.49)
3 Doubling of serum creatinine: extended follow-up
CYCLOFA-LUNE 2010 2/19 2/19 100.0 % 1.00 [ 0.16, 6.38 ]
Subtotal (95% CI) 19 19 100.0 % 1.00 [ 0.16, 6.38 ]
Total events: 2 (CNI), 2 (IV CPA)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
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Analysis 6.4. Comparison 6 Calcineurin inhibitors (CNI) versus IV cyclophosphamide (CPA), Outcome 4
Stable kidney function.
Review: Immunosuppressive treatment for proliferative lupus nephritis
Comparison: 6 Calcineurin inhibitors (CNI) versus IV cyclophosphamide (CPA)
Outcome: 4 Stable kidney function
Study or subgroup CNI IV CPA Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Hong 2007 6/13 3/12 16.0 % 1.85 [ 0.59, 5.79 ]
Li 2012 9/20 6/20 22.3 % 1.50 [ 0.66, 3.43 ]
CYCLOFA-LUNE 2010 9/19 18/21 30.7 % 0.55 [ 0.33, 0.92 ]
Chen 2011 22/42 15/39 31.0 % 1.36 [ 0.83, 2.22 ]
Total (95% CI) 94 92 100.0 % 1.11 [ 0.61, 2.00 ]
Total events: 46 (CNI), 42 (IV CPA)
Heterogeneity: Tau2 = 0.23; Chi2 = 9.11, df = 3 (P = 0.03); I2 =67%
Test for overall effect: Z = 0.34 (P = 0.73)
Test for subgroup differences: Not applicable
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Analysis 6.5. Comparison 6 Calcineurin inhibitors (CNI) versus IV cyclophosphamide (CPA), Outcome 5
Ovarian failure.
Review: Immunosuppressive treatment for proliferative lupus nephritis
Comparison: 6 Calcineurin inhibitors (CNI) versus IV cyclophosphamide (CPA)
Outcome: 5 Ovarian failure
Study or subgroup CNI IV CPA Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Ovarian failure
CYCLOFA-LUNE 2010 0/19 1/21 47.7 % 0.37 [ 0.02, 8.50 ]
Chen 2011 0/39 2/34 52.3 % 0.18 [ 0.01, 3.52 ]
Subtotal (95% CI) 58 55 100.0 % 0.25 [ 0.03, 2.18 ]
Total events: 0 (CNI), 3 (IV CPA)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.11, df = 1 (P = 0.74); I2 =0.0%
Test for overall effect: Z = 1.25 (P = 0.21)
2 Premature ovarian failure: extended follow-up
CYCLOFA-LUNE 2010 0/14 1/13 100.0 % 0.31 [ 0.01, 7.02 ]
Subtotal (95% CI) 14 13 100.0 % 0.31 [ 0.01, 7.02 ]
Total events: 0 (CNI), 1 (IV CPA)
Heterogeneity: not applicable
Test for overall effect: Z = 0.73 (P = 0.46)
Test for subgroup differences: Chi2 = 0.01, df = 1 (P = 0.91), I2 =0.0%
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Analysis 6.6. Comparison 6 Calcineurin inhibitors (CNI) versus IV cyclophosphamide (CPA), Outcome 6
Menstrual irregularities.
Review: Immunosuppressive treatment for proliferative lupus nephritis
Comparison: 6 Calcineurin inhibitors (CNI) versus IV cyclophosphamide (CPA)
Outcome: 6 Menstrual irregularities
Study or subgroup CNI IV CPA Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Li 2012 0/20 4/20 33.9 % 0.11 [ 0.01, 1.94 ]
El-Sehemy 2006 4/7 5/7 66.1 % 0.80 [ 0.36, 1.77 ]
Total (95% CI) 27 27 100.0 % 0.41 [ 0.04, 4.05 ]
Total events: 4 (CNI), 9 (IV CPA)
Heterogeneity: Tau2 = 1.90; Chi2 = 2.66, df = 1 (P = 0.10); I2 =62%
Test for overall effect: Z = 0.76 (P = 0.45)
Test for subgroup differences: Not applicable
0.005 0.1 1 10 200
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Analysis 6.7. Comparison 6 Calcineurin inhibitors (CNI) versus IV cyclophosphamide (CPA), Outcome 7
Infection.
Review: Immunosuppressive treatment for proliferative lupus nephritis
Comparison: 6 Calcineurin inhibitors (CNI) versus IV cyclophosphamide (CPA)
Outcome: 7 Infection
Study or subgroup CNI IV CPA Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Major infection
Hong 2007 1/13 1/12 8.9 % 0.92 [ 0.06, 13.18 ]
Li 2012 3/20 8/20 41.2 % 0.38 [ 0.12, 1.21 ]
Chen 2011 7/39 5/34 49.9 % 1.22 [ 0.43, 3.49 ]
Subtotal (95% CI) 72 66 100.0 % 0.73 [ 0.33, 1.63 ]
Total events: 11 (CNI), 14 (IV CPA)
Heterogeneity: Tau2 = 0.05; Chi2 = 2.19, df = 2 (P = 0.34); I2 =9%
Test for overall effect: Z = 0.76 (P = 0.45)
2 Herpes zoster virus
CYCLOFA-LUNE 2010 1/19 2/21 31.5 % 0.55 [ 0.05, 5.62 ]
Chen 2011 5/39 2/34 68.5 % 2.18 [ 0.45, 10.52 ]
Subtotal (95% CI) 58 55 100.0 % 1.41 [ 0.38, 5.20 ]
Total events: 6 (CNI), 4 (IV CPA)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.92, df = 1 (P = 0.34); I2 =0.0%
Test for overall effect: Z = 0.52 (P = 0.60)
Test for subgroup differences: Chi2 = 0.71, df = 1 (P = 0.40), I2 =0.0%
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Analysis 6.8. Comparison 6 Calcineurin inhibitors (CNI) versus IV cyclophosphamide (CPA), Outcome 8
Malignancy: extended follow-up.
Review: Immunosuppressive treatment for proliferative lupus nephritis
Comparison: 6 Calcineurin inhibitors (CNI) versus IV cyclophosphamide (CPA)
Outcome: 8 Malignancy: extended follow-up
Study or subgroup CNI IV CPA Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
CYCLOFA-LUNE 2010 2/19 0/19 100.0 % 5.00 [ 0.26, 97.70 ]
Total (95% CI) 19 19 100.0 % 5.00 [ 0.26, 97.70 ]
Total events: 2 (CNI), 0 (IV CPA)
Heterogeneity: not applicable
Test for overall effect: Z = 1.06 (P = 0.29)
Test for subgroup differences: Not applicable
0.005 0.1 1 10 200
Less with CNI Less with CPA
Analysis 6.9. Comparison 6 Calcineurin inhibitors (CNI) versus IV cyclophosphamide (CPA), Outcome 9
Leucopenia.
Review: Immunosuppressive treatment for proliferative lupus nephritis
Comparison: 6 Calcineurin inhibitors (CNI) versus IV cyclophosphamide (CPA)
Outcome: 9 Leucopenia
Study or subgroup CNI IV CPA Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Chen 2011 0/39 5/34 18.5 % 0.08 [ 0.00, 1.39 ]
Li 2012 1/20 1/20 20.8 % 1.00 [ 0.07, 14.90 ]
CYCLOFA-LUNE 2010 2/19 4/21 60.7 % 0.55 [ 0.11, 2.68 ]
Total (95% CI) 78 75 100.0 % 0.44 [ 0.13, 1.49 ]
Total events: 3 (CNI), 10 (IV CPA)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.99, df = 2 (P = 0.37); I2 =0.0%
Test for overall effect: Z = 1.32 (P = 0.19)
Test for subgroup differences: Not applicable
0.002 0.1 1 10 500
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Analysis 6.10. Comparison 6 Calcineurin inhibitors (CNI) versus IV cyclophosphamide (CPA), Outcome 10
Alopecia.
Review: Immunosuppressive treatment for proliferative lupus nephritis
Comparison: 6 Calcineurin inhibitors (CNI) versus IV cyclophosphamide (CPA)
Outcome: 10 Alopecia
Study or subgroup CNI IV CPA Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
CYCLOFA-LUNE 2010 0/19 1/21 46.5 % 0.37 [ 0.02, 8.50 ]
Chen 2011 0/39 3/34 53.5 % 0.13 [ 0.01, 2.34 ]
Total (95% CI) 58 55 100.0 % 0.21 [ 0.02, 1.76 ]
Total events: 0 (CNI), 4 (IV CPA)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.25, df = 1 (P = 0.62); I2 =0.0%
Test for overall effect: Z = 1.44 (P = 0.15)
Test for subgroup differences: Not applicable
0.005 0.1 1 10 200
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Analysis 6.11. Comparison 6 Calcineurin inhibitors (CNI) versus IV cyclophosphamide (CPA), Outcome 11
Gastrointestinal (GI) adverse events.
Review: Immunosuppressive treatment for proliferative lupus nephritis
Comparison: 6 Calcineurin inhibitors (CNI) versus IV cyclophosphamide (CPA)
Outcome: 11 Gastrointestinal (GI) adverse events
Study or subgroup CNI IV CPA Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Chen 2011 4/39 10/34 100.0 % 0.35 [ 0.12, 1.01 ]
Total (95% CI) 39 34 100.0 % 0.35 [ 0.12, 1.01 ]
Total events: 4 (CNI), 10 (IV CPA)
Heterogeneity: not applicable
Test for overall effect: Z = 1.94 (P = 0.052)
Test for subgroup differences: Not applicable
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Analysis 6.12. Comparison 6 Calcineurin inhibitors (CNI) versus IV cyclophosphamide (CPA), Outcome 12
Daily proteinuria.
Review: Immunosuppressive treatment for proliferative lupus nephritis
Comparison: 6 Calcineurin inhibitors (CNI) versus IV cyclophosphamide (CPA)
Outcome: 12 Daily proteinuria
Study or subgroup CNI IV CPA
Mean
Difference Weight
Mean
Difference
N Mean(SD)[g/24 h] N Mean(SD)[g/24 h] IV,Random,95% CI IV,Random,95% CI
1 At 9 months
CYCLOFA-LUNE 2010 19 0.2 (0.19) 21 1.03 (1.24) 19.9 % -0.83 [ -1.37, -0.29 ]
Subtotal (95% CI) 19 21 19.9 % -0.83 [ -1.37, -0.29 ]
Heterogeneity: not applicable
Test for overall effect: Z = 3.03 (P = 0.0025)
2 At 12 months
Fu 1997 18 0.35 (0.29) 20 0.62 (0.21) 46.4 % -0.27 [ -0.43, -0.11 ]
Subtotal (95% CI) 18 20 46.4 % -0.27 [ -0.43, -0.11 ]
Heterogeneity: not applicable
Test for overall effect: Z = 3.26 (P = 0.0011)
3 At 18 months
CYCLOFA-LUNE 2010 19 0.41 (0.89) 21 1.41 (2.8) 5.2 % -1.00 [ -2.26, 0.26 ]
Subtotal (95% CI) 19 21 5.2 % -1.00 [ -2.26, 0.26 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.55 (P = 0.12)
4 Extended follow-up
CYCLOFA-LUNE 2010 19 0.4 (0.7) 19 0.5 (0.5) 28.5 % -0.10 [ -0.49, 0.29 ]
Subtotal (95% CI) 19 19 28.5 % -0.10 [ -0.49, 0.29 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.51 (P = 0.61)
Total (95% CI) 75 81 100.0 % -0.37 [ -0.67, -0.07 ]
Heterogeneity: Tau2 = 0.04; Chi2 = 6.07, df = 3 (P = 0.11); I2 =51%
Test for overall effect: Z = 2.40 (P = 0.016)
Test for subgroup differences: Chi2 = 6.07, df = 3 (P = 0.11), I2 =51%
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Analysis 6.13. Comparison 6 Calcineurin inhibitors (CNI) versus IV cyclophosphamide (CPA), Outcome 13
Creatinine clearance.
Review: Immunosuppressive treatment for proliferative lupus nephritis
Comparison: 6 Calcineurin inhibitors (CNI) versus IV cyclophosphamide (CPA)
Outcome: 13 Creatinine clearance
Study or subgroup CNI IV CPA
Mean
Difference Weight
Mean
Difference
N Mean(SD)[mL/min] N Mean(SD)[mL/min] IV,Random,95% CI IV,Random,95% CI
1 At 6 months
Mok 2016 76 91.4 (31) 74 79.7 (32) 100.0 % 11.70 [ 1.61, 21.79 ]
Subtotal (95% CI) 76 74 100.0 % 11.70 [ 1.61, 21.79 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.27 (P = 0.023)
2 At 9 months
CYCLOFA-LUNE 2010 19 94.5 (23.6) 21 79.6 (19.7) 100.0 % 14.90 [ 1.35, 28.45 ]
Subtotal (95% CI) 19 21 100.0 % 14.90 [ 1.35, 28.45 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.16 (P = 0.031)
3 At 12 months
Fu 1997 18 104.6 (16.8) 20 120.3 (4.5) 100.0 % -15.70 [ -23.71, -7.69 ]
Subtotal (95% CI) 18 20 100.0 % -15.70 [ -23.71, -7.69 ]
Heterogeneity: not applicable
Test for overall effect: Z = 3.84 (P = 0.00012)
4 At 18 months
CYCLOFA-LUNE 2010 19 84.2 (28.3) 21 85.6 (22.1) 100.0 % -1.40 [ -17.25, 14.45 ]
Subtotal (95% CI) 19 21 100.0 % -1.40 [ -17.25, 14.45 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.17 (P = 0.86)
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Analysis 6.14. Comparison 6 Calcineurin inhibitors (CNI) versus IV cyclophosphamide (CPA), Outcome 14
Serum creatinine.
Review: Immunosuppressive treatment for proliferative lupus nephritis
Comparison: 6 Calcineurin inhibitors (CNI) versus IV cyclophosphamide (CPA)
Outcome: 14 Serum creatinine
Study or subgroup CNI IV CPA
Mean
Difference Weight
Mean
Difference
N
Mean(SD)[
mol/L] N
Mean(SD)[
mol/L] IV,Random,95% CI IV,Random,95% CI
1 At 9 months
CYCLOFA-LUNE 2010 19 88.2 (20.1) 21 75.5 (13.9) 100.0 % 12.70 [ 1.88, 23.52 ]
Subtotal (95% CI) 19 21 100.0 % 12.70 [ 1.88, 23.52 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.30 (P = 0.021)
2 At 18 months
CYCLOFA-LUNE 2010 19 86.7 (24) 21 84 (21.57) 100.0 % 2.70 [ -11.50, 16.90 ]
Subtotal (95% CI) 19 21 100.0 % 2.70 [ -11.50, 16.90 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.37 (P = 0.71)
3 Extended follow-up
CYCLOFA-LUNE 2010 19 63 (15) 19 71 (23) 100.0 % -8.00 [ -20.35, 4.35 ]
Subtotal (95% CI) 19 19 100.0 % -8.00 [ -20.35, 4.35 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.27 (P = 0.20)
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Analysis 7.1. Comparison 7 Cyclophosphamide (CPA) versus azathioprine (AZA), Outcome 1 Death.
Review: Immunosuppressive treatment for proliferative lupus nephritis
Comparison: 7 Cyclophosphamide (CPA) versus azathioprine (AZA)
Outcome: 1 Death
Study or subgroup CPA AZA Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 At 5 years
Grootscholten 2006 2/50 3/37 41.6 % 0.49 [ 0.09, 2.81 ]
Dyadyk 2001 (1) 8/21 5/38 58.4 % 2.90 [ 1.08, 7.73 ]
Subtotal (95% CI) 71 75 100.0 % 1.39 [ 0.25, 7.77 ]
Total events: 10 (CPA), 8 (AZA)
Heterogeneity: Tau2 = 1.07; Chi2 = 3.07, df = 1 (P = 0.08); I2 =67%
Test for overall effect: Z = 0.37 (P = 0.71)
2 At 10 years
Dyadyk 2001 (2) 16/21 15/38 100.0 % 1.93 [ 1.22, 3.06 ]
Subtotal (95% CI) 21 38 100.0 % 1.93 [ 1.22, 3.06 ]
Total events: 16 (CPA), 15 (AZA)
Heterogeneity: not applicable
Test for overall effect: Z = 2.80 (P = 0.0051)
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Analysis 7.2. Comparison 7 Cyclophosphamide (CPA) versus azathioprine (AZA), Outcome 2 Remission in
proteinuria.
Review: Immunosuppressive treatment for proliferative lupus nephritis
Comparison: 7 Cyclophosphamide (CPA) versus azathioprine (AZA)
Outcome: 2 Remission in proteinuria
Study or subgroup CPA AZA Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Complete remission
Dyadyk 2001 11/38 3/21 100.0 % 2.03 [ 0.64, 6.46 ]
Subtotal (95% CI) 38 21 100.0 % 2.03 [ 0.64, 6.46 ]
Total events: 11 (CPA), 3 (AZA)
Heterogeneity: not applicable
Test for overall effect: Z = 1.19 (P = 0.23)
2 Partial remission
Dyadyk 2001 13/38 4/21 100.0 % 1.80 [ 0.67, 4.81 ]
Subtotal (95% CI) 38 21 100.0 % 1.80 [ 0.67, 4.81 ]
Total events: 13 (CPA), 4 (AZA)
Heterogeneity: not applicable
Test for overall effect: Z = 1.16 (P = 0.24)
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Analysis 7.3. Comparison 7 Cyclophosphamide (CPA) versus azathioprine (AZA), Outcome 3 Adverse
renal outcomes.
Review: Immunosuppressive treatment for proliferative lupus nephritis
Comparison: 7 Cyclophosphamide (CPA) versus azathioprine (AZA)
Outcome: 3 Adverse renal outcomes
Study or subgroup CPA AZA Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 ESKD
Grootscholten 2006 0/50 1/37 9.9 % 0.25 [ 0.01, 5.93 ]
Decker 1975 5/38 6/19 90.1 % 0.42 [ 0.15, 1.19 ]
Subtotal (95% CI) 88 56 100.0 % 0.40 [ 0.15, 1.07 ]
Total events: 5 (CPA), 7 (AZA)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.09, df = 1 (P = 0.76); I2 =0.0%
Test for overall effect: Z = 1.82 (P = 0.069)
2 ESKD at 9.6 years (median)
Grootscholten 2006 2/50 2/50 100.0 % 1.00 [ 0.15, 6.82 ]
Subtotal (95% CI) 50 50 100.0 % 1.00 [ 0.15, 6.82 ]
Total events: 2 (CPA), 2 (AZA)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
3 Renal relapse
Grootscholten 2006 2/50 10/37 100.0 % 0.15 [ 0.03, 0.64 ]
Subtotal (95% CI) 50 37 100.0 % 0.15 [ 0.03, 0.64 ]
Total events: 2 (CPA), 10 (AZA)
Heterogeneity: not applicable
Test for overall effect: Z = 2.57 (P = 0.010)
4 Renal relapse at 9.6 years (median)
Grootscholten 2006 5/50 14/37 100.0 % 0.26 [ 0.10, 0.67 ]
Subtotal (95% CI) 50 37 100.0 % 0.26 [ 0.10, 0.67 ]
Total events: 5 (CPA), 14 (AZA)
Heterogeneity: not applicable
Test for overall effect: Z = 2.81 (P = 0.0050)
5 Doubling of serum creatinine
Grootscholten 2006 2/50 6/37 20.2 % 0.25 [ 0.05, 1.15 ]
Decker 1975 9/38 8/19 79.8 % 0.56 [ 0.26, 1.22 ]
Subtotal (95% CI) 88 56 100.0 % 0.48 [ 0.24, 0.95 ]
Total events: 11 (CPA), 14 (AZA)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.93, df = 1 (P = 0.34); I2 =0.0%
Test for overall effect: Z = 2.10 (P = 0.036)
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(. . . Continued)
Study or subgroup CPA AZA Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
6 Deterioration of kidney function
Decker 1975 4/20 3/10 100.0 % 0.67 [ 0.18, 2.42 ]
Subtotal (95% CI) 20 10 100.0 % 0.67 [ 0.18, 2.42 ]
Total events: 4 (CPA), 3 (AZA)
Heterogeneity: not applicable
Test for overall effect: Z = 0.62 (P = 0.54)
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Analysis 7.4. Comparison 7 Cyclophosphamide (CPA) versus azathioprine (AZA), Outcome 4 Stable kidney
function.
Review: Immunosuppressive treatment for proliferative lupus nephritis
Comparison: 7 Cyclophosphamide (CPA) versus azathioprine (AZA)
Outcome: 4 Stable kidney function
Study or subgroup CPA AZA Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Decker 1975 29/38 11/19 100.0 % 1.32 [ 0.86, 2.01 ]
Total (95% CI) 38 19 100.0 % 1.32 [ 0.86, 2.01 ]
Total events: 29 (CPA), 11 (AZA)
Heterogeneity: not applicable
Test for overall effect: Z = 1.28 (P = 0.20)
Test for subgroup differences: Not applicable
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Analysis 7.5. Comparison 7 Cyclophosphamide (CPA) versus azathioprine (AZA), Outcome 5 Ovarian
failure.
Review: Immunosuppressive treatment for proliferative lupus nephritis
Comparison: 7 Cyclophosphamide (CPA) versus azathioprine (AZA)
Outcome: 5 Ovarian failure
Study or subgroup CPA AZA Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Grootscholten 2006 2/44 2/37 33.1 % 0.84 [ 0.12, 5.68 ]
Decker 1975 15/27 3/18 66.9 % 3.33 [ 1.12, 9.88 ]
Total (95% CI) 71 55 100.0 % 2.11 [ 0.59, 7.53 ]
Total events: 17 (CPA), 5 (AZA)
Heterogeneity: Tau2 = 0.32; Chi2 = 1.51, df = 1 (P = 0.22); I2 =34%
Test for overall effect: Z = 1.16 (P = 0.25)
Test for subgroup differences: Not applicable
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Analysis 7.6. Comparison 7 Cyclophosphamide (CPA) versus azathioprine (AZA), Outcome 6 Menstrual
irregularities.
Review: Immunosuppressive treatment for proliferative lupus nephritis
Comparison: 7 Cyclophosphamide (CPA) versus azathioprine (AZA)
Outcome: 6 Menstrual irregularities
Study or subgroup CPA AZA Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
El-Sehemy 2006 5/7 3/8 100.0 % 1.90 [ 0.69, 5.23 ]
Total (95% CI) 7 8 100.0 % 1.90 [ 0.69, 5.23 ]
Total events: 5 (CPA), 3 (AZA)
Heterogeneity: not applicable
Test for overall effect: Z = 1.25 (P = 0.21)
Test for subgroup differences: Not applicable
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Analysis 7.7. Comparison 7 Cyclophosphamide (CPA) versus azathioprine (AZA), Outcome 7 Infection.
Review: Immunosuppressive treatment for proliferative lupus nephritis
Comparison: 7 Cyclophosphamide (CPA) versus azathioprine (AZA)
Outcome: 7 Infection
Study or subgroup CPA AZA Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Major infection
Decker 1975 5/38 2/19 100.0 % 1.25 [ 0.27, 5.86 ]
Subtotal (95% CI) 38 19 100.0 % 1.25 [ 0.27, 5.86 ]
Total events: 5 (CPA), 2 (AZA)
Heterogeneity: not applicable
Test for overall effect: Z = 0.28 (P = 0.78)
2 Herpes zoster virus
Decker 1975 11/38 2/19 100.0 % 2.75 [ 0.68, 11.18 ]
Subtotal (95% CI) 38 19 100.0 % 2.75 [ 0.68, 11.18 ]
Total events: 11 (CPA), 2 (AZA)
Heterogeneity: not applicable
Test for overall effect: Z = 1.41 (P = 0.16)
Test for subgroup differences: Chi2 = 0.55, df = 1 (P = 0.46), I2 =0.0%
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Analysis 7.8. Comparison 7 Cyclophosphamide (CPA) versus azathioprine (AZA), Outcome 8 Malignancy.
Review: Immunosuppressive treatment for proliferative lupus nephritis
Comparison: 7 Cyclophosphamide (CPA) versus azathioprine (AZA)
Outcome: 8 Malignancy
Study or subgroup CPA AZA Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 CPA versus AZA
Grootscholten 2006 0/50 1/37 22.4 % 0.25 [ 0.01, 5.93 ]
Decker 1975 3/38 2/19 77.6 % 0.75 [ 0.14, 4.12 ]
Subtotal (95% CI) 88 56 100.0 % 0.59 [ 0.13, 2.63 ]
Total events: 3 (CPA), 3 (AZA)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.37, df = 1 (P = 0.54); I2 =0.0%
Test for overall effect: Z = 0.70 (P = 0.48)
2 10 year follow-up
Grootscholten 2006 2/50 2/37 100.0 % 0.74 [ 0.11, 5.01 ]
Subtotal (95% CI) 50 37 100.0 % 0.74 [ 0.11, 5.01 ]
Total events: 2 (CPA), 2 (AZA)
Heterogeneity: not applicable
Test for overall effect: Z = 0.31 (P = 0.76)
Test for subgroup differences: Chi2 = 0.04, df = 1 (P = 0.85), I2 =0.0%
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Analysis 7.9. Comparison 7 Cyclophosphamide (CPA) versus azathioprine (AZA), Outcome 9 Bone toxicity.
Review: Immunosuppressive treatment for proliferative lupus nephritis
Comparison: 7 Cyclophosphamide (CPA) versus azathioprine (AZA)
Outcome: 9 Bone toxicity
Study or subgroup CPA AZA Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Grootscholten 2006 0/50 0/37 Not estimable
Total (95% CI) 50 37 Not estimable
Total events: 0 (CPA), 0 (AZA)
Heterogeneity: not applicable
Test for overall effect: not applicable
Test for subgroup differences: Not applicable
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Analysis 7.10. Comparison 7 Cyclophosphamide (CPA) versus azathioprine (AZA), Outcome 10 Bladder
toxicity.
Review: Immunosuppressive treatment for proliferative lupus nephritis
Comparison: 7 Cyclophosphamide (CPA) versus azathioprine (AZA)
Outcome: 10 Bladder toxicity
Study or subgroup CPA AZA Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Grootscholten 2006 0/50 0/37 Not estimable
Decker 1975 3/38 0/19 100.0 % 3.59 [ 0.19, 66.14 ]
Total (95% CI) 88 56 100.0 % 3.59 [ 0.19, 66.14 ]
Total events: 3 (CPA), 0 (AZA)
Heterogeneity: not applicable
Test for overall effect: Z = 0.86 (P = 0.39)
Test for subgroup differences: Not applicable
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Analysis 8.1. Comparison 8 Rituximab (RTX) + mycophenolate mofetil (MMF) versus placebo + MMF,
Outcome 1 Death.
Review: Immunosuppressive treatment for proliferative lupus nephritis
Comparison: 8 Rituximab (RTX) + mycophenolate mofetil (MMF) versus placebo + MMF
Outcome: 1 Death
Study or subgroup RTX+MMF Placebo+MMF Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
LUNAR 2012 2/72 0/72 100.0 % 5.00 [ 0.24, 102.35 ]
Total (95% CI) 72 72 100.0 % 5.00 [ 0.24, 102.35 ]
Total events: 2 (RTX+MMF), 0 (Placebo+MMF)
Heterogeneity: not applicable
Test for overall effect: Z = 1.04 (P = 0.30)
Test for subgroup differences: Not applicable
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Analysis 8.2. Comparison 8 Rituximab (RTX) + mycophenolate mofetil (MMF) versus placebo + MMF,
Outcome 2 Remission.
Review: Immunosuppressive treatment for proliferative lupus nephritis
Comparison: 8 Rituximab (RTX) + mycophenolate mofetil (MMF) versus placebo + MMF
Outcome: 2 Remission
Study or subgroup RTX+MMF Placebo+MMF Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Complete renal response
LUNAR 2012 19/72 22/72 100.0 % 0.86 [ 0.51, 1.45 ]
Subtotal (95% CI) 72 72 100.0 % 0.86 [ 0.51, 1.45 ]
Total events: 19 (RTX+MMF), 22 (Placebo+MMF)
Heterogeneity: not applicable
Test for overall effect: Z = 0.55 (P = 0.58)
2 Partial renal response
LUNAR 2012 22/72 11/72 100.0 % 2.00 [ 1.05, 3.82 ]
Subtotal (95% CI) 72 72 100.0 % 2.00 [ 1.05, 3.82 ]
Total events: 22 (RTX+MMF), 11 (Placebo+MMF)
Heterogeneity: not applicable
Test for overall effect: Z = 2.10 (P = 0.035)
3 Complete remission in proteinuria
LUNAR 2012 34/72 39/72 100.0 % 0.87 [ 0.63, 1.21 ]
Subtotal (95% CI) 72 72 100.0 % 0.87 [ 0.63, 1.21 ]
Total events: 34 (RTX+MMF), 39 (Placebo+MMF)
Heterogeneity: not applicable
Test for overall effect: Z = 0.83 (P = 0.41)
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Analysis 8.3. Comparison 8 Rituximab (RTX) + mycophenolate mofetil (MMF) versus placebo + MMF,
Outcome 3 Stable kidney function.
Review: Immunosuppressive treatment for proliferative lupus nephritis
Comparison: 8 Rituximab (RTX) + mycophenolate mofetil (MMF) versus placebo + MMF
Outcome: 3 Stable kidney function
Study or subgroup RTX+MMF Placebo+MMF Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
LUNAR 2012 41/72 33/72 100.0 % 1.24 [ 0.90, 1.71 ]
Total (95% CI) 72 72 100.0 % 1.24 [ 0.90, 1.71 ]
Total events: 41 (RTX+MMF), 33 (Placebo+MMF)
Heterogeneity: not applicable
Test for overall effect: Z = 1.32 (P = 0.19)
Test for subgroup differences: Not applicable
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Analysis 8.4. Comparison 8 Rituximab (RTX) + mycophenolate mofetil (MMF) versus placebo + MMF,
Outcome 4 Infection.
Review: Immunosuppressive treatment for proliferative lupus nephritis
Comparison: 8 Rituximab (RTX) + mycophenolate mofetil (MMF) versus placebo + MMF
Outcome: 4 Infection
Study or subgroup RTX+MMF Placebo+MMF Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Major infection
LUNAR 2012 12/72 12/72 100.0 % 1.00 [ 0.48, 2.08 ]
Subtotal (95% CI) 72 72 100.0 % 1.00 [ 0.48, 2.08 ]
Total events: 12 (RTX+MMF), 12 (Placebo+MMF)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
2 Herpes zoster virus
LUNAR 2012 9/72 11/72 100.0 % 0.82 [ 0.36, 1.85 ]
Subtotal (95% CI) 72 72 100.0 % 0.82 [ 0.36, 1.85 ]
Total events: 9 (RTX+MMF), 11 (Placebo+MMF)
Heterogeneity: not applicable
Test for overall effect: Z = 0.48 (P = 0.63)
Test for subgroup differences: Chi2 = 0.13, df = 1 (P = 0.72), I2 =0.0%
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Analysis 8.5. Comparison 8 Rituximab (RTX) + mycophenolate mofetil (MMF) versus placebo + MMF,
Outcome 5 Leucopenia.
Review: Immunosuppressive treatment for proliferative lupus nephritis
Comparison: 8 Rituximab (RTX) + mycophenolate mofetil (MMF) versus placebo + MMF
Outcome: 5 Leucopenia
Study or subgroup RTX+MMF Placebo+MMF Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
LUNAR 2012 9/72 3/72 100.0 % 3.00 [ 0.85, 10.63 ]
Total (95% CI) 72 72 100.0 % 3.00 [ 0.85, 10.63 ]
Total events: 9 (RTX+MMF), 3 (Placebo+MMF)
Heterogeneity: not applicable
Test for overall effect: Z = 1.70 (P = 0.089)
Test for subgroup differences: Not applicable
0.05 0.2 1 5 20
Less with RTX+MMF Less with MMF
275Immunosuppressive treatment for proliferative lupus nephritis (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 9.1. Comparison 9 Rituximab (RTX) + cyclophosphamide (CPA) versus RTX, Outcome 1
Remission.
Review: Immunosuppressive treatment for proliferative lupus nephritis
Comparison: 9 Rituximab (RTX) + cyclophosphamide (CPA) versus RTX
Outcome: 1 Remission
Study or subgroup RTX+CPA RTX Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Complete renal response
Li 2009c 2/10 2/9 100.0 % 0.90 [ 0.16, 5.13 ]
Subtotal (95% CI) 10 9 100.0 % 0.90 [ 0.16, 5.13 ]
Total events: 2 (RTX+CPA), 2 (RTX)
Heterogeneity: not applicable
Test for overall effect: Z = 0.12 (P = 0.91)
2 Partial renal response
Li 2009c 5/10 6/9 100.0 % 0.75 [ 0.35, 1.62 ]
Subtotal (95% CI) 10 9 100.0 % 0.75 [ 0.35, 1.62 ]
Total events: 5 (RTX+CPA), 6 (RTX)
Heterogeneity: not applicable
Test for overall effect: Z = 0.73 (P = 0.47)
Test for subgroup differences: Chi2 = 0.04, df = 1 (P = 0.85), I2 =0.0%
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Analysis 9.2. Comparison 9 Rituximab (RTX) + cyclophosphamide (CPA) versus RTX, Outcome 2 Infection.
Review: Immunosuppressive treatment for proliferative lupus nephritis
Comparison: 9 Rituximab (RTX) + cyclophosphamide (CPA) versus RTX
Outcome: 2 Infection
Study or subgroup RTX+CPA RTX Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Major infection
Li 2009c 1/10 1/9 58.1 % 0.90 [ 0.07, 12.38 ]
Subtotal (95% CI) 10 9 58.1 % 0.90 [ 0.07, 12.38 ]
Total events: 1 (RTX+CPA), 1 (RTX)
Heterogeneity: not applicable
Test for overall effect: Z = 0.08 (P = 0.94)
2 Herpes zoster virus
Li 2009c 0/10 1/9 41.9 % 0.30 [ 0.01, 6.62 ]
Subtotal (95% CI) 10 9 41.9 % 0.30 [ 0.01, 6.62 ]
Total events: 0 (RTX+CPA), 1 (RTX)
Heterogeneity: not applicable
Test for overall effect: Z = 0.76 (P = 0.45)
Total (95% CI) 20 18 100.0 % 0.57 [ 0.08, 4.20 ]
Total events: 1 (RTX+CPA), 2 (RTX)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.28, df = 1 (P = 0.60); I2 =0.0%
Test for overall effect: Z = 0.55 (P = 0.58)
Test for subgroup differences: Chi2 = 0.28, df = 1 (P = 0.60), I2 =0.0%
0.01 0.1 1 10 100
Less with RTX+MMF Less with RTX
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Analysis 9.3. Comparison 9 Rituximab (RTX) + cyclophosphamide (CPA) versus RTX, Outcome 3 Daily
proteinuria.
Review: Immunosuppressive treatment for proliferative lupus nephritis
Comparison: 9 Rituximab (RTX) + cyclophosphamide (CPA) versus RTX
Outcome: 3 Daily proteinuria
Study or subgroup RTX+CPA RTX
Mean
Difference Weight
Mean
Difference
N Mean(SD)[g/24 h] N Mean(SD)[g/24 h] IV,Random,95% CI IV,Random,95% CI
Li 2009c 10 3.8 (2.1) 9 4.1 (2.3) 100.0 % -0.30 [ -2.29, 1.69 ]
Total (95% CI) 10 9 100.0 % -0.30 [ -2.29, 1.69 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.30 (P = 0.77)
Test for subgroup differences: Not applicable
-4 -2 0 2 4
Lower with RTX+CPA Lower with RTX
Analysis 9.4. Comparison 9 Rituximab (RTX) + cyclophosphamide (CPA) versus RTX, Outcome 4
Creatinine clearance.
Review: Immunosuppressive treatment for proliferative lupus nephritis
Comparison: 9 Rituximab (RTX) + cyclophosphamide (CPA) versus RTX
Outcome: 4 Creatinine clearance
Study or subgroup RTX+CPA RTX
Mean
Difference Weight
Mean
Difference
N Mean(SD)[mL/min]N Mean(SD)[mL/min] IV,Random,95% CI IV,Random,95% CI
Li 2009c 10 64.2 (27.8) 9 81.4 (43.9) 100.0 % -17.20 [ -50.66, 16.26 ]
Total (95% CI) 10 9 100.0 % -17.20 [ -50.66, 16.26 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.01 (P = 0.31)
Test for subgroup differences: Not applicable
-100 -50 0 50 100
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Analysis 9.5. Comparison 9 Rituximab (RTX) + cyclophosphamide (CPA) versus RTX, Outcome 5 Serum
creatinine.
Review: Immunosuppressive treatment for proliferative lupus nephritis
Comparison: 9 Rituximab (RTX) + cyclophosphamide (CPA) versus RTX
Outcome: 5 Serum creatinine
Study or subgroup RTX+CPA RTX
Mean
Difference Weight
Mean
Difference
N
Mean(SD)[
mol/L] N
Mean(SD)[
mol/L] IV,Random,95% CI IV,Random,95% CI
Li 2009c 10 134.8 (84.7) 9 99.8 (50.9) 100.0 % 35.00 [ -27.14, 97.14 ]
Total (95% CI) 10 9 100.0 % 35.00 [ -27.14, 97.14 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.10 (P = 0.27)
Test for subgroup differences: Not applicable
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Analysis 10.1. Comparison 10 Abatacept + other immunosuppressive agent (IS) + versus placebo + other
IS, Outcome 1 Death.
Review: Immunosuppressive treatment for proliferative lupus nephritis
Comparison: 10 Abatacept + other immunosuppressive agent (IS) + versus placebo + other IS
Outcome: 1 Death
Study or subgroup Abatacept Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Abatacept versus placebo
ACCESS 2014 0/66 1/68 12.5 % 0.34 [ 0.01, 8.28 ]
Furie 2014 4/198 7/100 87.5 % 0.29 [ 0.09, 0.96 ]
Subtotal (95% CI) 264 168 100.0 % 0.29 [ 0.10, 0.91 ]
Total events: 4 (Abatacept), 8 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.01, df = 1 (P = 0.92); I2 =0.0%
Test for overall effect: Z = 2.12 (P = 0.034)
2 High dose abatacept versus placebo
Furie 2014 2/99 7/100 100.0 % 0.29 [ 0.06, 1.36 ]
Subtotal (95% CI) 99 100 100.0 % 0.29 [ 0.06, 1.36 ]
Total events: 2 (Abatacept), 7 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.57 (P = 0.12)
3 Low dose abatacept versus placebo
Furie 2014 2/99 7/100 100.0 % 0.29 [ 0.06, 1.36 ]
Subtotal (95% CI) 99 100 100.0 % 0.29 [ 0.06, 1.36 ]
Total events: 2 (Abatacept), 7 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.57 (P = 0.12)
Test for subgroup differences: Chi2 = 0.00, df = 2 (P = 1.00), I2 =0.0%
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Analysis 10.2. Comparison 10 Abatacept + other immunosuppressive agent (IS) + versus placebo + other
IS, Outcome 2 Remission.
Review: Immunosuppressive treatment for proliferative lupus nephritis
Comparison: 10 Abatacept + other immunosuppressive agent (IS) + versus placebo + other IS
Outcome: 2 Remission
Study or subgroup Abatacept Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Complete remission: abatacept versus placebo
Furie 2014 20/198 8/100 28.3 % 1.26 [ 0.58, 2.77 ]
ACCESS 2014 22/66 21/68 71.7 % 1.08 [ 0.66, 1.77 ]
Subtotal (95% CI) 264 168 100.0 % 1.13 [ 0.74, 1.71 ]
Total events: 42 (Abatacept), 29 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.11, df = 1 (P = 0.74); I2 =0.0%
Test for overall effect: Z = 0.57 (P = 0.57)
2 Complete remission: high dose abatacept versus placebo
Furie 2014 9/99 8/100 100.0 % 1.14 [ 0.46, 2.83 ]
Subtotal (95% CI) 99 100 100.0 % 1.14 [ 0.46, 2.83 ]
Total events: 9 (Abatacept), 8 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.28 (P = 0.78)
3 Complete remission: low dose abatacept versus placebo
Furie 2014 11/99 8/100 100.0 % 1.39 [ 0.58, 3.31 ]
Subtotal (95% CI) 99 100 100.0 % 1.39 [ 0.58, 3.31 ]
Total events: 11 (Abatacept), 8 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.74 (P = 0.46)
4 Partial remission: abatacept versus placebo
Furie 2014 23/198 14/100 45.0 % 0.83 [ 0.45, 1.54 ]
ACCESS 2014 17/66 19/68 55.0 % 0.92 [ 0.53, 1.61 ]
Subtotal (95% CI) 264 168 100.0 % 0.88 [ 0.58, 1.33 ]
Total events: 40 (Abatacept), 33 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.06, df = 1 (P = 0.80); I2 =0.0%
Test for overall effect: Z = 0.61 (P = 0.54)
5 Partial remission: high dose abatacept versus placebo
Furie 2014 14/99 14/100 100.0 % 1.01 [ 0.51, 2.01 ]
Subtotal (95% CI) 99 100 100.0 % 1.01 [ 0.51, 2.01 ]
Total events: 14 (Abatacept), 14 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.03 (P = 0.98)
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More with placebo More with abatacept
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(. . . Continued)
Study or subgroup Abatacept Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
6 Partial remission: low dose abatacept versus placebo
Furie 2014 9/99 14/100 100.0 % 0.65 [ 0.29, 1.43 ]
Subtotal (95% CI) 99 100 100.0 % 0.65 [ 0.29, 1.43 ]
Total events: 9 (Abatacept), 14 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.07 (P = 0.28)
Test for subgroup differences: Chi2 = 2.46, df = 5 (P = 0.78), I2 =0.0%
0.1 0.2 0.5 1 2 5 10
More with placebo More with abatacept
Analysis 10.3. Comparison 10 Abatacept + other immunosuppressive agent (IS) + versus placebo + other
IS, Outcome 3 Adverse renal outcomes.
Review: Immunosuppressive treatment for proliferative lupus nephritis
Comparison: 10 Abatacept + other immunosuppressive agent (IS) + versus placebo + other IS
Outcome: 3 Adverse renal outcomes
Study or subgroup Abatacept Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 ESKD: Abatacept versus placebo
Furie 2014 5/198 3/100 100.0 % 0.84 [ 0.21, 3.45 ]
Subtotal (95% CI) 198 100 100.0 % 0.84 [ 0.21, 3.45 ]
Total events: 5 (Abatacept), 3 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.24 (P = 0.81)
2 ESKD: high dose abatacept versus placebo
Furie 2014 3/99 3/100 100.0 % 1.01 [ 0.21, 4.88 ]
Subtotal (95% CI) 99 100 100.0 % 1.01 [ 0.21, 4.88 ]
Total events: 3 (Abatacept), 3 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.01 (P = 0.99)
0.1 0.2 0.5 1 2 5 10
Less with abatacept Less with placebo
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Study or subgroup Abatacept Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
3 ESKD: low dose abatacept versus placebo
Furie 2014 2/99 3/100 100.0 % 0.67 [ 0.11, 3.94 ]
Subtotal (95% CI) 99 100 100.0 % 0.67 [ 0.11, 3.94 ]
Total events: 2 (Abatacept), 3 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.44 (P = 0.66)
4 Renal relapse: abatacept versus placebo
ACCESS 2014 3/66 3/68 100.0 % 1.03 [ 0.22, 4.92 ]
Subtotal (95% CI) 66 68 100.0 % 1.03 [ 0.22, 4.92 ]
Total events: 3 (Abatacept), 3 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.04 (P = 0.97)
Test for subgroup differences: Chi2 = 0.16, df = 3 (P = 0.98), I2 =0.0%
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Analysis 10.4. Comparison 10 Abatacept + other immunosuppressive agent (IS) + versus placebo + other
IS, Outcome 4 Major Infection.
Review: Immunosuppressive treatment for proliferative lupus nephritis
Comparison: 10 Abatacept + other immunosuppressive agent (IS) + versus placebo + other IS
Outcome: 4 Major Infection
Study or subgroup Abatacept Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Abatacept versus placebo
ACCESS 2014 8/66 5/68 18.8 % 1.65 [ 0.57, 4.78 ]
Furie 2014 41/198 17/100 81.2 % 1.22 [ 0.73, 2.03 ]
Subtotal (95% CI) 264 168 100.0 % 1.29 [ 0.81, 2.04 ]
Total events: 49 (Abatacept), 22 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.25, df = 1 (P = 0.62); I2 =0.0%
Test for overall effect: Z = 1.08 (P = 0.28)
2 High dose abatacept versus placebo
Furie 2014 23/99 17/100 100.0 % 1.37 [ 0.78, 2.40 ]
Subtotal (95% CI) 99 100 100.0 % 1.37 [ 0.78, 2.40 ]
Total events: 23 (Abatacept), 17 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.09 (P = 0.28)
3 Low dose abatacept versus placebo
Furie 2014 18/99 17/100 100.0 % 1.07 [ 0.59, 1.95 ]
Subtotal (95% CI) 99 100 100.0 % 1.07 [ 0.59, 1.95 ]
Total events: 18 (Abatacept), 17 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.22 (P = 0.83)
Test for subgroup differences: Chi2 = 0.37, df = 2 (P = 0.83), I2 =0.0%
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Analysis 10.5. Comparison 10 Abatacept + other immunosuppressive agent (IS) + versus placebo + other
IS, Outcome 5 Herpes zoster virus.
Review: Immunosuppressive treatment for proliferative lupus nephritis
Comparison: 10 Abatacept + other immunosuppressive agent (IS) + versus placebo + other IS
Outcome: 5 Herpes zoster virus
Study or subgroup Abatacept Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Abatacept versus placebo
Furie 2014 9/198 0/100 100.0 % 9.64 [ 0.57, 164.02 ]
Subtotal (95% CI) 198 100 100.0 % 9.64 [ 0.57, 164.02 ]
Total events: 9 (Abatacept), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.57 (P = 0.12)
2 High dose abatacept versus placebo
Furie 2014 3/99 0/100 100.0 % 7.07 [ 0.37, 135.11 ]
Subtotal (95% CI) 99 100 100.0 % 7.07 [ 0.37, 135.11 ]
Total events: 3 (Abatacept), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.30 (P = 0.19)
3 Low dose abatacept versus placebo
Furie 2014 6/99 0/100 100.0 % 13.13 [ 0.75, 229.99 ]
Subtotal (95% CI) 99 100 100.0 % 13.13 [ 0.75, 229.99 ]
Total events: 6 (Abatacept), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.76 (P = 0.078)
Test for subgroup differences: Chi2 = 0.09, df = 2 (P = 0.96), I2 =0.0%
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Analysis 10.6. Comparison 10 Abatacept + other immunosuppressive agent (IS) + versus placebo + other
IS, Outcome 6 Health-related quality of life.
Review: Immunosuppressive treatment for proliferative lupus nephritis
Comparison: 10 Abatacept + other immunosuppressive agent (IS) + versus placebo + other IS
Outcome: 6 Health-related quality of life
Study or subgroup Abatacept Placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Physical component
ACCESS 2014 66 45.3 (11) 68 45.3 (11) 100.0 % 0.0 [ -3.73, 3.73 ]
Subtotal (95% CI) 66 68 100.0 % 0.0 [ -3.73, 3.73 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
2 Mental component
ACCESS 2014 66 45.9 (12) 68 46.5 (11) 100.0 % -0.60 [ -4.50, 3.30 ]
Subtotal (95% CI) 66 68 100.0 % -0.60 [ -4.50, 3.30 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.30 (P = 0.76)
Test for subgroup differences: Chi2 = 0.05, df = 1 (P = 0.83), I2 =0.0%
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Analysis 10.7. Comparison 10 Abatacept + other immunosuppressive agent (IS) + versus placebo + other
IS, Outcome 7 Disease activity (BILAG).
Review: Immunosuppressive treatment for proliferative lupus nephritis
Comparison: 10 Abatacept + other immunosuppressive agent (IS) + versus placebo + other IS
Outcome: 7 Disease activity (BILAG)
Study or subgroup Abatacept Placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
ACCESS 2014 66 3.4 (1.8) 68 3.8 (3) 100.0 % -0.40 [ -1.23, 0.43 ]
Total (95% CI) 66 68 100.0 % -0.40 [ -1.23, 0.43 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.94 (P = 0.35)
Test for subgroup differences: Not applicable
-2 -1 0 1 2
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Analysis 11.1. Comparison 11 Laquinimod + other immunosuppressive agent (IS) versus placebo + other IS,
Outcome 1 Death.
Review: Immunosuppressive treatment for proliferative lupus nephritis
Comparison: 11 Laquinimod + other immunosuppressive agent (IS) versus placebo + other IS
Outcome: 1 Death
Study or subgroup Laquinimod Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Laquinimod versus placebo
Jayne 2013 1/31 0/15 100.0 % 1.50 [ 0.06, 34.79 ]
Subtotal (95% CI) 31 15 100.0 % 1.50 [ 0.06, 34.79 ]
Total events: 1 (Laquinimod), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.25 (P = 0.80)
2 High dose laquinimod versus placebo
Jayne 2013 1/15 0/15 100.0 % 3.00 [ 0.13, 68.26 ]
Subtotal (95% CI) 15 15 100.0 % 3.00 [ 0.13, 68.26 ]
Total events: 1 (Laquinimod), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.69 (P = 0.49)
3 Low dose laquinimod versus placebo
Jayne 2013 0/16 0/15 Not estimable
Subtotal (95% CI) 16 15 Not estimable
Total events: 0 (Laquinimod), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: not applicable
Test for subgroup differences: Chi2 = 0.09, df = 1 (P = 0.76), I2 =0.0%
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Analysis 11.2. Comparison 11 Laquinimod + other immunosuppressive agent (IS) versus placebo + other IS,
Outcome 2 Complete remission.
Review: Immunosuppressive treatment for proliferative lupus nephritis
Comparison: 11 Laquinimod + other immunosuppressive agent (IS) versus placebo + other IS
Outcome: 2 Complete remission
Study or subgroup Laquinimod Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Complete remission: laquinimod versus placebo
Jayne 2013 16/31 5/15 100.0 % 1.55 [ 0.70, 3.42 ]
Subtotal (95% CI) 31 15 100.0 % 1.55 [ 0.70, 3.42 ]
Total events: 16 (Laquinimod), 5 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.08 (P = 0.28)
2 Complete remission: high dose laquinimod versus placebo
Jayne 2013 6/15 5/15 100.0 % 1.20 [ 0.47, 3.09 ]
Subtotal (95% CI) 15 15 100.0 % 1.20 [ 0.47, 3.09 ]
Total events: 6 (Laquinimod), 5 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.38 (P = 0.71)
3 Complete remission: low dose laquinimod versus placebo
Jayne 2013 10/16 5/15 100.0 % 1.88 [ 0.83, 4.22 ]
Subtotal (95% CI) 16 15 100.0 % 1.88 [ 0.83, 4.22 ]
Total events: 10 (Laquinimod), 5 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.52 (P = 0.13)
Test for subgroup differences: Chi2 = 0.49, df = 2 (P = 0.78), I2 =0.0%
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Analysis 12.1. Comparison 12 Ocrelizumab + other immunosuppressive agent (IS) versus placebo + other
IS, Outcome 1 Death.
Review: Immunosuppressive treatment for proliferative lupus nephritis
Comparison: 12 Ocrelizumab + other immunosuppressive agent (IS) versus placebo + other IS
Outcome: 1 Death
Study or subgroup Ocrelizumab Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Ocrelizumab versus placebo
BELONG 2013 8/254 6/125 100.0 % 0.66 [ 0.23, 1.85 ]
Subtotal (95% CI) 254 125 100.0 % 0.66 [ 0.23, 1.85 ]
Total events: 8 (Ocrelizumab), 6 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.80 (P = 0.43)
2 High dose ocrelizumab versus placebo
BELONG 2013 5/128 6/125 100.0 % 0.81 [ 0.25, 2.60 ]
Subtotal (95% CI) 128 125 100.0 % 0.81 [ 0.25, 2.60 ]
Total events: 5 (Ocrelizumab), 6 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.35 (P = 0.73)
3 Low dose ocrelizumab versus placebo
BELONG 2013 3/126 6/125 100.0 % 0.50 [ 0.13, 1.94 ]
Subtotal (95% CI) 126 125 100.0 % 0.50 [ 0.13, 1.94 ]
Total events: 3 (Ocrelizumab), 6 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.01 (P = 0.31)
Test for subgroup differences: Chi2 = 0.29, df = 2 (P = 0.86), I2 =0.0%
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Analysis 12.2. Comparison 12 Ocrelizumab + other immunosuppressive agent (IS) versus placebo + other
IS, Outcome 2 Remission.
Review: Immunosuppressive treatment for proliferative lupus nephritis
Comparison: 12 Ocrelizumab + other immunosuppressive agent (IS) versus placebo + other IS
Outcome: 2 Remission
Study or subgroup Ocrelizumab Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Complete remission: ocrelizumab versus placebo
BELONG 2013 55/148 26/75 100.0 % 1.07 [ 0.74, 1.56 ]
Subtotal (95% CI) 148 75 100.0 % 1.07 [ 0.74, 1.56 ]
Total events: 55 (Ocrelizumab), 26 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.36 (P = 0.72)
2 Complete remission: high dose ocrelizumab versus placebo
BELONG 2013 23/73 26/75 100.0 % 0.91 [ 0.57, 1.44 ]
Subtotal (95% CI) 73 75 100.0 % 0.91 [ 0.57, 1.44 ]
Total events: 23 (Ocrelizumab), 26 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.41 (P = 0.68)
3 Complete remission: low dose ocrelizumab versus placebo
BELONG 2013 32/75 26/75 100.0 % 1.23 [ 0.82, 1.85 ]
Subtotal (95% CI) 75 75 100.0 % 1.23 [ 0.82, 1.85 ]
Total events: 32 (Ocrelizumab), 26 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.00 (P = 0.32)
4 Partial remission: ocrelizumab versus placebo
BELONG 2013 44/148 15/75 100.0 % 1.49 [ 0.89, 2.49 ]
Subtotal (95% CI) 148 75 100.0 % 1.49 [ 0.89, 2.49 ]
Total events: 44 (Ocrelizumab), 15 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.51 (P = 0.13)
5 Partial remission: high dose ocrelizumab versus placebo
BELONG 2013 26/73 15/75 100.0 % 1.78 [ 1.03, 3.08 ]
Subtotal (95% CI) 73 75 100.0 % 1.78 [ 1.03, 3.08 ]
Total events: 26 (Ocrelizumab), 15 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 2.06 (P = 0.039)
6 Partial remission: low dose ocrelizumab versus placebo
BELONG 2013 18/75 15/75 100.0 % 1.20 [ 0.65, 2.20 ]
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Study or subgroup Ocrelizumab Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Subtotal (95% CI) 75 75 100.0 % 1.20 [ 0.65, 2.20 ]
Total events: 18 (Ocrelizumab), 15 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.59 (P = 0.56)
Test for subgroup differences: Chi2 = 4.42, df = 5 (P = 0.49), I2 =0.0%
0.1 0.2 0.5 1 2 5 10
More with placebo More with ocrelizumab
Analysis 12.3. Comparison 12 Ocrelizumab + other immunosuppressive agent (IS) versus placebo + other
IS, Outcome 3 Major Infection.
Review: Immunosuppressive treatment for proliferative lupus nephritis
Comparison: 12 Ocrelizumab + other immunosuppressive agent (IS) versus placebo + other IS
Outcome: 3 Major Infection
Study or subgroup Ocrelizumab Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Ocrelizumab versus placebo
BELONG 2013 161/253 70/125 100.0 % 1.14 [ 0.95, 1.36 ]
Subtotal (95% CI) 253 125 100.0 % 1.14 [ 0.95, 1.36 ]
Total events: 161 (Ocrelizumab), 70 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.38 (P = 0.17)
2 High dose ocrelizumab versus placebo
BELONG 2013 75/127 70/125 100.0 % 1.05 [ 0.85, 1.30 ]
Subtotal (95% CI) 127 125 100.0 % 1.05 [ 0.85, 1.30 ]
Total events: 75 (Ocrelizumab), 70 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.49 (P = 0.62)
3 Low dose ocrelizumab versus placebo
BELONG 2013 86/126 70/125 100.0 % 1.22 [ 1.00, 1.48 ]
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(. . . Continued)
Study or subgroup Ocrelizumab Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Subtotal (95% CI) 126 125 100.0 % 1.22 [ 1.00, 1.48 ]
Total events: 86 (Ocrelizumab), 70 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.98 (P = 0.048)
Test for subgroup differences: Chi2 = 0.97, df = 2 (P = 0.62), I2 =0.0%
0.5 0.7 1 1.5 2
Less with ocrelizumab Less with placebo
Analysis 13.1. Comparison 13 Sirukumab + other immunosuppressive agent (IS) versus placebo + other IS,
Outcome 1 Death.
Review: Immunosuppressive treatment for proliferative lupus nephritis
Comparison: 13 Sirukumab + other immunosuppressive agent (IS) versus placebo + other IS
Outcome: 1 Death
Study or subgroup Sirukumab Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Rovin 2016 0/21 0/4 Not estimable
Total (95% CI) 21 4 Not estimable
Total events: 0 (Sirukumab), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: not applicable
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Less with sirukumab Less with placebo
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Analysis 13.2. Comparison 13 Sirukumab + other immunosuppressive agent (IS) versus placebo + other IS,
Outcome 2 Infection.
Review: Immunosuppressive treatment for proliferative lupus nephritis
Comparison: 13 Sirukumab + other immunosuppressive agent (IS) versus placebo + other IS
Outcome: 2 Infection
Study or subgroup Sirukumab Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Major infection
Rovin 2016 18/21 4/4 100.0 % 0.93 [ 0.66, 1.32 ]
Total (95% CI) 21 4 100.0 % 0.93 [ 0.66, 1.32 ]
Total events: 18 (Sirukumab), 4 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.39 (P = 0.70)
Test for subgroup differences: Not applicable
0.5 0.7 1 1.5 2
Less with sirukumab Less with placebo
Analysis 13.3. Comparison 13 Sirukumab + other immunosuppressive agent (IS) versus placebo + other IS,
Outcome 3 Malignancy.
Review: Immunosuppressive treatment for proliferative lupus nephritis
Comparison: 13 Sirukumab + other immunosuppressive agent (IS) versus placebo + other IS
Outcome: 3 Malignancy
Study or subgroup Sirukumab Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Rovin 2016 0/21 0/4 Not estimable
Total (95% CI) 21 4 Not estimable
Total events: 0 (Sirukumab), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: not applicable
Test for subgroup differences: Not applicable
0.1 0.2 0.5 1 2 5 10
Less with sirukumab Less with placebo
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Analysis 13.4. Comparison 13 Sirukumab + other immunosuppressive agent (IS) versus placebo + other IS,
Outcome 4 Gastrointestinal (GI) adverse events.
Review: Immunosuppressive treatment for proliferative lupus nephritis
Comparison: 13 Sirukumab + other immunosuppressive agent (IS) versus placebo + other IS
Outcome: 4 Gastrointestinal (GI) adverse events
Study or subgroup Sirukumab Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Diarrhoea
Rovin 2016 3/21 0/4 100.0 % 1.59 [ 0.10, 26.15 ]
Subtotal (95% CI) 21 4 100.0 % 1.59 [ 0.10, 26.15 ]
Total events: 3 (Sirukumab), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.33 (P = 0.75)
Test for subgroup differences: Not applicable
0.02 0.1 1 10 50
Less with sirukumab Less with placebo
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Analysis 14.1. Comparison 14 IV versus oral cyclophosphamide (CPA), Outcome 1 Death.
Review: Immunosuppressive treatment for proliferative lupus nephritis
Comparison: 14 IV versus oral cyclophosphamide (CPA)
Outcome: 1 Death
Study or subgroup IV CPA Oral CPA Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Yee 2004 2/13 1/16 28.4 % 2.46 [ 0.25, 24.21 ]
Decker 1975 4/20 7/18 71.6 % 0.51 [ 0.18, 1.47 ]
Total (95% CI) 33 34 100.0 % 0.80 [ 0.20, 3.24 ]
Total events: 6 (IV CPA), 8 (Oral CPA)
Heterogeneity: Tau2 = 0.42; Chi2 = 1.51, df = 1 (P = 0.22); I2 =34%
Test for overall effect: Z = 0.31 (P = 0.76)
Test for subgroup differences: Not applicable
0.02 0.1 1 10 50
Less with IV CPA Less with oral CPA
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Analysis 14.2. Comparison 14 IV versus oral cyclophosphamide (CPA), Outcome 2 Adverse renal outcomes.
Review: Immunosuppressive treatment for proliferative lupus nephritis
Comparison: 14 IV versus oral cyclophosphamide (CPA)
Outcome: 2 Adverse renal outcomes
Study or subgroup IV CPA Oral CPA Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 ESKD
Yee 2004 0/13 2/16 33.5 % 0.24 [ 0.01, 4.65 ]
Decker 1975 1/20 4/18 66.5 % 0.23 [ 0.03, 1.83 ]
Subtotal (95% CI) 33 34 100.0 % 0.23 [ 0.04, 1.28 ]
Total events: 1 (IV CPA), 6 (Oral CPA)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.00, df = 1 (P = 0.97); I2 =0.0%
Test for overall effect: Z = 1.68 (P = 0.093)
2 Doubling of serum creatinine
Yee 2004 0/13 1/16 12.0 % 0.40 [ 0.02, 9.18 ]
Decker 1975 4/20 5/18 88.0 % 0.72 [ 0.23, 2.27 ]
Subtotal (95% CI) 33 34 100.0 % 0.67 [ 0.23, 1.98 ]
Total events: 4 (IV CPA), 6 (Oral CPA)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.12, df = 1 (P = 0.73); I2 =0.0%
Test for overall effect: Z = 0.72 (P = 0.47)
3 Deterioration of kidney function
Decker 1975 4/20 5/18 100.0 % 0.72 [ 0.23, 2.27 ]
Subtotal (95% CI) 20 18 100.0 % 0.72 [ 0.23, 2.27 ]
Total events: 4 (IV CPA), 5 (Oral CPA)
Heterogeneity: not applicable
Test for overall effect: Z = 0.56 (P = 0.58)
0.01 0.1 1 10 100
Less with IV CPA Less with oral CPA
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Analysis 14.3. Comparison 14 IV versus oral cyclophosphamide (CPA), Outcome 3 Stable kidney function.
Review: Immunosuppressive treatment for proliferative lupus nephritis
Comparison: 14 IV versus oral cyclophosphamide (CPA)
Outcome: 3 Stable kidney function
Study or subgroup IV CPA Oral CPA Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Decker 1975 16/20 13/18 100.0 % 1.11 [ 0.77, 1.59 ]
Total (95% CI) 20 18 100.0 % 1.11 [ 0.77, 1.59 ]
Total events: 16 (IV CPA), 13 (Oral CPA)
Heterogeneity: not applicable
Test for overall effect: Z = 0.56 (P = 0.58)
Test for subgroup differences: Not applicable
0.2 0.5 1 2 5
More with oral CPA More with IV CPA
Analysis 14.4. Comparison 14 IV versus oral cyclophosphamide (CPA), Outcome 4 Ovarian failure.
Review: Immunosuppressive treatment for proliferative lupus nephritis
Comparison: 14 IV versus oral cyclophosphamide (CPA)
Outcome: 4 Ovarian failure
Study or subgroup IV CPA Oral CPA Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Decker 1975 8/17 7/10 94.5 % 0.67 [ 0.35, 1.28 ]
Yee 2004 1/13 1/16 5.5 % 1.23 [ 0.08, 17.83 ]
Total (95% CI) 30 26 100.0 % 0.70 [ 0.37, 1.30 ]
Total events: 9 (IV CPA), 8 (Oral CPA)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.20, df = 1 (P = 0.65); I2 =0.0%
Test for overall effect: Z = 1.13 (P = 0.26)
Test for subgroup differences: Not applicable
0.05 0.2 1 5 20
Less with IV CPA Less with oral CPA
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Analysis 14.5. Comparison 14 IV versus oral cyclophosphamide (CPA), Outcome 5 Infection.
Review: Immunosuppressive treatment for proliferative lupus nephritis
Comparison: 14 IV versus oral cyclophosphamide (CPA)
Outcome: 5 Infection
Study or subgroup IV CPA Oral CPA Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Major infection
Decker 1975 2/20 3/18 29.9 % 0.60 [ 0.11, 3.19 ]
Yee 2004 5/13 4/16 70.1 % 1.54 [ 0.52, 4.59 ]
Subtotal (95% CI) 33 34 100.0 % 1.16 [ 0.47, 2.90 ]
Total events: 7 (IV CPA), 7 (Oral CPA)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.87, df = 1 (P = 0.35); I2 =0.0%
Test for overall effect: Z = 0.32 (P = 0.75)
2 Herpes zoster virus
Decker 1975 5/20 6/18 100.0 % 0.75 [ 0.28, 2.04 ]
Subtotal (95% CI) 20 18 100.0 % 0.75 [ 0.28, 2.04 ]
Total events: 5 (IV CPA), 6 (Oral CPA)
Heterogeneity: not applicable
Test for overall effect: Z = 0.56 (P = 0.57)
0.1 0.2 0.5 1 2 5 10
Less with IV CPA Less with oral CPA
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Analysis 14.6. Comparison 14 IV versus oral cyclophosphamide (CPA), Outcome 6 Malignancy.
Review: Immunosuppressive treatment for proliferative lupus nephritis
Comparison: 14 IV versus oral cyclophosphamide (CPA)
Outcome: 6 Malignancy
Study or subgroup IV CPA Oral CPA Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Yee 2004 1/13 0/16 15.9 % 3.64 [ 0.16, 82.62 ]
Decker 1975 4/20 3/18 84.1 % 1.20 [ 0.31, 4.65 ]
Total (95% CI) 33 34 100.0 % 1.43 [ 0.41, 4.96 ]
Total events: 5 (IV CPA), 3 (Oral CPA)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.42, df = 1 (P = 0.52); I2 =0.0%
Test for overall effect: Z = 0.57 (P = 0.57)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Less with IV CPA Less with oral CPA
Analysis 14.7. Comparison 14 IV versus oral cyclophosphamide (CPA), Outcome 7 Bladder toxicity.
Review: Immunosuppressive treatment for proliferative lupus nephritis
Comparison: 14 IV versus oral cyclophosphamide (CPA)
Outcome: 7 Bladder toxicity
Study or subgroup IV CPA Oral CPA Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Yee 2004 0/13 1/16 46.3 % 0.40 [ 0.02, 9.18 ]
Decker 1975 0/20 3/18 53.7 % 0.13 [ 0.01, 2.34 ]
Total (95% CI) 33 34 100.0 % 0.22 [ 0.03, 1.83 ]
Total events: 0 (IV CPA), 4 (Oral CPA)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.28, df = 1 (P = 0.60); I2 =0.0%
Test for overall effect: Z = 1.40 (P = 0.16)
Test for subgroup differences: Not applicable
0.005 0.1 1 10 200
Less with IV CPA Less with oral CPA
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Analysis 14.8. Comparison 14 IV versus oral cyclophosphamide (CPA), Outcome 8 Gastrointestinal (GI)
adverse events.
Review: Immunosuppressive treatment for proliferative lupus nephritis
Comparison: 14 IV versus oral cyclophosphamide (CPA)
Outcome: 8 Gastrointestinal (GI) adverse events
Study or subgroup IV CPA Oral CPA Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 GI upset
Yee 2004 3/13 1/16 100.0 % 3.69 [ 0.43, 31.43 ]
Subtotal (95% CI) 13 16 100.0 % 3.69 [ 0.43, 31.43 ]
Total events: 3 (IV CPA), 1 (Oral CPA)
Heterogeneity: not applicable
Test for overall effect: Z = 1.20 (P = 0.23)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours IV CPA Favours oral CPA
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Analysis 15.1. Comparison 15 Low versus high dose cyclophosphamide (CPA), Outcome 1 Death.
Review: Immunosuppressive treatment for proliferative lupus nephritis
Comparison: 15 Low versus high dose cyclophosphamide (CPA)
Outcome: 1 Death
Study or subgroup Low dose CPA High dose CPA Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 At 6 months
Mitwalli 2011 3/73 1/44 100.0 % 1.81 [ 0.19, 16.85 ]
Subtotal (95% CI) 73 44 100.0 % 1.81 [ 0.19, 16.85 ]
Total events: 3 (Low dose CPA), 1 (High dose CPA)
Heterogeneity: not applicable
Test for overall effect: Z = 0.52 (P = 0.60)
2 At 12 months
Sabry 2009 0/20 0/26 Not estimable
Mehra 2018 2/38 2/37 100.0 % 0.97 [ 0.14, 6.56 ]
Subtotal (95% CI) 58 63 100.0 % 0.97 [ 0.14, 6.56 ]
Total events: 2 (Low dose CPA), 2 (High dose CPA)
Heterogeneity: not applicable
Test for overall effect: Z = 0.03 (P = 0.98)
3 At 5 years
Houssiau 2002 0/44 3/41 100.0 % 0.13 [ 0.01, 2.51 ]
Subtotal (95% CI) 44 41 100.0 % 0.13 [ 0.01, 2.51 ]
Total events: 0 (Low dose CPA), 3 (High dose CPA)
Heterogeneity: not applicable
Test for overall effect: Z = 1.35 (P = 0.18)
4 At 10 years
Houssiau 2002 (1) 2/46 5/44 100.0 % 0.38 [ 0.08, 1.87 ]
Subtotal (95% CI) 46 44 100.0 % 0.38 [ 0.08, 1.87 ]
Total events: 2 (Low dose CPA), 5 (High dose CPA)
Heterogeneity: not applicable
Test for overall effect: Z = 1.19 (P = 0.24)
0.005 0.1 1 10 200
Less with high dose CPA Less with low dose CPA
(1) 73 months 0/44 vs 3 in 41 10 year 2/46 vs 5/44
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Analysis 15.2. Comparison 15 Low versus high dose cyclophosphamide (CPA), Outcome 2 Remission.
Review: Immunosuppressive treatment for proliferative lupus nephritis
Comparison: 15 Low versus high dose cyclophosphamide (CPA)
Outcome: 2 Remission
Study or subgroup Low dose CPA High dose CPA Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Complete renal remission
Mitwalli 2011 25/73 11/44 30.8 % 1.37 [ 0.75, 2.50 ]
Houssiau 2002 18/39 11/36 31.0 % 1.51 [ 0.83, 2.75 ]
Mehra 2018 17/38 24/37 38.2 % 0.69 [ 0.45, 1.06 ]
Subtotal (95% CI) 150 117 100.0 % 1.09 [ 0.63, 1.86 ]
Total events: 60 (Low dose CPA), 46 (High dose CPA)
Heterogeneity: Tau2 = 0.15; Chi2 = 6.00, df = 2 (P = 0.05); I2 =67%
Test for overall effect: Z = 0.30 (P = 0.76)
2 Partial renal remission
Mehra 2018 2/38 3/37 2.1 % 0.65 [ 0.11, 3.67 ]
Houssiau 2002 18/39 22/36 34.5 % 0.76 [ 0.49, 1.16 ]
Mitwalli 2011 42/73 26/44 63.4 % 0.97 [ 0.71, 1.33 ]
Subtotal (95% CI) 150 117 100.0 % 0.88 [ 0.69, 1.14 ]
Total events: 62 (Low dose CPA), 51 (High dose CPA)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.02, df = 2 (P = 0.60); I2 =0.0%
Test for overall effect: Z = 0.96 (P = 0.34)
Test for subgroup differences: Chi2 = 0.46, df = 1 (P = 0.50), I2 =0.0%
0.1 0.2 0.5 1 2 5 10
More with high dose CPA More with low dose CPA
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Analysis 15.3. Comparison 15 Low versus high dose cyclophosphamide (CPA), Outcome 3 Adverse renal
outcomes.
Review: Immunosuppressive treatment for proliferative lupus nephritis
Comparison: 15 Low versus high dose cyclophosphamide (CPA)
Outcome: 3 Adverse renal outcomes
Study or subgroup Low dose CPA High dose CPA Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 ESKD
Sabry 2009 0/26 0/20 Not estimable
Houssiau 2002 1/45 2/44 100.0 % 0.49 [ 0.05, 5.20 ]
Subtotal (95% CI) 71 64 100.0 % 0.49 [ 0.05, 5.20 ]
Total events: 1 (Low dose CPA), 2 (High dose CPA)
Heterogeneity: not applicable
Test for overall effect: Z = 0.59 (P = 0.55)
2 ESKD at 5 years
Houssiau 2002 3/44 1/41 100.0 % 2.80 [ 0.30, 25.81 ]
Subtotal (95% CI) 44 41 100.0 % 2.80 [ 0.30, 25.81 ]
Total events: 3 (Low dose CPA), 1 (High dose CPA)
Heterogeneity: not applicable
Test for overall effect: Z = 0.91 (P = 0.36)
3 ESKD at 10 years
Houssiau 2002 4/46 2/44 100.0 % 1.91 [ 0.37, 9.92 ]
Subtotal (95% CI) 46 44 100.0 % 1.91 [ 0.37, 9.92 ]
Total events: 4 (Low dose CPA), 2 (High dose CPA)
Heterogeneity: not applicable
Test for overall effect: Z = 0.77 (P = 0.44)
4 Renal relapse
Sabry 2009 3/26 0/20 21.4 % 5.44 [ 0.30, 99.72 ]
Mehra 2018 9/38 1/37 30.7 % 8.76 [ 1.17, 65.78 ]
Houssiau 2002 12/44 13/46 47.9 % 0.97 [ 0.50, 1.88 ]
Subtotal (95% CI) 108 103 100.0 % 2.75 [ 0.47, 15.98 ]
Total events: 24 (Low dose CPA), 14 (High dose CPA)
Heterogeneity: Tau2 = 1.57; Chi2 = 5.91, df = 2 (P = 0.05); I2 =66%
Test for overall effect: Z = 1.13 (P = 0.26)
5 Doubling of serum creatinine
Sabry 2009 0/26 0/20 Not estimable
Houssiau 2002 1/45 3/44 100.0 % 0.33 [ 0.04, 3.02 ]
Subtotal (95% CI) 71 64 100.0 % 0.33 [ 0.04, 3.02 ]
0.01 0.1 1 10 100
Less with low dose CPA Less with high dose CPA
(Continued . . . )
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(. . . Continued)
Study or subgroup Low dose CPA High dose CPA Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Total events: 1 (Low dose CPA), 3 (High dose CPA)
Heterogeneity: not applicable
Test for overall effect: Z = 0.99 (P = 0.32)
6 Doubling of serum creatinine at 5 years
Houssiau 2002 1/44 7/41 100.0 % 0.13 [ 0.02, 1.04 ]
Subtotal (95% CI) 44 41 100.0 % 0.13 [ 0.02, 1.04 ]
Total events: 1 (Low dose CPA), 7 (High dose CPA)
Heterogeneity: not applicable
Test for overall effect: Z = 1.93 (P = 0.054)
7 Doubling of serum creatinine at 10 years
Houssiau 2002 5/46 6/44 100.0 % 0.80 [ 0.26, 2.42 ]
Subtotal (95% CI) 46 44 100.0 % 0.80 [ 0.26, 2.42 ]
Total events: 5 (Low dose CPA), 6 (High dose CPA)
Heterogeneity: not applicable
Test for overall effect: Z = 0.40 (P = 0.69)
0.01 0.1 1 10 100
Less with low dose CPA Less with high dose CPA
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Analysis 15.4. Comparison 15 Low versus high dose cyclophosphamide (CPA), Outcome 4 Stable kidney
function.
Review: Immunosuppressive treatment for proliferative lupus nephritis
Comparison: 15 Low versus high dose cyclophosphamide (CPA)
Outcome: 4 Stable kidney function
Study or subgroup Low dose CPA High dose CPA Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 At 3 years
Houssiau 2002 22/45 30/44 100.0 % 0.72 [ 0.50, 1.03 ]
Subtotal (95% CI) 45 44 100.0 % 0.72 [ 0.50, 1.03 ]
Total events: 22 (Low dose CPA), 30 (High dose CPA)
Heterogeneity: not applicable
Test for overall effect: Z = 1.81 (P = 0.071)
2 At 5 years
Houssiau 2002 34/44 33/41 100.0 % 0.96 [ 0.77, 1.20 ]
Subtotal (95% CI) 44 41 100.0 % 0.96 [ 0.77, 1.20 ]
Total events: 34 (Low dose CPA), 33 (High dose CPA)
Heterogeneity: not applicable
Test for overall effect: Z = 0.36 (P = 0.72)
Test for subgroup differences: Chi2 = 1.83, df = 1 (P = 0.18), I2 =45%
0.2 0.5 1 2 5
More with high dose CPA More with low dose CPA
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Analysis 15.5. Comparison 15 Low versus high dose cyclophosphamide (CPA), Outcome 5 Ovarian failure.
Review: Immunosuppressive treatment for proliferative lupus nephritis
Comparison: 15 Low versus high dose cyclophosphamide (CPA)
Outcome: 5 Ovarian failure
Study or subgroup Low dose CPA High dose CPA Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Sabry 2009 0/22 0/18 Not estimable
Mehra 2018 1/38 2/37 13.5 % 0.49 [ 0.05, 5.14 ]
Houssiau 2002 2/43 2/41 19.5 % 0.95 [ 0.14, 6.46 ]
Mitwalli 2011 25/61 6/39 67.0 % 2.66 [ 1.20, 5.90 ]
Total (95% CI) 164 135 100.0 % 1.73 [ 0.70, 4.31 ]
Total events: 28 (Low dose CPA), 10 (High dose CPA)
Heterogeneity: Tau2 = 0.16; Chi2 = 2.46, df = 2 (P = 0.29); I2 =19%
Test for overall effect: Z = 1.18 (P = 0.24)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Less with low dose CPA Less with high dose CPA
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Analysis 15.6. Comparison 15 Low versus high dose cyclophosphamide (CPA), Outcome 6 Infection.
Review: Immunosuppressive treatment for proliferative lupus nephritis
Comparison: 15 Low versus high dose cyclophosphamide (CPA)
Outcome: 6 Infection
Study or subgroup Low dose CPA High dose CPA Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Major infection
Sabry 2009 4/26 5/20 18.0 % 0.62 [ 0.19, 2.00 ]
Houssiau 2002 10/45 5/44 23.7 % 1.96 [ 0.73, 5.26 ]
Mehra 2018 8/38 7/37 27.0 % 1.11 [ 0.45, 2.76 ]
Mitwalli 2011 23/73 6/44 31.4 % 2.31 [ 1.02, 5.23 ]
Subtotal (95% CI) 182 145 100.0 % 1.44 [ 0.83, 2.49 ]
Total events: 45 (Low dose CPA), 23 (High dose CPA)
Heterogeneity: Tau2 = 0.08; Chi2 = 3.98, df = 3 (P = 0.26); I2 =25%
Test for overall effect: Z = 1.29 (P = 0.20)
2 Herpes zoster virus
Mehra 2018 1/38 0/37 17.4 % 2.92 [ 0.12, 69.54 ]
Mitwalli 2011 0/44 3/73 20.1 % 0.23 [ 0.01, 4.44 ]
Houssiau 2002 5/45 2/44 62.6 % 2.44 [ 0.50, 11.94 ]
Subtotal (95% CI) 127 154 100.0 % 1.58 [ 0.41, 6.05 ]
Total events: 6 (Low dose CPA), 5 (High dose CPA)
Heterogeneity: Tau2 = 0.10; Chi2 = 2.12, df = 2 (P = 0.35); I2 =6%
Test for overall effect: Z = 0.66 (P = 0.51)
0.01 0.1 1 10 100
Less with low dose CPA Less with high dose CPA
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Analysis 15.7. Comparison 15 Low versus high dose cyclophosphamide (CPA), Outcome 7 Malignancy.
Review: Immunosuppressive treatment for proliferative lupus nephritis
Comparison: 15 Low versus high dose cyclophosphamide (CPA)
Outcome: 7 Malignancy
Study or subgroup Low dose CPA High dose CPA Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Houssiau 2002 (1) 0/45 1/44 47.3 % 0.33 [ 0.01, 7.80 ]
Mitwalli 2011 4/73 0/44 52.7 % 5.47 [ 0.30, 99.28 ]
Total (95% CI) 118 88 100.0 % 1.44 [ 0.09, 23.31 ]
Total events: 4 (Low dose CPA), 1 (High dose CPA)
Heterogeneity: Tau2 = 1.64; Chi2 = 1.68, df = 1 (P = 0.19); I2 =41%
Test for overall effect: Z = 0.26 (P = 0.80)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Less with low dose CPA Less with high dose CPA
(1) malignancy at 10 years 1/46 vs 6/44 ??? check
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Analysis 15.8. Comparison 15 Low versus high dose cyclophosphamide (CPA), Outcome 8 Leucopenia.
Review: Immunosuppressive treatment for proliferative lupus nephritis
Comparison: 15 Low versus high dose cyclophosphamide (CPA)
Outcome: 8 Leucopenia
Study or subgroup Low dose CPA High dose CPA Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Mitwalli 2011 4/73 0/44 24.6 % 5.47 [ 0.30, 99.28 ]
Mehra 2018 0/38 5/37 25.0 % 0.09 [ 0.01, 1.55 ]
Houssiau 2002 5/45 5/44 50.4 % 0.98 [ 0.30, 3.14 ]
Total (95% CI) 156 125 100.0 % 0.82 [ 0.13, 5.15 ]
Total events: 9 (Low dose CPA), 10 (High dose CPA)
Heterogeneity: Tau2 = 1.39; Chi2 = 4.09, df = 2 (P = 0.13); I2 =51%
Test for overall effect: Z = 0.21 (P = 0.83)
Test for subgroup differences: Not applicable
0.005 0.1 1 10 200
Less with low dose CPA Less with high dose CPA
Analysis 15.9. Comparison 15 Low versus high dose cyclophosphamide (CPA), Outcome 9 Bone toxicity.
Review: Immunosuppressive treatment for proliferative lupus nephritis
Comparison: 15 Low versus high dose cyclophosphamide (CPA)
Outcome: 9 Bone toxicity
Study or subgroup Low dose CPA High dose CPA Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Houssiau 2002 1/45 0/44 32.8 % 2.93 [ 0.12, 70.16 ]
Mehra 2018 3/38 1/37 67.2 % 2.92 [ 0.32, 26.83 ]
Total (95% CI) 83 81 100.0 % 2.93 [ 0.48, 18.02 ]
Total events: 4 (Low dose CPA), 1 (High dose CPA)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.00, df = 1 (P = 1.00); I2 =0.0%
Test for overall effect: Z = 1.16 (P = 0.25)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Less with low dose CPA Less with high dose CPA
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Analysis 15.10. Comparison 15 Low versus high dose cyclophosphamide (CPA), Outcome 10 Alopecia.
Review: Immunosuppressive treatment for proliferative lupus nephritis
Comparison: 15 Low versus high dose cyclophosphamide (CPA)
Outcome: 10 Alopecia
Study or subgroup Low dose CPA High dose CPA Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Mehra 2018 2/38 7/37 100.0 % 0.28 [ 0.06, 1.25 ]
Total (95% CI) 38 37 100.0 % 0.28 [ 0.06, 1.25 ]
Total events: 2 (Low dose CPA), 7 (High dose CPA)
Heterogeneity: not applicable
Test for overall effect: Z = 1.67 (P = 0.096)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Less with low dose CPA Less with high dose CPA
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Analysis 15.11. Comparison 15 Low versus high dose cyclophosphamide (CPA), Outcome 11
Gastrointestinal (GI) adverse events.
Review: Immunosuppressive treatment for proliferative lupus nephritis
Comparison: 15 Low versus high dose cyclophosphamide (CPA)
Outcome: 11 Gastrointestinal (GI) adverse events
Study or subgroup Low dose CPA High dose CPA Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 GI disturbance
Mehra 2018 0/38 4/37 100.0 % 0.11 [ 0.01, 1.94 ]
Subtotal (95% CI) 38 37 100.0 % 0.11 [ 0.01, 1.94 ]
Total events: 0 (Low dose CPA), 4 (High dose CPA)
Heterogeneity: not applicable
Test for overall effect: Z = 1.51 (P = 0.13)
Test for subgroup differences: Not applicable
0.005 0.1 1 10 200
Less with low dose CPA Less with high dose CPA
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Analysis 15.12. Comparison 15 Low versus high dose cyclophosphamide (CPA), Outcome 12 Daily
proteinuria.
Review: Immunosuppressive treatment for proliferative lupus nephritis
Comparison: 15 Low versus high dose cyclophosphamide (CPA)
Outcome: 12 Daily proteinuria
Study or subgroup Low dose CPA High dose CPA
Mean
Difference Weight
Mean
Difference
N Mean(SD)[g/24 h] N Mean(SD)[g/24 h] IV,Random,95% CI IV,Random,95% CI
Sabry 2009 26 2.9 (1.5) 20 2.1 (1.6) 22.1 % 0.80 [ -0.11, 1.71 ]
Houssiau 2002 39 0.7 (0.97) 36 1.12 (1.34) 36.1 % -0.42 [ -0.95, 0.11 ]
Mitwalli 2011 44 0.91 (1.1) 77 1.2 (1.1) 41.8 % -0.29 [ -0.70, 0.12 ]
Total (95% CI) 109 133 100.0 % -0.10 [ -0.65, 0.46 ]
Heterogeneity: Tau2 = 0.15; Chi2 = 5.50, df = 2 (P = 0.06); I2 =64%
Test for overall effect: Z = 0.34 (P = 0.74)
Test for subgroup differences: Not applicable
-2 -1 0 1 2
Lower with low dose CPA Lower with high dose CPA
Analysis 15.13. Comparison 15 Low versus high dose cyclophosphamide (CPA), Outcome 13 Creatinine
clearance.
Review: Immunosuppressive treatment for proliferative lupus nephritis
Comparison: 15 Low versus high dose cyclophosphamide (CPA)
Outcome: 13 Creatinine clearance
Study or subgroup Low dose CPA High dose CPA
Mean
Difference Weight
Mean
Difference
N Mean(SD)[mL/min] N Mean(SD)[mL/min] IV,Random,95% CI IV,Random,95% CI
Mitwalli 2011 44 55.1 (30) 73 67.7 (28.6) 100.0 % -12.60 [ -23.63, -1.57 ]
Total (95% CI) 44 73 100.0 % -12.60 [ -23.63, -1.57 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.24 (P = 0.025)
Test for subgroup differences: Not applicable
-50 -25 0 25 50
Higher with high dose CPA Higher with low dose CPA
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Analysis 15.14. Comparison 15 Low versus high dose cyclophosphamide (CPA), Outcome 14 Serum
creatinine.
Review: Immunosuppressive treatment for proliferative lupus nephritis
Comparison: 15 Low versus high dose cyclophosphamide (CPA)
Outcome: 14 Serum creatinine
Study or subgroup Low dose CPA High dose CPA
Mean
Difference Weight
Mean
Difference
N
Mean(SD)[
mol/L] N
Mean(SD)[
mol/L] IV,Random,95% CI IV,Random,95% CI
Mitwalli 2011 44 126 (102) 73 95.4 (43.6) 9.3 % 30.60 [ -1.15, 62.35 ]
Houssiau 2002 41 88.4 (31.82) 43 88.4 (44.2) 25.1 % 0.0 [ -16.41, 16.41 ]
Sabry 2009 26 115 (0.8) 20 115 (0.9) 65.6 % 0.0 [ -0.50, 0.50 ]
Total (95% CI) 111 136 100.0 % 2.85 [ -7.61, 13.31 ]
Heterogeneity: Tau2 = 43.38; Chi2 = 3.57, df = 2 (P = 0.17); I2 =44%
Test for overall effect: Z = 0.53 (P = 0.59)
Test for subgroup differences: Not applicable
-100 -50 0 50 100
Lower with low dose CPA Lower with high dose CPA
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Analysis 15.15. Comparison 15 Low versus high dose cyclophosphamide (CPA), Outcome 15 Disease
activity (SLEDAI).
Review: Immunosuppressive treatment for proliferative lupus nephritis
Comparison: 15 Low versus high dose cyclophosphamide (CPA)
Outcome: 15 Disease activity (SLEDAI)
Study or subgroup Low dose CPA High dose CPA
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Mehra 2018 38 8.4 (3.4) 37 9.9 (3.4) 100.0 % -1.50 [ -3.04, 0.04 ]
Total (95% CI) 38 37 100.0 % -1.50 [ -3.04, 0.04 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.91 (P = 0.056)
Test for subgroup differences: Not applicable
-4 -2 0 2 4
Lower with low dose CPA Lower with high dose CPA
Analysis 16.1. Comparison 16 Standard versus reduced dose oral corticosteroids, Outcome 1 Death.
Review: Immunosuppressive treatment for proliferative lupus nephritis
Comparison: 16 Standard versus reduced dose oral corticosteroids
Outcome: 1 Death
Study or subgroup Standard dose Reduced dose Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
MyLupus 2011 2/42 0/39 100.0 % 4.65 [ 0.23, 93.95 ]
Total (95% CI) 42 39 100.0 % 4.65 [ 0.23, 93.95 ]
Total events: 2 (Standard dose), 0 (Reduced dose)
Heterogeneity: not applicable
Test for overall effect: Z = 1.00 (P = 0.32)
Test for subgroup differences: Not applicable
0.005 0.1 1 10 200
Less with standard dose Less with reduced dose
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Analysis 16.2. Comparison 16 Standard versus reduced dose oral corticosteroids, Outcome 2 Remission.
Review: Immunosuppressive treatment for proliferative lupus nephritis
Comparison: 16 Standard versus reduced dose oral corticosteroids
Outcome: 2 Remission
Study or subgroup Standard dose Reduced dose Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Complete renal remission
MyLupus 2011 8/42 8/39 100.0 % 0.93 [ 0.39, 2.23 ]
Subtotal (95% CI) 42 39 100.0 % 0.93 [ 0.39, 2.23 ]
Total events: 8 (Standard dose), 8 (Reduced dose)
Heterogeneity: not applicable
Test for overall effect: Z = 0.17 (P = 0.87)
2 Partial renal remission
MyLupus 2011 20/42 14/39 100.0 % 1.33 [ 0.78, 2.24 ]
Subtotal (95% CI) 42 39 100.0 % 1.33 [ 0.78, 2.24 ]
Total events: 20 (Standard dose), 14 (Reduced dose)
Heterogeneity: not applicable
Test for overall effect: Z = 1.05 (P = 0.29)
0.1 0.2 0.5 1 2 5 10
More with reduced dose More with standard dose
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Analysis 16.3. Comparison 16 Standard versus reduced dose oral corticosteroids, Outcome 3 Relapse.
Review: Immunosuppressive treatment for proliferative lupus nephritis
Comparison: 16 Standard versus reduced dose oral corticosteroids
Outcome: 3 Relapse
Study or subgroup Standard dose Reduced dose Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
MyLupus 2011 1/28 0/22 100.0 % 2.38 [ 0.10, 55.72 ]
Total (95% CI) 28 22 100.0 % 2.38 [ 0.10, 55.72 ]
Total events: 1 (Standard dose), 0 (Reduced dose)
Heterogeneity: not applicable
Test for overall effect: Z = 0.54 (P = 0.59)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
More with reduced dose More with standard dose
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Analysis 16.4. Comparison 16 Standard versus reduced dose oral corticosteroids, Outcome 4 Infection.
Review: Immunosuppressive treatment for proliferative lupus nephritis
Comparison: 16 Standard versus reduced dose oral corticosteroids
Outcome: 4 Infection
Study or subgroup Standard dose Reduced dose Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Major infection
MyLupus 2011 5/42 1/39 100.0 % 4.64 [ 0.57, 38.00 ]
Subtotal (95% CI) 42 39 100.0 % 4.64 [ 0.57, 38.00 ]
Total events: 5 (Standard dose), 1 (Reduced dose)
Heterogeneity: not applicable
Test for overall effect: Z = 1.43 (P = 0.15)
2 Herpes zoster virus
MyLupus 2011 7/42 0/39 100.0 % 13.95 [ 0.82, 236.48 ]
Subtotal (95% CI) 42 39 100.0 % 13.95 [ 0.82, 236.48 ]
Total events: 7 (Standard dose), 0 (Reduced dose)
Heterogeneity: not applicable
Test for overall effect: Z = 1.83 (P = 0.068)
0.002 0.1 1 10 500
Less with standard dose Less with reduced dose
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Analysis 16.5. Comparison 16 Standard versus reduced dose oral corticosteroids, Outcome 5
Gastrointestinal (GI) adverse events.
Review: Immunosuppressive treatment for proliferative lupus nephritis
Comparison: 16 Standard versus reduced dose oral corticosteroids
Outcome: 5 Gastrointestinal (GI) adverse events
Study or subgroup Standard dose Reduced dose Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Diarrhoea
MyLupus 2011 10/42 8/39 100.0 % 1.16 [ 0.51, 2.64 ]
Subtotal (95% CI) 42 39 100.0 % 1.16 [ 0.51, 2.64 ]
Total events: 10 (Standard dose), 8 (Reduced dose)
Heterogeneity: not applicable
Test for overall effect: Z = 0.36 (P = 0.72)
2 Vomiting
MyLupus 2011 4/42 4/39 100.0 % 0.93 [ 0.25, 3.46 ]
Subtotal (95% CI) 42 39 100.0 % 0.93 [ 0.25, 3.46 ]
Total events: 4 (Standard dose), 4 (Reduced dose)
Heterogeneity: not applicable
Test for overall effect: Z = 0.11 (P = 0.91)
3 Nausea
MyLupus 2011 3/42 1/39 100.0 % 2.79 [ 0.30, 25.67 ]
Subtotal (95% CI) 42 39 100.0 % 2.79 [ 0.30, 25.67 ]
Total events: 3 (Standard dose), 1 (Reduced dose)
Heterogeneity: not applicable
Test for overall effect: Z = 0.90 (P = 0.37)
0.01 0.1 1 10 100
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Analysis 16.6. Comparison 16 Standard versus reduced dose oral corticosteroids, Outcome 6 Creatinine
clearance.
Review: Immunosuppressive treatment for proliferative lupus nephritis
Comparison: 16 Standard versus reduced dose oral corticosteroids
Outcome: 6 Creatinine clearance
Study or subgroup Standard dose Reduced dose
Mean
Difference Weight
Mean
Difference
N Mean(SD)[mL/min] N Mean(SD)[mL/min] IV,Random,95% CI IV,Random,95% CI
MyLupus 2011 42 100.9 (33.5) 32 106.7 (33) 100.0 % -5.80 [ -21.08, 9.48 ]
Total (95% CI) 42 32 100.0 % -5.80 [ -21.08, 9.48 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.74 (P = 0.46)
Test for subgroup differences: Not applicable
-50 -25 0 25 50
Higher with reduced dose Higher with standard dose
Analysis 16.7. Comparison 16 Standard versus reduced dose oral corticosteroids, Outcome 7 Serum
creatinine.
Review: Immunosuppressive treatment for proliferative lupus nephritis
Comparison: 16 Standard versus reduced dose oral corticosteroids
Outcome: 7 Serum creatinine
Study or subgroup Standard dose Reduced dose
Mean
Difference Weight
Mean
Difference
N
Mean(SD)[
mol/L] N
Mean(SD)[
mol/L] IV,Random,95% CI IV,Random,95% CI
MyLupus 2011 42 73.3 (35) 39 75.7 (27.1) 100.0 % -2.40 [ -15.98, 11.18 ]
Total (95% CI) 42 39 100.0 % -2.40 [ -15.98, 11.18 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.35 (P = 0.73)
Test for subgroup differences: Not applicable
-20 -10 0 10 20
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Analysis 17.1. Comparison 17 IV versus oral corticosteroids, Outcome 1 Death.
Review: Immunosuppressive treatment for proliferative lupus nephritis
Comparison: 17 IV versus oral corticosteroids
Outcome: 1 Death
Study or subgroup IV Oral Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Barron 1982 0/7 0/15 Not estimable
Total (95% CI) 7 15 Not estimable
Total events: 0 (IV), 0 (Oral)
Heterogeneity: not applicable
Test for overall effect: not applicable
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Less with IV Less with oral
Analysis 17.2. Comparison 17 IV versus oral corticosteroids, Outcome 2 Adverse renal outcomes.
Review: Immunosuppressive treatment for proliferative lupus nephritis
Comparison: 17 IV versus oral corticosteroids
Outcome: 2 Adverse renal outcomes
Study or subgroup IV Oral Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Renal relapse
Barron 1982 4/7 9/15 100.0 % 0.95 [ 0.44, 2.04 ]
Subtotal (95% CI) 7 15 100.0 % 0.95 [ 0.44, 2.04 ]
Total events: 4 (IV), 9 (Oral)
Heterogeneity: not applicable
Test for overall effect: Z = 0.13 (P = 0.90)
Test for subgroup differences: Not applicable
0.2 0.5 1 2 5
More with oral More with IV
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Analysis 18.1. Comparison 18 Cyclophosphamide (CPA) + corticosteroids versus corticosteroids, Outcome
1 Death.
Review: Immunosuppressive treatment for proliferative lupus nephritis
Comparison: 18 Cyclophosphamide (CPA) + corticosteroids versus corticosteroids
Outcome: 1 Death
Study or subgroup CPA+steroid Steroid Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Steinberg 1971 1/7 0/6 4.1 % 2.63 [ 0.13, 54.64 ]
Gourley 1996 10/55 1/27 9.1 % 4.91 [ 0.66, 36.40 ]
Sesso 1994a 2/14 3/15 13.3 % 0.71 [ 0.14, 3.66 ]
Donadio 1976 5/24 5/26 26.7 % 1.08 [ 0.36, 3.28 ]
Decker 1975 11/38 6/14 46.7 % 0.68 [ 0.31, 1.48 ]
Total (95% CI) 138 88 100.0 % 0.98 [ 0.53, 1.82 ]
Total events: 29 (CPA+steroid), 15 (Steroid)
Heterogeneity: Tau2 = 0.05; Chi2 = 4.43, df = 4 (P = 0.35); I2 =10%
Test for overall effect: Z = 0.07 (P = 0.94)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Less with CPA+steroid Less with steroid
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Analysis 18.2. Comparison 18 Cyclophosphamide (CPA) + corticosteroids versus corticosteroids, Outcome
2 Complete remission of proteinuria.
Review: Immunosuppressive treatment for proliferative lupus nephritis
Comparison: 18 Cyclophosphamide (CPA) + corticosteroids versus corticosteroids
Outcome: 2 Complete remission of proteinuria
Study or subgroup CPA+steroid Steroid Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Steinberg 1971 1/7 0/6 100.0 % 2.63 [ 0.13, 54.64 ]
Total (95% CI) 7 6 100.0 % 2.63 [ 0.13, 54.64 ]
Total events: 1 (CPA+steroid), 0 (Steroid)
Heterogeneity: not applicable
Test for overall effect: Z = 0.62 (P = 0.53)
Test for subgroup differences: Not applicable
0.005 0.1 1 10 200
More with steroid More with CPA+steroid
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Analysis 18.3. Comparison 18 Cyclophosphamide (CPA) + corticosteroids versus corticosteroids, Outcome
3 Adverse renal outcomes.
Review: Immunosuppressive treatment for proliferative lupus nephritis
Comparison: 18 Cyclophosphamide (CPA) + corticosteroids versus corticosteroids
Outcome: 3 Adverse renal outcomes
Study or subgroup CPA+steroid Steroid Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 ESKD
Sesso 1994a 2/14 3/15 8.8 % 0.71 [ 0.14, 3.66 ]
Donadio 1976 4/24 6/26 18.2 % 0.72 [ 0.23, 2.25 ]
Decker 1975 5/38 5/14 20.3 % 0.37 [ 0.13, 1.08 ]
Boumpas 1992 7/40 6/25 25.1 % 0.73 [ 0.28, 1.92 ]
Gourley 1996 9/55 6/27 27.6 % 0.74 [ 0.29, 1.86 ]
Subtotal (95% CI) 171 107 100.0 % 0.63 [ 0.39, 1.03 ]
Total events: 27 (CPA+steroid), 26 (Steroid)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.23, df = 4 (P = 0.87); I2 =0.0%
Test for overall effect: Z = 1.84 (P = 0.066)
2 Renal relapse
Gourley 1996 1/31 4/11 23.5 % 0.09 [ 0.01, 0.71 ]
Donadio 1976 3/21 10/21 76.5 % 0.30 [ 0.10, 0.94 ]
Subtotal (95% CI) 52 32 100.0 % 0.23 [ 0.08, 0.62 ]
Total events: 4 (CPA+steroid), 14 (Steroid)
Heterogeneity: Tau2 = 0.01; Chi2 = 1.02, df = 1 (P = 0.31); I2 =1%
Test for overall effect: Z = 2.88 (P = 0.0039)
3 Doubling serum creatinine
Sesso 1994a 4/14 5/15 13.0 % 0.86 [ 0.29, 2.56 ]
Decker 1975 9/38 7/14 26.0 % 0.47 [ 0.22, 1.03 ]
Gourley 1996 12/55 8/27 26.6 % 0.74 [ 0.34, 1.59 ]
Boumpas 1992 10/40 12/25 34.4 % 0.52 [ 0.27, 1.02 ]
Subtotal (95% CI) 147 81 100.0 % 0.59 [ 0.40, 0.88 ]
Total events: 35 (CPA+steroid), 32 (Steroid)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.22, df = 3 (P = 0.75); I2 =0.0%
Test for overall effect: Z = 2.58 (P = 0.0099)
Test for subgroup differences: Chi2 = 3.44, df = 2 (P = 0.18), I2 =42%
0.01 0.1 1 10 100
Less with CPA+steroid Less with steroid
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Analysis 18.4. Comparison 18 Cyclophosphamide (CPA) + corticosteroids versus corticosteroids, Outcome
4 Deterioration of kidney function.
Review: Immunosuppressive treatment for proliferative lupus nephritis
Comparison: 18 Cyclophosphamide (CPA) + corticosteroids versus corticosteroids
Outcome: 4 Deterioration of kidney function
Study or subgroup CPA+steroid Steroid Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Gourley 1996 8/27 3/13 12.6 % 1.28 [ 0.41, 4.06 ]
Sesso 1994a 4/14 5/15 13.9 % 0.86 [ 0.29, 2.56 ]
Decker 1975 4/20 4/7 14.1 % 0.35 [ 0.12, 1.04 ]
Boumpas 1992 7/20 6/13 23.8 % 0.76 [ 0.33, 1.75 ]
Donadio 1976 9/24 11/26 35.6 % 0.89 [ 0.45, 1.76 ]
Total (95% CI) 105 74 100.0 % 0.78 [ 0.52, 1.18 ]
Total events: 32 (CPA+steroid), 29 (Steroid)
Heterogeneity: Tau2 = 0.0; Chi2 = 3.00, df = 4 (P = 0.56); I2 =0.0%
Test for overall effect: Z = 1.19 (P = 0.24)
Test for subgroup differences: Not applicable
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Analysis 18.5. Comparison 18 Cyclophosphamide (CPA) + corticosteroids versus corticosteroids, Outcome
5 Stable kidney function.
Review: Immunosuppressive treatment for proliferative lupus nephritis
Comparison: 18 Cyclophosphamide (CPA) + corticosteroids versus corticosteroids
Outcome: 5 Stable kidney function
Study or subgroup CPA+steroid Steroid Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Decker 1975 29/38 6/14 8.4 % 1.78 [ 0.95, 3.34 ]
Sesso 1994a 10/14 10/15 14.0 % 1.07 [ 0.66, 1.74 ]
Donadio 1976 15/24 15/26 16.3 % 1.08 [ 0.69, 1.70 ]
Boumpas 1992 30/40 13/25 19.2 % 1.44 [ 0.95, 2.19 ]
Gourley 1996 43/55 19/27 42.0 % 1.11 [ 0.84, 1.47 ]
Total (95% CI) 171 107 100.0 % 1.20 [ 1.00, 1.45 ]
Total events: 127 (CPA+steroid), 63 (Steroid)
Heterogeneity: Tau2 = 0.0; Chi2 = 3.11, df = 4 (P = 0.54); I2 =0.0%
Test for overall effect: Z = 1.99 (P = 0.046)
Test for subgroup differences: Not applicable
0.2 0.5 1 2 5
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Analysis 18.6. Comparison 18 Cyclophosphamide (CPA) + corticosteroids versus corticosteroids, Outcome
6 Ovarian failure.
Review: Immunosuppressive treatment for proliferative lupus nephritis
Comparison: 18 Cyclophosphamide (CPA) + corticosteroids versus corticosteroids
Outcome: 6 Ovarian failure
Study or subgroup CPA+steroid Steroid Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Boumpas 1992 8/29 0/15 5.9 % 9.07 [ 0.56, 147.16 ]
Decker 1975 15/27 2/12 24.1 % 3.33 [ 0.90, 12.35 ]
Gourley 1996 24/43 7/21 70.0 % 1.67 [ 0.86, 3.24 ]
Total (95% CI) 99 48 100.0 % 2.18 [ 1.10, 4.34 ]
Total events: 47 (CPA+steroid), 9 (Steroid)
Heterogeneity: Tau2 = 0.06; Chi2 = 2.27, df = 2 (P = 0.32); I2 =12%
Test for overall effect: Z = 2.23 (P = 0.026)
Test for subgroup differences: Not applicable
0.005 0.1 1 10 200
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Analysis 18.7. Comparison 18 Cyclophosphamide (CPA) + corticosteroids versus corticosteroids, Outcome
7 Infection.
Review: Immunosuppressive treatment for proliferative lupus nephritis
Comparison: 18 Cyclophosphamide (CPA) + corticosteroids versus corticosteroids
Outcome: 7 Infection
Study or subgroup CPA+steroid Steroid Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Major infection
Steinberg 1971 0/7 1/6 3.3 % 0.29 [ 0.01, 6.07 ]
Boumpas 1992 2/40 0/25 3.4 % 3.17 [ 0.16, 63.45 ]
Sesso 1994a 2/14 1/15 5.8 % 2.14 [ 0.22, 21.10 ]
Donadio 1976 2/24 4/26 11.9 % 0.54 [ 0.11, 2.69 ]
Decker 1975 5/38 4/14 22.6 % 0.46 [ 0.14, 1.47 ]
Gourley 1996 16/55 7/27 53.0 % 1.12 [ 0.53, 2.40 ]
Subtotal (95% CI) 178 113 100.0 % 0.87 [ 0.50, 1.51 ]
Total events: 27 (CPA+steroid), 17 (Steroid)
Heterogeneity: Tau2 = 0.0; Chi2 = 3.73, df = 5 (P = 0.59); I2 =0.0%
Test for overall effect: Z = 0.51 (P = 0.61)
2 Herpes zoster virus
Boumpas 1992 3/40 3/25 30.8 % 0.63 [ 0.14, 2.86 ]
Gourley 1996 16/55 2/27 34.3 % 3.93 [ 0.97, 15.86 ]
Decker 1975 11/38 2/14 34.9 % 2.03 [ 0.51, 8.03 ]
Subtotal (95% CI) 133 66 100.0 % 1.77 [ 0.63, 4.99 ]
Total events: 30 (CPA+steroid), 7 (Steroid)
Heterogeneity: Tau2 = 0.31; Chi2 = 3.16, df = 2 (P = 0.21); I2 =37%
Test for overall effect: Z = 1.08 (P = 0.28)
Test for subgroup differences: Chi2 = 1.42, df = 1 (P = 0.23), I2 =30%
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Analysis 18.8. Comparison 18 Cyclophosphamide (CPA) + corticosteroids versus corticosteroids, Outcome
8 Malignancy.
Review: Immunosuppressive treatment for proliferative lupus nephritis
Comparison: 18 Cyclophosphamide (CPA) + corticosteroids versus corticosteroids
Outcome: 8 Malignancy
Study or subgroup CPA+steroid Steroid Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Boumpas 1992 0/40 1/25 46.8 % 0.21 [ 0.01, 5.00 ]
Decker 1975 3/38 0/14 53.2 % 2.69 [ 0.15, 49.06 ]
Total (95% CI) 78 39 100.0 % 0.82 [ 0.07, 9.90 ]
Total events: 3 (CPA+steroid), 1 (Steroid)
Heterogeneity: Tau2 = 0.85; Chi2 = 1.36, df = 1 (P = 0.24); I2 =26%
Test for overall effect: Z = 0.16 (P = 0.87)
Test for subgroup differences: Not applicable
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Analysis 18.9. Comparison 18 Cyclophosphamide (CPA) + corticosteroids versus corticosteroids, Outcome
9 Bone toxicity.
Review: Immunosuppressive treatment for proliferative lupus nephritis
Comparison: 18 Cyclophosphamide (CPA) + corticosteroids versus corticosteroids
Outcome: 9 Bone toxicity
Study or subgroup CPA+steroid Steroid Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Donadio 1976 0/24 1/26 5.5 % 0.36 [ 0.02, 8.43 ]
Boumpas 1992 7/40 3/25 34.5 % 1.46 [ 0.41, 5.12 ]
Gourley 1996 8/55 6/27 60.0 % 0.65 [ 0.25, 1.70 ]
Total (95% CI) 119 78 100.0 % 0.84 [ 0.40, 1.75 ]
Total events: 15 (CPA+steroid), 10 (Steroid)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.28, df = 2 (P = 0.53); I2 =0.0%
Test for overall effect: Z = 0.48 (P = 0.63)
Test for subgroup differences: Not applicable
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Analysis 18.10. Comparison 18 Cyclophosphamide (CPA) + corticosteroids versus corticosteroids,
Outcome 10 Bladder toxicity.
Review: Immunosuppressive treatment for proliferative lupus nephritis
Comparison: 18 Cyclophosphamide (CPA) + corticosteroids versus corticosteroids
Outcome: 10 Bladder toxicity
Study or subgroup CPA+steroid Steroid Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Steinberg 1971 1/7 0/6 47.8 % 2.63 [ 0.13, 54.64 ]
Decker 1975 3/38 0/14 52.2 % 2.69 [ 0.15, 49.06 ]
Total (95% CI) 45 20 100.0 % 2.66 [ 0.33, 21.68 ]
Total events: 4 (CPA+steroid), 0 (Steroid)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.00, df = 1 (P = 0.99); I2 =0.0%
Test for overall effect: Z = 0.91 (P = 0.36)
Test for subgroup differences: Not applicable
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Analysis 18.11. Comparison 18 Cyclophosphamide (CPA) + corticosteroids versus corticosteroids,
Outcome 11 Daily proteinuria.
Review: Immunosuppressive treatment for proliferative lupus nephritis
Comparison: 18 Cyclophosphamide (CPA) + corticosteroids versus corticosteroids
Outcome: 11 Daily proteinuria
Study or subgroup CPA+steroid Steroid
Mean
Difference Weight
Mean
Difference
N Mean(SD)[g/24 h] N Mean(SD)[g/24 h] IV,Random,95% CI IV,Random,95% CI
Steinberg 1971 7 2.6 (0) 6 3.7 (0) Not estimable
Donadio 1976 24 2.9 (2.8) 26 2.2 (1.6) 9.0 % 0.70 [ -0.58, 1.98 ]
Sesso 1994a 14 1.6 (0.5) 15 1.5 (0.6) 91.0 % 0.10 [ -0.30, 0.50 ]
Total (95% CI) 45 47 100.0 % 0.15 [ -0.23, 0.54 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.77, df = 1 (P = 0.38); I2 =0.0%
Test for overall effect: Z = 0.79 (P = 0.43)
Test for subgroup differences: Not applicable
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Analysis 18.12. Comparison 18 Cyclophosphamide (CPA) + corticosteroids versus corticosteroids,
Outcome 12 Serum creatinine.
Review: Immunosuppressive treatment for proliferative lupus nephritis
Comparison: 18 Cyclophosphamide (CPA) + corticosteroids versus corticosteroids
Outcome: 12 Serum creatinine
Study or subgroup CPA+steroid Steroid
Mean
Difference Weight
Mean
Difference
N
Mean(SD)[
mol/L] N
Mean(SD)[
mol/L] IV,Random,95% CI IV,Random,95% CI
Sesso 1994a 14 269 (75) 15 321 (88) 100.0 % -52.00 [ -111.39, 7.39 ]
Total (95% CI) 14 15 100.0 % -52.00 [ -111.39, 7.39 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.72 (P = 0.086)
Test for subgroup differences: Not applicable
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Analysis 18.13. Comparison 18 Cyclophosphamide (CPA) + corticosteroids versus corticosteroids,
Outcome 13 Creatinine clearance.
Review: Immunosuppressive treatment for proliferative lupus nephritis
Comparison: 18 Cyclophosphamide (CPA) + corticosteroids versus corticosteroids
Outcome: 13 Creatinine clearance
Study or subgroup CPA+steroid Steroid
Mean
Difference Weight
Mean
Difference
N Mean(SD)[mL/min] N Mean(SD)[mL/min] IV,Random,95% CI IV,Random,95% CI
Donadio 1976 24 84.4 (23.9) 26 80.5 (24.3) 36.4 % 3.90 [ -9.47, 17.27 ]
Steinberg 1971 7 65 (0.01) 6 48 (0.01) 63.6 % 17.00 [ 16.99, 17.01 ]
Total (95% CI) 31 32 100.0 % 12.23 [ -0.13, 24.58 ]
Heterogeneity: Tau2 = 62.55; Chi2 = 3.69, df = 1 (P = 0.05); I2 =73%
Test for overall effect: Z = 1.94 (P = 0.052)
Test for subgroup differences: Not applicable
-50 -25 0 25 50
Higher with steroid Higher with CPA+steroid
333Immunosuppressive treatment for proliferative lupus nephritis (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 19.1. Comparison 19 Cyclophosphamide (CPA) + azathioprine (AZA) + corticosteroids versus
corticosteroids alone, Outcome 1 Death.
Review: Immunosuppressive treatment for proliferative lupus nephritis
Comparison: 19 Cyclophosphamide (CPA) + azathioprine (AZA) + corticosteroids versus corticosteroids alone
Outcome: 1 Death
Study or subgroup CPA+AZA+steroid Steroid Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Decker 1975 5/22 3/7 100.0 % 0.53 [ 0.17, 1.68 ]
Total (95% CI) 22 7 100.0 % 0.53 [ 0.17, 1.68 ]
Total events: 5 (CPA+AZA+steroid), 3 (Steroid)
Heterogeneity: not applicable
Test for overall effect: Z = 1.08 (P = 0.28)
Test for subgroup differences: Not applicable
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Analysis 19.2. Comparison 19 Cyclophosphamide (CPA) + azathioprine (AZA) + corticosteroids versus
corticosteroids alone, Outcome 2 Adverse renal outcomes.
Review: Immunosuppressive treatment for proliferative lupus nephritis
Comparison: 19 Cyclophosphamide (CPA) + azathioprine (AZA) + corticosteroids versus corticosteroids alone
Outcome: 2 Adverse renal outcomes
Study or subgroup CPA+AZA+steroid Steroid Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 ESKD
Decker 1975 2/22 3/7 100.0 % 0.21 [ 0.04, 1.02 ]
Subtotal (95% CI) 22 7 100.0 % 0.21 [ 0.04, 1.02 ]
Total events: 2 (CPA+AZA+steroid), 3 (Steroid)
Heterogeneity: not applicable
Test for overall effect: Z = 1.93 (P = 0.054)
2 Doubling of serum creatinine
Decker 1975 2/22 4/7 100.0 % 0.16 [ 0.04, 0.69 ]
Subtotal (95% CI) 22 7 100.0 % 0.16 [ 0.04, 0.69 ]
Total events: 2 (CPA+AZA+steroid), 4 (Steroid)
Heterogeneity: not applicable
Test for overall effect: Z = 2.45 (P = 0.014)
Test for subgroup differences: Chi2 = 0.07, df = 1 (P = 0.79), I2 =0.0%
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Analysis 19.3. Comparison 19 Cyclophosphamide (CPA) + azathioprine (AZA) + corticosteroids versus
corticosteroids alone, Outcome 3 Stable kidney function.
Review: Immunosuppressive treatment for proliferative lupus nephritis
Comparison: 19 Cyclophosphamide (CPA) + azathioprine (AZA) + corticosteroids versus corticosteroids alone
Outcome: 3 Stable kidney function
Study or subgroup CPA+AZA+steroid Steroid Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Decker 1975 20/22 4/7 100.0 % 1.59 [ 0.83, 3.06 ]
Total (95% CI) 22 7 100.0 % 1.59 [ 0.83, 3.06 ]
Total events: 20 (CPA+AZA+steroid), 4 (Steroid)
Heterogeneity: not applicable
Test for overall effect: Z = 1.39 (P = 0.16)
Test for subgroup differences: Not applicable
0.2 0.5 1 2 5
More with steroid alone More with CPA+AZA+steroid
Analysis 19.4. Comparison 19 Cyclophosphamide (CPA) + azathioprine (AZA) + corticosteroids versus
corticosteroids alone, Outcome 4 Ovarian failure.
Review: Immunosuppressive treatment for proliferative lupus nephritis
Comparison: 19 Cyclophosphamide (CPA) + azathioprine (AZA) + corticosteroids versus corticosteroids alone
Outcome: 4 Ovarian failure
Study or subgroup CPA+AZA+steroid Steroid Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Decker 1975 11/21 0/6 100.0 % 7.32 [ 0.49, 108.96 ]
Total (95% CI) 21 6 100.0 % 7.32 [ 0.49, 108.96 ]
Total events: 11 (CPA+AZA+steroid), 0 (Steroid)
Heterogeneity: not applicable
Test for overall effect: Z = 1.44 (P = 0.15)
Test for subgroup differences: Not applicable
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Analysis 19.5. Comparison 19 Cyclophosphamide (CPA) + azathioprine (AZA) + corticosteroids versus
corticosteroids alone, Outcome 5 Infection.
Review: Immunosuppressive treatment for proliferative lupus nephritis
Comparison: 19 Cyclophosphamide (CPA) + azathioprine (AZA) + corticosteroids versus corticosteroids alone
Outcome: 5 Infection
Study or subgroup CPA+AZA+steroid Steroid Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Major infection
Decker 1975 3/22 2/7 100.0 % 0.48 [ 0.10, 2.30 ]
Subtotal (95% CI) 22 7 100.0 % 0.48 [ 0.10, 2.30 ]
Total events: 3 (CPA+AZA+steroid), 2 (Steroid)
Heterogeneity: not applicable
Test for overall effect: Z = 0.92 (P = 0.36)
2 Herpes zoster virus
Decker 1975 7/22 0/7 100.0 % 5.22 [ 0.33, 81.40 ]
Subtotal (95% CI) 22 7 100.0 % 5.22 [ 0.33, 81.40 ]
Total events: 7 (CPA+AZA+steroid), 0 (Steroid)
Heterogeneity: not applicable
Test for overall effect: Z = 1.18 (P = 0.24)
Test for subgroup differences: Chi2 = 2.19, df = 1 (P = 0.14), I2 =54%
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Analysis 19.6. Comparison 19 Cyclophosphamide (CPA) + azathioprine (AZA) + corticosteroids versus
corticosteroids alone, Outcome 6 Bladder toxicity.
Review: Immunosuppressive treatment for proliferative lupus nephritis
Comparison: 19 Cyclophosphamide (CPA) + azathioprine (AZA) + corticosteroids versus corticosteroids alone
Outcome: 6 Bladder toxicity
Study or subgroup CPA+AZA+steroid Steroid Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Decker 1975 3/22 0/7 100.0 % 2.43 [ 0.14, 42.17 ]
Total (95% CI) 22 7 100.0 % 2.43 [ 0.14, 42.17 ]
Total events: 3 (CPA+AZA+steroid), 0 (Steroid)
Heterogeneity: not applicable
Test for overall effect: Z = 0.61 (P = 0.54)
Test for subgroup differences: Not applicable
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Analysis 20.1. Comparison 20 Azathioprine (AZA) + corticosteroids versus corticosteroids alone, Outcome
1 Death.
Review: Immunosuppressive treatment for proliferative lupus nephritis
Comparison: 20 Azathioprine (AZA) + corticosteroids versus corticosteroids alone
Outcome: 1 Death
Study or subgroup AZA+steroid Steroid Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Hahn 1975 2/11 4/13 11.2 % 0.59 [ 0.13, 2.64 ]
Decker 1975 7/19 3/7 23.3 % 0.86 [ 0.30, 2.43 ]
Cade 1973 6/13 13/15 65.4 % 0.53 [ 0.29, 0.99 ]
Total (95% CI) 43 35 100.0 % 0.60 [ 0.36, 0.99 ]
Total events: 15 (AZA+steroid), 20 (Steroid)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.61, df = 2 (P = 0.74); I2 =0.0%
Test for overall effect: Z = 1.98 (P = 0.048)
Test for subgroup differences: Not applicable
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Analysis 20.2. Comparison 20 Azathioprine (AZA) + corticosteroids versus corticosteroids alone, Outcome
2 Complete remission of proteinuria.
Review: Immunosuppressive treatment for proliferative lupus nephritis
Comparison: 20 Azathioprine (AZA) + corticosteroids versus corticosteroids alone
Outcome: 2 Complete remission of proteinuria
Study or subgroup AZA+steroid Steroid Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Donadio 1972 1/7 0/9 3.4 % 3.75 [ 0.18, 80.19 ]
Hahn 1975 8/11 8/10 96.6 % 0.91 [ 0.56, 1.46 ]
Total (95% CI) 18 19 100.0 % 0.95 [ 0.54, 1.69 ]
Total events: 9 (AZA+steroid), 8 (Steroid)
Heterogeneity: Tau2 = 0.03; Chi2 = 1.02, df = 1 (P = 0.31); I2 =2%
Test for overall effect: Z = 0.16 (P = 0.87)
Test for subgroup differences: Not applicable
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Analysis 20.3. Comparison 20 Azathioprine (AZA) + corticosteroids versus corticosteroids alone, Outcome
3 Adverse renal outcomes.
Review: Immunosuppressive treatment for proliferative lupus nephritis
Comparison: 20 Azathioprine (AZA) + corticosteroids versus corticosteroids alone
Outcome: 3 Adverse renal outcomes
Study or subgroup AZA+steroid Steroid Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 ESKD
Cade 1973 2/13 7/15 48.6 % 0.33 [ 0.08, 1.32 ]
Decker 1975 7/19 2/7 51.4 % 1.29 [ 0.35, 4.78 ]
Subtotal (95% CI) 32 22 100.0 % 0.66 [ 0.17, 2.55 ]
Total events: 9 (AZA+steroid), 9 (Steroid)
Heterogeneity: Tau2 = 0.47; Chi2 = 1.99, df = 1 (P = 0.16); I2 =50%
Test for overall effect: Z = 0.60 (P = 0.55)
2 Renal relapse
Donadio 1972 3/9 3/7 100.0 % 0.78 [ 0.22, 2.74 ]
Subtotal (95% CI) 9 7 100.0 % 0.78 [ 0.22, 2.74 ]
Total events: 3 (AZA+steroid), 3 (Steroid)
Heterogeneity: not applicable
Test for overall effect: Z = 0.39 (P = 0.70)
3 Doubling of serum creatinine
Decker 1975 8/19 3/7 100.0 % 0.98 [ 0.36, 2.68 ]
Subtotal (95% CI) 19 7 100.0 % 0.98 [ 0.36, 2.68 ]
Total events: 8 (AZA+steroid), 3 (Steroid)
Heterogeneity: not applicable
Test for overall effect: Z = 0.03 (P = 0.97)
Test for subgroup differences: Chi2 = 0.22, df = 2 (P = 0.89), I2 =0.0%
0.05 0.2 1 5 20
Less with AZA+steroid Less with steroid alone
341Immunosuppressive treatment for proliferative lupus nephritis (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 20.4. Comparison 20 Azathioprine (AZA) + corticosteroids versus corticosteroids alone, Outcome
4 Stable kidney function.
Review: Immunosuppressive treatment for proliferative lupus nephritis
Comparison: 20 Azathioprine (AZA) + corticosteroids versus corticosteroids alone
Outcome: 4 Stable kidney function
Study or subgroup AZA+steroid Steroid Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Decker 1975 11/19 4/7 100.0 % 1.01 [ 0.48, 2.14 ]
Total (95% CI) 19 7 100.0 % 1.01 [ 0.48, 2.14 ]
Total events: 11 (AZA+steroid), 4 (Steroid)
Heterogeneity: not applicable
Test for overall effect: Z = 0.03 (P = 0.97)
Test for subgroup differences: Not applicable
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Analysis 20.5. Comparison 20 Azathioprine (AZA) + corticosteroids versus corticosteroids alone, Outcome
5 Ovarian failure.
Review: Immunosuppressive treatment for proliferative lupus nephritis
Comparison: 20 Azathioprine (AZA) + corticosteroids versus corticosteroids alone
Outcome: 5 Ovarian failure
Study or subgroup AZA+steroid Steroid Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Decker 1975 3/18 0/6 100.0 % 2.58 [ 0.15, 43.86 ]
Total (95% CI) 18 6 100.0 % 2.58 [ 0.15, 43.86 ]
Total events: 3 (AZA+steroid), 0 (Steroid)
Heterogeneity: not applicable
Test for overall effect: Z = 0.66 (P = 0.51)
Test for subgroup differences: Not applicable
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Analysis 20.6. Comparison 20 Azathioprine (AZA) + corticosteroids versus corticosteroids alone, Outcome
6 Infection.
Review: Immunosuppressive treatment for proliferative lupus nephritis
Comparison: 20 Azathioprine (AZA) + corticosteroids versus corticosteroids alone
Outcome: 6 Infection
Study or subgroup AZA+steroid Steroid Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Herpes zoster virus
Decker 1975 2/19 0/7 49.4 % 2.00 [ 0.11, 37.22 ]
Donadio 1972 2/7 0/9 50.6 % 6.25 [ 0.35, 112.52 ]
Subtotal (95% CI) 26 16 100.0 % 3.56 [ 0.46, 27.79 ]
Total events: 4 (AZA+steroid), 0 (Steroid)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.30, df = 1 (P = 0.59); I2 =0.0%
Test for overall effect: Z = 1.21 (P = 0.23)
Test for subgroup differences: Not applicable
0.005 0.1 1 10 200
Less with AZA+steroid Less with steroid alone
Analysis 20.7. Comparison 20 Azathioprine (AZA) + corticosteroids versus corticosteroids alone, Outcome
7 Malignancy.
Review: Immunosuppressive treatment for proliferative lupus nephritis
Comparison: 20 Azathioprine (AZA) + corticosteroids versus corticosteroids alone
Outcome: 7 Malignancy
Study or subgroup AZA+steroid Steroid Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Decker 1975 2/19 0/7 100.0 % 2.00 [ 0.11, 37.22 ]
Total (95% CI) 19 7 100.0 % 2.00 [ 0.11, 37.22 ]
Total events: 2 (AZA+steroid), 0 (Steroid)
Heterogeneity: not applicable
Test for overall effect: Z = 0.46 (P = 0.64)
Test for subgroup differences: Not applicable
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Analysis 20.8. Comparison 20 Azathioprine (AZA) + corticosteroids versus corticosteroids alone, Outcome
8 Bone toxicity.
Review: Immunosuppressive treatment for proliferative lupus nephritis
Comparison: 20 Azathioprine (AZA) + corticosteroids versus corticosteroids alone
Outcome: 8 Bone toxicity
Study or subgroup AZA+steroid Steroid Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Hahn 1975 3/11 1/13 100.0 % 3.55 [ 0.43, 29.42 ]
Total (95% CI) 11 13 100.0 % 3.55 [ 0.43, 29.42 ]
Total events: 3 (AZA+steroid), 1 (Steroid)
Heterogeneity: not applicable
Test for overall effect: Z = 1.17 (P = 0.24)
Test for subgroup differences: Not applicable
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Analysis 20.9. Comparison 20 Azathioprine (AZA) + corticosteroids versus corticosteroids alone, Outcome
9 Creatinine clearance.
Review: Immunosuppressive treatment for proliferative lupus nephritis
Comparison: 20 Azathioprine (AZA) + corticosteroids versus corticosteroids alone
Outcome: 9 Creatinine clearance
Study or subgroup AZA+steroid Steroid
Mean
Difference Weight
Mean
Difference
N Mean(SD)[mL/min] N Mean(SD)[mL/min] IV,Random,95% CI IV,Random,95% CI
Hahn 1975 11 102 (11) 13 97 (9) 100.0 % 5.00 [ -3.14, 13.14 ]
Total (95% CI) 11 13 100.0 % 5.00 [ -3.14, 13.14 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.20 (P = 0.23)
Test for subgroup differences: Not applicable
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Analysis 21.1. Comparison 21 Cyclosporin (CSA) + corticosteroids versus corticosteroids alone, Outcome
1 Daily proteinuria.
Review: Immunosuppressive treatment for proliferative lupus nephritis
Comparison: 21 Cyclosporin (CSA) + corticosteroids versus corticosteroids alone
Outcome: 1 Daily proteinuria
Study or subgroup CSA+steroid Steroid
Mean
Difference Weight
Mean
Difference
N Mean(SD)[g/24 h] N Mean(SD)[g/24 h] IV,Random,95% CI IV,Random,95% CI
Balletta 1992 5 0.3 (0.1) 5 2.1 (0.9) 100.0 % -1.80 [ -2.59, -1.01 ]
Total (95% CI) 5 5 100.0 % -1.80 [ -2.59, -1.01 ]
Heterogeneity: not applicable
Test for overall effect: Z = 4.44 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 21.2. Comparison 21 Cyclosporin (CSA) + corticosteroids versus corticosteroids alone, Outcome
2 Serum creatinine.
Review: Immunosuppressive treatment for proliferative lupus nephritis
Comparison: 21 Cyclosporin (CSA) + corticosteroids versus corticosteroids alone
Outcome: 2 Serum creatinine
Study or subgroup CSA+steroid Steroid
Mean
Difference Weight
Mean
Difference
N
Mean(SD)[
mol/L] N
Mean(SD)[
mol/L] IV,Random,95% CI IV,Random,95% CI
Balletta 1992 5 91.9 (17.7) 5 123.8 (44.2) 100.0 % -31.90 [ -73.63, 9.83 ]
Total (95% CI) 5 5 100.0 % -31.90 [ -73.63, 9.83 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.50 (P = 0.13)
Test for subgroup differences: Not applicable
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Analysis 21.3. Comparison 21 Cyclosporin (CSA) + corticosteroids versus corticosteroids alone, Outcome
3 Creatinine clearance.
Review: Immunosuppressive treatment for proliferative lupus nephritis
Comparison: 21 Cyclosporin (CSA) + corticosteroids versus corticosteroids alone
Outcome: 3 Creatinine clearance
Study or subgroup CSA+steroid Steroid
Mean
Difference Weight
Mean
Difference
N Mean(SD)[mL/min] N Mean(SD)[mL/min] IV,Random,95% CI IV,Random,95% CI
Balletta 1992 5 81.3 (20) 5 123.8 (44.2) 100.0 % -42.50 [ -85.02, 0.02 ]
Total (95% CI) 5 5 100.0 % -42.50 [ -85.02, 0.02 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.96 (P = 0.050)
Test for subgroup differences: Not applicable
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Analysis 22.1. Comparison 22 Misoprostol + corticosteroids versus corticosteroids alone, Outcome 1
Adverse renal outcomes.
Review: Immunosuppressive treatment for proliferative lupus nephritis
Comparison: 22 Misoprostol + corticosteroids versus corticosteroids alone
Outcome: 1 Adverse renal outcomes
Study or subgroup Misoprostol+steroid Steroid Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Doubling of serum creatinine
Belmont 1995 0/7 0/7 Not estimable
Subtotal (95% CI) 7 7 Not estimable
Total events: 0 (Misoprostol+steroid), 0 (Steroid)
Heterogeneity: not applicable
Test for overall effect: not applicable
Test for subgroup differences: Chi2 = 0.0, df = -1 (P = 0.0), I2 =0.0%
0.01 0.1 1 10 100
Less with misoprostol+steroid Less with steroid alone
Analysis 23.1. Comparison 23 Plasma exchange (PE) + immunosuppression (IS) versus IS alone, Outcome 1
Death.
Review: Immunosuppressive treatment for proliferative lupus nephritis
Comparison: 23 Plasma exchange (PE) + immunosuppression (IS) versus IS alone
Outcome: 1 Death
Study or subgroup PE+IS IS Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Clark 1984 1/20 0/19 8.7 % 2.86 [ 0.12, 66.11 ]
Lewis 1992 8/40 6/46 91.3 % 1.53 [ 0.58, 4.04 ]
Total (95% CI) 60 65 100.0 % 1.62 [ 0.64, 4.09 ]
Total events: 9 (PE+IS), 6 (IS)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.14, df = 1 (P = 0.71); I2 =0.0%
Test for overall effect: Z = 1.02 (P = 0.31)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Less with PE+IS Less with IS alone
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Analysis 23.2. Comparison 23 Plasma exchange (PE) + immunosuppression (IS) versus IS alone, Outcome 2
Adverse renal outcomes.
Review: Immunosuppressive treatment for proliferative lupus nephritis
Comparison: 23 Plasma exchange (PE) + immunosuppression (IS) versus IS alone
Outcome: 2 Adverse renal outcomes
Study or subgroup PE+IS IS Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 ESKD
Clark 1984 0/20 1/19 3.0 % 0.32 [ 0.01, 7.35 ]
Wallace 1998 2/9 2/9 9.4 % 1.00 [ 0.18, 5.63 ]
Lewis 1992 10/40 8/46 32.4 % 1.44 [ 0.63, 3.29 ]
Subtotal (95% CI) 69 74 44.8 % 1.24 [ 0.60, 2.57 ]
Total events: 12 (PE+IS), 11 (IS)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.91, df = 2 (P = 0.63); I2 =0.0%
Test for overall effect: Z = 0.59 (P = 0.56)
2 Doubling of serum creatinine
Clark 1984 0/20 3/19 3.5 % 0.14 [ 0.01, 2.47 ]
Clark 1981 0/6 2/6 3.6 % 0.20 [ 0.01, 3.46 ]
Subtotal (95% CI) 26 25 7.2 % 0.17 [ 0.02, 1.26 ]
Total events: 0 (PE+IS), 5 (IS)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.03, df = 1 (P = 0.85); I2 =0.0%
Test for overall effect: Z = 1.73 (P = 0.083)
3 Deterioration of kidney function
Clark 1984 0/20 3/19 3.5 % 0.14 [ 0.01, 2.47 ]
Wallace 1998 6/9 6/9 44.5 % 1.00 [ 0.52, 1.92 ]
Subtotal (95% CI) 29 28 48.1 % 0.53 [ 0.06, 4.83 ]
Total events: 6 (PE+IS), 9 (IS)
Heterogeneity: Tau2 = 1.78; Chi2 = 2.55, df = 1 (P = 0.11); I2 =61%
Test for overall effect: Z = 0.57 (P = 0.57)
Total (95% CI) 124 127 100.0 % 0.89 [ 0.51, 1.55 ]
Total events: 18 (PE+IS), 25 (IS)
Heterogeneity: Tau2 = 0.07; Chi2 = 6.75, df = 6 (P = 0.34); I2 =11%
Test for overall effect: Z = 0.41 (P = 0.68)
Test for subgroup differences: Chi2 = 3.64, df = 2 (P = 0.16), I2 =45%
0.005 0.1 1 10 200
Less with PE+IS Less with IS alone
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Analysis 23.3. Comparison 23 Plasma exchange (PE) + immunosuppression (IS) versus IS alone, Outcome 3
Stable kidney function.
Review: Immunosuppressive treatment for proliferative lupus nephritis
Comparison: 23 Plasma exchange (PE) + immunosuppression (IS) versus IS alone
Outcome: 3 Stable kidney function
Study or subgroup PE+IS IS Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Wallace 1998 3/9 3/9 1.6 % 1.00 [ 0.27, 3.69 ]
Doria 1994 5/5 13/13 39.2 % 1.00 [ 0.77, 1.30 ]
Clark 1984 20/20 16/19 59.3 % 1.18 [ 0.96, 1.46 ]
Total (95% CI) 34 41 100.0 % 1.10 [ 0.94, 1.30 ]
Total events: 28 (PE+IS), 32 (IS)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.98, df = 2 (P = 0.61); I2 =0.0%
Test for overall effect: Z = 1.19 (P = 0.23)
Test for subgroup differences: Not applicable
0.1 0.2 0.5 1 2 5 10
More with IS alone More with PE+IS
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Analysis 23.4. Comparison 23 Plasma exchange (PE) + immunosuppression (IS) versus IS alone, Outcome 4
Infection.
Review: Immunosuppressive treatment for proliferative lupus nephritis
Comparison: 23 Plasma exchange (PE) + immunosuppression (IS) versus IS alone
Outcome: 4 Infection
Study or subgroup PE+IS IS Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Major infection
Clark 1984 1/20 0/19 4.7 % 2.86 [ 0.12, 66.11 ]
Lewis 1992 9/40 16/46 95.3 % 0.65 [ 0.32, 1.30 ]
Subtotal (95% CI) 60 65 100.0 % 0.69 [ 0.35, 1.37 ]
Total events: 10 (PE+IS), 16 (IS)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.83, df = 1 (P = 0.36); I2 =0.0%
Test for overall effect: Z = 1.05 (P = 0.29)
2 Herpes zoster virus
Lewis 1992 0/40 1/46 48.9 % 0.38 [ 0.02, 9.13 ]
Doria 1994 1/5 0/13 51.1 % 7.00 [ 0.33, 148.46 ]
Subtotal (95% CI) 45 59 100.0 % 1.69 [ 0.10, 29.42 ]
Total events: 1 (PE+IS), 1 (IS)
Heterogeneity: Tau2 = 1.73; Chi2 = 1.68, df = 1 (P = 0.19); I2 =41%
Test for overall effect: Z = 0.36 (P = 0.72)
Test for subgroup differences: Chi2 = 0.35, df = 1 (P = 0.55), I2 =0.0%
0.005 0.1 1 10 200
Less with PE+IS Less with IS alone
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Analysis 23.5. Comparison 23 Plasma exchange (PE) + immunosuppression (IS) versus IS alone, Outcome 5
Leucopenia.
Review: Immunosuppressive treatment for proliferative lupus nephritis
Comparison: 23 Plasma exchange (PE) + immunosuppression (IS) versus IS alone
Outcome: 5 Leucopenia
Study or subgroup PE+IS IS Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Doria 1994 1/5 1/13 100.0 % 2.60 [ 0.20, 34.07 ]
Total (95% CI) 5 13 100.0 % 2.60 [ 0.20, 34.07 ]
Total events: 1 (PE+IS), 1 (IS)
Heterogeneity: not applicable
Test for overall effect: Z = 0.73 (P = 0.47)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Less with PE+IS Less with IS alone
Analysis 23.6. Comparison 23 Plasma exchange (PE) + immunosuppression (IS) versus IS alone, Outcome 6
Daily proteinuria.
Review: Immunosuppressive treatment for proliferative lupus nephritis
Comparison: 23 Plasma exchange (PE) + immunosuppression (IS) versus IS alone
Outcome: 6 Daily proteinuria
Study or subgroup PE+IS IS
Mean
Difference Weight
Mean
Difference
N Mean(SD)[g/24 h] N Mean(SD)[g/24 h] IV,Random,95% CI IV,Random,95% CI
Clark 1981 6 7.2 (6.1) 6 7.3 (8.9) 29.2 % -0.10 [ -8.73, 8.53 ]
Wallace 1998 9 4.43 (6.5) 9 5.18 (5.47) 70.8 % -0.75 [ -6.30, 4.80 ]
Total (95% CI) 15 15 100.0 % -0.56 [ -5.23, 4.11 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.02, df = 1 (P = 0.90); I2 =0.0%
Test for overall effect: Z = 0.24 (P = 0.81)
Test for subgroup differences: Not applicable
-10 -5 0 5 10
Lower with PE+IS Lower with IS alone
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Analysis 23.7. Comparison 23 Plasma exchange (PE) + immunosuppression (IS) versus IS alone, Outcome 7
Serum creatinine.
Review: Immunosuppressive treatment for proliferative lupus nephritis
Comparison: 23 Plasma exchange (PE) + immunosuppression (IS) versus IS alone
Outcome: 7 Serum creatinine
Study or subgroup PE+IS IS
Mean
Difference Weight
Mean
Difference
N
Mean(SD)[
mol/L] N
Mean(SD)[
mol/L] IV,Random,95% CI IV,Random,95% CI
Wallace 1998 9 178.8 (157.5) 9 240.5 (267.5) 0.1 % -61.70 [ -264.51, 141.11 ]
Clark 1981 6 97.2 (26.5) 6 150.3 (97.2) 0.5 % -53.10 [ -133.71, 27.51 ]
Clark 1984 20 97.2 (8.8) 19 114.9 (8.8) 99.5 % -17.70 [ -23.23, -12.17 ]
Total (95% CI) 35 34 100.0 % -17.90 [ -23.41, -12.39 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.92, df = 2 (P = 0.63); I2 =0.0%
Test for overall effect: Z = 6.37 (P < 0.00001)
Test for subgroup differences: Not applicable
-200 -100 0 100 200
Lower with PE+IS Lower with IS alone
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Analysis 23.8. Comparison 23 Plasma exchange (PE) + immunosuppression (IS) versus IS alone, Outcome 8
Creatinine clearance.
Review: Immunosuppressive treatment for proliferative lupus nephritis
Comparison: 23 Plasma exchange (PE) + immunosuppression (IS) versus IS alone
Outcome: 8 Creatinine clearance
Study or subgroup PE+IS IS
Mean
Difference Weight
Mean
Difference
N Mean(SD)[mL/min]N Mean(SD)[mL/min] IV,Random,95% CI IV,Random,95% CI
Clark 1981 6 92 (37) 6 66 (40) 100.0 % 26.00 [ -17.60, 69.60 ]
Total (95% CI) 6 6 100.0 % 26.00 [ -17.60, 69.60 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.17 (P = 0.24)
Test for subgroup differences: Not applicable
-100 -50 0 50 100
Higher with IS alone Higher with PE+IS
Analysis 23.9. Comparison 23 Plasma exchange (PE) + immunosuppression (IS) versus IS alone, Outcome 9
Disease activity (SLAM).
Review: Immunosuppressive treatment for proliferative lupus nephritis
Comparison: 23 Plasma exchange (PE) + immunosuppression (IS) versus IS alone
Outcome: 9 Disease activity (SLAM)
Study or subgroup PE+IS IS
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Wallace 1998 9 7.11 (4.78) 9 6.44 (4.16) 100.0 % 0.67 [ -3.47, 4.81 ]
Total (95% CI) 9 9 100.0 % 0.67 [ -3.47, 4.81 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.32 (P = 0.75)
Test for subgroup differences: Not applicable
-10 -5 0 5 10
Lower with IS Lower with PE+IS
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Analysis 24.1. Comparison 24 Plasma exchange (PE) versus immunosuppression (IS), Outcome 1 Adverse
renal outcomes.
Review: Immunosuppressive treatment for proliferative lupus nephritis
Comparison: 24 Plasma exchange (PE) versus immunosuppression (IS)
Outcome: 1 Adverse renal outcomes
Study or subgroup PE IS Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 ESKD
Derksen 1988 0/9 2/11 100.0 % 0.24 [ 0.01, 4.44 ]
Subtotal (95% CI) 9 11 100.0 % 0.24 [ 0.01, 4.44 ]
Total events: 0 (PE), 2 (IS)
Heterogeneity: not applicable
Test for overall effect: Z = 0.96 (P = 0.34)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Less with PE Less with IS
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Analysis 24.2. Comparison 24 Plasma exchange (PE) versus immunosuppression (IS), Outcome 2 Infection.
Review: Immunosuppressive treatment for proliferative lupus nephritis
Comparison: 24 Plasma exchange (PE) versus immunosuppression (IS)
Outcome: 2 Infection
Study or subgroup PE IS Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Major infection
Derksen 1988 0/9 1/11 100.0 % 0.40 [ 0.02, 8.78 ]
Subtotal (95% CI) 9 11 100.0 % 0.40 [ 0.02, 8.78 ]
Total events: 0 (PE), 1 (IS)
Heterogeneity: not applicable
Test for overall effect: Z = 0.58 (P = 0.56)
2 Herpes zoster virus
Derksen 1988 0/9 2/11 100.0 % 0.24 [ 0.01, 4.44 ]
Subtotal (95% CI) 9 11 100.0 % 0.24 [ 0.01, 4.44 ]
Total events: 0 (PE), 2 (IS)
Heterogeneity: not applicable
Test for overall effect: Z = 0.96 (P = 0.34)
0.01 0.1 1 10 100
Less with PE Less with IS
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Analysis 24.3. Comparison 24 Plasma exchange (PE) versus immunosuppression (IS), Outcome 3
Leucopenia.
Review: Immunosuppressive treatment for proliferative lupus nephritis
Comparison: 24 Plasma exchange (PE) versus immunosuppression (IS)
Outcome: 3 Leucopenia
Study or subgroup PE IS Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Derksen 1988 0/9 2/11 100.0 % 0.24 [ 0.01, 4.44 ]
Total (95% CI) 9 11 100.0 % 0.24 [ 0.01, 4.44 ]
Total events: 0 (PE), 2 (IS)
Heterogeneity: not applicable
Test for overall effect: Z = 0.96 (P = 0.34)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Less with PE Less with IS
Analysis 24.4. Comparison 24 Plasma exchange (PE) versus immunosuppression (IS), Outcome 4 Alopecia.
Review: Immunosuppressive treatment for proliferative lupus nephritis
Comparison: 24 Plasma exchange (PE) versus immunosuppression (IS)
Outcome: 4 Alopecia
Study or subgroup PE IS Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Derksen 1988 0/9 0/11 Not estimable
Total (95% CI) 9 11 Not estimable
Total events: 0 (PE), 0 (IS)
Heterogeneity: not applicable
Test for overall effect: not applicable
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Less with PE Less with IS
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Analysis 24.5. Comparison 24 Plasma exchange (PE) versus immunosuppression (IS), Outcome 5 Daily
proteinuria.
Review: Immunosuppressive treatment for proliferative lupus nephritis
Comparison: 24 Plasma exchange (PE) versus immunosuppression (IS)
Outcome: 5 Daily proteinuria
Study or subgroup PE IS
Mean
Difference Weight
Mean
Difference
N Mean(SD)[g/24 h] N Mean(SD)[g/24 h] IV,Random,95% CI IV,Random,95% CI
Nakamura 2002e 10 0.7 (0.4) 10 0.8 (0.4) 100.0 % -0.10 [ -0.45, 0.25 ]
Total (95% CI) 10 10 100.0 % -0.10 [ -0.45, 0.25 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.56 (P = 0.58)
Test for subgroup differences: Not applicable
-2 -1 0 1 2
Lower with PE Lower with IS
Analysis 24.6. Comparison 24 Plasma exchange (PE) versus immunosuppression (IS), Outcome 6
Creatinine clearance.
Review: Immunosuppressive treatment for proliferative lupus nephritis
Comparison: 24 Plasma exchange (PE) versus immunosuppression (IS)
Outcome: 6 Creatinine clearance
Study or subgroup PE IS
Mean
Difference Weight
Mean
Difference
N Mean(SD)[mL/min]N Mean(SD)[mL/min] IV,Random,95% CI IV,Random,95% CI
Derksen 1988 9 55 (26.2) 11 39.7 (19.7) 100.0 % 15.30 [ -5.40, 36.00 ]
Total (95% CI) 9 11 100.0 % 15.30 [ -5.40, 36.00 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.45 (P = 0.15)
Test for subgroup differences: Not applicable
-100 -50 0 50 100
Higher with IS Higher with PE
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Analysis 25.1. Comparison 25 Long versus short duration cyclophosphamide (CPA), Outcome 1 Adverse
renal outcomes.
Review: Immunosuppressive treatment for proliferative lupus nephritis
Comparison: 25 Long versus short duration cyclophosphamide (CPA)
Outcome: 1 Adverse renal outcomes
Study or subgroup Longer CPA Shorter CPA Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 ESKD
Boumpas 1992 2/20 5/20 100.0 % 0.40 [ 0.09, 1.83 ]
Subtotal (95% CI) 20 20 100.0 % 0.40 [ 0.09, 1.83 ]
Total events: 2 (Longer CPA), 5 (Shorter CPA)
Heterogeneity: not applicable
Test for overall effect: Z = 1.18 (P = 0.24)
2 Doubling of serum creatinine
Boumpas 1992 3/20 7/20 100.0 % 0.43 [ 0.13, 1.43 ]
Subtotal (95% CI) 20 20 100.0 % 0.43 [ 0.13, 1.43 ]
Total events: 3 (Longer CPA), 7 (Shorter CPA)
Heterogeneity: not applicable
Test for overall effect: Z = 1.38 (P = 0.17)
3 Deterioration of kidney function
Boumpas 1992 3/20 7/20 100.0 % 0.43 [ 0.13, 1.43 ]
Subtotal (95% CI) 20 20 100.0 % 0.43 [ 0.13, 1.43 ]
Total events: 3 (Longer CPA), 7 (Shorter CPA)
Heterogeneity: not applicable
Test for overall effect: Z = 1.38 (P = 0.17)
0.05 0.2 1 5 20
Less with longer CPA Less with shorter CPA
358Immunosuppressive treatment for proliferative lupus nephritis (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 25.2. Comparison 25 Long versus short duration cyclophosphamide (CPA), Outcome 2 Stable
kidney function.
Review: Immunosuppressive treatment for proliferative lupus nephritis
Comparison: 25 Long versus short duration cyclophosphamide (CPA)
Outcome: 2 Stable kidney function
Study or subgroup Longer CPA Shorter CPA Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Boumpas 1992 17/20 13/20 100.0 % 1.31 [ 0.90, 1.89 ]
Total (95% CI) 20 20 100.0 % 1.31 [ 0.90, 1.89 ]
Total events: 17 (Longer CPA), 13 (Shorter CPA)
Heterogeneity: not applicable
Test for overall effect: Z = 1.42 (P = 0.16)
Test for subgroup differences: Not applicable
0.1 0.2 0.5 1 2 5 10
More with shorter CPA More with longer CPA
Analysis 25.3. Comparison 25 Long versus short duration cyclophosphamide (CPA), Outcome 3 Ovarian
failure.
Review: Immunosuppressive treatment for proliferative lupus nephritis
Comparison: 25 Long versus short duration cyclophosphamide (CPA)
Outcome: 3 Ovarian failure
Study or subgroup Longer CPA Shorter CPA Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Boumpas 1992 5/13 3/16 100.0 % 2.05 [ 0.60, 7.02 ]
Total (95% CI) 13 16 100.0 % 2.05 [ 0.60, 7.02 ]
Total events: 5 (Longer CPA), 3 (Shorter CPA)
Heterogeneity: not applicable
Test for overall effect: Z = 1.14 (P = 0.25)
Test for subgroup differences: Not applicable
0.1 0.2 0.5 1 2 5 10
Less with longer CPA Less with shorter CPA
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Analysis 25.4. Comparison 25 Long versus short duration cyclophosphamide (CPA), Outcome 4 Infection.
Review: Immunosuppressive treatment for proliferative lupus nephritis
Comparison: 25 Long versus short duration cyclophosphamide (CPA)
Outcome: 4 Infection
Study or subgroup Longer CPA Shorter CPA Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Major infection
Boumpas 1992 1/20 1/20 100.0 % 1.00 [ 0.07, 14.90 ]
Subtotal (95% CI) 20 20 100.0 % 1.00 [ 0.07, 14.90 ]
Total events: 1 (Longer CPA), 1 (Shorter CPA)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
2 Herpes zoster virus
Boumpas 1992 1/20 2/20 100.0 % 0.50 [ 0.05, 5.08 ]
Subtotal (95% CI) 20 20 100.0 % 0.50 [ 0.05, 5.08 ]
Total events: 1 (Longer CPA), 2 (Shorter CPA)
Heterogeneity: not applicable
Test for overall effect: Z = 0.59 (P = 0.56)
0.02 0.1 1 10 50
Less with longer CPA Less with shorter CPA
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Analysis 25.5. Comparison 25 Long versus short duration cyclophosphamide (CPA), Outcome 5 Malignancy.
Review: Immunosuppressive treatment for proliferative lupus nephritis
Comparison: 25 Long versus short duration cyclophosphamide (CPA)
Outcome: 5 Malignancy
Study or subgroup Longer CPA Shorter CPA Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Boumpas 1992 1/20 0/20 100.0 % 3.00 [ 0.13, 69.52 ]
Total (95% CI) 20 20 100.0 % 3.00 [ 0.13, 69.52 ]
Total events: 1 (Longer CPA), 0 (Shorter CPA)
Heterogeneity: not applicable
Test for overall effect: Z = 0.69 (P = 0.49)
Test for subgroup differences: Not applicable
0.005 0.1 1 10 200
Less with longer CPA Less with shorter CPA
Analysis 25.6. Comparison 25 Long versus short duration cyclophosphamide (CPA), Outcome 6 Bone
toxicity.
Review: Immunosuppressive treatment for proliferative lupus nephritis
Comparison: 25 Long versus short duration cyclophosphamide (CPA)
Outcome: 6 Bone toxicity
Study or subgroup Longer CPA Shorter CPA Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Boumpas 1992 4/20 3/20 100.0 % 1.33 [ 0.34, 5.21 ]
Total (95% CI) 20 20 100.0 % 1.33 [ 0.34, 5.21 ]
Total events: 4 (Longer CPA), 3 (Shorter CPA)
Heterogeneity: not applicable
Test for overall effect: Z = 0.41 (P = 0.68)
Test for subgroup differences: Not applicable
0.05 0.2 1 5 20
Less with longer CPA Less with shorter CPA
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Analysis 25.7. Comparison 25 Long versus short duration cyclophosphamide (CPA), Outcome 7 Bladder
toxicity.
Review: Immunosuppressive treatment for proliferative lupus nephritis
Comparison: 25 Long versus short duration cyclophosphamide (CPA)
Outcome: 7 Bladder toxicity
Study or subgroup Longer CPA Shorter CPA Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Boumpas 1992 0/20 0/20 Not estimable
Total (95% CI) 20 20 Not estimable
Total events: 0 (Longer CPA), 0 (Shorter CPA)
Heterogeneity: not applicable
Test for overall effect: not applicable
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Less with longer CPA Less with shorter CP
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Analysis 26.1. Comparison 26 Maintenance: azathioprine (AZA) versus mycophenolate mofetil (MMF),
Outcome 1 Death.
Review: Immunosuppressive treatment for proliferative lupus nephritis
Comparison: 26 Maintenance: azathioprine (AZA) versus mycophenolate mofetil (MMF)
Outcome: 1 Death
Study or subgroup AZA MMF Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 At end of treatment duration or follow-up
ALMS 2007 1/111 0/115 14.4 % 3.11 [ 0.13, 75.47 ]
Contreras 2004 0/19 1/20 14.9 % 0.35 [ 0.02, 8.10 ]
MAINTAIN Nephritis 2010 0/52 2/53 16.2 % 0.20 [ 0.01, 4.14 ]
Kaballo 2016 4/40 2/41 54.5 % 2.05 [ 0.40, 10.57 ]
Subtotal (95% CI) 222 229 100.0 % 1.15 [ 0.34, 3.87 ]
Total events: 5 (AZA), 5 (MMF)
Heterogeneity: Tau2 = 0.0; Chi2 = 2.70, df = 3 (P = 0.44); I2 =0.0%
Test for overall effect: Z = 0.23 (P = 0.82)
2 At 10 years
MAINTAIN Nephritis 2010 2/45 3/42 100.0 % 0.62 [ 0.11, 3.54 ]
Subtotal (95% CI) 45 42 100.0 % 0.62 [ 0.11, 3.54 ]
Total events: 2 (AZA), 3 (MMF)
Heterogeneity: not applicable
Test for overall effect: Z = 0.53 (P = 0.59)
0.005 0.1 1 10 200
Less with AZA Less with MMF
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Analysis 26.2. Comparison 26 Maintenance: azathioprine (AZA) versus mycophenolate mofetil (MMF),
Outcome 2 Renal relapse.
Review: Immunosuppressive treatment for proliferative lupus nephritis
Comparison: 26 Maintenance: azathioprine (AZA) versus mycophenolate mofetil (MMF)
Outcome: 2 Renal relapse
Study or subgroup AZA MMF Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 At end of treatment duration or follow-up
Kaballo 2016 4/40 4/41 8.2 % 1.03 [ 0.28, 3.82 ]
Contreras 2004 6/19 3/20 9.3 % 2.11 [ 0.61, 7.24 ]
MAINTAIN Nephritis 2010 13/52 10/53 26.5 % 1.33 [ 0.64, 2.75 ]
ALMS 2007 36/111 18/116 56.0 % 2.09 [ 1.26, 3.45 ]
Subtotal (95% CI) 222 230 100.0 % 1.75 [ 1.20, 2.55 ]
Total events: 59 (AZA), 35 (MMF)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.76, df = 3 (P = 0.62); I2 =0.0%
Test for overall effect: Z = 2.91 (P = 0.0036)
2 At 10 years
MAINTAIN Nephritis 2010 22/45 19/42 100.0 % 1.08 [ 0.69, 1.69 ]
Subtotal (95% CI) 45 42 100.0 % 1.08 [ 0.69, 1.69 ]
Total events: 22 (AZA), 19 (MMF)
Heterogeneity: not applicable
Test for overall effect: Z = 0.34 (P = 0.73)
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Analysis 26.3. Comparison 26 Maintenance: azathioprine (AZA) versus mycophenolate mofetil (MMF),
Outcome 3 End-stage kidney disease.
Review: Immunosuppressive treatment for proliferative lupus nephritis
Comparison: 26 Maintenance: azathioprine (AZA) versus mycophenolate mofetil (MMF)
Outcome: 3 End-stage kidney disease
Study or subgroup AZA MMF Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 At end of treatment duration or follow-up
ALMS 2007 3/111 0/116 16.0 % 7.31 [ 0.38, 139.97 ]
MAINTAIN Nephritis 2010 1/52 1/53 18.5 % 1.02 [ 0.07, 15.87 ]
Contreras 2004 1/19 1/20 19.1 % 1.05 [ 0.07, 15.66 ]
Kaballo 2016 3/40 2/41 46.3 % 1.54 [ 0.27, 8.72 ]
Subtotal (95% CI) 222 230 100.0 % 1.70 [ 0.52, 5.54 ]
Total events: 8 (AZA), 4 (MMF)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.26, df = 3 (P = 0.74); I2 =0.0%
Test for overall effect: Z = 0.88 (P = 0.38)
2 At 10 years
MAINTAIN Nephritis 2010 1/45 3/42 100.0 % 0.31 [ 0.03, 2.88 ]
Subtotal (95% CI) 45 42 100.0 % 0.31 [ 0.03, 2.88 ]
Total events: 1 (AZA), 3 (MMF)
Heterogeneity: not applicable
Test for overall effect: Z = 1.03 (P = 0.30)
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Analysis 26.4. Comparison 26 Maintenance: azathioprine (AZA) versus mycophenolate mofetil (MMF),
Outcome 4 Doubling of serum creatinine.
Review: Immunosuppressive treatment for proliferative lupus nephritis
Comparison: 26 Maintenance: azathioprine (AZA) versus mycophenolate mofetil (MMF)
Outcome: 4 Doubling of serum creatinine
Study or subgroup AZA MMF Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
ALMS 2007 5/111 1/116 12.6 % 5.23 [ 0.62, 44.02 ]
Kaballo 2016 5/40 2/41 22.8 % 2.56 [ 0.53, 12.45 ]
MAINTAIN Nephritis 2010 4/52 3/53 27.2 % 1.36 [ 0.32, 5.78 ]
Contreras 2004 6/19 3/20 37.4 % 2.11 [ 0.61, 7.24 ]
Total (95% CI) 222 230 100.0 % 2.19 [ 1.03, 4.66 ]
Total events: 20 (AZA), 9 (MMF)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.12, df = 3 (P = 0.77); I2 =0.0%
Test for overall effect: Z = 2.04 (P = 0.042)
Test for subgroup differences: Not applicable
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Analysis 26.5. Comparison 26 Maintenance: azathioprine (AZA) versus mycophenolate mofetil (MMF),
Outcome 5 Ovarian failure.
Review: Immunosuppressive treatment for proliferative lupus nephritis
Comparison: 26 Maintenance: azathioprine (AZA) versus mycophenolate mofetil (MMF)
Outcome: 5 Ovarian failure
Study or subgroup AZA MMF Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
MAINTAIN Nephritis 2010 1/48 2/48 39.5 % 0.50 [ 0.05, 5.33 ]
Kaballo 2016 2/40 2/41 60.5 % 1.03 [ 0.15, 6.93 ]
Total (95% CI) 88 89 100.0 % 0.77 [ 0.17, 3.42 ]
Total events: 3 (AZA), 4 (MMF)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.21, df = 1 (P = 0.64); I2 =0.0%
Test for overall effect: Z = 0.34 (P = 0.73)
Test for subgroup differences: Not applicable
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Analysis 26.6. Comparison 26 Maintenance: azathioprine (AZA) versus mycophenolate mofetil (MMF),
Outcome 6 Infection.
Review: Immunosuppressive treatment for proliferative lupus nephritis
Comparison: 26 Maintenance: azathioprine (AZA) versus mycophenolate mofetil (MMF)
Outcome: 6 Infection
Study or subgroup AZA MMF Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Major infection
Kaballo 2016 1/40 1/41 4.7 % 1.03 [ 0.07, 15.83 ]
MAINTAIN Nephritis 2010 6/52 7/53 33.9 % 0.87 [ 0.31, 2.43 ]
ALMS 2007 13/111 11/115 61.3 % 1.22 [ 0.57, 2.62 ]
Subtotal (95% CI) 203 209 100.0 % 1.08 [ 0.60, 1.96 ]
Total events: 20 (AZA), 19 (MMF)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.27, df = 2 (P = 0.87); I2 =0.0%
Test for overall effect: Z = 0.26 (P = 0.79)
2 Herpes zoster virus
MAINTAIN Nephritis 2010 5/52 4/53 100.0 % 1.27 [ 0.36, 4.48 ]
Subtotal (95% CI) 52 53 100.0 % 1.27 [ 0.36, 4.48 ]
Total events: 5 (AZA), 4 (MMF)
Heterogeneity: not applicable
Test for overall effect: Z = 0.38 (P = 0.71)
Test for subgroup differences: Chi2 = 0.05, df = 1 (P = 0.82), I2 =0.0%
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Analysis 26.7. Comparison 26 Maintenance: azathioprine (AZA) versus mycophenolate mofetil (MMF),
Outcome 7 Malignancy.
Review: Immunosuppressive treatment for proliferative lupus nephritis
Comparison: 26 Maintenance: azathioprine (AZA) versus mycophenolate mofetil (MMF)
Outcome: 7 Malignancy
Study or subgroup AZA MMF Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 At end of treatment duration or follow-up
Contreras 2004 0/19 0/20 Not estimable
ALMS 2007 1/111 0/115 47.1 % 3.11 [ 0.13, 75.47 ]
MAINTAIN Nephritis 2010 2/52 0/53 52.9 % 5.09 [ 0.25, 103.62 ]
Subtotal (95% CI) 182 188 100.0 % 4.04 [ 0.45, 36.07 ]
Total events: 3 (AZA), 0 (MMF)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.05, df = 1 (P = 0.82); I2 =0.0%
Test for overall effect: Z = 1.25 (P = 0.21)
2 At 10 years
MAINTAIN Nephritis 2010 2/45 1/42 100.0 % 1.87 [ 0.18, 19.84 ]
Subtotal (95% CI) 45 42 100.0 % 1.87 [ 0.18, 19.84 ]
Total events: 2 (AZA), 1 (MMF)
Heterogeneity: not applicable
Test for overall effect: Z = 0.52 (P = 0.60)
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Analysis 26.8. Comparison 26 Maintenance: azathioprine (AZA) versus mycophenolate mofetil (MMF),
Outcome 8 Leucopenia.
Review: Immunosuppressive treatment for proliferative lupus nephritis
Comparison: 26 Maintenance: azathioprine (AZA) versus mycophenolate mofetil (MMF)
Outcome: 8 Leucopenia
Study or subgroup AZA MMF Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Kaballo 2016 1/40 0/41 14.4 % 3.07 [ 0.13, 73.28 ]
ALMS 2007 4/111 0/115 17.2 % 9.32 [ 0.51, 171.14 ]
MAINTAIN Nephritis 2010 11/52 2/53 68.4 % 5.61 [ 1.31, 24.07 ]
Total (95% CI) 203 209 100.0 % 5.61 [ 1.68, 18.72 ]
Total events: 16 (AZA), 2 (MMF)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.26, df = 2 (P = 0.88); I2 =0.0%
Test for overall effect: Z = 2.80 (P = 0.0050)
Test for subgroup differences: Not applicable
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Analysis 26.9. Comparison 26 Maintenance: azathioprine (AZA) versus mycophenolate mofetil (MMF),
Outcome 9 Bone toxicity.
Review: Immunosuppressive treatment for proliferative lupus nephritis
Comparison: 26 Maintenance: azathioprine (AZA) versus mycophenolate mofetil (MMF)
Outcome: 9 Bone toxicity
Study or subgroup AZA MMF Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
MAINTAIN Nephritis 2010 1/52 0/53 100.0 % 3.06 [ 0.13, 73.36 ]
Total (95% CI) 52 53 100.0 % 3.06 [ 0.13, 73.36 ]
Total events: 1 (AZA), 0 (MMF)
Heterogeneity: not applicable
Test for overall effect: Z = 0.69 (P = 0.49)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
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Analysis 26.10. Comparison 26 Maintenance: azathioprine (AZA) versus mycophenolate mofetil (MMF),
Outcome 10 Alopecia.
Review: Immunosuppressive treatment for proliferative lupus nephritis
Comparison: 26 Maintenance: azathioprine (AZA) versus mycophenolate mofetil (MMF)
Outcome: 10 Alopecia
Study or subgroup AZA MMF Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Kaballo 2016 1/40 0/41 5.1 % 3.07 [ 0.13, 73.28 ]
MAINTAIN Nephritis 2010 1/52 2/53 9.2 % 0.51 [ 0.05, 5.45 ]
ALMS 2007 11/111 12/115 85.7 % 0.95 [ 0.44, 2.06 ]
Total (95% CI) 203 209 100.0 % 0.95 [ 0.46, 1.95 ]
Total events: 13 (AZA), 14 (MMF)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.79, df = 2 (P = 0.67); I2 =0.0%
Test for overall effect: Z = 0.13 (P = 0.89)
Test for subgroup differences: Not applicable
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Analysis 26.11. Comparison 26 Maintenance: azathioprine (AZA) versus mycophenolate mofetil (MMF),
Outcome 11 Gastrointestinal (GI) adverse events.
Review: Immunosuppressive treatment for proliferative lupus nephritis
Comparison: 26 Maintenance: azathioprine (AZA) versus mycophenolate mofetil (MMF)
Outcome: 11 Gastrointestinal (GI) adverse events
Study or subgroup AZA MMF Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 GI symptoms
MAINTAIN Nephritis 2010 8/52 8/53 100.0 % 1.02 [ 0.41, 2.51 ]
Subtotal (95% CI) 52 53 100.0 % 1.02 [ 0.41, 2.51 ]
Total events: 8 (AZA), 8 (MMF)
Heterogeneity: not applicable
Test for overall effect: Z = 0.04 (P = 0.97)
2 Nausea
Kaballo 2016 4/40 4/41 15.1 % 1.03 [ 0.28, 3.82 ]
ALMS 2007 21/111 20/115 84.9 % 1.09 [ 0.63, 1.89 ]
Subtotal (95% CI) 151 156 100.0 % 1.08 [ 0.65, 1.80 ]
Total events: 25 (AZA), 24 (MMF)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.01, df = 1 (P = 0.93); I2 =0.0%
Test for overall effect: Z = 0.29 (P = 0.77)
3 Diarrhoea
Kaballo 2016 2/40 6/41 24.1 % 0.34 [ 0.07, 1.59 ]
ALMS 2007 20/111 22/115 75.9 % 0.94 [ 0.55, 1.63 ]
Subtotal (95% CI) 151 156 100.0 % 0.74 [ 0.31, 1.73 ]
Total events: 22 (AZA), 28 (MMF)
Heterogeneity: Tau2 = 0.17; Chi2 = 1.50, df = 1 (P = 0.22); I2 =33%
Test for overall effect: Z = 0.70 (P = 0.49)
4 Vomiting
Kaballo 2016 1/40 4/41 30.3 % 0.26 [ 0.03, 2.19 ]
ALMS 2007 18/111 14/115 69.7 % 1.33 [ 0.70, 2.55 ]
Subtotal (95% CI) 151 156 100.0 % 0.81 [ 0.18, 3.62 ]
Total events: 19 (AZA), 18 (MMF)
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(. . . Continued)
Study or subgroup AZA MMF Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Heterogeneity: Tau2 = 0.73; Chi2 = 2.11, df = 1 (P = 0.15); I2 =53%
Test for overall effect: Z = 0.28 (P = 0.78)
Test for subgroup differences: Chi2 = 0.63, df = 3 (P = 0.89), I2 =0.0%
0.02 0.1 1 10 50
Less with AZA Less with MMF
Analysis 26.12. Comparison 26 Maintenance: azathioprine (AZA) versus mycophenolate mofetil (MMF),
Outcome 12 Daily proteinuria.
Review: Immunosuppressive treatment for proliferative lupus nephritis
Comparison: 26 Maintenance: azathioprine (AZA) versus mycophenolate mofetil (MMF)
Outcome: 12 Daily proteinuria
Study or subgroup AZA MMF
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Kaballo 2016 40 1.6 (2.4) 41 1.2 (1.8) 100.0 % 0.40 [ -0.53, 1.33 ]
Total (95% CI) 40 41 100.0 % 0.40 [ -0.53, 1.33 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.85 (P = 0.40)
Test for subgroup differences: Not applicable
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Analysis 27.1. Comparison 27 Maintenance: azathioprine (AZA) versus cyclosporin (CSA), Outcome 1
Death.
Review: Immunosuppressive treatment for proliferative lupus nephritis
Comparison: 27 Maintenance: azathioprine (AZA) versus cyclosporin (CSA)
Outcome: 1 Death
Study or subgroup AZA CSA Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Moroni 2006 0/33 0/36 Not estimable
Total (95% CI) 33 36 Not estimable
Total events: 0 (AZA), 0 (CSA)
Heterogeneity: not applicable
Test for overall effect: not applicable
Test for subgroup differences: Not applicable
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Analysis 27.2. Comparison 27 Maintenance: azathioprine (AZA) versus cyclosporin (CSA), Outcome 2
Adverse renal outcomes.
Review: Immunosuppressive treatment for proliferative lupus nephritis
Comparison: 27 Maintenance: azathioprine (AZA) versus cyclosporin (CSA)
Outcome: 2 Adverse renal outcomes
Study or subgroup AZA CSA Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 ESKD
Moroni 2006 0/36 0/33 Not estimable
Subtotal (95% CI) 36 33 Not estimable
Total events: 0 (AZA), 0 (CSA)
Heterogeneity: not applicable
Test for overall effect: not applicable
2 Renal relapse
Moroni 2006 8/33 7/36 100.0 % 1.25 [ 0.51, 3.06 ]
Subtotal (95% CI) 33 36 100.0 % 1.25 [ 0.51, 3.06 ]
Total events: 8 (AZA), 7 (CSA)
Heterogeneity: not applicable
Test for overall effect: Z = 0.48 (P = 0.63)
Test for subgroup differences: Not applicable
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Analysis 27.3. Comparison 27 Maintenance: azathioprine (AZA) versus cyclosporin (CSA), Outcome 3
Infection.
Review: Immunosuppressive treatment for proliferative lupus nephritis
Comparison: 27 Maintenance: azathioprine (AZA) versus cyclosporin (CSA)
Outcome: 3 Infection
Study or subgroup AZA CSA Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Major infection
Moroni 2006 14/33 7/36 100.0 % 2.18 [ 1.01, 4.73 ]
Subtotal (95% CI) 33 36 100.0 % 2.18 [ 1.01, 4.73 ]
Total events: 14 (AZA), 7 (CSA)
Heterogeneity: not applicable
Test for overall effect: Z = 1.97 (P = 0.048)
Test for subgroup differences: Not applicable
0.1 0.2 0.5 1 2 5 10
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Analysis 27.4. Comparison 27 Maintenance: azathioprine (AZA) versus cyclosporin (CSA), Outcome 4
Leucopenia.
Review: Immunosuppressive treatment for proliferative lupus nephritis
Comparison: 27 Maintenance: azathioprine (AZA) versus cyclosporin (CSA)
Outcome: 4 Leucopenia
Study or subgroup AZA CSA Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Moroni 2006 10/33 4/36 100.0 % 2.73 [ 0.95, 7.86 ]
Total (95% CI) 33 36 100.0 % 2.73 [ 0.95, 7.86 ]
Total events: 10 (AZA), 4 (CSA)
Heterogeneity: not applicable
Test for overall effect: Z = 1.86 (P = 0.063)
Test for subgroup differences: Not applicable
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Analysis 27.5. Comparison 27 Maintenance: azathioprine (AZA) versus cyclosporin (CSA), Outcome 5
Gastrointestinal (GI) adverse events.
Review: Immunosuppressive treatment for proliferative lupus nephritis
Comparison: 27 Maintenance: azathioprine (AZA) versus cyclosporin (CSA)
Outcome: 5 Gastrointestinal (GI) adverse events
Study or subgroup AZA CSA Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 GI disturbance
Moroni 2006 3/33 11/36 100.0 % 0.30 [ 0.09, 0.97 ]
Subtotal (95% CI) 33 36 100.0 % 0.30 [ 0.09, 0.97 ]
Total events: 3 (AZA), 11 (CSA)
Heterogeneity: not applicable
Test for overall effect: Z = 2.00 (P = 0.045)
Test for subgroup differences: Not applicable
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Analysis 27.6. Comparison 27 Maintenance: azathioprine (AZA) versus cyclosporin (CSA), Outcome 6
Daily proteinuria.
Review: Immunosuppressive treatment for proliferative lupus nephritis
Comparison: 27 Maintenance: azathioprine (AZA) versus cyclosporin (CSA)
Outcome: 6 Daily proteinuria
Study or subgroup AZA CSA
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Moroni 2006 33 0.53 (0.78) 36 0.38 (0.85) 100.0 % 0.15 [ -0.23, 0.53 ]
Total (95% CI) 33 36 100.0 % 0.15 [ -0.23, 0.53 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.76 (P = 0.44)
Test for subgroup differences: Not applicable
-2 -1 0 1 2
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Analysis 27.7. Comparison 27 Maintenance: azathioprine (AZA) versus cyclosporin (CSA), Outcome 7
Disease activity (SLEDAI).
Review: Immunosuppressive treatment for proliferative lupus nephritis
Comparison: 27 Maintenance: azathioprine (AZA) versus cyclosporin (CSA)
Outcome: 7 Disease activity (SLEDAI)
Study or subgroup AZA CSA
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Moroni 2006 33 5.6 (3) 36 8.8 (7.2) 100.0 % -3.20 [ -5.77, -0.63 ]
Total (95% CI) 33 36 100.0 % -3.20 [ -5.77, -0.63 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.45 (P = 0.014)
Test for subgroup differences: Not applicable
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Analysis 28.1. Comparison 28 Maintenance: azathioprine (AZA) versus cyclophosphamide (CPA), Outcome
1 Death.
Review: Immunosuppressive treatment for proliferative lupus nephritis
Comparison: 28 Maintenance: azathioprine (AZA) versus cyclophosphamide (CPA)
Outcome: 1 Death
Study or subgroup AZA CPA Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Contreras 2004 0/19 4/20 100.0 % 0.12 [ 0.01, 2.03 ]
Total (95% CI) 19 20 100.0 % 0.12 [ 0.01, 2.03 ]
Total events: 0 (AZA), 4 (CPA)
Heterogeneity: not applicable
Test for overall effect: Z = 1.47 (P = 0.14)
Test for subgroup differences: Not applicable
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Analysis 28.2. Comparison 28 Maintenance: azathioprine (AZA) versus cyclophosphamide (CPA), Outcome
2 Adverse renal outcomes.
Review: Immunosuppressive treatment for proliferative lupus nephritis
Comparison: 28 Maintenance: azathioprine (AZA) versus cyclophosphamide (CPA)
Outcome: 2 Adverse renal outcomes
Study or subgroup AZA CPA Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 ESKD
Contreras 2004 1/19 3/20 100.0 % 0.35 [ 0.04, 3.09 ]
Subtotal (95% CI) 19 20 100.0 % 0.35 [ 0.04, 3.09 ]
Total events: 1 (AZA), 3 (CPA)
Heterogeneity: not applicable
Test for overall effect: Z = 0.94 (P = 0.35)
2 Renal relapse
Contreras 2004 6/19 8/20 100.0 % 0.79 [ 0.34, 1.85 ]
Subtotal (95% CI) 19 20 100.0 % 0.79 [ 0.34, 1.85 ]
Total events: 6 (AZA), 8 (CPA)
Heterogeneity: not applicable
Test for overall effect: Z = 0.54 (P = 0.59)
3 Doubling of serum creatinine
Contreras 2004 6/19 8/20 100.0 % 0.79 [ 0.34, 1.85 ]
Subtotal (95% CI) 19 20 100.0 % 0.79 [ 0.34, 1.85 ]
Total events: 6 (AZA), 8 (CPA)
Heterogeneity: not applicable
Test for overall effect: Z = 0.54 (P = 0.59)
Test for subgroup differences: Chi2 = 0.50, df = 2 (P = 0.78), I2 =0.0%
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Analysis 28.3. Comparison 28 Maintenance: azathioprine (AZA) versus cyclophosphamide (CPA), Outcome
3 Bladder toxicity.
Review: Immunosuppressive treatment for proliferative lupus nephritis
Comparison: 28 Maintenance: azathioprine (AZA) versus cyclophosphamide (CPA)
Outcome: 3 Bladder toxicity
Study or subgroup AZA CPA Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Contreras 2004 0/19 0/20 Not estimable
Total (95% CI) 19 20 Not estimable
Total events: 0 (AZA), 0 (CPA)
Heterogeneity: not applicable
Test for overall effect: not applicable
Test for subgroup differences: Not applicable
0.1 0.2 0.5 1 2 5 10
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Analysis 28.4. Comparison 28 Maintenance: azathioprine (AZA) versus cyclophosphamide (CPA), Outcome
4 Creatinine clearance.
Review: Immunosuppressive treatment for proliferative lupus nephritis
Comparison: 28 Maintenance: azathioprine (AZA) versus cyclophosphamide (CPA)
Outcome: 4 Creatinine clearance
Study or subgroup AZA CPA
Mean
Difference Weight
Mean
Difference
N Mean(SD)[mL/min]N Mean(SD)[mL/min] IV,Random,95% CI IV,Random,95% CI
Fu 1997 18 104.6 (16.8) 20 120.3 (4.5) 100.0 % -15.70 [ -23.71, -7.69 ]
Total (95% CI) 18 20 100.0 % -15.70 [ -23.71, -7.69 ]
Heterogeneity: not applicable
Test for overall effect: Z = 3.84 (P = 0.00012)
Test for subgroup differences: Not applicable
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Analysis 29.1. Comparison 29 Maintenance: azathioprine (AZA) versus tacrolimus (TAC), Outcome 1
Adverse renal outcomes.
Review: Immunosuppressive treatment for proliferative lupus nephritis
Comparison: 29 Maintenance: azathioprine (AZA) versus tacrolimus (TAC)
Outcome: 1 Adverse renal outcomes
Study or subgroup AZA TAC Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Renal relapse
Chen 2011 3/36 0/34 100.0 % 6.62 [ 0.35, 123.63 ]
Subtotal (95% CI) 36 34 100.0 % 6.62 [ 0.35, 123.63 ]
Total events: 3 (AZA), 0 (TAC)
Heterogeneity: not applicable
Test for overall effect: Z = 1.27 (P = 0.21)
Test for subgroup differences: Not applicable
0.005 0.1 1 10 200
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Analysis 29.2. Comparison 29 Maintenance: azathioprine (AZA) versus tacrolimus (TAC), Outcome 2
Infection.
Review: Immunosuppressive treatment for proliferative lupus nephritis
Comparison: 29 Maintenance: azathioprine (AZA) versus tacrolimus (TAC)
Outcome: 2 Infection
Study or subgroup AZA TAC Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Major infection
Chen 2011 4/36 3/34 100.0 % 1.26 [ 0.30, 5.22 ]
Subtotal (95% CI) 36 34 100.0 % 1.26 [ 0.30, 5.22 ]
Total events: 4 (AZA), 3 (TAC)
Heterogeneity: not applicable
Test for overall effect: Z = 0.32 (P = 0.75)
Test for subgroup differences: Not applicable
0.1 0.2 0.5 1 2 5 10
Less with AZA Less with TAC
382Immunosuppressive treatment for proliferative lupus nephritis (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 29.3. Comparison 29 Maintenance: azathioprine (AZA) versus tacrolimus (TAC), Outcome 3
Gastrointestinal (GI) adverse events.
Review: Immunosuppressive treatment for proliferative lupus nephritis
Comparison: 29 Maintenance: azathioprine (AZA) versus tacrolimus (TAC)
Outcome: 3 Gastrointestinal (GI) adverse events
Study or subgroup AZA TAC Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 GI disturbance
Chen 2011 2/36 1/34 100.0 % 1.89 [ 0.18, 19.89 ]
Subtotal (95% CI) 36 34 100.0 % 1.89 [ 0.18, 19.89 ]
Total events: 2 (AZA), 1 (TAC)
Heterogeneity: not applicable
Test for overall effect: Z = 0.53 (P = 0.60)
Test for subgroup differences: Not applicable
0.02 0.1 1 10 50
Less with AZA Less with TAC
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Analysis 30.1. Comparison 30 Maintenance: prednisone withdrawal versus prednisone continuation,
Outcome 1 Relapse.
Review: Immunosuppressive treatment for proliferative lupus nephritis
Comparison: 30 Maintenance: prednisone withdrawal versus prednisone continuation
Outcome: 1 Relapse
Study or subgroup Withdrawal Continuation Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Renal relapse
SIMPL 2014 1/7 3/8 100.0 % 0.38 [ 0.05, 2.88 ]
Subtotal (95% CI) 7 8 100.0 % 0.38 [ 0.05, 2.88 ]
Total events: 1 (Withdrawal), 3 (Continuation)
Heterogeneity: not applicable
Test for overall effect: Z = 0.93 (P = 0.35)
2 Non-renal relapse
SIMPL 2014 0/7 1/8 100.0 % 0.38 [ 0.02, 7.96 ]
Subtotal (95% CI) 7 8 100.0 % 0.38 [ 0.02, 7.96 ]
Total events: 0 (Withdrawal), 1 (Continuation)
Heterogeneity: not applicable
Test for overall effect: Z = 0.63 (P = 0.53)
Test for subgroup differences: Chi2 = 0.00, df = 1 (P = 0.99), I2 =0.0%
0.01 0.1 1 10 100
Less with withdrawal Less with continuation
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Analysis 30.2. Comparison 30 Maintenance: prednisone withdrawal versus prednisone continuation,
Outcome 2 Major infection.
Review: Immunosuppressive treatment for proliferative lupus nephritis
Comparison: 30 Maintenance: prednisone withdrawal versus prednisone continuation
Outcome: 2 Major infection
Study or subgroup Withdrawal Continuation Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
SIMPL 2014 1/7 2/8 100.0 % 0.57 [ 0.06, 5.03 ]
Total (95% CI) 7 8 100.0 % 0.57 [ 0.06, 5.03 ]
Total events: 1 (Withdrawal), 2 (Continuation)
Heterogeneity: not applicable
Test for overall effect: Z = 0.50 (P = 0.61)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Less with withdrawal Less with continuation
Analysis 31.1. Comparison 31 Maintenance: intravenous immunoglobulin (IVIG) versus intravenous
cyclophosphamide (IV CPA), Outcome 1 Creatinine clearance.
Review: Immunosuppressive treatment for proliferative lupus nephritis
Comparison: 31 Maintenance: intravenous immunoglobulin (IVIG) versus intravenous cyclophosphamide (IV CPA)
Outcome: 1 Creatinine clearance
Study or subgroup IVIG IV CPA
Mean
Difference Weight
Mean
Difference
N Mean(SD)[mL/min] N Mean(SD)[mL/min] IV,Random,95% CI IV,Random,95% CI
Boletis 1999 5 89.2 (33.2) 8 87 (39.7) 100.0 % 2.20 [ -37.85, 42.25 ]
Total (95% CI) 5 8 100.0 % 2.20 [ -37.85, 42.25 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.11 (P = 0.91)
Test for subgroup differences: Not applicable
-100 -50 0 50 100
Higher with IV CPA Higher with IVIG
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Analysis 31.2. Comparison 31 Maintenance: intravenous immunoglobulin (IVIG) versus intravenous
cyclophosphamide (IV CPA), Outcome 2 Daily proteinuria.
Review: Immunosuppressive treatment for proliferative lupus nephritis
Comparison: 31 Maintenance: intravenous immunoglobulin (IVIG) versus intravenous cyclophosphamide (IV CPA)
Outcome: 2 Daily proteinuria
Study or subgroup IVIG IV CPA
Mean
Difference Weight
Mean
Difference
N Mean(SD)[g/24 h] N Mean(SD)[g/24 h] IV,Random,95% CI IV,Random,95% CI
Boletis 1999 5 0.67 (0.73) 8 0.75 (0.84) 100.0 % -0.08 [ -0.95, 0.79 ]
Total (95% CI) 5 8 100.0 % -0.08 [ -0.95, 0.79 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.18 (P = 0.86)
Test for subgroup differences: Not applicable
-2 -1 0 1 2
Lower with IVIG Lower with IV CPA
Analysis 31.3. Comparison 31 Maintenance: intravenous immunoglobulin (IVIG) versus intravenous
cyclophosphamide (IV CPA), Outcome 3 Serum creatinine.
Review: Immunosuppressive treatment for proliferative lupus nephritis
Comparison: 31 Maintenance: intravenous immunoglobulin (IVIG) versus intravenous cyclophosphamide (IV CPA)
Outcome: 3 Serum creatinine
Study or subgroup IVIG IV CPA
Mean
Difference Weight
Mean
Difference
N
Mean(SD)[
mol/L] N
Mean(SD)[
mol/L] IV,Random,95% CI IV,Random,95% CI
Boletis 1999 5 102.5 (43.3) 9 137.9 (130.8) 100.0 % -35.40 [ -128.90, 58.10 ]
Total (95% CI) 5 9 100.0 % -35.40 [ -128.90, 58.10 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.74 (P = 0.46)
Test for subgroup differences: Not applicable
-200 -100 0 100 200
Lower with IVIG Lower with IV CPA
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A D D I T I O N A L T A B L E S
Table 1. Description of health-related quality of life outcomes
Study ID Comparison Therapy Measure Time point Description of results
ACCESS 2014 Abatacept versus
placebo
Induction SF-36physical andmen-
tal component
(mean ± SD)
6 months • In the abatacept group after 6
months of therapy the physical
component score increased from 39
± 11 to 45.3 ± 11. In the placebo +
standard of care therapy group after
6 months of therapy, the physical
component score increased from 39
± 10 to 46.5 ± 11
• In the abatacept group after 6
months of therapy the mental
component score increased from 40
± 13 to 45.9 ± 12. In the placebo +
standard of care group after 6
months of therapy, the mental
component score increased from 40
± 13 to 46.5 ± 11
Furie 2014 Abatacept versus
placebo
Induction SF-36 (adjusted mean
change ± SE)
12 months • In the high dose abatacept
group after 12 months of therapy
the adjusted mean ± SE of SF-36
scores were: physical component 4.
2 ± 0.91, mental component 2.5 ±
1.0, physical functioning 2.6 ± 0.
96, role-physical 4.2 ± 1.2, bodily
pain 4.5 ± 1.1, general health 4.7 ±
0.9, vitality 3.9 ± 0.98, social
functioning 4.0 ± 1.0, role-
emotional 1.6 ± 1.3, and mental
health 3.1 ± 1.1
• In the low dose abatacept
group after 12 months of therapy,
the adjusted mean ± SE of SF-36
scores were: physical component, 5.
0 ± 0.91, mental component 4.7 ±
1.0, physical functioning 4.2 ± 0.
95, role-physical 6.9 ± 1.2, bodily
pain 4.6 ± 1.0, general health 4.4 ±
0.89, vitality 4.6 ± 0.97, social
functioning 6.1 ± 1.0, role-
emotional 5.6 ± 1.3, and mental
health 4.0 ± 1.1. In the placebo +
standard of care group after 12
months of therapy, the adjusted
mean ± SE of SF-36 scores were:
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Table 1. Description of health-related quality of life outcomes (Continued)
physical component 3.8 ± 0.9,
mental component 4.4 ± 1.0,
physical functioning 2.8 ± 0.94,
role-physical 5.3 ± 1.2, bodily pain
4.3 ± 1.0, general health 4.0 ± 0.88,
vitality 4.8 ± 0.96, social
functioning 5.1 ± 1.0, role-
emotional 4.7 ± 1.3, and mental
health 3.2 ± 1.1
LUNAR 2012 Rituximab versus
placebo
Induction SF-36 - physical func-
tioning (mean change ±
SD)
12 months • In the rituximab group after
12 months of therapy the SF-36
physical functioning score increased
by 4.8 ± 10.4
• In the placebo + standard of
care therapy group, after 12 months
of therapy the SF-36 physical
functioning score increased by 5.7 ±
9.4
Table 2. Description of fatigue outcomes
Study ID Comparison Therapy Measure Time point Description of results
Furie 2014 Abatacept versus
placebo
Induction Fatigue VAS (adjusted
mean change ± SE)
6 months • In the high dose abatacept group
after 6 months of therapy the fatigue
VAS decreased by 12.2 ± 2.7
• In the low dose abatacept group
after 6 months of therapy the fatigue
VAS decreased by 12.3 ± 2.7
• In the placebo + standard of care
group after 6 months of therapy the
fatigue VAS decreased by 11.1 ± 2.7
Fatigue severity score (ad-
justed mean change ± SE)
• In the high dose abatacept group
after 6 months of therapy the fatigue
VAS decreased by 12.2 ± 2.7
• In the low dose abatacept group
after 6 months of therapy the fatigue
VAS decreased by 12.3 ± 2.7
• In the placebo + standard of care
group after 6 months of therapy the
fatigue VAS decreased by 11.1 ± 2.7
VAS - visual analogue scale
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Table 3. Description of disease activity outcomes
Study ID Comparison Measure Time point Description of results
Induction therapy
ACCESS 2014 Abatacept versus placebo BILAG (mean ± SD) 6 months • In the placebo + standard of
care therapy group after 6 months
of therapy the BILAG scores were 3.
4 ± 1.8
• In the abatacept group after 6
months of therapy the BILAG
scores were 3.8 ± 3.0
ALMS 2007 MMF versus IV CPA SLEDAI (mean change ±
SD)
6 months • In the IV CPA group after 6
months of therapy the SLEDAI
scores decreased by 6.6 ± 8.0
• In the MMF group after 6
months of therapy the SLEDAI
scores decreased by 6.2 ± 10.1
• The mean difference between
the groups was 0.41 (95% CI -1.48
to 2.30)
Deng 2016 Leflunomide versus CPA SLEDAI 6 months ”SLEDAI scores were reduced“
El-Shafey 2010 MMF versus IV CPA SLAM (mean change ±
SD)
6 months • In the IV CPA group after 6
months of therapy SLAM scores
decreased by 22.1 ± 7.72
• In the MMF group after 6
months of therapy SLAM scores
decreased by 17.84 ± 7.25
Grootscholten 2006 IV CPA versus AZA SLEDAI 24 months “SLEDAI andVAS scores did not dif-
fer between groups and decreased sig-
nificantly and paralleled each other (r
= 0.673, P<0.01)”
Hong 2007 TAC versus IC CPA SLEDAI 6 months “SLEDAI level of FK506 (TAC)
group is better than that of CPA
group, (P<0.05)”
Houssiau 2002 High CPA versus low
CPA
ECLAM 12 months “ECLAM score significantly im-
proved in both groups during the first
year of follow-up. No significant dif-
ference was noted between patients
in the low-dose and high-dose IV
CYC groups for any of the parame-
ters examined (P>0.05)”
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Table 3. Description of disease activity outcomes (Continued)
Kamanamool 2017 MMF versus TAC SLEDAI-2K (mean ±
SD)
12 months • In the MMF group, mean
SLEDAI-2K was decreased from 11.
6 ± 4.8 to 6.3 ± 3.9 after 6 months
therapy, and 5.4 ± 4.4 after 12
months
• In the TAC group, mean
SLEDAI-2K was decreased from 9.0
± 3.7 to 6.3 ± 5.1 after 6 months
and to 7.1 ± 5.4 after 12 months
• The results showed a similar
pattern with respect to renal
SLEDAI and modified SLEDAI
Li 2009c Rituximab versus ritux-
imab + CPA
SLEDAI (mean ± SD) 12 months • The overall SLEDAI of both
groups at baseline was 9.2 ± 3.4,
this decreased to 2.5 ± 2.5 after 12
months of therapy
• There was significant
improvements in SLEDAI in both
groups
Li 2012 MMF versus TAC versus
IV CPA
SLEDAI (mean ± SD) 6 months • In all three groups (IV CPA,
MMF, TAC) after 6 months of
therapy the SLEDAI across all three
groups was 7.7 ± 4.7. In all three
groups the SLEDAI scores decreased
Liu 2015 MMF + TAC versus IV
CPA
SLEDAI (mean change ±
SD)
6 months • In the IV CPA group after 6
months of therapy SLEDAI
decreased by 11.01 ± 6.07
• In the MMF+TAC group after
6 months of therapy SLEDAI
decreased by 8.55 ± 5.05
Loo 2010 PEX versus IA SLEDAI 6 months “The SLEDAI gap between the study
groups remained the same through-
out the study. The improvements in
SLEDAI score of both groups were
also significantly demonstrated.”
LUNAR 2012 Rituximab versus
placebo
BILAG (Time adjusted
area under the curve mi-
nus baseline mean ± SD)
12 months • In the rituximab group after
12 months of therapy SLEDAI
decreased to 8.49 ± 5.79
• In the placebo + standard of
care group after 12 months of
therapy SLEDAI decreased to 8.58
± 5.14
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Table 3. Description of disease activity outcomes (Continued)
Mehra 2018 High-dose CPA versus
low-dose CPA
Renal SLEDAI 6 months At 24weeks, renal SLEDAIwere sim-
ilar between high-dose and low-dose
cyclophosphamide
Mok 2016 MMF versus TAC Renal SLEDAI (mean ±
SD)
6 months • In the MMF group after 6
months of therapy renal SLEDAI
scores were 3.9 ± 3.1
• In the tacrolimus group after 6
months of therapy renal SLEDAI
scores were 3.3 ± 3.1
Extrarenal SLEDAI
(mean ± SD)
• In the MMF group after 6
months of therapy extrarenal
SLEDAI scores were 1.7 ± 1.9
• In the tacrolimus group after 6
months of therapy extrarenal
SLEDAI scores were 1.9 ± 1.7
MyLupus 2011 Stan-
dard dose PRED versus
reduced dose PRED
Global BILAG (mean ±
SD)
6 months For both groups (reduced dose and
standard dose corticosteroids) at the
end of 6 months of treatment global
BILAG reduced from 14 ± 5.4 to 5.
0 ± 3.8 (P < 0.001)
SLEDAI (mean ± SD) For both groups (reduced dose and
standard dose corticosteroids) at the
end of 6 months of treatment
SLEDAI reduced from16.2 ± 6.9 to
6.2 ± 5.1 (P < 0.001)
Ong 2005 MMF versus IV CPA SLEDAI (mean change ±
SD)
6 months • In the IV CPA group after 6
months of therapy SLEDAI
decreased by 6.8 ± 6.6
• In the MMF group after 6
months of therapy SLEDAI
decreased by -7.2 ± 7.7
Rathi 2016 MMF versus IV CPA SLEDAI 6 months “SLEDAI improved significantly in
both the groups over the study pe-
riod, and there were no differences
between the treatment groups.”
Rovin 2016 Sirukumab versus
placebo
SLEDAI-2K 6 months “Eighteen
patients (14 in the sirukumab group
and 4 in the placebo group) had a
SLEDAI-2K RI-50 response at any
time through week 24.”
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Table 3. Description of disease activity outcomes (Continued)
Physician’s and patients
global assessment of dis-
ease activity
“Neither the patient’s nor the physi-
cian’s global assessment scores of
disease activity showed notable im-
provement over time in either treat-
ment group (data not shown).”
Wallace 1998 PE versus standard of
care
SLAM (mean ± SD) 12 months • In the standard of care group
after 12 months of therapy SLAM
scores were 6.44 ± 4.16
• In the PEX group after 12
months of therapy SLAM scores
were 7.11 ± 4.78
Maintenance therapy
MAINTAIN Nephritis
2010
AZA versus MMF SLEDAI 36 months “SLEDAI and ECLAM scores de-
creased similarly in both groups”
ECLAM
Moroni 2006 AZA versus CSA SLEDAI (mean ± SD) 24 months • In the AZA group after 24
months of therapy SLEDAI scores
were 5.6 ± 3.0
• In the CSA group after 24
months of therapy SLEDAI scores
were 8.8 ± 7.2
AZA - azathioprine; BILAG - British Isles Lupus Assessment Group; CPA - cyclophosphamide; CSA - cyclosporin; ECLAM - European
Consensus Lupus Activity Measurement; IA - immunoadsorption; MMF - mycophenolate mofetil; IV - intravenous; PE - plasma
exchange; PEX - plasmapheresis; PRED - corticosteroid; SLAM - Systemic Lupus Activity Measure; SLEDAI - Systemic Lupus
Erythematosus Disease Activity Index; TAC - tacrolimus
A P P E N D I C E S
Appendix 1. Electronic search strategies
Database Search terms
MEDLINE 1. Lupus Nephritis/
2. lupus nephritis.tw
3. or/1-2
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(Continued)
CENTRAL 1. MeSH descriptor Lupus Nephritis, this term only
2. (lupus):ti,ab,kw in Clinical Trials
3. (#1 OR #2)
EMBASE 1. exp Lupus Erythematosus Nephritis/
2. lupus nephritis.tw.
3. or/1-2
Appendix 2. Risk of bias assessment tool
Potential source of bias Assessment criteria
Random sequence generation
Selection bias (biased allocation to interventions) due to inade-
quate generation of a randomised sequence
Low risk of bias: Random number table; computer random num-
ber generator; coin tossing; shuffling cards or envelopes; throwing
dice; drawing of lots; minimization (minimization may be imple-
mented without a random element, and this is considered to be
equivalent to being random)
High risk of bias: Sequence generated by odd or even date of birth;
date (or day) of admission; sequence generated by hospital or
clinic record number; allocation by judgement of the clinician; by
preference of the participant; based on the results of a laboratory
test or a series of tests; by availability of the intervention
Unclear: Insufficient information about the sequence generation
process to permit judgement
Allocation concealment
Selection bias (biased allocation to interventions) due to inade-
quate concealment of allocations prior to assignment
Low risk of bias: Randomisation method described that would not
allow investigator/participant to know or influence intervention
group before eligible participant entered in the study (e.g. central
allocation, including telephone, web-based, and pharmacy-con-
trolled, randomisation; sequentially numbered drug containers of
identical appearance; sequentially numbered, opaque, sealed en-
velopes)
High risk of bias:Using an open random allocation schedule (e.g. a
list of random numbers); assignment envelopes were used without
appropriate safeguards (e.g. if envelopes were unsealed or non-
opaque or not sequentially numbered); alternation or rotation;
date of birth; case record number; any other explicitly unconcealed
procedure
Unclear: Randomisation stated but no information on method
used is available
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(Continued)
Blinding of participants and personnel
Performance bias due to knowledge of the allocated interventions
by participants and personnel during the study
Low risk of bias: No blinding or incomplete blinding, but the re-
view authors judge that the outcome is not likely to be influenced
by lack of blinding; blinding of participants and key study per-
sonnel ensured, and unlikely that the blinding could have been
broken
High risk of bias: No blinding or incomplete blinding, and the
outcome is likely to be influenced by lack of blinding; blinding
of key study participants and personnel attempted, but likely that
the blinding could have been broken, and the outcome is likely
to be influenced by lack of blinding
Unclear: Insufficient information to permit judgement
Blinding of outcome assessment
Detection bias due to knowledge of the allocated interventions by
outcome assessors
Low risk of bias:Noblinding of outcome assessment, but the review
authors judge that the outcome measurement is not likely to be
influenced by lack of blinding; blinding of outcome assessment
ensured, and unlikely that the blinding could have been broken
High risk of bias: No blinding of outcome assessment, and the
outcome measurement is likely to be influenced by lack of blind-
ing; blinding of outcome assessment, but likely that the blinding
could have been broken, and the outcome measurement is likely
to be influenced by lack of blinding
Unclear: Insufficient information to permit judgement
Incomplete outcome data
Attrition bias due to amount, nature or handling of incomplete
outcome data
Low risk of bias: No missing outcome data; reasons for missing
outcome data unlikely to be related to true outcome (for survival
data, censoring unlikely to be introducing bias); missing outcome
data balanced in numbers across intervention groups, with similar
reasons for missing data across groups; for dichotomous outcome
data, the proportion ofmissing outcomes comparedwith observed
event risk not enough to have a clinically relevant impact on the
intervention effect estimate; for continuous outcome data, plau-
sible effect size (difference in means or standardized difference in
means) among missing outcomes not enough to have a clinically
relevant impact on observed effect size; missing data have been
imputed using appropriate methods
High risk of bias: Reason for missing outcome data likely to be
related to true outcome, with either imbalance in numbers or rea-
sons for missing data across intervention groups; for dichotomous
outcome data, the proportion ofmissing outcomes comparedwith
observed event risk enough to induce clinically relevant bias in
intervention effect estimate; for continuous outcome data, plau-
sible effect size (difference in means or standardized difference in
means) among missing outcomes enough to induce clinically rel-
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(Continued)
evant bias in observed effect size; ‘as-treated’ analysis done with
substantial departure of the intervention received from that as-
signed at randomisation; potentially inappropriate application of
simple imputation
Unclear: Insufficient information to permit judgement
Selective reporting
Reporting bias due to selective outcome reporting
Low risk of bias: The study protocol is available and all of the
study’s pre-specified (primary and secondary) outcomes that are of
interest in the review have been reported in the pre-specified way;
the study protocol is not available but it is clear that the published
reports include all expected outcomes, including those that were
pre-specified (convincing text of this nature may be uncommon)
High risk of bias: Not all of the study’s pre-specified primary out-
comes have been reported; one or more primary outcomes is re-
ported using measurements, analysis methods or subsets of the
data (e.g. subscales) that were not pre-specified; one or more re-
ported primary outcomes were not pre-specified (unless clear jus-
tification for their reporting is provided, such as an unexpected
adverse effect); one or more outcomes of interest in the review are
reported incompletely so that they cannot be entered in a meta-
analysis; the study report fails to include results for a key outcome
that would be expected to have been reported for such a study
Unclear: Insufficient information to permit judgement
Other bias
Bias due to problems not covered elsewhere in the table
Low risk of bias: The study appears to be free of other sources of
bias.
High risk of bias: Had a potential source of bias related to the spe-
cific study design used; stopped early due to some data-dependent
process (including a formal-stopping rule); had extreme baseline
imbalance; has been claimed to have been fraudulent; had some
other problem
Unclear: Insufficient information to assess whether an important
risk of bias exists; insufficient rationale or evidence that an iden-
tified problem will introduce bias
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WH A T ’ S N E W
Last assessed as up-to-date: 2 March 2018.
Date Event Description
20 June 2018 New citation required and conclusions have changed New studies incorporated
20 June 2018 New search has been performed Review updated; 26 new studies added
H I S T O R Y
Protocol first published: Issue 1, 2001
Review first published: Issue 1, 2004
Date Event Description
7 November 2012 New citation required and conclusions have changed New studies, interventions and authors
7 November 2012 New search has been performed Review updated; 25 new studies added
15 October 2008 Amended Converted to new review format.
C O N T R I B U T I O N S O F A U T H O R S
The work of this review update has been in the main conducted by David Tunnicliffe and Suetonia Palmer.
Each author individually contributed the following:
• David J Tunnicliffe: conduct data analysis, author
• Suetonia C Palmer: conduct data analysis, author
• Lorna Henderson: 2012 update design, analysis, reading drafts and co-author
• Philip Masson: 2012 update design, analysis, reading drafts and co-author
• Jonathan C Craig: reading drafts and co-author
• Allison Tong: reading drafts and co-author
• Davinder Singh-Grewal: reading drafts and co-author
• Robert Flanc: original design and author
• Matthew Roberts: original design and author
• Angela Webster: 2012 update design, analysis, reading drafts and co-author
• Giovanni FM Strippoli: conduct data analysis, reading drafts, original design and author
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D E C L A R A T I O N S O F I N T E R E S T
None known.
S O U R C E S O F S U P P O R T
Internal sources
• Cochrane Kidney and Transplant, Australia.
External sources
• Cochrane Review Support Programme 2017, UK.
D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
Risk of bias assessment tool has replaced quality assessment checklist.
N O T E S
The numbering of comparisons for induction therapy in the data and analyses section is reflected throughout the main text.
I N D E X T E R M S
Medical Subject Headings (MeSH)
Azathioprine [therapeutic use]; Cyclophosphamide [∗therapeutic use]; Glucocorticoids [therapeutic use]; Immunosuppressive Agents
[∗therapeutic use]; Induction Chemotherapy [methods]; Lupus Nephritis [∗drug therapy]; Maintenance Chemotherapy [methods];
Mycophenolic Acid [∗analogs & derivatives; therapeutic use]; Randomized Controlled Trials as Topic
MeSH check words
Adult; Child; Humans
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